Supplement to
Cancer Research
AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH

INDEX
TO VOLUME 55, 1995

'95

December 15, 1995
Index Issue
Volume 55 • Number 24
PP. 6267-6341
ISSN 0008-5472 • CNREA 8

Notice to Members of the American Association for Cancer Research

Officers for 1995–1996

President: Joseph R. Bertino, Memorial Sloan-Kettering Cancer Center, New York, NY 10021
President-Elect: Louise C. Strong, UT M. D. Anderson Cancer Center, Houston, TX 77030
Treasurer: Bayard D. Clarkson, Memorial Sloan-Kettering Cancer Center, New York, NY 10021
Executive Director: Margaret Foti, AACR, Public Ledger Bldg., Suite 816, 150 South Independence Mall West, Philadelphia, PA 19106-3483

Annual Dues

The annual dues of active members of the American Association for Cancer Research are $160, $80 of which may be applied to a subscription to *Cancer Research*. Corresponding members of the Association will be charged an appropriate fee to offset postage costs. Payment of dues and changes of address of members of the Association should be sent promptly to: Member Services, American Association for Cancer Research, Inc., Public Ledger Bldg., Suite 816, 150 South Independence Mall West, Philadelphia, PA 19106-3483. Telephone: (215) 440-9300; FAX: (215) 440-9313.

Back Issues and Single Copy Sales of the Journal

Copies of back stock of the journal *Cancer Research* may be ordered from *Cancer Research*, P.O. Box 3000, Denville, NJ 07834 [Telephone: (800) 875-2997 or (201) 627-2427; FAX: (201) 627-5872]. As long as supplies permit, single copies of *Cancer Research* will be sold at $30 per copy for regular and Supplement issues, plus $2 shipping for orders outside the U.S. The annual *Proceedings of the American Association for Cancer Research* is available at $35 per copy, plus $4 shipping for orders outside the U.S.

Advertisements in *Cancer Research*

Advertisement insertion orders and copy must be received approximately 5 weeks prior to the date of the issue in which the advertisement is to be published. The journal is mailed approximately 5 days preceding the date of issue. Inquiries about advertising should be directed to: M. J. Mrvica Associates, Inc., 155 South White Horse Pike, Berlin, NJ 08009 [Telephone: (609) 768-9360; FAX: (609) 753-0064].

Historical Cover Themes

Readers are invited to submit themes (events, persons, institutions) for consideration for the illustrated covers of *Cancer Research*. Correspondence regarding suggested cover themes, or other matters regarding covers, should be addressed to the Cover Editor, AACR Publications Department.

Submission of Manuscripts

Manuscripts should be sent to the attention of: Dr. Carlo M. Croce, Editor-in-Chief, AACR Publications Department, American Association for Cancer Research, Public Ledger Bldg., Suite 816, 150 South Independence Mall West, Philadelphia, PA 19106-3483. Telephone: (215) 440-9300. If accepted, they will be listed under one of ten categories in the Table of Contents. Please specify in a covering letter which category applies to your submission: biochemistry and biophysics, carcinogenesis, clinical investigations; endocrinology, epidemiology; experimental therapeutics; immunology, molecular biology and genetics, tumor biology, and virology. (Final categorization in the Table of Contents is at the discretion of the Editor-in-Chief.) Consult the "Instructions for Authors" printed in the January 1 issue of the journal for other submission requirements. Reprints of the "Instructions" are available upon request.

Manuscript Processing Fee

Journal policy requires that a manuscript processing fee of $75 be assessed for each paper to defray the expenses incurred in the editorial review process. Each manuscript submitted for publication should be accompanied by a check (drawn on a U.S. bank) or purchase order for $75 in U. S. currency, payable to AACR, Inc. Note: If an author resubmits a manuscript that our Editors previously found unacceptable for publication, it is journal policy to consider it a new submission, assign it a new manuscript number, and charge the author another $75 handling fee to cover the cost of review.

Page Charges

Accepted manuscripts will be published with the understanding that the author(s) will pay a charge of $65 per printed page. Under exceptional circumstances, when no source of grant or other support exists, the author(s) may apply to Dr. Carlo M. Croce, Editor-in-Chief, *at the time of submission*, for a waiver of the page charges. All such applications must be countersigned by an appropriate institutional official stating that no funds are available for the payment of page charges.

Copyright and Copyright Clearance Center

The Copyright Revision Act (PL 94-553), which became effective January 1, 1978, states that the copyright of a work is vested in the author from the moment of creation. Therefore, all authors who wish to publish in *Cancer Research* must formally transfer copyright to the proprietor of the journal, the American Association for Cancer Research, Inc. It is understood by this transfer that the authors relinquish all exclusive rights of copyright ownership, including the rights of reproduction, derivation, distribution, sale, and display.

Authors who prepared their articles as part of their official duties as employees of the U. S. Federal Government are not required to transfer copyright to the American Association for Cancer Research, Inc., since these articles are considered to be in the public domain. However, it is necessary for these authors to sign the appropriate section of the transfer form. In the case of articles supported by federal grants or contracts, copyright transfer to the American Association for Cancer Research, Inc., is required. The federal government may retain a nonexclusive license to publish or republish such material.

Copies of articles for which the American Association for Cancer Research, Inc. owns the copyright may be made for personal or internal use, provided that the copier pay the per-copy fee of $2 through the Copyright Clearance Center, Inc. This Center is a nonprofit organization through which individuals and institutions may reimburse a copyright owner for photocopying journal articles beyond what is defined as "fair use" in Sections 107 and 108 of the Copyright Revision Act of 1978. Those who wish to photocopy *Cancer Research* articles may report the number of copies they have made, together with the fee code 0008-5472/95 $02.00, to: Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923; (508) 750-8400. Remittances may be sent to the Center at the time of reporting or the Center will bill the user on a monthly basis. Deposit accounts and prepayment plans may also be arranged.

Between June 1978 and August 1983, a fee code appeared on the first page of all articles for which *Cancer Research* owned the copyright. For those issues, it is understood that any articles which did not carry this code are in the public domain.

Cancer Research is abstracted or indexed in Biological Abstracts, Chemical Abstracts, Index Medicus, MEDLINE, Current Contents, and Reference Update. This journal is printed on acid-free paper.

No responsibility is accepted by the Editors, by the American Association for Cancer Research, Inc., or by Cadmus Journal Services for the opinions expressed by contributors or for the content of the advertisements.

Cancer Research (ISSN 0008-5472) is published twice a month by the American Association for Cancer Research, Inc., Public Ledger Bldg., Suite 816, 150 South Independence Mall West, Philadelphia, PA 19106–3483 for $80 annually for members and $460 for individual nonmembers. *Cancer Research* is only available to institutions as a combined subscription with *Clinical Cancer Research*. The combined 1995 institutional subscription price of $495 includes a subscription to *Clinical Cancer Research*. Second-class postage paid at Philadelphia, PA and additional mailing offices. POSTMASTER: Send address changes to *Cancer Research*, P.O. Box 3000, Denville, NJ 07834. Copyright 1995 by the American Association for Cancer Research, Inc. Printed in the U.S.A.

Cancer Research

AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH

American Association for Cancer Research, Inc.

Publications Staff
Managing Editor
Margaret Foti

Assistant Managing Editor
Mary Anne Mennite

Manager, Editorial Services
Heide M. Pusztay

Staff Editors
Lisa A. Chippendale
Pamela M. Grebow
Michael J. Beveridge
Kathleen C. Assenmacher
Pamela R. Arnold
Laurie B. Baker

Senior Editorial Assistant
Theresa A. Griffith

Staff Assistant
Mary Ellen Pirring

Editorial Assistants
Valerie L. Taylor
Andrea Conrad
Katherine V. Pawlowski
Bethann Massarella
Edward L. Dodd III

Administrative Staff
Executive Director
Margaret Foti

Director of Administration
Adam D. Blistein

Controller
Joan D. Brokenshire

Coordinator, Financial Operations
George L. Moore

Meetings Coordinator
Jeffrey M. Ruben

Meeting Planner
Carole L. Kanoff

Public Information Coordinator
Jenny Anne Horst-Martz

Assistant to the Executive Director
Ruth E. Fortson

Membership Development Coordinator
Robin E. Felder

Administrative Assistant
Margaret A. Pickels

Systems Specialist
Lydia I. Rodriguez

Secretary
Malika L. Wright

Editorial Secretary
Diana F. Certo

Office Clerk
James J. Waters

Data Entry Clerk
Robert A. Simms II

Editor-in-Chief
Carlo M. Croce

Associate Editors

Stuart A. Aaronson	Riccardo Dalla-Favera	Kay Huebner	Ruth J. Muschel	Eric J. Stanbridge
David S. Alberts	Nancy E. Davidson	John T. Isaacs	Yusuke Nakamura	Patricia S. Steeg
Carmen J. Allegra	Richard L. Davidson	Mark A. Israel	Garth L. Nicolson	Glenn Steele, Jr.
Frederick R. Appelbaum	Eugene R. DeSombre	Elaine S. Jaffe	Kenneth Nilsson	Gary S. Stein
Silvia Bacchetti	T. Michael Dexter	Rakesh K. Jain	Susumu Nishimura	Bernard S. Strauss
William M. Baird	Ralph E. Durand	Peter A. Jones	Jeffrey A. Norton	Takashi Sugimura
Allan Balmain	Alan Eastman	V. Craig Jordan	Kenneth Olden	Saraswati Sukumar
J. Carl Barrett	Gertrude B. Elion	John H. Kersey	Gilbert S. Omenn	James A. Swenberg
Renato Baserga	Leonard C. Erickson	Young S. Kim	Richard J. O'Reilly	Paul Talalay
William T. Beck	Nelson Fausto	Kenneth W. Kinzler	Robert F. Ozols	Tadatsugu Taniguchi
Joseph R. Bertino	Eric R. Fearon	Hynda K. Kleinman	Michael A. Pailadino, Jr.	Steven R. Tannenbaum
Diane F. Birt	Isaiah J. Fidler	Alfred G. Knudson, Jr.	Luis F. Parada	Masaaki Terada
Mina J. Bissell	Robert A. Floyd	Kurt W. Kohn	Peter L. Pedersen	Kenneth D. Tew
Clara D. Bloomfield	Judah Folkman	Richard D. Kolodner	Anthony E. Pegg	Donald J. Tindall
Ronald H. Blum	Kenneth A. Foon	Laurence N. Kolonel	Pier Giuseppe Pelicci	Thea D. Tlsty
Gianni Bonadonna	Joseph F. Fraumeni, Jr.	Donald W. Kufe	Angel Pellicer	George J. Todaro
Ernest C. Borden	Stephen H. Friend	John S. Lazo	Bice Perussia	Jeffrey M. Trent
G. Tim Bowden	Minoru Fukuda	Jay A. Levy	Lester J. Peters	Giorgio Trinchieri
Edward Bresnick	Philip Furmanski	Victor Ling	Gordon L. Phillips	Takashi Tsuruo
Samuel Broder	Eugene W. Gerner	Lance A. Liotta	Cecil B. Pickett	Axel Ullrich
Ronald N. Buick	Eli Glatstein	Martin Lipkin	Jacalyn H. Pierce	Peter Vaupel
Paul A. Bunn, Jr.	David W. Golde	Marc E. Lippman	Vito Quaranta	Giancarlo Vecchio
C. Patrick Burns	Michael M. Gottesman	Gerald Litwack	Frank J. Rauscher III	Peter K. Vogt
Fernando Cabanillas	Joe W. Gray	Leroy F. Liu	Donald J. Reed	Daniel D. Von Hoff
Bruno Calabretta	J. W. Grisham	Lawrence A. Loeb	John C. Reed	Cheryl Walker
Eli Canaani	F. Peter Guengerich	Dan L. Longo	Ralph A. Reisfeld	Michael D. Waterfield
Robert L. Capizzi	Sen-itiroh Hakomori	Reuben Lotan	Richard A. Rifkind	Lee W. Wattenberg
Webster K. Cavenee	Philip C. Hanawalt	David B. Ludlum	Leslie L. Robison	Ralph R. Weichselbaum
Ann F. Chambers	Curtis C. Harris	Tak W. Mak	Igor B. Roninson	I. Bernard Weinstein
Bruce D. Cheson	John C. Harshbarger	Michael J. Mastrangelo	Howard I. Scher	Bengt Westermark
David Colcher	Stephen S. Hecht	Lynn M. Matrisian	Robert T. Schimke	Raymond L. White
Robert L. Comis	Carl-Henrik Heldin	W. Gillies McKenna	J. Schlessinger	Gordon F. Whitmore
Allan H. Conney	Ingegerd Hellström	Anna T. Meadows	Manfred Schwab	Alice S. Whittemore
Neal G. Copeland	Brian E. Henderson	John Mendelsohn	Joseph V. Simone	Max S. Wicha
Pelayo Correa	Richard B. Hochberg	Christopher J. Michejda	Francis M. Sirotnak	Wendell Wierenga
Joseph G. Cory	Waun Ki Hong	John D. Minna	Anna Marie Skalka	Sheldon Wolff
William M. Crist	Tasuku Honjo	Beatrice Mintz	Michael B. Sporn	Stuart H. Yuspa
Benoit de Crombrugghe	H. Robert Horvitz	Malcolm S. Mitchell	Martha R. Stampfer	Harald zur Hausen

Cover Editorial Board

Sidney Weinhouse, *Cover Editor*	Hugh J. Creech	Edwin A. Mirand	Takashi Sugimura
	Clark W. Heath, Jr.	Raymond W. Ruddon	John H. Weisburger

***Cancer Research* is sponsored by the American Association for Cancer Research, Inc. Publication costs are also met by a grant from the Elsa U. Pardee Foundation. Through the kind assistance of the Japanese Cancer Association, accelerated mailing of all AACR journals to AACR members in Japan is fully supported by a generous grant from the Banyu Pharmaceutical Company, Tsukuba, Japan.**

Subscription Information

Cancer Research is published twice a month, one volume per year, by the American Association for Cancer Research, Inc. (AACR). Subscriptions include the *Proceedings of the American Association for Cancer Research*, issued in March of each year. Except for members of the AACR, all subscriptions are payable in advance to *Cancer Research*, P.O. Box 3000, Denville, NJ 07834 [Telephone: (800) 875-2997 or (201) 627-2427; FAX: (201) 627-5872], to which all business communications, remittances (in United States currency or its equivalent), and subscription orders should be sent. In Japan, send orders and inquiries to (sole agent): USACO Corporation, Tsutsumi Bldg., 13–12, Shimbashi 1-chome, Minato-ku, Tokyo 105, Japan; Tel. (03) 502–6471. Individuals who are not AACR members may subscribe to Volume 55 (1995) of *Cancer Research* at the rate of $460 U.S./$520 foreign. *Cancer Research* is only available to institutions as a combined subscription with *Clinical Cancer Research*. The combined 1995 institutional subscription price of $495 U.S./$575 foreign includes a subscription to *Clinical Cancer Research*. Canadian subscribers should add 7% GST. Changes of address notification should be sent 60 days in advance and include both old and new addresses. Member subscribers should send address changes to: AACR Member Services, Public Ledger Bldg., Suite 816, 150 South Independence Mall West, Philadelphia, PA 19106-3483. Nonmember subscribers should send changes of address to: *Cancer Research*, P.O. Box 3000, Denville, NJ 07834. Copies of the journal which are undeliverable because of address changes will be destroyed.

Cancer Research

VOLUME 55 • NUMBER 24 • INDEX ISSUE • CNREA 8 • PP. 6267–6341

CONTENTS

INDEX TO VOLUME 55

6267 **Author Index**

6287 **Subject Index**

i **Contents of Volume 55**

xviii **Cover Illustrations for Volume 55**

AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.

Officers

President, Joseph R. Bertino
President-Elect, Louise C. Strong
Treasurer, Bayard D. Clarkson
Past President, Edward Bresnick
Past President, Margaret L. Kripke
Executive Director, Margaret Foti

Board of Directors

Until 1996
Anna D. Barker
Donald S. Coffey
Michael B. Sporn
Daniel D. Von Hoff

Until 1997
Webster K. Cavenee
Philip C. Hanawalt
Stanley J. Korsmeyer
Thea D. Tlsty

Until 1998
Clara Derber Bloomfield
Michael M. Gottesman
Ann R. Kennedy
Frederick P. Li

Ex Officio
Joseph R. Bertino
Edward Bresnick
Bayard D. Clarkson
Margaret Foti
Margaret L. Kripke
Louise C. Strong

AUTHOR INDEX*

A

Aagaard, L., 4818
Aaronson, S. A., 5342
Abarzúa, P., 3490
Abbondandolo, A., 4658
Abbott, B. J., 862
Abdel-Malek, Z. A., 4041, 4047
Abdel-Raheem, M. H., 1092
Abe, T., 1379
Abraham, D., 2463, 3739
Abramovitch, R., 153, 1956
Abrams, S. I., 3598
Adachi, D., 1139
Adachi, M., 4127, 6040
Adam, L., 5156
Adams, G. P., 5983s
Adams, L., 2090
Adamson, E. D., 5054
Adamson, P. C., 482, 4069
Adema, G. J., 5330
Adeyanju, M. O., 984
Adluri, S., 2783
Affabris, E., 3158
Afonso, A., 5106
Afshar, A., 4972
Agbaria, R., 1306
Agostini, C., 6140
Agrawal, B., 2257
Åhlström, K. R., 5868s
Ahnen, D. J., 3110
Aikou, T., 4196
Aizu-Yokota, E., 1863
Akamatsu, K-i., 590
Akao, Y., 3444
Akbasak, A., 6166
Åkerström, G., 5794s
Åkervall, J., 3204
Akhlynina, T. V., 1014
Akhtar, A. J., 1811
Akie, K., 1559
Akiyama, M., 921
Akiyama, S-i., 1687
Akiyoshi., T., 3417
Akman, S., 4646
Akman, S. A., 330
Aksentijevich, I., 1086
Alaoui-Jamali, M. A., 4760
Alavaikko, M., 2660
Alberts, D. S., 3110
Albino, A. P., 2713, 5531
Albores-Saavedra, J., 2511
Alcorta, D. A., 2500
Aldape, K. D., 727
Aldaz, C. M., 2892, 3976, 4566
Alder, J., 830
Alderson, L. M., 999
Alexander, B., 4302
Alexandrow, M. G., 1452, 3928
Alfano, R., 5049
Alfieri, A. A., 1248
Alho, H., 2691
Ali-Osman, F., 5025
Alisauskas, R., 1105
Alisauskus, R., 5743s
Alison, M. R., 6084
Allaart, H. A., 253
Allalunis-Turner, M. J., 5200
Alldersea, J., 4237
Allegra, C. J., 1407
Allen, B. J., 874
Allen, S. L., 1199
Allen, W. E., 3772
Alley, M. C., 2794
Allolio, B., 4957
Allsbrook, W. C., Jr., 1621
Almquist, K. C., 102
Alnemri, E. S., 548, 2737, 6045
Alpaugh, R. K., 4586
Alpert, L., 4760
Alsbeih, G., 1232
Amadio, L., 4552
Amano., Y., 3438
Amara, F. M., 4503
Ambros, R. A., 3654
Ambrosone, C. B., 3483
Amici, C., 4452
Amin, S., 2310
Amiot, M., 3647
Amler, L. C., 5366, 5504
Amor-Guéret, M., 5520
Amorosi, A., 2665
Amos, C. I., 557
Amstutz, H. P., 46
Amyx, H., 6117
Anamthawat-Jonsson, K., 646
Ananthaswamy, H. N., 3604
Anaraki, F., 4168
Andersen, A., 1670
Andersen, J. W., 6196
Anderson, C. J., 5714s
Anderson, G. R., 1122
Anderson, I. C., 4120
Anderson, K., 5957s
Anderson, L. M., 3043, 4875, 6017
Anderson, P. M., 1321
Anderson, W. F., 5283, 5493
Andoh, T., 2299
Andreotti, P. E., 5276
Andria, M., 31, 1565
Andrulis, I. L., 129
Ang, C. Y., 4486
Angerler, J., 3854
Anichini, A., 414, 3374, 4702
Anichini, E., 90
Aninipot, R., 5857s
Annegers, J. F., 557
Antakly, T., 823
Antoku, S., 739
Antonia, S. J., 2253, 3982
Antonio, L. B., 2035
Anttila, S., 3305
Anver, M. R., 4875, 5621
Anzano, M. A., 5621
Anzick, S. L., 3380, 3790
Aoki, K., 3810
Aplan, P. D., 1917
Aquilina, G., 2569
Arakawa, H., 1310, 1316
Aramaki, R., 739
Arap, W., 1351, 1941
Arason, A., 4830
Arbogast, D., 57
Archer, G. E., 3803, 4375
Ardelt, B., 444
Arden, K. C., 2494
Arenkiel, J. M., 4536
Aricò, M., 3835
Arienti, F., 3374
Arista, A., 5952s
Arlestig, L., 5868s
Arlett, C. F., 1232, 2245
Armstrong, L., 5106
Armstrong, R., 6045
Arnal, M., 4416
Arnaud, E., 5075
Arnold, J. T., 537
Artuc, M., 4432
Aruffo, A., 4425
Arwert, F., 5465
Asa, S. L., 1603
Asai, K., 3785
Asai, O., 5335
Asano, M., 5296
Asao, T., 1473
Ashour, O. M., 1092
Asiedu, C., 3716
Astakhova, L., 5617
Au, J. L-S., 5315
Auclair, C., 3211
Auer, G., 5415
Augenlicht, L. H., 174
Ault, J. G., 792
Austin, E. A., 4808
Averett, D. R., 3352
Axenovich, S., 4023

B

Baba, H., 1977
Baba, M., 4196
Baba, S., 836, 1479, 4881
Babcock, G., 4041
Baccanari, D. P., 6227
Bacchetti, S., 2533
Bacciardi, D., 5911s
Bachert, L. A., 792
Bacic, G., 2249
Bacus, S. S., 3890
Badawi, A. F., 5226, 5230
Bader, S., 1227
Badie, C., 1232
Bae, I., 2116, 2387
Baer, T., 478
Baetta, R., 597
Bailey, D., 2871
Bailey, G., 57
Bailey, H. H., 4771
Bailie, J. R., 3772
Bair, H-J., 3825, 5786s
Baker, M. A., 957
Bakker, A., 4409
Bakker, A. B. H., 5330
Bakkus, M., 2730
Bakogeorgou, E., 5632
Balázs, M., 2720
Baldin, V., 1590
Balis, F. M., 482, 4069, 4606
Balleine, R. L., 5063
Ballon, D., 1248
Balm, A., 975
Balmain, A., 3883, 5168
Balshem, A. M., 2789
Baltzer, K., 5749s
Bandera, C. A., 490
Bang, Y-J., 5545
Bani, D., 5272
Bani, M. R., 1139, 4174
Bannasch, P., 989, 3318
Baptiste, N., 3543
Baranov, V., 2963
Barber, J. P., 1811
Barberi, T., 440
Barbuto, J. A. M., 3584
Bardeesy, N., 215
Bar-Eli, M., 3669
Bargonetti, J., 4257
Barillé, S., 3647
Barkardottir, R. B., 4830
Barker, D., 4041
Barlozzari, T., 3085
Barna, B. P., 6166
Barnard, G. F., 3417
Barnard, J., 3197
Barnes, D. M., 39
Barnett, G. H., 3456, 6166
Barr, E. B., 5251
Barr, P. J., 2936
Barracchini, K. C., 3149
Barrack, E R., 2596
Barrett, J. C., 1621, 3576, 4813, 5664, 6063
Barron, G. M., 5200
Bartek, J., 949, 4818
Bartkova, J., 949
Bartlett, J., 2422
Bartnitzke, S., 2497, 6038
Bartoli, E., 111
Bartram, C. R., 2266, 5377
Bartsch, G., 3068
Baserga, R., 249, 303, 663, 1006, 2463, 3739
Bashirelahi, N., 4999
Basnakian, A. G., 1894
Basse, P. H., 4627
Basset, P., 2896
Bast, R. C., Jr., 944
Basu, A., 3132
Bataille, R., 1355, 3647
Batra, S. K., 3140
Batsakis, J. G., 16, 2656
Battey, J. F., 1853
Battista, P., 5677
Baumann, R. G., 4999
Baxter, L. T., 4611, 5451
Bayard, F., 5075
Bayko, L., 4575
Baylin, S. B., 2048, 2279, 4525, 5195
Bazan, V., 6103
Beach, D., 1607
Beach, D. H., 1448
Beardsley, G. P., 566
Bearman, S. I., 5921s
Beart, R. W., 3742, 4531
Beattie, B., 1902
Beaune, P., 5574, 5611
Bebok, Z., 3339
Bechtold, H. A., 3295
Beck, S. A., 1458
Beck, W. T., 1509
Becker, W., 5777s
Becker, W. S., 3825, 5771s, 5786s
Beckett, M. A., 5561
Beckner, M. E., 2140
Beckwith, J. B., 215
Becquemont, L., 5574
Bedi, A., 463, 1811
Bedi, G., 2995
Bedi, G. C., 1811
Bednarek, A., 4566
Beebe, L. E., 4875
Beger, H. G., 2007, 5499
Begg, A. C., 1232
Beggs, A. H., 3865
Behbakht, K., 2998

** For title of article and coauthors, see listing in Contents of Volume 55 beginning on page i at the end of this index issue.*

Behr, T., 5777s, 5827s, 5899s, 5935s, 5946s
Behr, T. M., 3825, 5771s, 5786s
Bejcek, B. E., 2346
Bekersky, I., 307
Belair, C., 493
Beland, F. A., 2316
Belasco, J. E., 4069
Bell, D. A., 2169, 3537, 5226, 5230
Bell, R. S., 129
Belldegrun, A., 4633
Bellet, D., 3735
Bello, M. G., 5272
Bellocq, J-P., 2896
Beltinger, C. P., 2053, 4664
Beltran, P. J., 141
Ben-David, Y., 1139
Bender, C. M., 4531
Benedict, W. F., 1613
Ben-Horin, H., 2814
Benichou, J., 4899
Benjamin, I., 2998
Benjamin, R., 1397
Ben-Josef, E., 698
Bennett, D. C., 2528
Benson, J. M., 5251
Benson, P. D., 5390
Bentley, R. C., 1168
Bentz, M., 3475
Benz, C. C., 5400
Benze, J., 5589
Berchem, G. J., 735
Berchuck, A., 944, 5664
Berdel, W. E., 2173, 2212
Berean, K., 2070
Berebitsky, D., 3610
Berg, S. L., 4069, 4606
Berger, A., 5611
Berger, M. S., 1261, 1941
Berger, N. A., 868, 3697, 4029
Berger, R., 4220
Berger, R. B., 868
Berger, S. J., 868, 3697
Bergh, J., 3908
Bergmann, U., 2007
Bergthorsson, J. T., 4830
Berk, D. A., 3752
Berkowitz, R. S., 490, 2169
Berlingieri, M. T., 1787
Bermudez, E., 530, 3634
Bernard, O., 4220
Berner, A., 1817
Bernhard, E. J., 995
Bernhard, H., 1099
Bernstein, R. M., 3584
Berthold, F., 5366
Bertram, J. S., 705
Bertram, K. A., 2984
Bertrand, O., 3513
Berven, E., 2346
Berx, G. J., 4722
Besterman, J. M., 603
Betz, C., 4283
Beverloo, H. B., 4220
Bevilacqua, M. P., 4425
Bhadkamkar, V., 5925s
Bhakoo, K. K., 420
Bhatia, K., 1431, 2387
Bhatia, U., 3093
Bhattacharya-Chatterjee, M., 1525
Bhattacharyya, N., 1531
Bianchi, R., 6231
Bicknell, R., 510
Bidart, J. M., 3735
Biegel, J. A., 5536
Bies, J., 501
Bigazzi, M., 5272
Biggar, S., 2640
Biggs, J., 3716
Bignami, M., 2569
Bigner, D. D., 2853, 3140, 3803, 4375
Bigotti, A., 1787
Billadeau, D., 3640
Billi, A. M., 2978
Bilous, A. M., 5063
Binaglia, L., 6231
Binderup, L., 2822
Biondi, A., 1625
Birrer, S., 2866
Bischoff, E. D., 3183
Bishop, D. T., 242
Bishop, J. A. N., 4099
Bissett, D., 2090
Bissonnette, M., 3050, 5257
Biswas, C., 434
Bitar, K., 4886
Bittner, G., 6215
Bittner, M. L., 3380, 3954
Bjornsti, M-A., 2883, 4287
Black, A., 3486
Black, K. C., 810
Black, M., 4557
Black, P. M., 3865
Blackburn, B., 63
Blagosklonny, M. V., 4623
Blanchard, G., 2169
Blanco, G., 2660
Blaney, S. M., 4069
Blank, E. W., 1717, 5852s
Blankenstein, T., 4747
Blasberg, R., 1902
Blasberg, R. G., 6126
Blaser, M. J., 562, 2111
Blättler, W. A., 4079
Blaydes, J. P., 2404
Blazes, M. S., 5556
Blegen, H., 5415
Bleiweiss, I. J., 5173
Blend, M. J., 5764s
Blessing, M., 4205
Bloemers, H. P. J., 6237
Bloigu, R., 5595
Blomqvist, C., 4471
Blumenthal, R. D., 3825, 5935s
Board, M., 3278
Bocca, P., 853
Bocker, T., 6002
Boczkowski, D., 2366
Boddy, A. V., 803
Bode, B. P., 3525
Bodell, W. J., 3012
Bodine, P. V. N., 548
Boente, M. P., 2150
Boerman, O. C., 5864s
Bogdany, J. K., 2713
Boggi, U., 5911s
Bögler, O., 2746
Bohlander, S. K., 984, 1206, 2394
Böhling, T., 1334
Boice, J. D., Jr., 294
Boiocchi, M., 2645, 3675
Boitier, E., 3028
Boland, C. R., 3721
Bollag, D. M., 2325
Bolodeoku, J., 4273
Bonavida, B., 590, 4633
Bond, J. A., 2404
Bondy, M., 3976
Bonetto, F., 4552
Bongarzone, I., 5617
Bonifaci, N., 675
Bonmassar, E., 6231
Bookman, M. A., 5983s
Boone, T., 5161
Booser, D., 3060
Boothman, D. A., 3706
Bootsma, D., 4325
Borell, T. J., 5408
Borgeat, P., 3615
Borisch, B., 2866
Borner, M. M., 2122
Borowsky, R., 159
Borsellino, N., 4633
Bosari, S., 5049
Bosch, F. X., 5030
Bosic, C., 1355
Bosman, F. T., 1971
Bosseler, M., 735
Bossi, P., 5049
Boβlet, K., 4036
Bostwick, D. G., 2959, 4114, 5408
Boucher, C. A., 34
Boucher, Y., 5451
Bouffler, S. D., 3883
Bouillé, P., 3211
Bourre, F., 4325
Bourret, L. A., 4079
Bousquet, P. F., 1176
Bowden, C., 5589
Bowen, W. D., 408, 3022
Bowling, W., 5242
Bowman, L. C., 721
Boyadjieva, N., 4892
Boyce, B. F., 1989, 3551
Boyce, R., 3551
Boyd, D., 963
Boyd, J., 1621, 2998
Boyer, I. J., 979
Boyer, J. C., 5664, 6063
Boynton, K. A., 5080
Boytos, C. M., 6117
Bracke, M. E., 4722
Bradbury, E. M., 4651
Bradley, A., 1146
Bradley, W. G., 1289
Brager, R., 5434
Brakebusch, C., 3223
Braña, M. F., 1176
Branch, P., 2304
Brasitus, T. A., 3050, 5257
Braslawsky, G., 3486
Brass, A. L., 3197
Brasure, J. R., 3483
Bratina, G., 3374
Brattain, M. G., 2056
Breda, M., 2090
Bredt, D. S., 727
Breier, G., 1358
Breinholt, V., 57
Breitz, H. B., 5817s
Brendel, K., 3110
Brenman, J. E., 727
Brennan, J., 4507
Brenner, A. J., 2892
Brenner, W., 5749s
Brent, R., 2972
Brentnall, T. A., 4264
Bresalier, R. S., 2476
Bresnahan, W., 4188
Breuninger, L. M., 5342
Briaire, I. H., 4398
Bright, S., 5881s
Brinster, R. L., 3915
Brock, I., 459
Brodeur, G. M., 721, 1792, 2053, 4664
Brodie., A., 3073
Brodt, P., 1006
Brody, M. D., 6222
Broeders, N. L. H. L., 1701
Bronner, M. P., 4264
Bronson, D., 2871
Brooks, T., 1215
Broome, J., 4237
Brossart, P., 4065
Brothman, A. R., 3389
Brouty-Boyé, D., 1633
Brown, C. C., 5621
Brown, E. D., 4516
Brown, G. A., 78
Brown, H. R., 603
Brown, L. M., 4899
Brown, N. S., 307
Brown, P. D., 3629
Brown., T. R., 3286
Broxterman, H. J., 4214
Bruckner, H. W., 5276
Brünner, N., 1664, 4146
Brunt, E. M., 5242
Bruyneel, E. A., 4722
Bryant, J. L., 4627
Bryne, M., 1817
Brzoska, P. M., 3055
Bucana, C. D., 2470, 3964
Buchberg, A. M., 5504
Buchegger, F., 83
Buchsbaum, D., 5881s
Buchsbaum, D. J., 5729s, 5811s
Buchwald, J., 4283
Bucy, R. P., 4339
Budunova, I., 4566
Buessecker, F., 1423
Buetow, K. H., 2150
Bugert, P., 5383
Buick, R. N., 6181
Bull, J. M. C., 5459
Bullerdiek, J., 2497, 6038
Bullrich, F., 1199
Bunn, P., 5921s
Bunni, M. A., 566
Buraggi, G. L., 5764s
Burgaud, J-L., 3739
Burger, A. M., 2794
Bürger, C., 817
Burhans, W. C., 1122
Burke, P. J., 1255
Burke, T. R., Jr., 4950
Burlingame, A. L., 3012
Burn, J., 242
Burnette, R. J., 1994
Burrell, M., 2910, 2972
Burres, N., 830
Burt, R. W., 3110
Bush, C., 1235
Busque, L., 3865
Butchko, G., 5921s
Butelli, E., 312

** For title of article and coauthors, see listing in Contents of Volume 55 beginning on page i at the end of this index issue.*

Butler, W. F., 4611
Buttafoco, P., 498
Butti, G., 597
Butti, M. G., 5617
Buttyan, R., 2431, 4438
Buxton, N., 4237
Buzard, G. S., 2665
Buzdar, A., 3060
Byrd, D. R., 2984, 4264
Byrne, J. A., 2896

C

Cabrera, G., 2024
Caignard, A., 685
Cairns, P., 224, 3246, 5213, 5396
Calabretta, B., 2275
Caldas, C., 4670
Calves, M., 2783
Calvieri, S., 5677
Calvo, B., 5957s
Cama, A., 5677
Camellini, L., 498
Campani, D., 5911s
Campbell, D., 4237
Campomenosi, P., 4658
Canaani, E., 1625
Cance, W. G., 2752, 3969
Cangiarella, J., 907
Cann, S. A., 4486
Cantarella, A., 5173
Canzonieri, V., 2645
Cao, S., 1239, 6227
Capaccioli, S., 90
Capogrossi, M. C., 4210
Caporaso, N. E., 2665
Capozzi, E., 2645
Capranico, G., 312
Caramia, F. G., 5677
Carbone, A., 2645
Carcangiu, M. L., 6172
Cardarelli, C. O., 1086
Cardillo, T., 3817
Cardonick, A., 2998
Carethers, J. M., 3721
Carey, T. E., 5434
Cargile, C. B., 3380
Carlesimo, M., 5677
Carlsson, S., 5801s
Carney, D. N., 2743
Carnochan, P., 5842s
Carnot, F., 5611
Caron, P. C., 5908s
Caronni, E., 3374
Carothers, A. M., 3576
Carpenter, C. L., 6035
Carrasquillo, J., 5957s
Carrasquillo, J. A., 2858, 5323
Carrière, V., 5611
Carson, D., 4010
Carson, E. B., 2048
Carteau, S., 3211
Carter, C. R. D., 3840
Carter, H. W., 3702
Carter, J. H., 3702
Carter, P., 63
Carter, S. L., 1752, 3003
Carthew, P., 544
Caruso, P. A., 5276
Casero, R. A., Jr., 3233
Cashmore, A. R., 566
Casi, M., 5952s
Casorati, G., 2236
Cassidy, J., 2090
Castanas, E., 5632
Castle, V. P., 2576
Castleberg, R. L., 999
Castleberry, R. P., 721, 4664
Castranio, T., 3537
Catapano, C. V., 4352
Catino, J. J., 2853
Cavanaugh, P. G., 4458
Cavenee, W. K., 1351, 1941, 2494, 2660, 2746, 3003
Ceballos-Picot, I., 3028
Cecconi, O., 4425
Ceccotti, S., 2569
Celli, G., 2774
Čemažar, M., 3450
Ceriani, R. L., 1525, 1717, 5847s, 5852s, 5921s, 5973s
Cerutti, A., 6140
Cesano, A., 96
Cha, Y., 668
Chabner, B. A., 4488
Chachoua, A., 5759s
Chadeneau, C., 2533
Chae, M-Y., 4085
Chagnovich, D., 721
Chakraborty, M., 1525
Chambers, A. F., 2520
Chambers, S. K., 1578
Chan, A., 5342
Chan, J., 2380
Chan, O., 2035
Chan, V. T-W., 6109
Chaney, S. G., 2837
Chang, C-j., 3890
Chang, H. K., 5323
Chang, H. W., 5540
Chang, J., 2920
Chang, K-W., 2560
Chang, W. Y. H., 5396
Chang, W. Y-H., 3246
Chang-Liu, C-M., 4788
Chao, W-r., 4446
Chapkin, R. S., 2293
Chaplin, D. J., 6026
Chapman, A. J., 1517
Chapman, M., 3551
Chapman, P., 242
Charbonnier, F., 1839
Chari, R. S., 979
Chari, R. V. J., 4079
Charles, W. C., 6152
Charron, M., 1255
Chatani, Y., 4182
Chatterjee, S., 868, 3697, 4029
Chauvin, P. J., 4557
Chavan, A., 5161
Cheever, M. A., 1099, 2984
Chen, A., 1869
Chen, C., 4230
Chen, C. H., 5207
Chen, C-J., 1296, 1301, 3873
Chen, F., 1517, 4544, 4804
Chen, J., 174
Chen, L., 428, 581
Chen, L. B., 2063
Chen, M., 991, 1509
Chen, M-W., 4438
Chen, R., 4264
Chen, S-H., 1080
Chen, T., 3976
Chen, T-L., 810, 3424
Chen, V. W., 1485
Chen, W., 2984
Chen, X., 3757, 4257
Chen, Y. Q., 4520, 4536
Chen, Z., 5434
Cheng, C., 1883
Cheng, L., 5025
Cheng, M-F., 868
Cheng, R. C., 5288
Cheng, Y-C., 3008
Cheong, N., 1232
Chervinsky, D. S., 1917
Cherwitz, D. L., 2681
Chesler, L., 721
Chevallier-Lagente, O., 4325
Chhabra, S. K., 6017
Chi, S-G., 5837s
Chiang, M-H., 1296
Chiang, Y. L., 5283
Chiao, C., 3576
Chida, K., 4865
Chiesa, V., 853
Chihara, K., 276
Childs, S., 2029
Chiorazzi, N., 1199
Chiou, H-Y., 1296
Chirivi, R. G. S., 414
Chitambar, C. R., 4361
Chiu, H-C., 2998
Cho, K. R., 4420, 5545, 5556
Choi, C. W., 5323
Cholody, W. M., 2338
Choo, K. H. A., 2021
Chopin, D., 3735
Chopra, H., 5195
Choraży, M., 1417
Chou, C-Y., 6077
Chou, H-C., 525
Chrest, F. J., 399, 2920
Christian, R. B., 5973s
Christiani, D. C., 4910
Christman, M. F., 1227, 3055
Christodoulopoulos, G. R., 3933
Christofori, G., 6071
Chu, C. K., 3008
Chu, D. T. W., 830
Chu, F-F., 957
Chuaqui, R., 467
Chuaqui, R. F., 4995
Chubb, S., 1517
Church, D. R., 3706
Chyou, P. H., 562, 2111
Cimino, G., 1625
Cin, P. D., 1565
Ciocco, G. M., 4085
Cipriano, S. C., 4536
Cirielli, C., 4210
Ciupitu, A-M. T., 5648
Civoli, F., 4844
Clapper, M. L., 2789
Clark, H. M., 1436
Clark, J. I., 4586
Clarke, C. L., 5063
Clarke, M. F., 2507
Clarke, R., 1664
Clarkson, B., 4488
Claudio, P. P., 3992
Clayman, G., 963
Clayman, G. L., 1, 3117, 3604
Cleary, K. R., 237, 3964
Cleaver, J. E., 4325, 6152
Clement, J. J., 830
Clemente, C., 3374
Clifford, A., 1680
Clingen, P. H., 2245
Cnaan, A., 1792
Cobbs, C. S., 727
Cocchiaro, C., 1176
Cocchiaro, C. A., 3085
Cocco, L., 2978
Coetzee, G. A., 1937
Coffey, R. J., Jr., 1401, 1883
Coggi, G., 5049
Cohen, H., 907
Cohen, P. S., 2380
Cohn, S. L., 721
Cole, D. E., 4606
Cole, D. J., 748
Cole, M., 803
Cole, R. W., 792
Cole, S. P. C., 102, 459, 2129, 4214
Coleman, A., 1181
Coles, B., 5574
Collin, F., 4416
Collins, T. J., 3060
Collins, V. P., 731
Colombo, M. P., 2200
Colquhoun, A., 3278
Coltrera, M. D., 2703
Coltrini, D., 4729
Columbyova, L., 3509
Colvin, M. E., 1491
Colvin, O. M., 810, 1491, 2012
Comley, M., 5628
Comoglio, P. M., 1129
Condorelli, G., 3992
Cone, R. D., 141
Conlon, D., 1176
Connell, P., 1643
Connell-Crowley, L., 5151
Connett, J. M., 5714s
Conney, A. H., 1550
Conradt, C., 5030
Conry, R. M., 1397
Conti, C. J., 1347
Cooke, T., 2422
Cooke, T. A., 3183
Coombes, R. C., 1070
Coons, S. W., 1569
Cooper, L. T., 4010
Cooper, M. J., 2576
Copeland, E. M., 3525
Coppen, M., 3331
Cordon-Cardo, C., 1211
Corless, C., 4140
Cornetta, K., 3610
Cornforth, M. N., 3310
Correa, P., 1485
Corson, J. M., 2968
Corstens, F. H. M., 5864s
Corvi, R., 3471
Cosand, W. L., 2357
Costa, J., 1010
Cotter, R. J., 1491
Couch, F. J., 2998
Couch, J. A., 2438
Coucke, P., 83
Coughlan, S. J., 2743
Coughlin, C. M., 4980
Couto, J. R., 1717, 5847s, 5852s, 5973s
Covalcuic, K., 1321
Cover, T. L., 2111
Cowan, K. H., 3790, 4004, 4561

** For title of article and coauthors, see listing in Contents of Volume 55 beginning on page i at the end of this index issue.*

Cowherd, R., 3369
Cox, R., 3883
Coy, D. H., 4886
Craig, C., 4069
Cranston, D., 510
Craven, R. J., 2752, 3969
Cree, I. A., 5276
Cremer, T., 5415
Crépin, M., 5156
Cretton-Scott, E., 3036
Crichton, V. Z., 5774s
Crimmin, M. J., 3629
Croce, C. M., 1199, 1603, 1625, 1752, 2904, 3003, 3988, 4855, 6045, 6053
Crofts, F., 472
Crottet, P., 4425
Crotty, P., 1010
Crowe, J. S., 4099
Cugnenc, P-H., 5611
Cui, P., 4640
Cuisenier, J., 4416
Culig, Z., 3068
Cullen, K. J., 2448
Cumme, F., 5771s
Cummings, K. K., 3604
Cummings, L. M., 4640
Cunningham, J., 3976
Cunningham, M., 4688
Curiel, D. T., 1397, 2024
Custer, M., 748
Cuthbert, J. A., 1732
Cymes, K., 2035
Czarnetzki, B. M., 4432

D

Dabholkar, M. D., 1261, 3933
da Costa, L. T., 4570, 4670
Daffada, A. A. I., 288
Dairkee, S. H., 2516
Dal Cin, P., 24
Dall'Agnese, L., 2645
Dalton, M. B., 3295
Daly, A. K., 6035
Dämmrich, J., 4283
Dams, E., 1547
Danen, E. H. J., 5330
Danenberg, K. D., 1407
Danenberg, P. V., 1407
Dang, T. D., 781
Danhauser, L. L., 5459
Daniel, L. W., 4844
Daniele, E., 6103
Danielsen, H. E., 1817
Danielson, K. G., 3495
Danks, R. A., 4302
Dannecker, G. E., 623
Danø, K., 4132
Dapunt, O., 2135
Dardanoni, G., 6103
Darwiche, N., 1883, 2774
Darzynkiewicz, Z., 444, 3093
Dashner, K., 3865
D'Atri, S., 6231
Davegna, C., 597
Davey, M., 4586
Davidson, A., 3610
Davidson, N. E., 2279, 4525, 5195
Davidson., N. E., 3233
Davies, P. J. A., 3183
Davis, C. M., 3310
Davis, S. T., 6227
Dawson, M. I., 232, 4446
Dawson, T. P., 915
Daxenbichler, G., 2135
Day, M. L., 4438
Day, N. K., 1289
Day, R. S., III, 5200
Dayananth, P., 2988
De, A., 4892
Deakin, M., 3537
Dean, C. J., 5842s
DeAngelo, A. B., 3702
de Arruda, M., 3085
De Baetselier, P., 2730
De Benedetti, F., 3835
de Boer, A. J., 5330
de Boer, R. W., 840
DeBoni, U., 1045
De Broe, M. E., 4383
DeBruin, L. S., 799
De Bruyne, G. K., 4722
De Campos-Lima, P. O., 3675
DeCastro, R., 434
Decensi, A., 853
de Coppet, P., 5520
De Coster, R., 5589
Deeley, R. G., 102, 459, 4214
de Fabritiis, P., 4552
Defer, N., 3028
DeFrank, J. S., 1643
Degott, C., 1590
De Gregorio, L., 135
Deguchi, M., 3623
de Haan, G., 324
Deisseroth, A. B., 668
De Jager, R. L., 5774s
Dejana, E., 414
Dejean, A., 1590
de Jong, P. J., 4570
DeJoy, S. Q., 4929
de Klein, A., 4220
Delacey, K. A., 411*
Delaloye, A. B., 83
Delaloye, B., 83
Delbaldo, C., 4688
de Leij, L., 4409
DeLeo, A. B., 124
DeLeo, R. M., 124
Delia, D., 3192
Della Porta, G., 135
Dellian, M., 3752
Deloherey, T., 5207
Del Rosso, M., 90
De Luca, A., 3992
De Luca, L. M., 2774, 4850
DeMaio, L., 3295
Demant, P., 3179
De Matteis, F., 544
Demers, G. W., 1639
Demetrick, D. J., 1448
Demidchik, E. P., 5617
Demopoulos, R., 472
Dempsey, P. J., 1883
DeNardo, G. L., 878, 5837s, 5893s, 5916s
DeNardo, S. J., 878, 5726s, 5837s, 5893s, 5916s
Denekamp, J., 83
Deng, G., 2516
Dennis, M. F., 6026
Denny, W. A., 574
Dent, G. A., 2752
DePalatis, L. R., 5288
de Palazzo, I. G., 4586
Deprest, J., 1565
De Re, V., 3675
DeRemer, S., 3687
De Renzis, M. R., 597
deRojas-Walker, T., 4391
Derr, S. M., 4079
Desai, D., 2310
Desai, R., 1902, 6126
Deshane, J., 2024
de Sousa, G., 3036
Detre, S., 288
Dettmar, P., 3958
Deuchars, K. L., 78
Deuel, T. F., 1792
Devilder, M. C., 1355
Devine, P., 928
Devor, D. E., 5265
de Vos, S., 2822
Devos, S., 2730
de Vries, E. G. E., 4214
de Vries, T. J., 4681
de Waziers, I., 5611
deWeijert, M. C. A., 5864s
Dhingra, K., 3060
Diamandis, E. P., 1603, 2104
Diamond, R., 1242
Dias, P. S., 4237
Dickman, M., 1655
Dictus, E. L. J. T., 1701
Dietrich, P-Y., 685
Dietrich, W., 6071
Diez, S. G., 3735
DiGiovanna, M. P., 1946
Di Renzo, M. F., 1129
Dirven, H. A. A. M., 1701
Disis, M. L., 1099, 2984
Diwan, B. A., 4875, 5265
Dixit, V. M., 4676
Dixon, K., 4041
Dixon, K. H., 3790
Djeu, J. Y., 4988
Dlugosz, A. A., 1883
Dmitrovsky, E., 1365, 5038
Dobry, C. J., 1836
Dohi, D. F., 5603
Dohlsten, M., 623
Döhner, H., 3475
Doi, O., 6040
Dolan, M. E., 2853
Dolber-Smith, E. G., 5893s
Dolcetti, R., 3675
Dole, M. G., 2576
Doll, J., 115
Doll, M. A., 3531
Dolter, K. E., 5551
Dombkowski, D., 392, 1643
Donehower, L. A., 1146, 1763, 1963
Dong, M-S., 799
Dong, Z., 3123, 5106
Donghi, R., 135
Donis-Keller, H., 5180
Donis-Keller., H., 3399
Dontje, B., 324
Dorman, B. M., 544
Doroshow, J., 4646
Doroshow, J. H., 1328, 4073
Dosaka-Akita, H., 1559
Dosescu, J., 5358
Dosik, J., 907
Dou, Q. P., 5222
Doukas, M., 5161
Dove, W. F., 4479
Dowsett, M., 288, 1070
Dowsett., M., 3331
Drach, J., 3854
Dragan, Y. P., 1780
Dragani, T. A., 3988
Dressler, G. R., 4092
Dreyling, M. H., 984
Dritschilo, A., 3016, 4240
Driver, C. L., 5621
Druck, T., 1199, 5348
Drucker, Y., 761
Druker, B. J., 4157
Duan, W., 20
Duba, D., 1649
Dubin, N., 1444
Dubinett, S. M., 3847
Dubois, D., 1869
Dubois, S., 1590
Duch, D. S., 6117
Dufton, C., 5921s
Dugani, A., 498
Duguid, J. R., 5146, 6097
Duh, F-M., 4804
Duh, Q-Y., 2476
du Manoir, S., 1010, 5415
Duncan, H., 3537
Duncan, J. R., 5714s
Dunn, A. R., 1883
Dunn, J. F., 2249
Dunn, L. A., 2635
Dunn, R., 5899s, 5935s
Dunn, R. M., 3825
Dunnick, J. K., 5251
Dunstan, C., 1989
Duray, P., 3954
Duray, P. H., 2959
Durham, J. S., 5817s
Duty, L., 4168
Dvorak, A. M., 376
Dvorak, H. F., 360, 369, 376
Dykes, D. J., 862

E

Eady, J. J., 1235
Ealovega, M. W., 2507
Earabino, C., 242
Earnest, D. L., 5257
Earnshaw, W. C., 6045
Eastham, J. A., 5151
Eastmond, D. A., 640
Easty, D. J., 2528
Ebbs, S. R., 3331
Eble, J. N., 5146, 6097
Eblen, S. T., 1994
Eby, Y., 224
Eccles, S. A., 5842s
Eck, S. L., 4980
Eckelman, W. C., 5323
Eda, Y., 1933
Eder, J. P., Jr., 6109
Edler, L., 5366
Edwards, C. D., 505, 2995, 6200
Edwards, D. W., 2366
Edwards, R. E., 544
Edwards, W. B., 5714s
Eerola, A-K., 5595
Efange, S. M. N., 3022
Efird, J., 392
Egan, S., 1531
Egawa, S., 2418

** For title of article and coauthors, see listing in Contents of Volume 55 beginning on page i at the end of this index issue.*

Eggensperger, D. L., 2455
Egilsson, V., 4830
Egner, P. A., 4319
Eguchi, K., 2334
Egwuagu, C., 1261
Ehrlich, M., 2876
Eichstetter, I., 3495
Eisenbach, L., 4941
Eitelbach, F., 2173
Eker, A. P. M., 4325
Ekimoto, H., 2615
Elbendary, A., 944
El-Deiry, W. S., 2910
Elder, J., 3537
Elexpuru-Camiruaga, J., 4237
Elfgang, C., 629
Elgas, M., 3318
Elia, L., 1625
el Kouni, M. H., 1092
Elledge, S. J., 5151
Ellingham, T., 2394
Ellis, L. M., 3964
El-Naggar, A., 5693
El-Naggar, A. K., 1, 2656, 3117, 3604
Elomaa, I., 1334
Elovaara, E., 3305
Elstner, E., 2822
Elwell, M. R., 5251
Ely, K. R., 4446
Emerman, J. T., 617
Emerson, D. L., 603
Emmerich, B., 4157
Emmert-Buck, M. R., 467, 2959, 4995
Emons, G., 817
Emswiler, J. E., 2357
Enami, T., 5238
Endo, G., 1271
Engel, C., 324
Engelman, R. W., 1289
English, J., 1070
Engstrom, P. F., 2789
Enomoto, H., 895
Ensminger, W. D., 3687
Eogan, M., 1643
Epenetos, A. A., 1020, 1060
Epstein, A. L., 2673
Epstein, J. I., 5213
Eraiser, T., 3615
Erdi, A. K., 5823s
Erdi, Y. E., 5823s
Erlichman, C., 1505
Ermak, G., 4594
Escudier, B., 685
Eshhar, Z., 3369
Eshleman, J. R., 5101
Esposito, D. L., 5677
Esteban, J. M., 5929s
Estes, L., 4936
Esumi, H., 4743
Esworthy, R. S., 957
Eto, S., 3592
Evans, A. C., 5664
Evans, D. H., 799
Evans, D. L., 2883
Evans, G. A., 2660
Evans, J. F., 2556
Evans, M. G., 603
Evans, R. M., 3295
Eveno, E., 4325
Everitt, J., 530
Everitt, J. I., 3634
Everley, L. C., 2789
Everson, M. P., 4339
Ewel, A., 5146
Ewen, M. E., 6200
Ewing, C. M., 4813
Eyfjörd, J. E., 646

F

Faa, G., 31
Fabris, C., 111
Facco, M., 6140
Fagarasan, M., 4886
Fagerberg, J., 1824
Fagioli, M., 440
Fair, K. L., 3399, 5180
Fair, W. R., 1441
Fairbrother, K. S., 6035
Falleti, E., 111
Fan, S., 1431, 1649, 2387
Fan, Y., 5054
Fan, Y-J., 5670
Fand, I., 5983s
Fantle, K. S., 3295
Faraoni, I., 6231
Farber, E., 3759
Farr, C. J., 2528
Farrell, P., 4784
Fautsch, M. P., 1994
Fawcett, J., 5628
Fecarotta, E., 2158
Feinberg, A. P., 1836
Feldhoff, P. W., 1707
Feldman, M., 4941
Felix, C. A., 4287
Felix, J. C., 4793, 5693
Felix., C. A., 3237
Felsani, A., 4552
Felton, J. S., 4516
Feng, M., 2024
Fentiman, I. S., 39
Fenton, R. G., 2984
Ferguson, A. T., 2279
Ferguson, R. J., 3531
Fernandes, D. J., 4352
Fernandes-Alnemri, T., 2737, 6045
Fernando, G. J. P., 2635
Ferone, R., 6117
Ferrari, G., 2200
Ferrario, A., 1820
Ferriola, P. C., 530
Ferris, D. K., 5335
Ferroni, P., 111
Fertala, J., 4287
Feuerstein, B. G., 5400
Fey, M. F., 2866
Fibbi, G., 90
Fidler, I. J., 141, 2470, 3123
Fiegl, M., 348, 3854
Figdor, C. G., 5330
Figge, J., 4594
Fijneman, R. J. A., 3179
Filmus, J., 4575
Finan, P. J., 242
Finch, P., 1152
Fine, J. S., 3692
Finn, R. D., 5908s
Fiorucci, G., 3158
Firsching, A., 4957
Fischer, A., 4670
Fischer, E. G., 1629
Fischer, K., 3475
Fishbaugh, P. M., 490
Fishel, R., 5146
Fisher, D. R., 5817s
Fisher, H., 2542
Fisher, J., 4465
Fisher, R. A., 1111
Fishman, C. L., 1444
Fitzgerald, D. J., 3513
Fitzgerald, K. M., 1176
Fiumicino, S., 2569
Fizzotti, M., 1625
Flam, F., 1111
Flavell, R. A., 2253
Flejou, J-F., 1590
Fletcher, C. D. M., 24
Fletcher, J., 3569
Fletcher, J. A., 2968
Fleuren, G. J., 4398
Florence, C. D., 2959
Flores, J. F., 2713, 5531
Florian, C. L., 420
Floridi, A., 4552
Flye, M. W., 5242
Foekens, J. A., 1423
Foglieni, C., 414
Foidart, J. M., 166
Fok, K. S., 5642
Folkman, J., 4230
Fong, K. M., 28, 220, 4268
Fontana, A., 2936
Fontana, J. A., 4446, 4999
Foon, K. A., 1525
Foray, N., 1232
Ford, T. D., 3483
Fornace, A. J., Jr., 1649, 2387
Fornaciari, G., 5911s
Fornwald, L. W., 4875
Forough, R., 2240
Forrest, G. L., 330, 4646
Forrester, K., 6012
Foster, T. H., 1723
Fountain, J. W., 2713, 5531
Fox, J. G., 4391
Franano, F. N., 5714s
Franceschi, D., 5774s
Franceschi, G., 5952s
Francisco, J. A., 3099
Franco, J. L., 3840
François, S., 1355
Frängsmyr, L., 2963
Franke, F., 901, 5424
Frankel, A., 1982
Frankl, H. D., 1224, 2017
Franssila, K., 4471
Frassanito, M. A., 124
Frati, L., 5677
Frattarelli, M., 5952s
Fraumeni, J. F., Jr., 2665
Frawley, B. P., Jr., 5257
Frazer, I. H., 2635
Frazier, K. A., 5288
Frebourg, T., 1839
Freed, J. J., 6189
Freedman, M. H., 78
Freedman, R. S., 5736s
Freeman, M. R., 4140
Freemantle, S. J., 6030
French, D. L., 267
Frenkel, B., 5019
Frenzel, K. R., 386
Freudenheim, J. L., 3483
Fridman, R., 2548
Friedl, P., 4557
Friedlander, D. R., 907
Friedman, C., 1206
Friedman, H. S., 2853, 3803
Friedman, L. S., 2998
Friedrichs, K., 901, 5424
Friend, S., 1643
Frisan, T., 3675
Frisch, S. M., 5551
Fritsch, M., 2583
Fritsche, H., 3060
Fritz, L., 6045
Frödin, J. E., 6092
Frödin, J-E., 1824
Fronza, G., 4658
Frosch, M. P., 3865
Frucht, H., 2789
Frydman, B., 3706
Fryer, A. A., 4237
Fu, K. K., 3055
Fuchs, E. J., 463
Fuchs, H. E., 3803
Fueger, J. J., 557
Fugazzola, L., 5617
Fuggle, S., 510
Fujii, R., 4225
Fujiki, H., 2081
Fujimori, A., 1339
Fujimoto-Ouchi, K., 921
Fujioka, N., 921
Fujita, H., 3228
Fujita, K., 2603
Fujita, M., 3105
Fujita, N., 2186
Fujiwara, H., 4404
Fukao, K., 2756
Fuks, Z., 991
Fukuda, M., 2191, 2334
Fukui, M., 1189
Fukumoto, T., 4196
Fukumura, D., 3752, 4824
Fukushima, K., 1675
Fukushima, S., 1271, 4743
Fukutake, M., 4333
Fukutome, K., 4333
Fukutomi, T., 3521
Fullerton, N. F., 2316
Fumagalli, R., 597
Funakoshi, S., 5335
Funatomi, H., 2007
Funayama, Y., 1075
Furcht, L. T., 2177
Furihata, C., 5670
Furnari, F. B., 1351, 1941
Furukawa, F., 5238
Furukawa, K., 1977
Furukawa, Y., 1828
Furusato, M., 1621, 2998
Furuuchi, K., 3228
Fusco, A., 1787
Futakuchi, M., 4333

G

Gabius, H-J., 2191
Gadbois, D. M., 4651
Gadi, V. K., 3339
Gaetano, C., 2380
Gagnon, M. L., 4140
Gal, A., 4391
Galati, A., 1039
Galili, U., 4168
Galivan, J., 566

** For title of article and coauthors, see listing in Contents of Volume 55 beginning on page i at the end of this index issue.*

Gallardo, J. A., 2140
Galli, M., 2665
Gallinger, S., 2533
Gallo, J. M., 4507
Gallo, M., 1774
Galloway, D. A., 1639, 1763, 2500
Galy, B., 5075
Gambel, A. M., 668
Gamcsik, M. P., 2012
Gamero, A. M., 4988
Gandhi, S. S., 3364
Gandhi, V., 1517
Ganesh, S., 2696
Ganju, R. K., 4120
Gansauge, F., 5499
Gansauge, S., 5499
Gansbacher, B., 1902, 6126
Gansow, O. A., 5908s
Gao, J., 743
Gao, X., 1002
Gao, Z., 3008
Garcia, A. M., 5310
Gardiner, D. S., 2422
Garg, P. K., 5842s
Garkavij, M., 5874s
Garnier, J-M., 2896
Garofalo, A., 414
Garrett, E., 2743
Garrigue-Antar, L., 3982
Garte, S. J., 472, 3757
Garver, R. I., Jr., 3339
Garvin, A. J., 4540
Garza, L., 995
Gasdaska, P. Y., 2542
Gasparini, M., 5764s
Gasparini, V., 111
Gasparro, F. P., 1283
Gass, C., 5161
Gatenby, R. A., 4151
Gatter, K. C., 5191, 5628
Gaudin, C., 685
Gaughan, K., 5342
Gawrisch, K., 518
Gazdar, A. F., 1227, 2511
Gazit, G., 1660
Gearing, A. J., 414
Geerlings, M. W., 5908s
Gehring, M., 5366
Geldhof, A. B., 2730
Geley, S., 348
Gelmann, E. P., 735
Geng, H., 5358
Geng, Y., 4010
Gentile, F. P., 4552
George, J., 1176, 5693
Georges, E., 2029
Geradts, J., 6006
Gerasimov, G., 4594
Gerdes, M. J., 781
Germain, L., 3223
Germino, J. F., 4352
Gersell, D. J., 1922
Gerson, S. L., 4606
Gertz, R. E., 1578
Gesmonde, J., 3982
Gewert, D., 4099
Gewirtz, A., 2275
Ghosh, P., 3840
Giaccia, A. J., 3726, 5512
Giai, M., 2104
Giandomenico, V., 3158
Giardiello, F. M., 1811
Giarola, M., 135
Giavazzi, R., 414, 4729
Gibbs, J. B., 5302
Gibson, M. K., 6012
Gibson, S. L., 1723
Gilboa, E., 1902, 2366
Gill, P. S., 823
Gille, I., 901, 5424
Gilliland, D. G., 3865
Gilliland, L. K., 3099
Gillum, D. R., 1752
Gilmour, R. S., 2978
Gilmour, S., 1680
Gilmour, S. K., 4205
Ginsburg, E., 2591
Giordano, A., 1199, 3992, 5019
Giovanella, B. C., 5637
Giovangrandi, Y., 3735
Gipp, J. J., 4771
Girinsky, T., 3726
Gismondi, A., 4702
Giulianotti, P. C., 5911s
Glas, R., 1911
Glassner, B. J., 2608
Glatfelter, A. A., 4640
Glazer, P. M., 1283, 4420
Gleeson, C. M., 3406
Gleiberman, I., 5276
Glendening, J. M., 2713, 5531
Glenn, S. D., 5921s
Glick, A. B., 2774
Gloghini, A., 3675
Glover, T., 3569
Gnarra, J. R., 4092
Goda, F., 2249
Godleski, J., 505
Godwin, A. K., 2150, 4367, 5536
Godwin, K., 4606
Godwin, K. A., 482
Goepfert, H., 1, 2656
Goetz, A., 2373
Goetz, M., 2325
Goh, H-S., 5217
Goji, J., 5445
Gold, D. V., 1105, 5743s, 5911s
Goldenberg, D. M., 3132, 3825, 5708s, 5721s, 5764s, 5771s, 5777s, 5827s, 5857s, 5899s, 5911s, 5935s, 5946s, 5968s, 5978s
Goldenberg, G. J., 78
Goldfarb, R. H., 4627
Golding, M. H. C., 6084
Goldmacher, V. S., 4079
Goldstein, D. S., 5893s
Goldwasser, F., 2116
Gombart, A. F., 2503
Gomer, C. J., 1820
Gonano, F., 111
Gong, J., 3093
Gong, M., 3790
Gonzales, M. F., 4302
Gonzalez, B., 4646
Gonzalez, F. J., 710, 1052
Gonzalez-Zulueta, M., 4531
Good, R. A., 1289
Goodfellow, P. J., 1922
Goodison, S., 4273
Goodman, H. M., 490
Goodwin, R. G., 4157
Goosenberg, E. B., 2789
Gordon, E. M., 5493
Gordon, J., 4784
Gorelik, E., 4168
Gorunova, L., 3204
Goss, P. E., 2871
Goto, S., 4297
Gotoh, J., 1847
Gotoh, M., 2206
Gottardis, M. M., 3183
Gottesman, M. M., 1086
Goulaouic, H., 3211
Gould, M. N., 979
Govindan, S. V., 5721s
Gown, A. M., 2703
Goyer, R. A., 5265
Grady, H. L., 7
Graeber, T. G., 3726
Graeff, H., 3958
Graff, J. R., 5195
Graham, J. D., 5063
Graham, S., 3483
Gralla, R., 5038
Gralow, J. R., 1099
Gramatzki, M., 5771s
Grant, E. J., 5925s
Granzow, C., 4837
Grasela, D., 3060
Grasso, L., 668
Grattan, M., 2520
Gray, I. C., 4800
Gray, J. W., 3055, 6172
Gray, K. D., 1168
Graziani, G., 6231
Grdina, D. J., 4788
Greco, A., 5617
Greco, M. A., 907
Greco, W. R., 3078
Green, D. M., 5621
Green, M. H. L., 2245
Greenberg, R. E., 6189
Greenberg, R. S., 4899
Greenberger, L., 4214
Gregory, M. L., 3183
Greiner, D. P., 878
Greiner, J. W., 2858, 5925s
Greipp, P. R., 2727
Gresser, I., 6133
Grever, M. R., 862, 2794
Griffin, B. E., 39
Griffin, C. A., 2394
Griffioen, G., 2696
Griffiths, G. L., 3825, 5721s, 5935s, 5968s
Griggs, L. J., 1070
Grignani, F., 440
Grignon, D. J., 1002, 5390
Grigoriadis, A. E., 6244
Grimes, W. J., 3584
Grimm, T., 3254
Grinnell, C. M., 3085
Griswold, M. D., 2431
Grochow, L. B., 810
Groden, J., 1531, 4797
Grohmann, U., 6231
Groom, A. C., 2520
Gross, P. H., 3110
Grosse, Y., 5611
Grottola, A., 498
Groudine, M., 1639
Grove, K. L., 3008
Grumet, M., 907
Grunberger, D., 3576
Gruss, H-J., 4157
Grzybowska, E., 1417
Gsur, A., 3854
Gu, L., 78
Gualandris, A., 4729
Guan, X., 4570
Guan, X-Y., 3380
Guaspari, A., 3803
Gubler, M. L., 3490
Gudas, J. M., 4561
Gudat, F., 2236
Gudkov, A. V., 4023
Gudmundsson, J., 4830
Guengerich, F. P., 799, 5574
Guerrin, J., 4416
Guguen-Guillouzo, C., 3028
Guillard, M., 685
Guillouzo, B. K., 5574
Gulden, M. E., 3022
Gulec, S. A., 5774s
Gum, R., 963
Gumerlock, P. H., 5837s
Gunn, G., 5536
Gunther, E. J., 1283
Günther, H-J., 1160, 1373
Günthert, U., 5424
Guo, H., 434
Guo, M., 5207
Guo, W-X., 823
Guo, X., 3008
Guo, Z., 799
Gusterson, B., 949
Guthrie, B. A., 2528
Gutman, M., 2470, 3123, 3669
Gypen, L., 5589
Gyuris, J., 2972

H

Haag-Zeino, B., 478
Haapasalo, H., 2691
Haber, D. A., 4540
Haberkorn, U., 3318
Hachiya, T., 3444
Hacker, H. J., 3318
Hadaczek, P., 5348
Hafenrichter, D. G., 5242
Hagemeijer, A., 4220
Haggitt, R. C., 4264
Hagiwara, A., 4870
Hagiwara, K., 1448
Hagmüller, E., 1160, 1373
Hahn, F. F., 5251
Hahn, J. F., 3456
Hahn, S. A., 4570, 4670
Hahnel, L., 4416
Haile, R. W., 1224, 2017
Haines, D. C., 3949
Hakomori, S-i., 691, 1869
Hála, M., 348
Halabi, S., 2876
Halbherr, T., 4507
Hale, L. P., 3140
Haley, B., 5161
Halicka, H. D., 444
Hall, D. J., 2883
Hall, F. L., 5493, 6058
Hall, N. R., 242
Hall, S. J., 5151
Hallahan, D. E., 5561
Hallek, M., 4157
Hallenbeck, P., 5283
Hallett, M. B., 5043
Halliday, G. M., 874

** For title of article and coauthors, see listing in Contents of Volume 55 beginning on page i at the end of this index issue.*

Halmos, G., 280
Haluska, F. G., 2713
Hamada, K., 2769
Hamada, S., 5386
Hamaoka, T., 4404
Hamatake, M., 2299
Hamid, R., 4311
Hamilton, A. D., 4243
Hamilton, S. R., 1811, 2910
Hamilton, T. C., 2150, 4367, 4507
Hammarström, S., 2963
Hampson, R., 2304
Hampton, G. M., 2494, 2660, 3003
Han, C-Y., 1224, 2017
Han, G. R., 5603
Hanahan, D., 6071
Hanai, N., 1748
Hanai, S., 2756
Hanaoka, K., 2186
Hanasaki, K., 4425
Hanawalt, P. C., 336
Hand, P. H., 2455, 5957s
Hand, S., 1099
Hanisch, F-G., 4036
Hanley, D., 5899s, 5946s
Hanna, N., 3486
Hannappel, E., 5777s
Hannon, G. J., 1448
Hansen, H. J., 5721s, 5899s, 5935s, 5968s, 5978s
Hansen, M. F., 1963
Hanski, C., 928
Hanski, M-L., 928
Hara, A., 1277, 4053, 4059
Hara, T., 2075
Harabayashi, T., 3228
Harada, A., 921
Harada, M., 6146
Harada, Y., 3421
Haraga, L., 5978s
Haraguchi, M., 1687
Harbaugh, J. W., 6017
Hardcastle, J. D., 3629
Harder, F., 2236
Harding, A. J., 874
Harel, G., 5276
Hariharan, K., 3486
Harjuntausta, T., 2691
Harker, W. G., 1339, 1707, 4962
Harousseau, J-L., 3647
Harpaz, N., 2035
Harper, J. W., 5151
Harpole, D. H., Jr., 51
Harrap, K. R., 2761
Harrington, A., 3483
Harrington, J. A., 1239
Harris, A. L., 510, 5191, 5628
Harris, C. C., 1448, 6012
Harsh, G. R., IV, 999
Hart, A., 975
Hart, A. A. M., 840, 2627
Hart, J., 3050
Hartmann, B. L., 348
Hartmann, D. M., 5276
Hartmann, S., 5257
Harvey, M., 1146
Harvey, S. S., 5063
Hasebe, T., 4743
Hasegawa, K., 1479, 2603
Hasegawa, L., 640
Hasegawa, R., 4333, 4870
Hashimoto, H., 787, 3697, 4029
Hashiramoto, A., 3785
Hasz, D. E., 1321
Hata, J-i., 3438
Hatta, Y., 2266, 5377
Hattmannstorfer, R., 348
Hatton, D. H., 181
Hatzoglou, A., 5632
Hauda, K. M., 2394
Haugen, A., 3996
Haughton, M. F., 2404
Haupt, A., 3085
Haupt, R., 2497
Hauser, H., 115
Havre, P. A., 4420
Havrilesky, L. J., 944
Hawley, R. G., 1139, 2262
Hawn, M. T., 3721
Hay, K., 2533
Hay, M. P., 574
Hayashi, H., 1586
Hayashi, M., 1586
Hayes, J. D., 3305
Hayes, J. S., 3183
Hayes, R. B., 4899
Hayes, R. L., 5536
Haynes, B. P., 1070
He, J., 4833
He, R., 3790
He, Y., 2615
Headon, D. R., 2743
Healy, B. E., 1168
Healy, E., 2910
Heber, D., 2822
Heberer, M., 2236
Hecht, F., 2400
Hecht, S. S., 5580
Hecker, L. M., 4264
Hedborg, F., 5681
Hedley, D. W., 78, 1505
Hedlund, B., 3817
Hedrick, L., 4420, 5545, 5556
Heerdt, B. G., 174
Heflich, R. H., 2316
Heim, S., 3204
Heimfeld, S., 1099
Hein, D. W., 3531
Heinen, C. D., 4797
Heintz, N. H., 2085
Heinz, R., 3854
Hekman, A., 840, 2627
Heldin, P., 3908
Helén, P., 2691
Helin, H., 2691
Helling, F., 2783
Hellman, S., 5561
Hellström, I., 3558
Hellström, K. E., 3558
Helmig, F., 5749s
Henderson, B. E., 3973
Henderson, G., 1655
Hendricks, J., 57
Hendrickse, C., 3537
Hendrix, M., 3747
Hénin, D., 1590
Henkler, F., 6084
Hennig, E. E., 1550
Hennig, Y., 6038
Hensens, O., 2325
Henson, J. W., 999
Herath, J. F., 5408
Herbst, R. A., 2494
Herlyn, M., 2528, 4702
Herman, J. G., 4525, 5195
Hermsen, M. A. J. A., 5465
Hernandez, L., 2338
Herndon, J. E., II, 51
Herr, K. D., 1413
Herrmann, S., 4404
Hersh, E. M., 3584
Herskovic, T., 5899s
Hertel, L. W., 1517
Herzberg, K. T., 360, 369, 376
Herzog, P., 3237
Herzog, T. J., 1922
Hess, A. D., 463
Hess, P., 2569
Heston, W. D. W., 1441
Heubner, K., 1199
Hewitt, S. M., 5386
Heydon, R. T., 544
Heyman, R. A., 3183
Higashiyama, M., 6040
Hilf, R., 1723
Hill, D. E., 2910, 2972
Hill, L. A., 3604
Hill, M. L., 3140
Hill, S. A., 6026
Hilton, J., 1491
Hino, O., 989
Hipfner, D. R., 102, 459
Hirabayashi, K., 4676
Hirabayashi, M., 2651
Hirai, A., 4188
Hirai, K., 3623
Hirai, M., 4188
Hirai, S., 1748
Hirakawa, K., 1379
Hirano, K., 3897
Hirashima, Y., 1847
Hirata, T., 862
Hirohashi, S., 2206
Hirohashi., S., 3395
Hirohata, M., 3478
Hirose, K., 652
Hirose, M., 895, 4870
Hirose, Y., 4053
Hiroumi, H., 1559
Hirte, H. W., 2533
Hirvonen, A., 2981, 3305, 5226, 5230
Hisatake, K., 2651
Hiscox, S., 5043
Hittelman, W. N., 16
Hittmair, A., 3068
Hiyama, E., 3258
Hiyama, K., 3258
Hjelm, A-L., 1824
Hla, T., 3785
Ho, A. D., 1117
Ho, D. H., 307
Ho, I., 1869
Ho, J. J. L., 3659
Ho, J. P., 4214
Ho, S. B., 2681
Ho, V. C., 2070
Hobbs, C. H., 5251
Hobbs, P. D., 4446
Hobisch, A., 3068
Hodge, J. W., 3598
Hoeijmakers, J. H. J., 4325, 6012
Hoffman, R. M., 681
Höfler, H., 3958
Hofstädter, F., 6002
Hogg, D., 2871
Höglund, P., 1911
Hoki, Y., 1339
Hokland, M. E., 4627
Holbrook, D. J., 2837
Holbrook, T., 721
Holder, G. M., 1052
Holgado-Madruga, M., 5536
Holguin, M. H., 1707, 4962
Holland, J. F., 5173
Hollyoake, M., 4784
Holm, E., 1160, 1373
Holmberg, A., 5710s
Holmes, C., 6035
Holt, M., 5180
Holt, M. S., 3399
Holtgreve-Grez, H., 5415
Hölzel, F., 5424
Holzer, U., 623
Holzmayer, T. A., 4023
Honda, K-i., 3623
Hong, W. K., 16, 5507, 5603
Hongyo, T., 2665
Honn, K. V., 698, 1002
Hooijberg, E., 840, 2627
Hoover, R. N., 4899
Hop, W. C. J., 1971
Hopman, A. H. N., 5030
Hoque, A. T. M. S., 4570, 4670
Hori, M., 2756
Horisberger, U., 5805s
Horng, S-F., 1296
Hornick, J. L., 2673
Horrobin, D. F., 5043
Horsman, D., 5133
Hortobagyi, G., 3060
Horton, J. K., 4004
Hoshino, R., 4182
Hosler, M. R., 3237, 4287
Houston, L. L., 5983s
Howe, C., 1010
Hoylaerts, M. F., 4383
Hromas, R., 3610
Hruban, R. H., 2394, 4670
Hsieh, H-H., 1301
Hsieh, J-T., 190, 1215, 2831
Hsu, H-C., 4717
Hsu, N-Y., 1328
Hsu, T. C., 557
Hsu, T-C., 548
Hsueh, Y-M., 1296
Hu, L-T., 330
Hua, Z., 1723
Huang, A., 1758, 4503
Huang, C., 1655
Huang, C-H., 1296
Huang, C-L., 4127, 6040
Huang, D. P., 2039
Huang, H-J. S., 1351, 1941, 2746
Huang, I-P., 1441
Huang, L-R., 4717
Huang, M., 3847
Huang, P., 1517
Huang, R-P., 5054
Huang, S., 3123
Huang, Y-W., 610
Hubchak, S., 2560
Huber, B. E., 4808
Huber, H., 3854
Huber, M., 934
Hudson, E., 1963
Hudson, E. A., 2338
Hudziak, R. M., 5983s

** For title of article and coauthors, see listing in Contents of Volume 55 beginning on page i at the end of this index issue.*

Huebner, K., 4855, 5348
Huennekens, F. M., 478
Huff, V., 2656
Hughes, B. W., 3339
Hughes, L., 5764s
Huijbens, R. J. F., 5330
Hum, S. T., 2789
Humphrey, P. A., 3140
Hung, J., 2511
Hung, M-C., 3890
Hunter, N. R., 3564
Hurr, K., 2656
Hursting, S. D., 3949
Hurta, R. A. R., 4503
Hurteau, J. A., 944
Hussain, M., 2640
Hussain, S. P., 1448
Huston, J. S., 5983s
Hutson, P., 3706
Huynh, H. T., 2225
Hwu, P., 3369
Hyun, H., 5764s
Hyytinen, E., 1334
Hyytinen, E. R., 342

I

Iacobelli, S., 3223
Iannone, R., 4658
Iavarone, A., 4711
Ichikawa, Y., 2756
Ichimura, K., 731
Ide, T., 2734
Idle, J. R., 803, 6035
Ido, A., 3105
Ieki, Y., 4127, 6040
Igaki, H., 3421
Igarashi, K., 2615
Igarashi, Y., 691
Iglehart, J. D., 51
Iguchi, T., 1316
Ihle, J., 623
Iida, J., 2177
Iijima, H., 6146
Iizuka, M., 2166
Iizuka, N., 652
Ikeda, H., 2524
Ikenaga, M., 4268
Ikezaki, K., 1189
Ikezaki, S., 5238
Ikonomidis, G., 4776
Ikuta, T., 4865
Ilett, K. F., 5226
Iliakis, G., 1232
Im, S., 4041, 4047
Imagawa, M., 2651
Imahori, Y., 4225
Imai, Y., 4248
Imaida, K., 4870
Imamura, Y., 3258
Imazawa, T., 5238
Imhof, B. A., 901
Imrich, A. C., 1842
Inagake, M., 2081
Incardona, F., 166
Inga, A., 4658
Ingles, S. A., 1224, 2017
Ingria, F., 6103
Ingvarsson, S., 4830
Innes, C. L., 1763
Inohara, H., 3267
Inoue, H., 3417
Inoue, R., 3521
Inoue, S., 2603
Inoue, Y., 3525
Inskip, A., 4237
Ioachim, H. L., 3664
Iozzo, R. V., 3495
Ip, G., 885
Irie, S., 2418
Irmer, G., 817
Irvine, K. R., 1741
Irvine, R. A., 1937
Isaacs, J. T., 1499, 3517
Isaacs, W. B., 4813, 5195
Ishibashi, T., 2927
Ishida, R., 2299
Ishii, N., 3105
Ishikawa, N., 2075
Ishikawa, T., 658
Ishiko, O., 3623
Islas, A. L., 336
Isola, J. J., 342
Israël, L., 5156
Israel, M. A., 727, 4711
Issa, J-P. J., 4525
Ito, K., 2075
Ito, M., 276
Ito, N., 4333, 4870
Ito, O., 6146
Ito, S., 2603
Ito, Y., 2927
Itoh, K., 3478, 4248
Itoh, S., 787
Itoi, S-i., 4127
Itzkowitz, S. H., 1869, 3364
Iwabuchi, H., 6172
Iwama, T., 3165
Iwamoto, Y., 2927
Iwamura, M., 2418
Iwasaki, H., 1473
Iwasaki, K., 1977
Iwata, N., 276

J

Jackel, K. A., 4079
Jacobs, J., 3223
Jacobson, D. R., 1444
Jaffe, E. S., 1436
Jaffee, E. M., 2394
Jäger, U., 3854
Jagoda, E., 5323
Jain, R. K., 3752, 4611, 4824, 5451
Jallal, B., 3223
James, C. D., 4833
James, S. J., 1894
Jänicke, F., 3958
Jans, D. A., 1014
Jansen, G., 3795
Jansen, J. G., 1875
Janson, E. T., 5801s
Janssen, B., 3085
Janssen, Y. M. W., 2085
Janssen, Y. W. M., 2723
Janz, S., 518, 5012
Jarad, J., 761
Jarman, M., 1070
Jarrard, D. F., 5195
Jarvis, K., 830
Jasty, R., 2576
Jaulin, C., 5520
Jefcoate, C. R., 1780
Jeffers, M., 1963
Jeggo, P. A., 1235
Jelinek, D. F., 3640
Jenkins, G. N., 5459
Jenkins, R. B., 4114, 5408
Jennings, S. B., 2959
Jennings, T., 4594
Jensen, C. G., 792
Jensen, L. C. W., 792
Jensen, P. B., 459
Jessup, J. M., 2191
Jeyaseelan, R., Sr., 4929
Ji, W., 2876
Jiang, H-Y., 2035
Jiang, P., 2988
Jiang, S-Y., 2583
Jiang, W. G., 5043
Jiménez-Cervantes, C., 2603
Jin, C., 3204
Jin, D., 5983s
Jin, H., 1758
Jin, X., 3250
Jin, Y., 3204
Jirtle, R. L., 979
Jochemsen, A. G., 486
Joenje, H., 5465
Johannesdottir, G., 4830
Johanning, F., 1397
Johansson, B. R., 4627
John, C. S., 408, 3022
Johns, D. G., 1306
Johnson, B. E., 1917
Johnson, D. K., 5929s
Johnson, F. B., 294
Johnson, K. R., 4813
Johnson, P. C., 1569
Johnson, R. T., 181
Johnson, S. W., 4367
Johnson, T., 5921s
Johnson., J. P., 3254
Johnston, P. G., 1407
Johnston, S. R. D., 288, 3331
Jonat, W., 4512
Jones, A. B., 6017
Jones, C., 1655
Jones, C. S., 4850
Jones, D., 1531
Jones, L. A., 5693
Jones, M., 5881s
Jones, N. J., 1267
Jones, P., 4237
Jones, P. A., 3742, 4531
Jones, R. J., 463, 1811
Jong, L., 232, 4446
Jordan, V. C., 1780, 2583
Jørgensen, T., 1817
Josephy, P. D., 799
Joshi, V. V., 721
Joslyn, G., 1531
Jothy, S., 2556
Joyner, S. S., 6227
Juarez, J., 963
Judde, J-G., 1431
Judson, I. R., 1070
Juhl, H., 5749s
Juhlin, C., 5794s
Junien, C., 2904
Jurcic, J. G., 5908s
Juretic, A., 2236
Just, K. E., 5415
Juweid, M., 5827s, 5899s, 5935s
Juweid, M. E., 3825, 5946s

K

Kaalhus, O., 1817
Kacinski, B. M., 1578
Kadlubar, F. F., 525, 5226, 5230
Kageshita, T., 1748
Kaido, T. J., 6133
Kajikawa, A., 2769
Kajiyama, G., 2734
Kajstura, J., 2463
Kakar, S. S., 817
Kakegawa, T., 4248
Kakehi, Y., 4182
Kakishita, E., 3192
Kaklamanis, L., 5191, 5628
Kalden, J. R., 5771s
Kälkner, K-M., 5801s, 5805s
Kalland, T., 623
Kallioniemi, A., 1334
Kallioniemi, A. H., 342
Kallioniemi, O-P., 342
Kallioniemi., O-P., 1334
Kalns, J. E., 5315
Kalthoff, H., 5749s
Kamada, S., 354
Kamataki, T., 787
Kamb, A., 2988
Kamei, M., 3444
Kamen, B. A., 847
Kamiya, K., 5670
Kanakaraj, P., 2275
Kanamaru, A., 3192
Kanayama, N., 1847
Kandula, V., 4237
Kane, M., 6063
Kane, M. F., 242
Kane, S. E., 1660, 4073
Kanehira, E., 3897
Kaneko, H., 3192
Kaneko, S., 5283
Kaneko, T., 5459
Kanjilal, S., 3604
Kantor, J. A., 2455, 3598
Kanzawa, F., 2806
Kaplan, D. R., 1798
Kaplan, M. J., 3055
Kaplan, O., 2814
Kaplan, W. D., 4646
Kaplitt, M., 1902
Kapur, V., 3604
Karacay, H., 5968s
Karaharju, E., 1334
Kargman, S. L., 2556
Karhu, R., 342, 1334
Karjalainen, A., 2981, 3305
Karp, J. E., 1255
Karr, J. F., 2455
Karran, P., 2304
Kärre, K., 1911
Kasahara, T., 921
Kasai, N., 2524
Kashiwagi, K., 2615
Kashmiri, S. V. S., 5957s
Kasi, L. P., 5925s
Kaskel, P., 4696
Kasliwal, R., 5921s
Kast, W. M., 2627
Kastury, K., 5348
Katabuchi, H., 5556
Katakami, N., 276
Kataoka, H., 434
Katcher, H., 2988
Kato, H., 3421, 3785, 4676
Kato, T., 4333
Kato, Y., 3105, 3781
Katoh, O., 5687

** For title of article and coauthors, see listing in Contents of Volume 55 beginning on page i at the end of this index issue.*

Katsaros, D., 2104
Katyal, S., 5759s
Katz, R. L., 5925s
Kaufman, D. C., 4465
Kaufmann, S. H., 1255
Kaufmann, W. K., 7, 1763, 2500
Kaur, G., 2794
Kawahito, Y., 3785
Kawai, K., 4581
Kawaichi, M., 4182
Kawaishi, K., 5687
Kawakami, K., 3897
Kawakami, Y., 748, 1559, 3149, 4972
Kawamata, H., 4581
Kawamata, N., 2266
Kawamori, T., 1277, 4053
Kawanami, K., 3860
Kawashima, S., 3897
Kayama, T., 2166
Kaye, A. H., 20, 4302
Kaye, S. B., 2090
Kazarov, A. R., 4023
Kazianis, S., 159
Kazmierczak, B., 2497, 6038
Kehrberg, E., 3817
Keilhauer, G., 1176
Keilholz, U., 4065
Keir, S., 2853
Kelley, J. A., 1306
Kelley, M. R., 5146, 6097
Kelley, S., 3060
Kelloff, G., 1464
Kelloff, G. J., 4311, 4319
Kelly, J., 5106
Kelner, M. J., 4936
Kelsey, K. T., 12, 4910
Kemp, C. J., 3883
Kemp, J. D., 3817
Kenck, C., 5383
Kennedy, M. J., 810
Kennedy, S. C., 5242
Kenny, P., 4278
Kensler, T. W., 4319
Kerbel, R. S., 1139, 4174, 4575
Kern, P. M., 5771s
Kern, S. E., 4570, 4670
Kerr, D. E., 3558
Kersey, J. H., 2346
Kerwar, S. S., 4929
Keski-Oja, J., 1540
Ketterer, B., 3305, 5574
Khalifa, M. M. A., 1092
Khamzina, L., 3615
Khan, S. H., 1458
Khan, W. B., 3431
Khanna, C., 1321
Kharbanda, S., 3242, 4000
Khare, S., 3050, 5257
Khawli, L. A., 2673
Khazaeli, M. B., 3060, 4339, 5881s
Khokha, R., 2520
Khoshkhou, N. I., 3318
Kick, G., 2373
Kida, Y., 4268
Kieback, D. G., 2743
Kiessling, R., 5648
Kihara, A., 71
Kikuchi, K., 2524
Kikuchi, Y., 989
Kikuchi-Yanoshita, R., 3165
Kim, H-R. C., 4520
Kim, S-J., 5545
Kim, Y. S., 2476, 2681, 3659
Kim, Y-H., 5603
Kim, Y-M., 5524
Kim, Y-S., 4549
Kimmey, M. B., 4264
Kimura, A., 4248, 5687
Kimura, G., 6146
Kimura, J., 4333
Kimura, S., 1379, 3785, 4999
Kimura, T., 1748, 3421
Kind, P., 2373
King, M-C., 2998
King, N., 288
King, S. A., 2998
Kinoshita, I., 1559
Kinouchi, T., 2769
Kinsella, T. J., 2800
Kinzler, K. W., 1206, 2910, 2972, 5184, 5187, 5545, 5548
Kirby, M., 5434
Kirsch, I. R., 1917
Kirschling, D. J., 4023
Kishida, T., 4544, 4804
Kishimoto, Y., 2511
Kitadai, Y., 3964
Kitagawa, I., 1221
Kitagawa, T., 2651, 3781
Kitajima, M., 2206
Kitamoto, M., 2734
Kitamura, Y., 354
Kitao, Y., 2081
Kitson, J. L., 4681
Kiviniemi, H., 2660
Kivioja, A. H., 1334
Klagsbrun, M., 4140
Kleanthous, H., 2111
Kleihues, P., 5528
Kleijer, W. J., 4325
Klein, G., 1911, 5648
Klein, J. L., 5774s
Klein, M. W., 5786s
Kleinerman, D. I., 190, 1215, 2831
Kleinman, H. K., 2476
Klein-Szanto, A. J. P., 1347
Kley, N., 743
Klijn, J. G. M., 1423
Klimek, F., 989
Klimstra, D., 1365, 5038
Klivényi, G., 115
Klocker, H., 3068
Knabbe, C., 4512
Knapek, D. F., 1607
Knapp, M. A., 6222
Knapp, R. C., 490
Knick, V. C., 4808
Knight, J. C., 24
Knize, M. G., 4516
Knol, J. A., 3687
Knox, S. J., 5832s
Knox., S. J., 3431
Knuutila, S., 1334
Kobayashi, H., 1847
Kobayashi, K., 3500
Kobayashi, M., 2719, 4404
Kobayashi, R., 6058
Kobzik, L., 505, 4120
Koch, C. J., 995, 6222
Kocher, T., 2236
Kocialkowski, S., 5628
Kodama, K., 6040
Kodama, T., 3258
Koeffler, H. P., 2266, 2503, 2822, 5377
Koeffler., H. P., 3386
Koehler, B., 2173
Koenigsmann, M., 2173, 2212
Koff, A., 1199
Kofler, R., 348
Koga, K., 2615
Koganty, R., 2783
Koganty, R. R., 3364
Kogawa, K., 6210
Kogner, P., 5681
Koh, N., 3500
Koh, T., 4127, 6040
Kohl, N. E., 5302
Köhler, H., 1525
Kohler, M. F., 1168
Kohlhagen, G., 1339
Kohn, E. C., 1856
Kohn, K. W., 228, 1649, 2387
Kohno, K., 1189, 3860, 4293
Kohno, M., 4182
Kohri, K., 4162
Kohsaki, M., 3192
Koi, M., 3721
Koike, K., 6210
Koishihara, Y., 590
Koizumi, T., 1479
Kojiri, K., 1316
Kokura, S., 1617
Koli, K., 1540
Kollmar, H. B., 1160, 1373
Kolodner, R., 6092
Kolodner, R. D., 242, 6063
Kolonias, D., 1633
Komai, M., 3192
Komatsu, K., 1774
Kominami, R., 5670
Komschlies, K. L., 3840
Komuro, H., 721
Kondo, M., 1617, 3785
Kondo, S., 5296, 6166
Kondo, T., 4297
Kondo, Y., 474, 2021
Kondoh, H., 354
Konishi, M., 3165
Konishi, Y., 1271
Konno, H., 836
Kono, K., 5648
Kononen, J., 2691
Konstanty, W., 1687
Koo, L. C., 5354
Kools, P., 1565
Koop, S., 2520
Kopp, A., 4512
Kopp-Schneider, A., 3318
Kopun, M., 4837
Korc, M., 2007
Kornberg, L., 2752
Kósa, K., 4850
Koshiba, K., 2418
Koshikawa, T., 514
Koshy, R., 6084
Kostianovsky, M., 907
Kotani, T., 5283
Kotite, N. J., 5288
Kotomura, N., 5670
Kotts, C. E., 63
Koukourakis, M., 5191
Koumenis, C., 3726
Koupal, L., 2325
Koutcher, J., 1902
Koutcher, J. A., 1248
Kovacs, G., 5383
Kovacs, K., 1613
Kowdley, K. V., 4264
Koyanagi, T., 3228
Kozam, M., 2035
Kozielski, A. J., 5637
Kozloff, M., 5764s
Kozlowski, J. M., 2431
Kraemer, P. M., 4651
Kraft, A. S., 3716
Krainick, U., 1423
Krajewska, M., 4471
Krajewski, S., 4471
Kramer, E. L., 5759s
Kramer, M. D., 1423
Kranenborg, M. H. G. C., 5864s
Krantz, M., 2257
Krasnow, S. W., 6017
Kratzke, R. A., 6006
Kraut, E., 2097
Krauter, K., 1211
Krebs, J., 6045
Kreitman, R. J., 318, 3357
Krenitsky., T. A., 3352
Krett, N. L., 2727
Krigel, R. L., 3286
Kripke, M. L., 3604
Kris, M., 5038
Krishnadath, K. K., 1971
Kristensen, C. A., 1664, 4146
Kristjansen, P. E. G., 1664, 4146
Kröber, T., 4837
Kroesen, B-J., 4409
Kroger, L. A., 5893s
Krüger, S., 4065
Kruh, G. D., 5342
Krull, F., 623
Krutovskikh, V., 629
Krutzsch, H. C., 2140
Krutzsch, M., 3110
Krystosek, A., 3295
Kubo, A., 3438
Kubo, T., 3860
Kubo, Y., 989
Kubota, N., 1774, 2806
Kubota, T., 681
Kubota, Y., 3777
Kufe, D., 4000
Kufe, D. W., 991, 3242
Kuga, T., 6210
Kügler, G., 5424
Kuhn, W., 3958
Kukis, D. L., 878, 5726s
Kumar, A., 685
Kumar, C. C., 5106
Kummermehr, J., 386
Kung, H-F., 5106
Kunkel, T. A., 3721, 5664, 6063
Kuno, K., 921
Kuno, R., 4465
Kunugi, K. A., 2800
Kuo, M-L., 2800
Kuo, S-M., 474
Kura, S., 739
Kurahashi, H., 5007
Kurbacher, C. M., 5276
Kurie, J. M., 5603
Kuroda, K., 1271
Kuroda, M., 2490
Kuroki, M., 1675
Kuroki, T., 3500, 4865

** For title of article and coauthors, see listing in Contents of Volume 55 beginning on page i at the end of this index issue.*

Kurpad, S. N., 3140, 3803, 4375
Kurzawa, H. L., 4980
Kusafuka, T., 5007
Kusano, C., 4196
Kusser, W., 4278
Kuwano, M., 1189, 3860, 4293
Kuwata, K., 2081
Kuzumaki., N., 3228
Kyaw, K., 5354
Kyriakis, J., 3242
Kyritsis, A. P., 3250
Kyrtopoulos, S. A., 6017

L

Labrecque, L. G., 39
Lacombe, L., 1211
Lacombe, M-J. T., 685
Laconi, S., 2560
Laderoute, K. R., 6222
Ladisch, S., 211
LaForgia, S., 4855, 5348
Lai, E., 5540
Laidlaw, J., 743
Lainé, R., 5520
Laird, D. W., 4557
Laissue, J. A., 5805s
Lake, D. F., 3584
Lalwani, R., 1479
Lam, S., 5133
Lambe, C. U., 3352
Lambers, A. R., 5556
Lambert, P. F., 2635
Lambert, S., 166
Lamborn, K. R., 5837s, 5893s
Laminet, A. A., 5983s
Lampe, J., 5528
Lamph, W. W., 3183
Lampidis, T. J., 1633
Lampo, A., 5589
Lamppu, D. M., 6021
Lancillotti, F., 3158
Lander, E. S., 6071
Lang, L., 5323
Lang, N. P., 525, 5226, 5230
Langason, R. B., 3022
Lange, B., 4069
Lange, B. J., 4287
Langouët, S., 5574
Lapidus, R. G., 2279, 4525, 5195
Larkin, E. C., 5893s
Larsen, M., 781
Larson, A., 2494
Larson, J. J., 4696
Larson, S. M., 5756s, 5908s
Larsson, C., 2225
Lasorella, A., 4711
Lasota, J., 5348
Latham, C., 5415
Latres, E., 1211
Lau, C. C., 490
Lau, K-M., 2039
Laub, P. B., 4507
Laughlin, R., 3483
Laurent, A., 3735
Lavin, M., 20
Lawrence, T. S., 3687
Lazar, V., 3735
Lazarides, E., 2325
Lazo, J. S., 474, 2021
Le, N., 5323
Leach, F. S., 5556
Leach, R. J., 3389
Lear, J., 5921s
LeBherz, D., 5925s
LeBien, T. W., 3640
Lechner, K., 3854
Le Coniat, M., 4220
Ledbetter, J. A., 3099
Lee, A. K. C., 5049
Lee, A. S., 1660
Lee, C., 2063, 2431
Lee, D. B., 1224, 2017
Lee, D. C., 3915
Lee, E., 5377
Lee, E. R., 1224, 2017
Lee, E. Y-H. P., 1146
Lee, F., 307
Lee, H. Y., 5545
Lee, J. G., 4264
Lee, J. J., 16, 237, 5507
Lee, J. S., 5507
Lee, J. T., 5323
Lee, M-H., 1211
Lee, P., 3847
Lee, S. J., 4800
Lee, S. Y., 2044
Lee, S-H., 2186
Lee, W. M. F., 4980
Lee, W-J., 1428
Lee, Y. S., 1075
Lee, Y. Y., 2266
Leek, R., 5191
Lees-Miller, S. P., 5200
Legerski, R. J., 5025
Legrand, C., 166
Legrand, Y., 166
Lehmann, A., 5656
Lehmann, A. R., 968
Lehto, V-P., 5595
Leichman, C. G., 1407
Leichman, L., 1407
Leigh, B. R., 3431
Leippe, D. M., 2635
Leitner, P. P., 603
Lemoine, N. R., 1129
Lempka, T., 1401
Lengyel, E., 963
Lenz, H-J., 1407
Leof, E. B., 1994
Le Paslier, D., 1355, 5504
LeRiche, J., 5133
Lerman, M. I., 4544
Leroux, J-P., 3028
Lescoe, M. K., 5146
Lester, D. S., 518
Letterio, J. J., 2380
Leung, S-o., 5721s, 5899s, 5935s, 5968s, 5978s
Leunig, M., 3752
Leupolt, E., 3475
Levander, O. A., 4516
Levedakou, E. N., 7, 1763, 2500
Levesque, M., 1603
Levesque, M. A., 2104
Levi, H., 5764s
Levin, B., 237
Levin, D. B., 4278
Levin, N. A., 3055
Levy, G. N., 3043
Levy, R., 5642
Lewalle, J. M., 166
Leweling, H., 1373
Lewis, M. D., 5310
Li, C. J., 3712
Li, C-W., 3286
Li, C-Y., 1842
Li, D., 2968
Li, G., 2070, 4520
Li, J., 5540
Li, J. J., 4347
Li, L-J., 3873
Li, M., 5726s
Li, R., 211
Li, S., 663, 3992
Li, S. A., 4347
Li, T., 4561
Li, W. S., 4586
Li, X., 444, 3093, 4391
Li, X-S., 4999
Lian, J. B., 5019
Liang, J., 6244
Liaw, K-F., 1296
Liber, H. L., 12
Libertin, C. R., 1696
Lichter, P., 3475
Lidereau, R., 4416
Lieber, M. M., 4114, 5408
Lieber, M. R., 1774
Liebmann, J., 4465
Liem, A., 2635
Liesch, J., 2325
Liff, J. M., 4899
Lillemoe, K. D., 4899
Lillington, D. M., 4220
Lilly, M., 3716
Lim, J. F., 1385
Lim, Y-P., 1152
Lin, B. K., 1224, 2017
Lin, H., 1941
Lin, H. J., 1224, 2017
Lin, H-K., 4105
Lin, J. S-N., 1296
Lin, J-j., 5106
Lin, J-R., 307
Lin, J-T., 1428
Lin, S-H., 190, 1215, 2831
Lin, Y., 4174
Lin, Y-Z., 5242
Linardopoulos, S., 5168
Lincoln, C. E., 6006
Lindberg, R. A., 2528
Lindblom, A., 6092
Lindenboim, L., 1242
Linder, D., 5276
Lindgren, L., 5874s
Lindstedt, B. A., 3996
Lindstrom, M. J., 2800
Linehan, W. M., 2959, 4995
Ling, C. C., 5207
Ling, V., 2029
Linge, C., 4099
Link, K. H., 5499
Linker-Israeli, M., 2822
Linkov, I., 1365
Linn, S., 5085
Linnainmaa, K., 2981
Lintott, L. G., 5200
Liotta, L. A., 467, 1856, 2140, 2959, 3954
Lipford, J., 242
Lipford, J. R., 6063, 6092
Lippman, M. E., 2448
Lippman, S. M., 16, 5507
Lipschultz, C., 4465
Lipsky, P. E., 1732
Lisboa, B-W., 5424
Little, J. B., 1842
Litvinov, S. V., 4398
Litwack, G., 548, 2737, 6045
Litwin, S., 2789
Liu, B., 1206, 5548
Liu, C., 4079, 5054
Liu, E. T., 2752, 3969
Liu, H., 4520
Liu, K. J., 2249
Liu, K. J-M., 761
Liu, L., 4606
Liu, P. C., 2998
Liu, S., 5983s
Liu, S-H., 3008
Liu, T., 4339, 5881s
Liu, T-J., 1, 3117
Liu, X., 5173
Liu, X. F., 1385
Livant, D. L., 5085
Livingston, P. O., 2783
Livingston., P. O., 3364
LiVolsi, V. A., 2998
Lizard-Nacol, S., 4416
Ljunggren, H-G., 1911
Lloyd, K. O., 3364
Lo, K-W., 2039
Lobel., P., 3424
LoBuglio, A. F., 1397, 3060, 4339
Lo Coco, F., 1625
Loda, M., 3509
Loe, D. W., 102
Loeffler, M., 324
Loew, M. H., 5823s
Loftus, B., 975
Logan, T. J., 2883
Loganzo, F., Jr., 2713
Logsdon, D. L., 5621
Lois, A. F., 4010
Lombardo, A., 4446
London, S. J., 6035
Long, L., 1006
Long, P. P., 2394
Longenecker, B. M., 2257, 2783, 3364
Longnecker, M. P., 1224, 2017
Longo, D. L., 3840, 5335
Longo, W. E., 2232
Look, A. T., 721, 4664
Look, M. P., 1423
Lopatina, N. G., 1894
Lord, E. M., 6222
Lord, H. L., 799
Lorico, A., 4352
LoSardo, J. E., 3490
Losi, L., 498
Losman, M. J., 5721s, 5968s, 5978s
Lotan, D., 232, 2191
Lotan, R., 16, 232, 2191, 5507, 5603
Lotze, M. T., 124
Lou, Z., 4855
Louie, R., 3237
Louis, D. N., 999
Lovric, J., 4432
Lu, B., 781
Lu, D., 1397
Lu, M., 1117
Lu, S-J., 1139
Lubinski, J., 5348
Lucia, M. S., 5621
Ludwig, H., 3854
Lui, V. W. Y., 5222

** For title of article and coauthors, see listing in Contents of Volume 55 beginning on page i at the end of this index issue.*

Lukas, J., 949, 4818
Luna, M. A., 2656
Luna, M. C., 1820
Luo, W., 190
Luostarinen, L., 3305
Lupton, J. R., 2293
Lutchman, M., 2270
Lutterbaugh, J., 5545
Luzzi, K., 2520
Luzzio, M. J., 603
Lyftogt, C., 2681
Lynch, H. T., 2448, 5545

M

Ma, C-c., 5354
Ma, L-W., 2620
Ma, Y-Y., 6172
Ma, Z., 5302
Maass, H., 5424
Maass, N., 2537
Maccario, R., 3835
MacConnell, P. B., 267
MacDonald, I. C., 2520
MacDougall, J. R., 4174
Macey, D. J., 5925s
Mach, J-P., 83
Maciag, T., 2240
Mack, P. C., 5837s
Mackay, W., 2608
Mäcke, H. R., 46
Mackensen, D. G., 4611
Mackie, J. E., 102
MacLachlan, T. K., 1199, 3992
MacMaster, J. F., 2357
Macoska, J. A., 5390
Macosko, H. D., 3692
MacPhee, D. G., 5489
Madersbacher, S., 3346
Maekawa, T., 1379
Maesawa, C., 891, 1933
Maggioni, A., 4702
Magrassi, L., 597
Magrath, I., 1431
Mahmood, U., 1248
Mai, M., 921, 3263
Maier-Borst, W., 115
Majumdar, A. P. N., 5358
Maki, C. G., 1842
Makino, M., 5459
Makino, R., 2166
Makino, Y., 4293
Makita, H., 4059
Maklansky, J., 1869
Makridakis, N., 3973
Malaise, E. P., 1232
Malapetsa, A., 3933
Malecka-Panas, E., 5358
Malik, A. B., 5736s
Malipiero, U., 2936
Malitschek, B., 159
Malspeis, L., 2794
Man, S., 1139
Mancini, J. A., 2556
Mandahl, N., 3204
Mandelli, F., 1625
Manenti, F., 498
Manenti, G., 135, 3988
Mang, T. S., 3078
Mangold, K. A., 2560
Mangum, J., 530
Mani, S., 5173
Mann, B., 1883
Manne, V., 3569
Mannermaa, A., 2660
Mannori, G., 4425
Manseau, E. J., 376
Mansel, R. E., 5043
Manz, H. J., 4752
Manzoli, L., 2978
Mao, J. T., 3847
Mao, L., 2995, 4525, 6200
Maraveyas, A., 1020, 1060
Marberger., M., 3346
Marcelli, S., 2853
Marcus, P. M., 4906
Mareel, M. M., 4722
Maret, A., 5075
Margison, G. P., 6231
Mariani, G., 440, 5911s
Mariani-Costantini, R., 5677
Marincola, F. M., 3149, 4972
Maris, J. M., 2053, 4664
Mark, E., 4910
Mark, S. D., 4516
Markowitz, A., 5899s, 5946s
Markowitz, S., 5101, 5184, 5548
Markowitz, S. D., 5545, 5548
Marks, J. R., 51
Markwart, S., 5085
Marland, G., 5330
Marquez, M., 5710s
Marra, G., 3721
Marras, S., 31, 1565
Marsac, C., 3028
Marshall, J. R., 3483
Martelli, A. M., 2978
Marth, C., 2135
Martin, C., 1839
Martin, E. A., 544
Martin, J-J., 1547
Martin, P. J., 2352
Martini, N., 5038
Martin-Padura, I., 414
Martinsson, T., 5681
Martuza, R. L., 4752
Marukawa, O., 3444
Maruya, A., 3873
Maruyama, I., 4196
Prince Masahito, 3781
Masamune, A., 691
Masciulli, R., 440
Masini, E., 5272
Mason, K. A., 3564
Mass, M. J., 1039
Massague, J., 1211
Masse, E. M., 360, 369
Masucci, M. G., 3675
Masuho, Y., 1586
Masui, T., 399
Matei, C., 1902
Mathew, S., 1211
Mathis, M., 5545
Matrisian, L. M., 1401
Matsubara, K., 4549
Matsuda, I., 836
Matsuda, T., 1271
Matsui, T., 276
Matsui-Yuasa, I., 1271
Matsumori, Y., 276
Matsumoto, K., 1798, 2380, 4225
Matsumoto, L., 4073
Matsumoto, M., 1310
Matsumoto, T., 5296
Matsumoto, Y., 3521
Matsumura, Y., 4273
Matsunaga, K., 6146
Matsuno, S., 1828
Matsuo, M., 4780
Matsuoka, Y., 1675
Matsushima, K., 921
Matsushima-Hibiya, Y., 5370
Matsushita, Y., 4196
Matsuura., Y., 3258
Matta, K. L., 1473
Mattei, M-G., 2896
Mattes, M. J., 3132, 5733s
Matteucci, A., 2978
Matthes, S., 5921s
Mattocks, K. M., 4079
Mattson, K., 2981
Matys, R., 115
Mauceri, H. J., 5561
Maung, K., 2528
Maury, C., 6133
Małusecka, E., 1417
Mayer, J. R., 566
Mayordomo, J. I., 124
Mayr, G. A., 2410
Mazo, I. A., 4023
Mazzini, G., 597
McBride, L., 781
McCabe, B. J., 1741
McCague, R., 1070
McCahill, L., 2984
McCarthy, J. B., 2177
McCartney, J. E., 5983s
McCauley, D., 5759s
McClain, C. D., 668
McCloskey, D. E., 3233
McCue, P., 5348
McDevitt, T. M., 1458
McDonnell, T. J., 3117, 5386
McDowell, M. L., 6152
McFerran, N. V., 3772
McGarrity, G., 5283
McGee, J. O'D., 294
McGill, J. R., 3380
McGovern, P. E., 2998
McGregor, A. D., 1267
McGuigan, J. A., 3406
McIntosh, J., 4237
McKenna, N. J., 2743
McKenna, W. G., 995
McLachlan, J. A., 1168
McLaughlin, J. P., 3598
McLaughlin, P. J., 4085
McLendon, R. E., 3140, 3803
McMahon, M., 2048
McManus, M. E., 1052
McMillan, T. J., 1235
McMorris, T. C., 4936
McPherson, J. P., 78
McQueney, P. A., 2325
McQuillan, A., 3933
Meares, C. F., 878, 5726s
Medrano, E. E., 4041, 4047
Megati, S., 3543
Megosh, L., 4205
Meijer, C. J. L. M., 5465
Meijne, A. M. L., 2177
Meir, G., 153, 1956
Meissner, H., 3847
Meko, J. B., 4765
Melamed, M. M., 444
Melana, S., 5173
Melder, R. J., 4824
Melief, C. J. M., 840, 2627
Mellerin, M. P., 1355
Mellstedt, H., 1824
Melmed, S., 1613
Meltzer, P. S., 3380, 3790, 3954, 4640
Meltzer, S. J., 2035
Mendonca, H. L., 6222
Mendoza, J., 5637
Mendrola, J., 4855
Menichini, P., 4658
Menon, A. G., 4696
Menzin, A. W., 2998
Merad-Boudia, M., 3028
Mercer, W. E., 668, 2883
Merchant, E., 242
Mercola, D., 5054
Meredith, R., 5881s
Merighi, A., 498
Merino, M. J., 467, 4995
Merlo, A., 2995, 4525, 6200
Merryman, J., 3504
Mertens, F., 3204
Mesnil, M., 629
Messer, G., 2373
Metcalf, D., 3462
Metz, M. Z., 4073
Meuth, M., 1531
Mew, D. J. Y., 1227
Meyer-Bolte, K., 2497
Meyers, D. E., 1321
Meyers, M. S., 360, 369
Meyn, M. S., 5991
Mezzina, M., 4325
Michalek, A. M., 3483
Michalides, R., 975
Michalska, A. E., 2021
Michejda, C. J., 2338
Miers, L., 5726s
Miers, L. A., 878, 5837s
Miettinen, H., 2691
Migita, K., 2075
Mihich, E., 3462
Miki, T., 5342
Miklavčič., D., 3450
Mikoshiba, K., 4302
Mikuta, J. J., 2998
Milani, A., 6140
Milas, L., 3564
Milbrandt, J., 1792
Milenic, D. E., 2858, 5957s
Millán, J. L., 4383
Millenbaugh, N. J., 5315
Miller, B. J., 1894
Miller, C. W., 2266, 5377
Miller, D. C., 907
Miller, D. W., 3456
Miller, F. R., 4536
Miller, J., 2253
Miller, R., 1176
Miller, R. G., 1982
Miller, S. J., 1111
Miller, W. H., Jr., 5908s
Milliken, J. S., 5063
Millis, K. K., 2012
Mills, G. B., 1982
Mills, G. Q., 5764s
Mills, J. J., 979
Mills, N. E., 1444
Milross, C. G., 3564
Mimnaugh, E. G., 4623
Mimori, K., 3417

* *For title of article and coauthors, see listing in Contents of Volume 55 beginning on page i at the end of this index issue.*

Mineishi, S., 1517
Minna, J. D., 1227
Minoletti, F., 135, 2400
Mintz, B., 4681
Miozzo, M., 135
Mirick, G. R., 878
Mirimanoff, R-O., 83
Mironov, N., 3513
Mirski, S. E. L., 2129
Mitchell, D., 4041
Mitchell, D. L., 181, 6152
Mitelman, F., 3204
Mithal, N. P., 1235
Mitrovski, B., 1505
Mitsuhashi, Y., 4575
Mitsui, M., 5238
Miura, K., 1828
Miura, M., 663
Mivechi, N. F., 5512
Miwa, M., 2756
Mixon, A., 3149
Miyadera, K., 1687
Miyakawa, A., 3438
Miyake, M., 4127, 6040
Miyaki, M., 3165
Miyamoto, T., 1586
Miyoshi, I., 5377
Mizoguchi, H., 3386
Mizutani, S., 3192
Mizutani, Y., 590
Moalli, P. A., 2727
Moan, J., 2620
Mobashery, S., 2548
Mock, B. A., 1181
Modlin, R., 3847
Moelling, K., 4432
Moerman, P., 1565
Moesta, K. T., 3078
Moffat, F. L., 5774s
Möhler, T., 4065
Mohn, G. R., 1875
Moisan, J. P., 1355
Mok, S. C., 2169
Mok, S. C-H., 490
Molea, N., 5911s
Molina, F., 4658
Molinari-Tosatti, M. P., 4729
Momozaki, N., 3840
Mondellini, P., 5617
Monden, Y., 2769
Mong, S., 307
Monne, M., 1603
Montagna, D., 3835
Montaldo, P. G., 853
Montejano, Y. D., 478
Montgomery, K., 1211
Montini, E., 3835
Montoya, M., 4936
Moody, T. W., 3022, 4886
Moore, D. C., 4014
Moore, D. E., 874
Moore, D. F., 2789
Moossa, A. R., 681
Mora, P., 4957
Moran, M., 1176
Moran, R. G., 6030
Morandi, V., 166
Mordenti, J., 63
Moreau, A., 1355
Moreau, V., 1839
Morel, F., 5574
Morello, V., 6103
Morgan, D., 1680
Morgan, E. S., 376
Morgan, M. A., 2998
Morgenthaler, J-J., 46
Mori, H., 1277, 4053, 4059
Mori, K., 921
Mori, M., 3417
Mori, N., 3592
Mori, T., 2245
Morikawa, H., 3444
Morikawa, T., 4297
Morimoto, K., 1221
Morimura, T., 6166
Morisue, K., 1479
Morita, M., 1316
Moritz, T., 2608
Moriya, S., 3228
Morosetti, R., 2266
Moroson, B. A., 566
Moroson, H., 3664
Morris, J., 3610
Morris, T. M., 3629
Morris, V. L., 2520
Morrison, P. T., 242
Morsberger, L. A., 2394
Mortarini, R., 414, 4702
Morton, D. M., 2596
Morton, J. D., 5888s
Morton, R. A., 4813
Mosca, F., 5911s
Moscatello, D., 3140
Moscatello, D. K., 4375, 5536
Moschel, R. C., 4085
Moscow, J. A., 3790
Moselen, J. W., 574
Moser, A. R., 4479
Moses, H. L., 1452, 3928
Moshier, J. A., 5358
Moskaluk, C. A., 4570
Mossman, B. T., 2085, 2723
Motykiewicz, G., 1417
Moustafa, A-E. A., 1853
Mrozek, M., 3318
Mu, J., 4404
Mueller, B. M., 1629, 2352
Mueller, R. A., 2920
Mueller-Klieser, W., 4757
Mukai, S., 3785
Mukaida, N., 921
Mukerjee, S., 1525
Mukhopadhyay, D., 6161
Mulcahy, R. T., 4771
Mulder, A. H., 1971
Mulder, K. M., 2056
Mulder, T. P. J., 2696
Müllauer, L., 3228
Müller, H., 949
Müller, J. R., 5012
Muller, M. T., 2097
Müller, R., 817
Müller, T., 1927
Müller-Hermelink, H. K., 4283
Mumby, M. C., 774
Mundy, G. R., 1989, 3551
Munn, D. H., 4339
Muñoz-Antonia, T., 2253, 3982
Murai, T., 1271
Murakami, A., 1379, 1559, 4865
Murakami, S., 3592
Murakami, T., 3093
Murakami, Y., 3258
Murakami, Y. S., 3389
Murakami-Murofushi, K., 3777
Muramatsu, H., 6210
Muramatsu, M., 2651, 4073
Muramatsu, T., 1792
Murata, F., 1675
Murata, K., 3105
Murphy, R. F., 482
Murphy, R. M., 3763
Murphy, W. J., 5335
Murphy-Boesch, J., 3286
Murray, D. M., 4808
Murray, J. L., 3060, 5925s
Muschel, R. J., 995
Mutch, D. G., 1922
Muto, M. G., 490
Mutter, G. L., 5080
Myeroff, L. L., 5545, 5548
Myers, C. E., 2122
Myers, M., 1020

N

Nabeshima, K., 434
Nagai, H., 1752, 4549
Nagamachi, Y., 1473
Nagao, M., 774, 3521
Nagar, C., 6103
Nagasato, A., 3897
Nagasawa, H., 1842
Nagasu, T., 5310
Nagatake, M., 514
Nagataki, S., 2075, 3105
Nagel, S., 2866
Naglich, J. G., 743
Naguib, F. N. M., 1092
Nagy, J. A., 360, 369, 376
Naito, M., 2186
Naito, Y., 1617
Nakabayashi, H., 5283
Nakabeppu, Y., 2927
Nakagawa, T., 787, 1479
Nakagawara, A., 1792
Nakai, K., 774
Nakajima, M., 767
Nakamaki, T., 2266
Nakamura, H., 5445
Nakamura, K., 739, 3438
Nakamura, S., 836
Nakamura, T., 434, 3012
Nakamura, Y., 895, 1828, 4053
Nakanishi, H., 399
Nakanishi, T., 2734
Nakano, K., 4127
Nakao, K., 3105, 3444
Nakao, M., 4248
Nakashima, E., 921
Nakashima, J., 4881
Nakashio, R., 2734
Nakata, K., 3105
Nakata, S-i., 3623
Nakatsuru, Y., 658
Nakayama, E., 1977, 4780
Nakazawa, A., 652
Nakazawa, H., 3513, 5528
Namba, H., 2075
Nanbara, S., 3417
Nannmark, U., 4627
Nanri, H., 4293
Narayanan, V. L., 862
Narimatsu, H., 1473
Narisawa, S., 4383
Narod, S., 2225
Narula, S. K., 3692
Natali, P. G., 1787
Natarajan, A. T., 3412
Natsugoe, S., 4196
Naumann, P. W., 3817
Navidi, W. C., 6035
Navon, G., 2814
Nawrath, M., 4432
Neckers, L., 4623
Neeman, M., 153, 1956
Negendank, W. G., 3286
Negrini, M., 1752, 2904, 3003, 3988, 6053
Neill, J. D., 817
Nelkin, B. D., 2048
Nelli, E. E., 4729
Nelson, C. M., 3085
Nelson, G. B., 1039
Nelson, J., 3772
Nelson, R. M., 4425
Nemoto, T., 3483
Neoptolemos, J. P., 4800
Neri, A., 3490
Nerurkar, P. V., 3043
Nesbitt, J. C., 5603
Nesland, J. M., 2620
Nesnow, S., 1039
Netti, P. A., 5451
Neumaier, M., 5929s
Nevalainen, J., 1334
Newby, J., 3331
Newcomb, E. W., 2044
Newcomb, P. A., 4906
Newman, R. A., 307
Newsham, I., 2660
Newsholme., E. A., 3278
Ng, S-W., 6109
Nguyen, D., 3250
Nguyen, H., 4561
Nguyen, P., 4623
Nguyen, T., 4531
Nichols, K. E., 4540
Nichols, M. A., 6058
Nichols, P., 1660
Nickel, P., 4957, 5161
Nicolson, G. L., 4458
Nicotra, M. R., 1787
Nieborowska-Skorska, M., 2275
Niehans, G. A., 2681, 6006
Nielsen, B. S., 459
Nieroda, C. A., 2858
Niethammer, D., 623
Niitsu, Y., 6210
Nijhof, W., 324
Nikaido, O., 2245, 4325
Niknejad, K., 4140
Nikula, K. J., 5251
Nikula, T. K., 5908s
Niles, R. M., 4446
Nilsson, B., 5868s
Nilsson, R., 5874s
Nilsson, S., 5710s, 5794s, 5801s, 5805s
Ninomiya, Y., 5670
Nishi, S., 5370
Nishi, T., 3438
Nishiguchi, S., 3500
Nishihara, S., 1473
Nishihori, Y., 6210
Nishii, H., 1621
Nishikawa, A., 5238
Nishikawa, M., 774
Nishikawa, R., 1351, 1941

** For title of article and coauthors, see listing in Contents of Volume 55 beginning on page i at the end of this index issue.*

Nishimura, J., 3192
Nishimura, M. I., 748, 1741
Nishimura, N., 5445
Nishimura, R., 1479
Nishimura, S., 1310, 1316
Nishio, K., 1075, 2806
Nishioka, M., 3781
Nishisho, I., 5007
Nishizawa, M., 5370
Niskanen, E., 4471
Nitiss, J. L., 2299
Nitta, Y., 5670
Niwa, O., 5670
Noble, M. D., 420
Noble, P. B., 4557
Nobori, T., 4010
Noda, T., 354
Noe, D. A., 810
Noguchi, K., 1310
Noguchi, M., 3478
Noguiez, P., 5520
Noma, T., 652
Nomoto, K., 6146
Nomura. A., 562, 2111
Nomura, H., 3263
Nomura, K., 2651, 3781
Noordzij, J., 2035
Nordenskjöld, M., 6092
Nordling, S., 4471
Nørrgren, K., 5874s
Norris, N. A., 3099
Norton, J. A., 4765
Notario, V., 3016, 4240
Noteborn, M. H. M., 486
Nöthiger, F., 2866
Nouvet, G., 5133
Novak-Hofer, I., 46
Nowak, B., 1517
Nowotny, H., 3854
Noz, M. E., 5759s
Nuara, R., 6103
Nuijens, A., 63
Numa, F., 4676
Numoto, M., 5670
Nuñez, G., 2507, 2576
Nuovo, G. J., 267
Nurminen, T., 3305
Nürnberg, W., 4432
Nurse-Finlay, S. O., 3078
Nussler, A. K., 5499
Nuwaysir, E. F., 1780
Nyce, J. W., 4741

O

Oak, J. N., 799
Obama, H., 4196
Oberberg, D., 2173, 2212
berg, K., 5801s
Oberley, T. D., 2490, 4347
O'Brien, T., 510
O'Brien, T. G., 4205
Ochoa, A. C., 3840
O'Connor, P. M., 228, 1431, 1649, 2387
Oda, H., 658
Oda, S., 3592
Odom-Maryon, T., 5929s
O'Dwyer, P. J., 4367, 4507
Oelmann, E., 2173, 2212
Oestreicher, M., 2866
Oettgen, H. F., 2783
Ogasawara, H., 774, 1075
Ogasawara, S., 891
Ogata, S., 1869, 3364
Ogawa, K., 4870
Ogawa, O., 4182
Ogiso, Y., 3228
Ogita, S., 3623
Ogiu, T., 3777
Ögmundsdottir, H. M., 646
Ogorek, D., 928
O'Grady, L. F., 5916s
Oguchi, Y., 6146
Ohannesian, D. W., 2191
O'Hara, J. A., 2249
Ohashi, C., 129
Ohe, Y., 2334
Ohga, T., 3860, 4293
Ohgaki, H., 5528
Ohira, T., 1075
Ohl, S., 3475
Ohlsson, R., 1111
Ohmori, Y., 4225
Ohnishi, M., 4053, 4059
Ohnishi, Y., 2769
Ohori, M., 2418
Öhrvall, U., 5794s
Ohsugi, Y., 590
Ohta, H., 691
Ohta, M., 2904, 5348
Ohta, S., 1748
Oikawa, T., 3777
Ojeifo, J. O. 2240
Oka, H., 4182
Oka, M., 652
Okada, A., 5007
Okada, H., 1310
Okada, K., 1977
Okada, S., 5007
Okada, Y., 4182
Okada., Y., 3263
Okamoto, A., 1448
Okamoto, M., 4581
Okamoto, T., 4162, 4293
Okayasu, R., 1232
Okita, K., 1828
Okumura, K., 6210
Okumura, Y., 1774
Okura, A., 1310, 1316
Oldfield, E. H., 1306
Olerud, C., 5805s
Oliff, A., 5302
Oliner, J. D., 2910
Oliver, J., 5038
Olivero, M., 1129
Olopade, O., 493
Olopade, O. I., 984
Olsen, J. H., 294
Olson, J. J., 4833
O'Malley, B. W., Jr., 1080
Omay, S. B., 774
Omura, K., 3897
O'Neill, G. P., 2556
Ono, M., 1189, 4293
Ono, T., 1748, 2166
Onozaki, K., 1586
Oosterwijk, E., 5864s
Oosterwijk-Wakka, J. C., 5864s
Oppenheim, H., 6196
Opperman, H., 5983s
Orcutt, M. L., 4804
Orian, J. M., 4302
Oridate, N., 5603
Orita, S., 5445
Orlando, L., 6231
Orloff, M., 3504
O'Rourke, K., 4676
Orr, R. B., 847
Orth, K., 5545
Ortmann, O., 817
Osada, H., 514, 5354
Osaka, G., 63
Oshima, H., 2719
Oshima, M., 2719
Oshiro, E. M., 1306
Oshita, F., 2334
Otani, S., 1271, 3500
Otori, K., 4743
Otsuki, T., 1436
Otter, B. A., 3543
Ottini, L., 5677
Ouafik, L'H., 5632
Oue, T., 5007
Overkamp, W. J. I., 3412
Owens, D. M., 3171
Owens, L. V., 2752
Owens, U. E., 1289
Oya, K., 2081
Oyasu, R., 4581
Ozaki, T., 895
Ozeki, H., 2603
Ozols, R. F., 2150, 4367, 4507

P

Pääkkö, P., 5595
Pacciarini, M. A., 2090
Pache, L., 3958
Pacini, F., 5617
Padavic-Shaller, K. A., 3286
Padin, C. J., 1168
Paff, M. T., 3352
Paggi, M. G., 4552
Paik, C. H., 5323
Paik, S., 2240
Pak, A. S., 885
Palcic, B., 5133
Palli, D., 2665
Palmirotta, R., 5677
Palmiter, R. D., 3915
Pamukcu, R., 3110
Pan, B-C., 1328
Pan, S-s., 330
Pan, W-H., 1301
Pan, Z-K., 4776
Panasci, L., 3933
Pandey, P., 4000
Panozzo, J., 1696
Pantellias, G. E., 1232
Panzica, M., 1152
Panzica, R. P., 1092
Paoletti, R., 597
Paonessa, G., 2200
Papadimitriou, C. A., 2173
Papadopoulos, E. B., 5908s
Papadopoulos, N., 1206
Papadopoulos, P., 34
Papadopoulos, T., 4283
Parangi, S., 4230, 6071
Paranka, N. S., 3110
Pardee, A. B., 3712
Pardoll, D., 4776
Parekh, H. K., 5203
Park, D., 2266
Park, J. E., 6200
Park, J-G., 5545
Park, K., 5545
Park, P. G., 3504
Park, S., 6021
Park, T-W., 4793
Parker, E. J., 5540
Parker, W. B., 3339
Parkins, C. S., 6026
Parmiani, G., 2200, 3374
Parolini, S., 4729
Parr, R. L., 1707, 4962
Parry, D., 2988, 5168
Parsons, J. A., 4347
Parsons, J. C., 3078
Parsons, R., 5545, 5548
Partis, R. A., 2920
Pasricha, P. J., 1811
Pass, H. I., 1227
Passaniti, A., 399, 2920, 4210
Passos-Coelho, J. L., 810
Pastan, I., 71, 318, 1086, 5323
Pastan., I., 3357
Pastorcic, M., 4892
Pastorino, U., 135
Patai, B. L., 3197
Patenia, R., 5736s
Paterson, J., 4760
Paterson, Y., 4776
Pathak, D. N., 3012
Paul, S., 5342
Paules, R. S., 7, 1763, 2500
Pauly, G., 2338
Pauly, J. L., 253
Paunesku, T., 4788
Payne, P., 5133
Peace, D. J., 2984
Pearson, A. D. J., 803
Pedeutour, F., 2400
Pedevilla, M., 3346
Peehl, D. M., 3726
Peek, R. M., 2111
Peer, C. W., 5621
Pegg, A. E., 2853, 4085
Pegram, C. N., 3140
Pei, L., 1613
Peiffer, S. L., 1922
Peiper, S. C., 2346
Pèlegrin, A., 83
Pelicci, P. G., 440
Pelin, K., 2981
Pelisson, I., 5173
Pellat-Deceunynck, C., 3647
Pelletier, J., 215
Peña, D., 2548
Peng, H-Q., 2871
Peng, Q., 2620
Penn, L. Z., 1982
Pennell, C. A., 2346
Penning, T. M., 4105
Peoples, G. E., 4140
Peralta Soler, A., 4205
Pereira, C., 57
Perera, F. P., 1417
Perez, L. A., 392
Perez-Perez, G. I., 2111
Periyasamy, S., 2056
Perkins, S. N., 3949
Perlman, H., 4438
Perron, D., 1176
Perrotti, D., 2275
Perussia, B., 2275
Peschle, C., 440
Peter, U., 817
Peters, G., 2988, 5168

* *For title of article and coauthors, see listing in Contents of Volume 55 beginning on page i at the end of this index issue.*

Peters, G. J., 3795
Peters, H. A., 1423
Peters, L. J., 3564
Peters, W. H. M., 2696
Peterson, J. A., 1717, 5847s, 5852s, 5973s
Peterson, S. R., 4651
Petersson, M., 5648
Petrelli, N. J., 1122
Petros, W. M., 3803
Pezzella, F., 5628
Pezzotta, S., 597
Pfeffer, U., 2158
Pfeiffer, G. R., 2789
Pfohl-Leszkowicz, A., 5611
Phang, J. M., 2487, 3949
Phelps, W. C., 2635
Philip, M., 2366
Philip, R., 2366
Phillips, N. J., 3399, 5180
Phillips, S. M. A., 4800
Piatyszek, M. A., 3258
Piazza, G. A., 3110
Piccoli, C., 629
Pickering, J. S., 2293
Pierotti, M. A., 135, 2400, 5617
Pietenpol, J. A., 1206
Pietruk, T., 5390
Pigott, R., 414
Pike, M. C., 3973
Pike, M. J., 1397
Pili, R., 2920
Pillay, S., 2727
Pilotti, S., 135, 5617
Pinchera, A., 5617
Pine, P., 4446
Pinedo, H. M., 3795
Pink, J. J., 2583
Pinkel, D., 6172
Pinsky, C. M., 5764s
Pirisi, M., 111
Pisa, P., 3675
Pisegna, J. R., 4886
Pisters, L. L., 1215
Pistoia, V., 853
Pitha, P. M., 5195
Pitot, H. C., 1780
Pizzorno, G., 566
Placidi, L., 3036
Placidi, M., 3036
Planchon, S. M., 3706
Plate, K. H., 1358
Plewig, G., 2373
Plon, S. E., 1639
Plowman, J., 862
Plunkett, W., 1517, 2847
Podoloff, D. A., 5925s
Podolski, J., 5348
Poggesi, I., 2090
Pogo, B. G-T., 5173
Pogribny, I. P., 1894
Poirier, L. A., 1894
Polascik, T. J., 3246, 5396
Pollak, M., 129, 2225
Polyak, K., 1211
Pommier, Y., 228, 1339, 2116
Pompon, D., 5520
Ponce-Castañeda, M. V., 1211
Ponder, K. P., 5242
Ponglikitmongkol, M., 4549
Pongracz, K., 3012
Ponzone, R., 2104
Ponzoni, M., 853
Poore, J., 5434
Poplack, D. G., 4069
Popovic, E. A., 20
Poppema, S., 2346
Porgador, A., 4941
Porter, A. T., 1002
Porter, D. J. T., 1239
Porter, P. L., 2703
Potmesil, M., 2044, 5637
Potter, G. A., 1070
Potter, M., 1181, 5012
Pottern, L. M., 4899
Poulin, R., 934
Poulsom, R., 1129
Powell, C. T., 1441
Powell, I. J., 5390
Powell, J., 3223
Powell, S. N., 1643
Powis, G., 2542
Pozzatti, R. O., 2959
Prager, D., 1613, 3592
Prall, F., 2963
Praml, C., 5504
Prasad, S., 4240
Prats, H., 5075
Pratt, M. A. C., 3902
Praz, F., 5520
Preece, N. E., 420
Preffer, F., 392, 1643
Press, M. F., 5693
Pressacco, J., 1505
Presta, L. G., 63
Presta., M., 4729
Preston, G. A., 3576
Price, B. D., 6021
Price, L., 803
Priest, D. G., 566
Primiano, T., 4319
Primus, F. J., 5929s
Prince Masahito, 3781
Prives, C., 4257
Probst-Hensch, N. M., 1224, 2017
Prorock-Rogers, C., 5106
Pu, Y-S., 1296
Pucci, M., 90
Puleo, C. A., 4988
Pullman, J., 3702
Puntis, M. C. A., 5043
Puri, R. K., 3357
Pursley, J. M., 3060
Puthenveettil, J., 493
Puthier, D., 3647
Pyke, C., 4132

Q

Qian, J., 5408
Qian, X-D., 1176
Qian, Y., 4243
Qin, H., 2984
Qin, Z., 4747
Qu, G-z., 2876
Quadri, S. M., 5736s, 5888s
Quarto, N., 4729
Quattrone, A., 90
Quelle, D. E., 5168
Qui, T. H., 3915
Quick, T. C., 4446
Quigley, M., 1070
Quilliet, X., 4325
Quintans, J., 991
Quistorff, B., 1664, 4146

R

Rabinowitz, J. R., 1039
Rabkin, S. D., 4752
Radaeva, S., 1028, 3318
Radford, D. M., 3399, 5180
Radice, P., 135
Radinsky, R., 141
Radmayr, C., 3068
Radovsky, A. E., 5251
Radulescu, A., 915
Radvanyi, F., 3735
Radvanyi, L. G., 1982
Raes, G., 2730
Raffaghello, L., 853
Raffeld, M., 1436
Raffo, A., 2431
Raffo, A. J., 4438
Ragnhammar, P., 1824
Rahm, A. L. K., 3110
Rahmani, R., 3036
Raimondi, R., 6140
Raimondi, S., 83
Rainier, S., 1836
Rainio, P., 5595
Raju, P. A., 4844
Rak, J., 4174, 4575
Ralfkiær, E., 4132
Rall, C. J. N., 1831
Ram, Z., 1306
Ramaekers, F. C. S., 5030
Ramirez, G., 5536
Ramsamooj, P., 3016
Rands, E., 5302
Rao, C. V., 259, 1464, 2310, 4311
Rao, P. V., 721
Rao, S., 3374
Rapanotti, M. C., 1625
Rapp, M-J., 3647
Rappa, G., 4352
Rapraeger, A., 4676
Rasio, D., 3003, 3988, 6053
Raska, K., Jr., 3424
Rasmussen, A., 2448
Rastad, J., 5794s
Rattan, S., 2904, 3003
Raubitschek, A. A., 5929s
Rauscher, F., III, 3610
Rauscher, F. J., III, 5386
Ravitz, M. J., 1413
Ray, R. B., 3747
Raychaudhuri, S., 3486
Raz., A., 3267
Re, G. G., 4540
Reardon, J. E., 3352
Rebane, B. A., 2998
Reddish, M., 3364
Reddish, M. A., 2257
Reddy, B. S., 259, 1464, 2310, 4311
Redston, M. S., 4670
Reed, E., 1261, 3933
Reed, J. A., 2713
Reed, J. C., 3902, 4471
Reed, M., 2410
Rees, J. L., 2910
Reeves, J., 2422
Regiert, T., 115
Reich, R., 3669
Reichardt, J. K. V., 3973
Reifenberger, G., 731
Reifenberger, J., 731
Reintgen, D. S., 4988
Reisfeld, R. A., 2352
Reiss, M., 3982
Reist, C. J., 3140, 4375
Reiter, A., 5377
Renaud, C., 698
Renbaum, P., 4804
Renschler, M. F., 5642
Rensing-Ehl, A., 2936
Renwick, P. J., 24
Resau, J. H., 1963, 2338
Resnicoff, M., 2463, 3739
Restifo, N. P., 1741, 3149
Restivo, S., 6103
Reubi, J. C., 5805s
Reufi, B., 2173, 2212
Reuning, U., 3958
Reynolds, R., 2490
Reznikoff, C., 493
Rhee, K., 4188
Rhim, J. S., 5434
Rhine, C., 1989
Rhodes, E. S., 2249
Rhodes, N., 1763
Ricca, C., 3569
Rice, J. M., 2665, 3043
Richards, W., 505
Richards, W. G., 4120
Richardson, D., 4797
Richardson, J. A., 610
Richardson, K., 5881s
Richardson, M. E., 1691
Richetta, A., 5677
Richman, C. M., 5916s
Ricks, S. H., 5276
Ridge, S. A., 34
Riecken, E-O., 928
Ried, T., 5415
Rieder, C. L., 792
Rieger, P. T., 5925s
Riggins, G. J., 5184
Riggs, C. W., 3043
Rigler, M. W., 2232
Rijnboutt, S., 3795
Ring, D. B., 4586
Rio, M-C., 2896
Ripple, M. O., 4234
Risau, W., 1358
Rishi, A. K., 4999
Risinger, J. I., 5664, 6063
Ritchie, A. J., 3406
Ritland, S. R., 4114
Ritter, J. H., 3399, 5180
Riva, N., 5952s
Riva, P., 5952s
Rivenson, A., 259, 1464, 2310, 4311
Rivera, H., 4646
Rivet, D. J., II, 1649
Rivoltini, L., 3149, 4972
Rizvi, N. A., 6109
Rizzo, S., 3675
Roa, I., 2511
Roagna, R., 2104
Robache, S., 685
Roberson, K. M., 2366
Roberson, P. L., 5811s
Roberts, A. B., 5545, 5621
Roberts, J. M., 1206
Robertson, C., 2366
Robertson, J. M., 3687
Robertson, M., 1531
Robertson, N. M., 548

** For title of article and coauthors, see listing in Contents of Volume 55 beginning on page i at the end of this index issue.*

Roberts-Thomson, S. J., 1052
Robinson, G., 3629
Robinson, J. C., 4813
Robinson, L., 4594
Rodabaugh, K. J., 2169
Rodrigues, M. L., 63
Rodriguez, G. C., 944
Rodriguez, M. I., 253
Rodriguez-Bigas, M., 1122
Rodriguez-Thomas, B., 450
Roebuck, B. D., 4319
Roederer, M., 4844
Roelofs, H. M. J., 2696
Rofstad, E. K., 4757
Rogalla, P., 6038
Rogers, B. E., 5714s
Rogers, M. A., 4844
Roggendorf, M., 3318
Roignot, P., 4416
Rojas, A., 83
Rollins, B. J., 505, 2995, 6200
Rom, W. N., 1444
Romeo, G., 3158
Rømer, J., 4132
Romerdahl, C. A., 1176
Rong, S., 1963
Roninson, I. B., 4023
Ronnett, B. M., 5556
Roos, E., 2177
Rosano, T. G., 3654
Rosen, N., 5302
Rosen, S. T., 2727
Rosenberg, A. L., 1752, 3003
Rosenberg, S. A., 748, 1741, 3149, 4972
Rosenberg., S. A., 3369
Rosenblum, M. G., 5925s
Rosenkranz, A. A., 1014
Rosenthal, F., 3854
Rosenthal, G. A., 4486
Rosigkeit, J., 2497
Rosin, M. P., 5213
Ross, A. S., 4486
Ross, G. M., 1235
Ross, J. A., 1039
Ross, J. S., 4594
Ross, R. K., 1937, 3973
Rossi, A., 4452
Rossi, G. B., 3158
Rossi, S. C., 4516
Rossitti, R., 5952s
Rössler, W., 5771s
Rossmann, C., 4099
Rosson, D., 4205
Roth, J. A., 1
Roth., J. A., 3250
Rothenberg, E., 1242
Rothermundt, C., 3854
Rothman, N., 4516
Rotman, H. L., 2463, 3739
Rouleau, G. A., 2270
Rouyer, N., 2896
Rovira, D., 5921s
Rowe, S. M., 2743
Rowe, S. T., 721
Rowell, C., 5310
Rowley, D. R., 781
Rowley, J. D., 1206
Rowlinson-Busza, G., 1020, 1060
Rowse, G. J., 617
Rowson, J., 2404
Roy, H. K., 5257
Roza, L., 2245, 4325
Rozenblum, E., 4570
Rozzo, C., 853
Ru, N., 4813
Ruan, S. B., 237
Rubartelli, A., 675
Rubbini, S., 2978
Rubin, A. D., 5899s, 5946s
Rubin, R., 303, 1006, 2463
Rubin, S. C., 2998
Rucker, N., 1820
Rudd, C. K., 4446
Rudoll, T., 2366
Ruf, W., 1629
Ruiz, P., 901
Rukstalis, D. B., 3197
Rupa, D. S., 640
Rusch, V., 1365, 5038
Rüschoff, J., 6002
Rusin, M. R., 1448
Russell, E., 1917
Russell, J., 4915
Russell, K. J., 1639
Russell, N. S., 1232
Russell., S. E. H., 3406
Russello, O., 566
Russo, A., 6103
Russo, C. A., 1122
Rustan, T. D., 3531
Rustgi, A. K., 1831
Rustum, Y. M., 1239, 6227
Rutherford, M., 4936
Rutten, A. A. J. J. L., 3634
Ryberg, D., 3996

S

Sabbioni, S., 2904, 3003
Saccani-Jotti, G., 3331
Sacchi, T. B., 5272
Sacks, N. P. M., 5842s
Sadinski, W. J., 6152
Saez, E., 6196
Saffari, B., 5693
Sagara, M., 4196
Sager, R., 2537
Sahin, A., 3976
Said, J., 2822
Saijo, N., 1075, 2334, 2806
Saito, H., 862
Saito, Y., 3564
Saji, S., 5354
Sakaguchi, Y., 5459
Sakai, M., 4073, 5370
Sakamoto, G. T., 2017
Sakamoto, M., 6172
Sakamoto, S., 3192
Sakata, K., 1933
Sakiyama, S., 895
Sakiyama, T., 1675
Sakr, W., 1002
Sakr, W. A., 5390
Sakunaga, H., 6172
Sakurada, S., 4162
Salako, Q., 5726s
Salazar, E. P., 5656
Salazar, H., 6189
Saleem, A., 3242
Saleh, M. N., 4339
Salehi, H. A., 4824
Salgaller, M. L., 4972
Salhany, K., 3237
Salkowski, A., 1002
Saller, R. M., 386
Sallinen, P., 2691
Salmon, C. P., 4516
Salo, S., 4132
Salter, J., 3331
Saltzman, D., 1321
Salvadori, P. A., 5911s
Salvato, M., 6103
Salveson, G., 6045
Salvi, D., 3197
Salvi, S., 3374
Salwen, H., 721
Samoto, K., 1189
Samowitz, W., 1531
Samowitz, W. S., 3732
Samson, K. M., 4936
Samson, L., 2608
Sancetta, R., 6140
Sanchez-Madrid, F., 414
Sandgren, E. P., 3915
Sandström, P., 5868s
Sang, J., 1152
Sang, N., 1199
Sano, H., 3785
Sano, K., 5445
Santarelli, G., 4552
Santella, R. M., 1417
Santoli, D., 96
Santoni, A., 4702
Santoro, E., 1787
Santoro, M. G., 4452
Sanz-Esponera, J., 4995
Sanz-Ortega, J., 4995
Sappino, A-P., 4688
Sarasin, A., 4325
Sarkar, D. K., 4892
Sarkar, F. H., 4520
Sartor, O., 2122
Sartorelli, A. C., 4352
Sartori, C., 5276
Sartori, M., 3374
Sasaki, A., 3551
Sasaki, H., 739, 3421
Sasaki, K., 3513
Sasazuki, T., 4575
Sato, E., 4196
Sato, H., 963, 3263, 3272
Sato, Y., 1206, 1863
Satodate, R., 891, 1933
Satoh, K., 1933, 4053, 4059
Satow, Y., 5687
Saunders, G. F., 5386
Sausville, E. A., 2794
Savaraj, N., 1633
Savelyeva, L., 3471, 5504
Savin, C., 5156
Savinov, A., 3073
Sawada, M., 787
Sawicki, J. A., 4205
Sayers, T. J., 3840
Scadden, D. T., 3509
Scaglione-Sewell, B. A., 5257
Scanlon, K. J., 2024
Scarpelli, D. G., 2560
Schadendorf, D., 4432
Schaefer, C., 2236
Schally, A. V., 280
Scharnweber, C., 5499
Schartl, A., 159
Schartl, M., 159
Scheele, J. R., 5786s
Scheer, W. D., 1485
Scheffer, G. L., 4214
Scheibenbogen, C., 4065
Scheinberg, D. A., 5908s
Scheithauer, B., 1613
Schellander, K., 6244
Scheper, R. J., 4214
Scherthan, H., 6002
Schiffenbauer, Y. S., 153
Schiffman, M., 4899
Schilder, R. J., 3286
Schiller, J. H., 6215
Schimke, R. T., 4922
Schlegel, J., 6002
Schlegel, R., 5019
Schlickeiser, G., 1373
Schlom, J., 2455, 2858, 3598, 4339, 5925s, 5957s
Schmahl, M., 4512
Schmalfeldt, B., 3958
Schmidt, E. E., 2520
Schmidt, L., 4804
Schmier, J-W., 4065
Schmitt, B., 4157
Schmitt, M., 3958
Schmutte, C., 3742
Schneck, F. X., 4140
Schneider, E., 2122, 4004
Schnipper, L. E., 6109
Schoenberg, J. B., 4899
Schoenberg, M. P., 3246, 5213, 5396
Schoenmakers, E. F. P. M., 2497
Schold, S. C., Jr., 2853
Schornagel, J. H., 3795
Schott, M. E., 5957s
Schow, S. R., 4929
Schreck, S., 1696
Schreiber, G. J., 3558
Schreiber, H., 5094
Schrier, D. M., 5921s
Schröck, E., 5415
Schröder, M., 3475
Schroeder, J. A., 3915
Schubiger, P. A., 46
Schuhmacher, J., 115
Schulgen, G., 294
Schuller, H. M., 3504
Schuller, I., 2212
Schulte, T. W., 4623
Schultz, D. C., 2150
Schultz-Hector, S., 386
Schultz-Thater, E., 2236
Schulz, K-D., 817
Schulz, S., 4741
Schuster, J., 3854
Schut, H. A. J., 3043
Schutte, M., 4570, 4670
Schwab, M., 3471, 5366, 5504
Schwartz, A. G., 4899
Schwartz, B., 2476
Schwartz, E. L., 3543
Schwartz, G. F., 1752, 3003
Schwartz, M. R., 1080
Schwarz, M. A., 3692
Schwarzbach, R., 46
Schwarze, M. M. K., 2262
Schwedes, J. F., 2410
Schwickert, G., 4757
Scott, R., 2422
Scott, W. N., 3772
Scotte, M., 1839
Sebti, S. M., 4243

** For title of article and coauthors, see listing in Contents of Volume 55 beginning on page i at the end of this index issue.*

Sechrist, G. L., 2056
Seeger, R. C., 721, 3386
Seftor, E., 3747
Segalla, F., 3374
Sehested, M., 459
Sehgal, I., 5151
Sei, Y., 2122
Seiki, M., 963, 3263, 3272
Seimiya, H., 2186
Sein, J. J., 840, 2627
Seizinger, B. R., 743, 3569
Seki, T., 514
Sekido, Y., 1227
Sekiguchi, M., 2927
Sekiya, T., 2166
Sekiyama, S., 1933
Sekyi-Otu, A., 129
Selkirk, A., 2044
Sell, C., 303
Selvanayagam, C. S., 3310
Semenzato, G., 6140
Semey, K., 4910
Sensi., M., 3374
Sensibar, J. A., 2431
Senter, P. D., 2357, 3558
Sepp-Lorenzino, L., 5302
Serafini, A. N., 5774s
Seriu, T., 5377
Serrano, M., 1448, 1607, 2503
Serša, G., 3450
Serve, H., 2212
Sessions, R. B., 5434
Setiawan, Y., 874
Seung, L. P., 5094, 5561
Seung, S. K., 5094
Seymour, A. B., 4670
Sfakianakis, G. N., 5774s
Sgagias, M. K., 3790
Sha, M., 3610
Shafer, G. E., 3369
Shaffer, J. E., 603
Shafman, T. D., 3242
Shah, N., 3640
Shah, S. A., 4079
Shalinsky, D. R., 3183
Shamsuddin, A. M., 149
Shan, A. L., 4114
Shang, A., 2783
Shao, H., 4676
Shao, Z-M., 4999
Shapiro, G. I., 505, 2995, 6200
Shapiro, J. R., 1569
Sharkey, R. M., 1105, 3825, 5827s, 5899s, 5911s, 5935s, 5946s
Sharma, S., 537, 3847
Shay, J. W., 2734, 3258
Shea, C. R., 2713
Sheikh, M. S., 4999
Sheinfeld, J., 1211
Shekels, L. L., 2681
Shen, M-R., 6077
Shen, S., 5837s, 5893s
Shen, W-f., 1117
Sherr, C. J., 5168
Sherwood, E. R., 1215
Sheu, J-C., 1428
Shevitz, J., 5899s, 5935s, 5978s
Shi, Y., 1982
Shiao, Y-H., 1485
Shibata, M-A., 1271, 4870
Shichijo, S., 3478
Shiel, M. J., 2713
Shields, P. G., 3483
Shih, L. B., 5857s, 5978s
Shii, K., 1479
Shikishima, H., 2524
Shiku, H., 774, 1977, 3105
Shiloh, Y., 3003
Shilyansky, J., 748
Shima, H., 774
Shimada, H., 681, 1385
Shimada, Y., 3777
Shimbara, N., 4780
Shimizu, K., 4780
Shimizu, T., 228, 4196
Shimogori, T., 2615
Shimono, A., 354
Shimotohno, K., 2524
Shimoyama, Y., 2206
Shin, D. M., 16
Shinkai, T., 2334
Shinohara, N., 3228
Shintaku, I. P., 2822
Shinto, Y., 354
Shipp, M. A., 4120
Shirahata, A., 2615
Shirai, T., 4333, 4870
Shirao, K., 4196
Shirasaka, T., 3897
Shirasawa, S., 4575
Shirley, M. A., 3183
Shiseki, M., 1448
Shively, J. E., 3873, 5929s
Shoemaker, A. R., 4479
Shono, T., 1189
Shpall, E. J., 5921s
Shrader, M. W., 5621
Shroot, B., 4446
Shu, L. M., 5957s
Shui, C., 3431
Shukla, R., 5978s
Shulman, E. P., 1741
Shun, C-T., 1428
Shupert, W. L., 3598
Shuster, J., 5085
Shuster, J. J., 4664
Shvarts, A., 486
Sibert, L., 1839
Siddiki, B., 3659
Sidransky, D., 224, 2995, 4525, 5213, 5396, 6200
Sidransky., D., 3246
Siegall, C. B., 3099
Siegel, J., 5946s
Siegel, J. A., 5827s, 5935s
Siemann, D. W., 1691
Sier, C. F. M., 2696
Sievers, M., 5749s
Sikorski, A., 5348
Silber, J. R., 1261
Silvani, A., 2200
Silverman, D. T., 4899
Silvers, W. K., 4681
Simi, B., 259, 1464, 2310, 4311
Simmons, D., 5628
Simon, M., 4696
Simon, M-P., 2400
Simonis, T. B., 3149
Simpkins, H., 5203
Simpson, J., 2266
Simsir, A., 267
Sinclair, A., 4784
Sinensky., M., 3295
Singer, C., 2448
Singer, M. I., 3055
Singer, S., 5140
Singh, G., 5164
Singh, R. K., 2470, 3669
Singhal, A., 1869
Sinha, R., 4516
Sinicrope, F. A., 237
Sioussat, T. M., 360
Siracusa, L. D., 5504
Sismondi, P., 2104
Sitia, R., 675
Sitrin, M. D., 3050, 5257
Sivam, G. P., 2352
Sjöberg, J., 3675
Sjöberg, R-M., 5681
Sjögren, H-O., 5874s
Skalak, R., 5451
Skorski, T., 2275
Skotzko, M., 5493
Skunca, M., 5358
Slade, D. L., 1707, 4962
Slade, J., 2232
Slaga, T. J., 4566
Slavin-Chiorini, D. C., 5957s
Slayter, M. V., 5621
Sleat, D. E., 3424
Sledge, G., 3610
Sloan, J. M., 3406
Slørdal, L., 1670
Slovak, M. L., 4214
Smalara, D., 4041
Smans, K. A., 4383
Smart, R. C., 3171
Smellie, W. J. B., 5842s
Smith, A., 3149
Smith, B. A., 2316
Smith, C., 2366
Smith, D. R., 5217
Smith, E., 5019
Smith, G. K., 6117
Smith, H. S., 2448, 2516
Smith, I. E., 288, 3331
Smith, J. R., 2404
Smith, L. L., 544
Smith, M. L., 1649
Smith, M. R., 2640, 3286
Smith, P. J., 28, 220, 4268
Smith, T. J., 5566
Smitherman, P. K., 4844
Smoluk, J., 6196
Snijders, P. J. F., 5465
Snoy, P., 5957s
Snyder, M., 1994
Snyder, R. D., 3702
Snyderwine, E. G., 3043
Soardo, G., 111
Sobolev, A. S., 1014
Soder, A. I., 5030
Soini, Y., 5595
Soker, S., 4140
Solano, F., 2603
Soldatenkov, V. A., 4240
Soldevila, G., 2253
Soler, A. P., 1680
Solomon, G., 3576
Soma, M. R., 597
Sommadossi, J-P., 3036
Son, K., 5524
Song, W., 190
Sonoda, Y., 2166
Sopracordevole, F., 2645
Sorensen, P. H. B., 1385
Sorio, C., 4855
Sormunen, R., 5595
Sorscher., E. J., 3339
Souba, W. W., 3525
Souliotis, V. L., 6017
Souza, K., 5140
Sozzi, G., 135, 2400
Spadea, A., 4552
Spagnoli, G. C., 2236
Spalding, J. W., 3171
Spangler, G., 1431
Spang-Thomsen, M., 1664, 4146
Spector, T., 1239, 6227
Speicher, M. R., 1010, 5415
Sperl, G., 3110
Spiegelman, B. M., 6196
Spiess, P. J., 1741
Spillare, E. A., 1448
Spirin, K. S., 2266
Spirio, L., 1531
Spirio, L. N., 3732
Spiro, R. C., 2177
Spitz, M. R., 557, 3604
Sporn, M. B., 2380, 5621
Spurr, N. K., 4800
Sreter, L., 2212
Srimatkandada, S., 4352
St. Clair, D. K., 2490
Stackhouse, T. M., 4544
Stadie, T., 4036
Stadler, M., 115
Stadler, W., 493
Staedt, U., 1373
Staehler, G., 5383
Stafford, N., 1020, 1060
Stafford, W. F., III, 5983s
Stampfer, M. R., 2516
Stanton, P., 4915
Stanwell, C., 4950
Staretz, M. E., 5580
Starr, R. J., 4936
Staubus, A., 2097
Stebbins, M. R., 3099
Stechmann-Lebakken, C., 4676
Steck, K. D., 3117
Steel, G. G., 1235
Steele, R., 3747
Steele, V., 1464, 4311
Steele, V. E., 537
Steenbergen, R. D. M., 5465
Stefanini, M., 4325, 5656
Stehlin, J. S., 5637
Stein, G. H., 7
Stein, G. S., 5019
Stein, H., 2173
Stein, J. L., 5019
Stein, R., 1242, 3132, 5857s
Steinarsdottir, M., 646
Steinberg, P., 1028
Steinbrueck, T., 3399
Steinfeld, A., 5759s
Stellrecht, K., 5173
Stemmer, S. M., 5921s
Stemmermann, G. N., 2111
Stephens, E. A., 3537
Stephens, L. C., 237, 5459
Stern, D. F., 1946
Sternbach, D. D., 603
Stetson, P. L., 3687
Stewart, B. C., 3817
Stewart, J. S. W., 1020, 1060
Stewart, W., 530, 3634

** For title of article and coauthors, see listing in Contents of Volume 55 beginning on page i at the end of this index issue.*

Stigbrand, T., 5868s
Stilgenbauer, S., 3475
Stockhammer, G., 6126
Stocking, C., 34
Stoler, D. L., 1122
Stone, J. G., 1267
Stone, S., 2988, 5531
Stoner, G. D., 1039, 5566
Storer, B. E., 4906
Storkus, W. J., 124
Story, B., 3551
Stoyanova, R., 3286
Stracke, M. L., 2140
Strand, S-E., 5874s
Strange, R. C., 3537, 4237
Strasser-Wozak, E. M. C., 348
Stratford, M. R. L., 6026
Strauss, E. A., 3237
Strauss, M., 949, 4818
Strebel, F. R., 5459
Streck, R. J., 253
Streeper, R. T., 1491
Street, A. J., 5168
Streitman, J. S., 4438
Strickland, P. T., 181
Strolin-Benedetti, M., 2090
Strom, S. S., 3604
Strong, L., 1963
Studzian, K., 3412
Studzinski, G. P., 4014
Stühler, A., 4784
Stumm, G., 6002
Sturiale, C., 5952s
Stürzbecher, H-W., 6012
Stüting, S., 4432
Su, L-K., 2972
Su, S. L., 1441
Subra, F., 3211
Subramanian, D., 2097
Subramanian, R., 5774s
Suda, H., 1310, 1316
Sugano, H., 3781
Suganuma, M., 2081
Sugarbaker, D. J., 505, 4120
Sugars, L. Y., 735
Sugimura, T., 3421, 3521, 3810, 4333
Sugino, D., 1847
Sugino, T., 4273
Sugio, K., 2511
Sugioka, Y., 2927
Sugiyama, K., 4743
Suit, H. D., 392
Sukhatme, V. P., 6161
Sullam, P. M., 2476
Sullivan, D. M., 1707
Sullivan, L. M., 3692
Sulman, E. P., 2053, 4664
Sumantran, V. N., 2507
Sumerel, L., 1397
Sumi, T., 3623
Sumizawa, T., 1687
Sun, J., 4243
Sun, L-Q., 83
Sunday, M., 4120
Sundfør, K., 4757
Sundström, B., 5868s
Supko, J. G., 2794
Surh, D. M., 5434
Susaki, A., 1863
Susani, M., 3346
Sutherland, D. J. A., 2104
Sutherland, R. M., 6222
Sutkowski, D. M., 2431
Sutter, T. R., 4319
Suyama, K., 2418
Suyama, M., 5354
Suzuki, A., 1933
Suzuki, H., 2756, 4253, 5296
Suzuki, K., 4297
Suzuki, N., 4253
Suzuki, T., 652, 2651
Suzuki, Y., 1933
Svensson, H. P., 2357, 3558
Swaffar, D. S., 4486
Swanson, C. A., 4516
Swanson, G. M., 4899
Swart, G. W. M., 6237
Swartz, H. M., 2249
Swayne, L. C., 5899s, 5935s, 5946s
Sweeney, E. A., 691
Sweet, S., 5164
Swiniarski, J., 830
Sylvester, S. R., 2431
Syvänen, A-C., 342
Szarka, C. E., 2789
Szczylik, C., 2275
Szöllösi, J., 5400

T

Tabah, R. J., 4557
Tachibana, M., 3438, 4881
Tachibana, O., 5528
Tachimori, Y., 3421
Tadayoni, B. M., 4079
Taetle, R., 3380, 4936
Taffs, S., 5921s
Tagawa, T., 4865
Tahara, E., 2734, 4273
Tahara, H., 2734
Tai, M-S., 5983s
Tai, X-G., 4404
Tainaka, K., 1617
Tainsky, M., 1963
Tainsky, M. A., 16, 1763
Taioli, E., 472, 3757
Takagi, Y., 5354
Takahashi, A., 6045
Takahashi, H., 1621, 2998
Takahashi, K., 3478
Takahashi, M., 2984, 5238
Takahashi, S., 4114, 4333, 5408
Takahashi, T., 354, 514, 2081, 5354
Takahashi, Y., 3964
Takai, Y., 5445
Takaishi, T., 276
Takami, K., 5007
Takayama, K., 5656
Takeshita, T., 1221
Taketo, M. M., 2719
Takeuchi, A., 1586
Takeuchi, J., 6166
Takeuchi, S., 2266, 5377
Taki, T., 4127, 6040
Tamada, K., 6146
Tamaoki, T., 3105, 5283
Tamir, S., 4391
Tammela, T., 342
Tammilehto, L., 2981
Tamori, A., 3500
Tamura, G., 891, 1933
Tamura, T., 2334
Tan, S-S., 4302
Tan, T. M. C., 4599
Tanaka, H., 1977
Tanaka, K., 2927
Tanaka, M., 2769, 3228, 6210
Tanaka, T., 836, 1277, 4053, 4059
Tanaka, Y., 921
Tang, D. G., 698
Tang, W., 1643
Tang, X-Z., 5736s
Taniguchi, K., 3860
Taniguchi, T., 276
Tannenbaum, S. R., 4391
Tannergård, P., 6092
Tardelli, L., 3692
Tarin, D., 4273
Tarkkanen, M., 1334
Tarmin, L., 2035
Tartof, K. D., 6189
Taskinen, P. J., 2660
Tassinari, C., 6140
Tassini, M., 2814
Tasso, M. J., 803
Tatematsu, M., 399
Tates, A. D., 1875
Tatsumoto, N., 3258
Tatsuta, I., 3623
Tauchi, H., 5687
Tavtigian, S. V., 2988
Tawa, A., 5007
Tawaraya, K., 3897
Taylor, C. R., 2673
Taylor, D. L., 1, 3117
Taylor, M. R., 5847s
Taylor, R. M., 399
Taylor, S. M., 6030
Tazaki, H., 3438, 4881
Teder, P., 3908
Tee, P. G., 298
Tegtmeyer, P., 2410
Teicher, B. A., 6109
Teijgeman, R., 1971
Teixeira, C., 3902
Telleman, P., 3412
Tempel, C., 153
Tennant, R. W., 3171
Tennenbaum, T., 2774
Tennvall, J., 5874s
Tepper, M. A., 3060
Terachi, T., 4182
Terada, M., 3810, 5472
Terada., M., 3421
Terao, T., 1847
Terasaki, T., 2206
Terashima, M., 1933
Terpe, H-J., 901, 5424
Terris, B., 1590
Testa, U., 440
Testi, A. M., 1625
Tew, J. M., Jr., 4696
Tezuka, Y., 4196
The, H. T., 4409
Thein, S. L., 2866
Thermos, K., 5632
Thiberville, L., 5133
Thibodeau, S. N., 4114
Thiel, E., 2173, 2212
Thiele, C. J., 1798, 2380
Thielemans, K., 2730
Thilly, W. G., 5140
Thimmapaya, R., 4023
Thliveris, A., 1531, 3732
Thomas, A., 2044
Thomas, G., 1385
Thomas, P., 2191
Thomazy, V., 3183
Thompson, C., 991
Thompson, C. B., 2576
Thompson, D. C., 2837
Thompson, E. A., 4188
Thompson, F. H., 3380
Thompson, J. C., 1347
Thompson, L. H., 5656
Thompson, N. L., 1152
Thompson, T. C., 5151
Thompson., E. W., 3272
Thorgeirsson, S. S., 3043
Thorlacius, S., 646
Thorpe, S. R., 3132
Thrash-Bingham, C. A., 6189
Tian, Z-G., 5335
Tilanus, H. W., 1971
Timblin, C. R., 2723
Timme, T. L., 5151
Tindle, R. W., 2635
Ting, R. C. Y., 4599
Tisdale, M. J., 1458
Tishler, R. B., 6021
Tjuvajev, J., 1902
Tjuvajev, J. G., 6126
Tlsty, T. D., 1763
Tobler, A., 2866
Todoroki, T., 2756
Todorov, P. T., 1458
Toge, T., 4273
Togo, S., 681
Toh, U., 4248
Toh, Y., 4248
Tokino, K., 224
Tokino, T., 2910
Toko, T., 2122
Tokus, M., 1373
Tolentino, M. J., 4230
Tolle, T., 3318
Toloczko, A., 5348
Tomaselli, K. J., 6045
Tomasetto, C., 2896
Tomasino, R. M., 6103
Tominaga, S., 5354
Tomlinson, F. H., 20
Toniatti, C., 2200
Toniolo, P., 472, 3757
Toniutto, P., 111
Topalian, S. L., 3149
Topp, M. S., 2173
Torchilin, V. P., 3752
Toribara, N. W., 2681
Torley, L. W., 4929
Törmänen, U., 5595
Torres, K., 2116
Toshkov., I., 3318
Toso, R., 78
Toso, R. J., 2528
Tosti, S., 1625
Toth, M., 2548
Toyoda, H., 774
Toyooka, M., 3165
Toyoshima, M., 767
Tozawa, K., 4162
Trachman, J., 472, 3757
Traganos, F., 1248, 3093
Tralongo, V., 6103
Trask, B. J., 1206
Traub, O., 629
Travali, S., 668
Travis, E. L., 298

** For title of article and coauthors, see listing in Contents of Volume 55 beginning on page i at the end of this index issue.*

Travis, L. B., 294
Traweek, S. T., 3140
Trede, M., 1160
Treisman, J., 3369
Trent, J., 2972
Trent, J. M., 3954, 4640
Trent., J. M., 3380
Trentin, L., 6140
Trepel, J., 4623
Trepel, J. B., 2122
Tribune, D. J., 1922
Triche, T. J., 1385
Triebel, F., 685
Trinchieri, G., 4980
Trinh, Q. T., 4808
Tron, V. A., 2070
Troncoso, P., 1215
Trono, D., 1607
Troshina, K., 4594
Trybus, T. M., 5390
Tryggvason, K., 4132
Tsai, M-L., 3697
Tsan, R., 141
Tsang, N-M., 12
Tsao, M-S., 1168, 1853, 4760
Tsao, S-W., 490
Tsarfaty, I., 1963
Tsarwhas, D. G., 4120
Tsiokas, L., 6161
Tsuda, H., 3395
Tsuji, K., 3417
Tsujimoto, Y., 354
Tsujimoto., Y., 3444
Tsujimura, T., 354
Tsumura, H., 4549
Tsunaga, N., 4676
Tsung, K., 4765
Tsuruo, T., 767, 2186
Tsutsui, T., 4404
Tsutsumi, M., 2719
Tukazaki, T., 2075
Tukey, R. H., 1052
Tuma, R. F., 4824
Turc-Carel, C., 2400
Tureaud, J., 5358
Turley, H., 5628
Turner, A. M., 3431
Tuthill, R. J., 3954
Tveter, K. J., 1817
Tyner, G. T., 149
Tzehoval, E., 4941

U

Uchida, K., 2756
Uchida, T., 2418
Uckun, F. M., 1321, 2346
Ueda, H., 3781
Ueda, R., 514, 5354
Ueda, S., 4225
Uehara, H., 6126
Uehling, D., 603
Uenaka, A., 4780
Ueno, M., 4881
Ueo, H., 3417
Ullen, A., 5868s
Ullrich., A., 3223
Ullrich., R. L., 3310
Ulm, E. H., 482
Umar, A., 3721, 5664, 6063
Umbach, D. M., 3537
Umemoto, A., 2769
Umiel, T., 2822
Underhill, C. B., 428
Underwood, M., 2422
Unger, M. L., 4627
Untch, M., 5276
Upadhyay, S., 4520
Urano, M., 2490
Urano, T., 1977
Urata, Y., 4297
Uschinsky, K., 2497
Ushijima, T., 3521
Uskokovic, M., 2822
Ussery, D., 4988
Usuki, Y., 3192
Utsumi, K., 399
Uyemura, K., 3847

V

Vadai, E., 4941
Vähäkangas, K., 5595
Vaidyanathan, G., 4375
Vainio, H., 3305
Valadares de Amorim, G., 4278
Valdes, E., 1565
Vale, W., 4892
Valea, F., 267
Valenti, M., 2116
Valentine, M. B., 721
Valero, V., 3060
Valgardsdottir, R., 646
Van, N. T., 190, 2831
van Bladeren, P. J., 1701
van Blankenstein, M., 1971
Van Cauteren, H., 5589
Van de Kelft, E. J. Z., 1547
van Dekken, H., 1971
Van Den Berghe, H., 24, 1565
Vandenberghe, J., 5589
van den Berk, P. C. M., 840, 2627
van der Eb, A. J., 486
van der Valk, M. A., 2627
Vanderveer, L., 2150
Van de Ven, W., 1565, 6038
Van de Ven, W. J. M., 2497
Vande Woude, G. F., 1963
Van Etten, R. A., 6196
van Groningen, J. J. M., 6237
van Lier, R. A. W., 4409
Van Ness, B., 3640
van Netten, J. P., 4486
Vanni, R., 31, 1565
van Ommen, B., 1701
van Ormondt, H., 486
van Putten, W. L. J., 1423
van Rees, B., 5556
van Rhijn, C. M., 4398
van Roy, F. M., 4722
van Teijlingen, C. M. M., 1875
Van Tornout, J. M., 4531
van Veelen, N., 975
Van Waes, C., 5434
van Wering, E., 4220
van Wessel, N., 3412
van Zeeland, A. A., 1875
Varani, J., 4676
Vardeman, D., 5637
Vargas-Cuba, R. D., 5774s
Varki, A., 4425
Varkonyi, A., 4910
Vasey, P. A., 2090
Vassalli, J-D., 4688
Vaury, C., 5520
Vecchio, G., 1787
Vecchione, A., 6103
Velculescu, V. E., 2910
Velders, M. P., 4398
Vellucci, V. F., 3982
Vena, J. E., 3483
Venkatraman, E., 5038
Vennekens, K. M., 4722
Verì, M. C., 5677
Verlooy, J., 1547
Vermeulen, S. J., 4722
Vermeulen, W., 6012
Veronese, M. L., 1199, 2904
Verspaget, H. W., 2696
Viale, G., 5049
Viallet, J., 1853, 4760
Vickers, P. J., 2556
Vidali, G., 2158
Vidaud, M., 3735
Viel, A., 2645
Vielkinds, J., 5133
Vienneau, D. S., 1045
Vieweg, J., 2366
Viggiano, V., 3149
Vijg, J., 2968
Villa, E., 498
Villacreses, N., 211
Vilner, B. J., 408, 3022
Vingers, L., 3346
Viola, J. J., 1306
Vionnet, J. A., 1261
Virmani, A. K., 2511
Visakorpi, T., 342, 3954
Visentin, M. C., 2645
Visonneau, S., 96
Vitetta, E. S., 610
Vitols, K. S., 478
Vitulli, D., 111
Vivi, A., 2814
Vleminckx, K. L., 4722
Vocke, C., 4995
Vocke, C. D., 2959
Voeller, H. J., 735
Vogel, C-A., 83
Vogel, H., 1146
Vogelstein, B., 1206, 2910, 2972, 5184, 5187, 5545, 5548
Vogt, P. K., 5540
Volpe, C. M., 1122
von Deimling, A., 4696
Vonderhaar, B. K., 2591
von Eschenbach, A. C., 1215, 2831
Vorontsova, T. V., 5617
Vrieling, H., 1875
Vriesendorp, H. M., 5736s, 5888s
Vrudhula, V. M., 2357, 3558
Vukanovic, J., 1499, 3517
Vuong, A., 603

W

Waalkes, M. P., 5265
Wada, H., 3192, 4780
Wada, H. G., 5642
Wada, M., 3386, 3860, 4293, 5377
Wada, R. K., 1798
Wadler, S., 3543
Wagener, C., 2963
Wagner, E. F., 6244
Waha, A., 4696
Wain, J. C., 4910
Wakabayashi, H., 4458
Wakabayashi, K., 4333
Wakamatsu, K., 2603
Wakisaka, A., 2524
Wakui, S., 1621
Walberg, L. A., 3364
Walboomers, J. M. M., 5465
Walbridge, S., 1306
Waldenström, M., 1911
Waldman, F. M., 2516, 5400
Waldman, T., 2910, 5187
Waleh, N. S., 6222
Walenta, S., 4757
Wali, R. K., 3050, 5257
Walker, B., 3772
Walker, C., 530
Walker, C. L., 1607, 3634
Walker, D. G., 20
Walker, G. J., 2713, 5531
Walker, S. C., 3687
Wall, M. E., 753
Wallace, P. M., 2357
Walmer, D. K., 1168
Walsh, C., 1111
Walsh, G. L., 5603
Walton, P. A., 4557
Walz, D. A., 698
Wang, C., 2418, 3712
Wang, C. Y., 5101
Wang, D., 2346
Wang, E., 2284
Wang, J., 2703, 3073, 3847, 5151
Wang, J. C., 2299
Wang, J-W., 3654
Wang, L., 6045
Wang, M., 3117
Wang, P., 2410
Wang, T. T. Y., 2487
Wang, T-H., 1428
Wang, X., 12
Wang, X. W., 6012
Wang, Y., 190, 1578, 2410, 5173
Wang, Y-H., 12
Wang, Z., 5670
Wang, Z-Q., 6244
Wani, M. C., 753
Wank, S. A., 4886
Wanschura, S., 2497, 6038
Ward, D. C., 1010
Ward, J. M., 3949, 5265
Warnaar, S. O., 4398
Warnick, R. E., 4696
Warrell, R. P., Jr., 5908s
Warren, B. F., 4273
Warren, D. J., 1670
Waseem, N., 6084
Wasenius, V-M., 4471
Washimi, O., 514
Wasserman, R. A., 2299
Watanabe, H., 3421
Watanabe, K., 5528, 6126
Watanabe, S-i., 3897
Watanabe, Y., 3897
Waters, R., 1267
Watkins, S. C., 474
Watson, A. J., 6231
Watson, M., 3537
Watson, S. A., 3629
Wattenberg, L. W., 5472
Waxman, D. J., 581
Webber, J., 4278
Webber, K. O., 318, 5323
Weber, B. L., 2998
Weber, C. A., 5656
Weber, G., 2978

** For title of article and coauthors, see listing in Contents of Volume 55 beginning on page i at the end of this index issue.*

Weber, M. J., 5106
Weber, P. B., 3654
Weber, R. S., 3604
Weber, T. K., 1122
Weber, W. W., 3043
Weghorst, C. M., 2665
Wei, Q., 5025
Wei, S-J. C., 1550
Weichselbaum, R., 3242
Weichselbaum, R. R., 991, 5561
Weiden, P. L., 5817s
Weil, D. P., 748
Weinberg, J., 617
Weinberg, R. A., 4488
Weiner, G., 3817
Weiner, L. M., 4586, 5983s
Weiner, T. M., 2752
Weinstein, C. L., 4670
Weintraub, M., 1431
Weiβ, G., 3475
Weiss, J., 2494
Weissenbach, J., 4800
Welborn, J., 4220
Welch, M. J., 5714s
Welch, W. R., 490, 2169
Wellenreuther, R., 4696
Weller, A. H., 4391
Weller, M., 2936
Wellmann, A., 1436
Wells, A. H., 3339
Wells, P. G., 1045
Wen, T., 5648
Wendler, J., 5771s
Wendtner, C-M., 4157
Wenner, C. E., 1413
Wennerberg, J., 3204
Wenning, L. A., 3763
Wereley, J. P., 4361
Wessels, B. W., 5823s
Westerhof, G. R., 3795
Westlin, J-E., 5710s, 5794s, 5801s, 5805s
Wetselaar, L., 3412
Whaley, J. M., 743
Wharton, W., 5069
Whealin, H., 3060
Wheeler, R. H., 4339
Wheelock, M. J., 4813
Wheldon, T. E., 4915
Whitacre, C. M., 3697
Whitaker, R. S., 944
White, I. N. H., 544
White, P. S., 2053, 4664
White, R., 1531, 3732, 4797
White, R. W. V., 5837s
White., R. L., 3389
Whysner, J., 294
Wicha, M. S., 2507
Wick, M. M., 4929
Widmer, M., 5335
Widschwendter, M., 2135
Wiedemann, L. M., 34
Wiedenmann, B., 2212
Wiencke, J. K., 4910
Wiener, F., 1181
Wiens, L. W., 1639
Wientjens, E., 975
Wientjes, M. G., 5315
Wigzell, H., 1824
Wijdenes, J., 840
Wijsman, J., 4220
Wikstrand, C. J., 3140, 4375
Wilander, E., 5794s
Wilczynski, S., 2266
Wilder, R. B., 3431
Wilder, R. L., 3785
Wilding, G., 3706, 4234
Wilhelm, M., 5383
Wilkinson, B. P., 537
Willecke, K., 629
Willems, P. J., 1547
Willhauck, M., 4065
Williams, B. R. G., 3456
Williams, D. A., 2608
Williams, E. K., 1883
Williams, G. M., 294
Williams, L. E., 5929s
Williams, P., 1989
Williams, S. R., 420
Williams, S. T., 2140
Willimann, T., 2236
Willingham, M. C., 4375
Willson, J. K. V., 5101, 5548
Wilson, D. J., 3772
Wilson, H. R., 6117
Wilson, J. G., 3352
Wilson, J. K., 5184
Wilson, K., 4278
Wilson, K. H., 1039
Wilson, P., 2090
Wilson, S. J., 1763
Wilson, T. M., 5146, 6097
Wilson, W. R., 574
Wiltrout, R. H., 3840
Wiltshire, R., 2972
Wiltshire, R. N., 3954
Winqvist, R., 2660
Winters, K. A., 4073
Winthrop, M. D., 5837s
Wirth, C., 63
Wistuba, I. I., 2511
Witiak, D. T., 3706
Wittliff, J. L., 280
Witty, J. P., 1401
Witwer, B., 4824
Wizigmann-Voos, S., 1358
Wogan, G. N., 4391
Wojno, K. D., 5390
Wojtukiewicz, M. Z., 698
Wolf, E. J., 5983s
Wolf, F., 5777s
Wolf, F. G., 3825, 5771s, 5786s
Wolf, G. T., 5434
Wolf, H., 5749s
Wolfe, W. G., 51
Wolff, L., 501
Wollman, J., 3847
Woloschak, G. E., 1696, 4788
Wong, A. J., 3140, 4375, 5536
Wong, G. Y., 5935s
Wong, G. Y. C., 5743s
Wong, J. Y. C., 5929s
Wong, W. L. T., 63
Woo, E. S., 2021
Woo, S. L. C., 1080
Woods, C. M., 2325
Woster, P. M., 3233
Wright, F. A., 2660
Wright, J. A., 1758, 4503
Wright, K. R., 3551
Wright, M., 1397
Wright, M. A., 885
Wright, T. C., Jr., 4793
Wrona, M. A., 1168
Wu, A. M., 5929s
Wu, C. J., 1633
Wu, L., 5493, 6058
Wu, M-S., 1428
Wu, S., 944
Wu, S. S., 2063
Wu, S-N., 6077
Wu, X., 557
Wu, X. C., 1485
Wuerzberger, S., 3706
Wyllie, F. S., 2404
Wyllie, R., 803
Wynford-Thomas, D., 915, 2404
Wyrick, S. D., 2837
Wysocka, M., 4980

X

Xia, F., 12
Xiao, S., 2968
Xie, C., 2847
Xie, K., 2470, 3123
Xiong, Y., 1448, 6058
Xu, L., 2752
Xu, R., 5195
Xu, X., 5025
Xu, X-C., 5507, 5603
Xuan, H., 5857s

Y

Yamada, S., 2524
Yamada, Y., 1687
Yamahara, J., 1277
Yamaji, K., 1586
Yamamoto, N., 2334, 4404
Yamamoto, S., 1271
Yamana, H., 4248
Yamanaka, N., 1479
Yamane, T., 2081
Yamasaki, H., 629, 3513
Yamashiro, J. M., 1798
Yamashita, K., 1675
Yamashita, S., 2075
Yamauchi, D. M., 5929s
Yamazaki, H., 2524
Yamazaki, I., 3781
Yamori, T., 767
Yan, N., 3569
Yan, S., 1413
Yan, Y. X., 4540
Yandell, D. W., 12
Yang, A. S., 3742, 4531
Yang, C., 4210
Yang, C. S., 5566
Yang, C-H. J., 4004
Yang, C-S., 1301
Yang, F., 4047
Yang, G., 5151
Yang, G. Y., 149
Yang, J. C., 1741, 3369
Yang, R., 2503
Yang, Y., 1517
Yang, Z., 3687
Yang-Feng, T. L., 6172
Yano, Y., 3500
Yanoma, S., 4248
Yao, J., 5217
Yao, K-S., 4367
Yao, T-J., 2783
Yaono, M., 4333
Yasuda, J., 2166
Yasui, T., 3623
Yasumoto, K., 921
Yatomi, Y., 691
Yazaki, T., 4752
Yazawa, S., 1473
Yazdi, P. T., 3763
Ye, P., 2876
Yeager, T., 493
Yeasky, T. M., 1283
Yeates, C., 5063
Yee, A., 6058
Yeh, H., 6012
Yeh, R. L., 2029
Yen, Y., 1328
Yeo, C. J., 2394, 4670
Yeo, K-T., 360
Yeo, T-K., 360
Yeung, M. M-W., 2963
Yim, J. H., 4765
Yin, D. X., 4922
Yin, J., 2035
Yin, S., 6063
Yodoi, J., 4293
Yokoi, T., 787
Yokomizo, A., 4293
Yokota, J., 1448
Yokoyama, M., 2007
Yokoyama, T., 3258
Yoneda, T., 1989, 3551
Yonezawa, S., 4196
Yoo, T. M., 5323
Yoshida, H., 1687
Yoshida, K., 4273, 4297
Yoshida, O., 590, 4182
Yoshida, S., 2756
Yoshida, T., 3810
Yoshikawa, T., 1617
Yoshiki, T., 2524
Yoshimatsu, K., 5310
Yoshimoto, T., 2166
Yoshimura, M., 1479
Yoshinaka, H., 4196
Yoshinari, T., 1310, 1316
Young, B. D., 4220
Young, D. C., 2097
Young, M. R. I., 885
Yu, H., 1603, 2104
Yu, J. J., 1261
Yu, M., 3272
Yu, M. C., 1937, 3973
Yu, M-W., 1301
Yu, Z., 6045
Yuan, F., 3752
Yuan, J., 4420, 6166
Yuan, S., 3456
Yue, W., 3073
Yuki, A., 2651
Yukita, A., 5296
Yule, S. M., 803
Yuspa, S. H., 1680, 1883, 2774, 4950
Yutanawiboonchai, W., 2463

Z

Zacharek, A., 1002
Zacharoulis, S., 6109
Zachwieja, J., 3223
Zagon, I. S., 4085
Zagzag, D., 907
Zalutsky, M. R., 3140, 4375, 5842s
Zambello, R., 6140
Zamperini, A., 90
Zang, E., 1464, 4311
Zänker, K. S., 4557
Zariwala, M., 1448

** For title of article and coauthors, see listing in Contents of Volume 55 beginning on page i at the end of this index issue.*

Zbar, B., 4544, 4804
Zdzienicka, M. Z., 3412
Zea, A. H., 3840
Zehnbauer, B. A., 1811
Zeitlin, S., 735
Zelnick, C. R., 4023
Zeng-Rong, N., 4760
Zenklusen, J. C., 1347
Zetterberg, A., 5415
Zhan, Q., 1649
Zhang, H., 3584
Zhang, H-Z., 5925s
Zhang, J., 4640
Zhang, L., 428, 3890
Zhang, M., 2537
Zhang, N., 1117
Zhang, R., 141
Zhang, S., 2783, 3364
Zhang, W., 668
Zhang, W-W., 1, 2831, 3250, 5151
Zhang, X-k., 4446
Zhang, X-Y., 2876
Zhang, Y., 434
Zhang, Y-J., 1417
Zhao, H., 1792
Zhao, J., 6181
Zhong, G. R., 5726s
Zhou, B-S., 1328
Zhou, G-H. K., 2056
Zhu, H., 4611
Zhu, J., 2325, 3865
Zhu, J. H., 1221
Zhu, W-G., 739
Zhuang, S-M., 486
Zhuang, Z., 467, 2959, 4995
Zia, F., 4886
Ziche, M., 4729
Zienolddiny, S., 3996
Zile, M. H., 5507
Zillmann, U., 3318
Zimmer, T., 928
Zimmerman, P. V., 28, 220, 4268
Zimmermann, K., 46
Zirngibl, H., 6002
Zobywalski, A., 5499
Zöller, M., 115
Zoltick, P., 2463
Zoltick, P. W., 5536
Zon, G., 2275
Zou, C-C., 232
Zou, C-P., 232, 5603
Zou, J-P., 4404
Zou, Z., 2537
Zucchi, F., 498
Zunino, F., 312
Zwiebel, J. A., 2240

* *For title of article and coauthors, see listing in Contents of Volume 55 beginning on page i at the end of this index issue.*

SUBJECT INDEX

Volume 55

A

A-8441
biological characterization, 830
AACR: *see* **American Association for Cancer Research**
Aberrant crypt foci
colonic
chemoprevention by naturally occurring products, F344 rats, 1277
hyperplastic to adenomatous, 4743
ABL
activation by fusion to *TEL*, 34
ABL-MYC retrovirus
-induced chromosome 11 duplications, murine plasmacytomas, 1181
AC6C3–2B12
^{111}In-labeled
intraperitoneal administration, preclinical analysis, 5736
Acetylation polymorphism
and colorectal adenomas, 2017
***N*-Acetyl-L-cysteine**
effects on asbestos induction of c-*fos* and c-*jun* expression, mesothelial cells, 2085
***N*-Acetyltransferase**
Ah congenic mice
IQ-DNA adducts, 3043
***N*-Acetyltransferase 1**
and carcinogen-DNA adducts, bladder, 5230
polymorphisms
bladder and colon tissue, 5226
and colorectal cancer risk, 3537
***N*-Acetyltransferase 2**
and carcinogen-DNA adducts, bladder, 5230
β-Actin
lymphocytes
amplification by multiplex RT-PCR, 5025
Activator protein 1
activation by photodynamic therapy
IL-6 regulation, 2373
Acylfulvene
illudin analogues
efficacy, 4936
Adeno-associated virus
-based plasmids, complexed to cationic liposomes
prostate cancer gene therapy, 2366
Adenocarcinoma
breast
cell adhesion to HUVECs, thrombospondin modulation, 166
tumor progression, spontaneous rat tumors, 399
colonic
cachexia, cytokine network, mice, 921
laminin-5 and uPA receptor coexpression, 4132
platelet-aggregating sialoglycoprotein gp44, 767
TJA-I reactive sugar chains expression, 1675
colorectal
full-length APC protein cells. microsatellite instability, 4797
esophageal
p53 mutations, 3406
Gal-GalNAc expression, 149
gastric
K-*ras* and *p53* mutations, Florence, Italy, 2665
microsatellite alterations, 1933
risk, *H. pylori cagA* and, 2111
lung
African-American *CYP1A1* polymorphism, 472
chromosome 11q loss of heterozygosity, 3988
K-*ras* mutations, 1444
metastatic, surfactant protein gene expression, RT-PCR detection, 4283
peripheral, β-adrenergic mitogenic signal transduction, 3504
ovarian
cisplatin-sensitive and -resistant, cytokeratin 18 expression, 5203
pancreatic
allelotypes, 4670
CD44 isoform expression, 1831
CD44 splice variants expression, 5499
chromosome abnormalities, 2394
[^{111}In]DTPA-D-[Phe^1]-octreotide scintigraphy, 5805s
microsatellite instability and K-*ras* mutations, 4264
photodynamic therapy *in vitro*, 3078
pancreatic ductal
genetic alterations, hamster, 2560
prostatic
metastatic hormone-refractory, somatostatin receptor expression, 5805s
Adenoma
angiogenesis
microvessel quantitation with clinicopathological correlations, 5049
colonic
apoptosis induction by TGF-β and substrate release, 5101
colorectal
acetylation polymorphism and, 2017
GSTM1 null genotype, smoking, and, 1224
gastric
microsatellite alterations, 1933
intestinal
N-ethyl-*N*-nitrosourea treatment and, *Min* mice, 4479
lung
PAH-induced, time-integrated DNA adduct levels and, A/J mouse, 1039
Adenomatous aberrant crypt foci
hyperplastic aberrant crypt foci to, 4743
Adenomatous polyposis coli
alternatively spliced transcripts, 3732
biallelic inactivation, hepatoblastoma, 5007
EB1 binding, 2972
full-length protein cells
colorectal adenocarcinoma, full-length APC protein cells, 4797
mutations
intestinal polyp formation, 2719
somatic, gastroduodenal tumors, 3165
ulcerative colitis, 2035
tumor suppression, colon cancer cell lines, 1531
Adenosine triphosphate
breast cancer progression marker, NMR spectroscopy study, 5140
chemosensitivity testing, ovarian carcinoma, 5276
-dependent VP-16 efflux, murine leukemia cells, 4352
Adenovirus
C-CAM1
androgen-independent prostate cancer therapy, preclinical study, 2831
-mediated delivery, anti-ras ribozyme neoplastic reversion, 2024
-mediated gene therapy
head and neck squamous cell carcinoma, nude mouse model, 1080
hepatocellular carcinoma, 5283
mediation of *p16*^{INK4} tumor suppressor effects, 3250
p52 or *p21*
gene therapy, prostate cancer, 5151
wild-type *p53*
apoptosis induction, head and neck squamous cell carcinoma, 3117
expression, prostatic tumor cells, 4210
microscopic residual disease, 1
Adenovirus *E1a*
-mediated tumor suppression, 5551
ADEPT
p185^{HER2} overexpressing tumors, 63
Adhesion molecules
epithelial
adenovirus, prostate cancer therapy, preclinical study, 2831
expression, prostate cancer, 1215
tumor suppressive role, prostate cancer, 190
expression changes
carcinoembryonic antigen-induced, 3250
myeloma cells, 3646
suprabasilar integrin
expression, human epidermal neoplasms, 5434
Adoptive immunotherapy
tumor microcirculation and, 4627
β-Adrenergic receptors
mitogenic signal transduction, peripheral lung adenocarcinoma, 3504
AF10
fusion with *MLL*
t(10;11) breakpoint heterogeneity, AML-M4/M5, 4220
Aflatoxin
-induced tumorigenesis
chemoprevention, intermittent oltipraz dosing, 4319
Aflatoxin B_1
chlorophyllin inhibition, rainbow trout, 57
dietary
synergy with hepadnaviral infection, woodchucks, 3318
metabolism
oltipraz effects, hepatocytes, 5574
AFP: *see* **α-Fetoprotein**
African-Americans
CYP1A1 polymorphism
lung adenocarcinoma, 472
lung cancer risk and, 6035
pancreatic cancer
alcohol and, 4899
women
breast cancer, *CYP1A1* restriction fragment length polymorphism and, 3757
AG17
tumor growth inhibition, 2794
Aging
ALL-1 gene rearrangements and, acute myeloid leukemia, 1625
apoptosis resistance, fibroblasts, 2284
cell
effects on radiation-induced apoptosis, 5207

mutant p53 and SDI1/WAF1, 2404
AGM-1470
disposition and metabolism, hepatocytes and tissue microsomes, 3036
***Ah/NAT* congenic mice**
IQ-DNA adducts, 3043
AIDS
-related Kaposi's sarcoma
retinoid inhibition, 823
A/J mouse
lung
time-integrated DNA adducts and PAH-induced adenoma, 1039
Alcohol
and pancreatic cancer, blacks and whites, United States, 4899
perillyl
apoptosis induction, liver tumors, 979
Aldehyde dehydrogenase
mitochondrial gene
fusion transcript with *HMG1-C*, 6038
Alkaloids
Vinca
riboflavin-mediated photosensitization, and drug sensitivity assays, 4837
Alkylating agents
resistance
DNA topoisomerase II α expression and, 6109
***O*^{6}-Alkylguanine**
and HOENU-induced *in vivo* mutagenesis, T-lymphocytes, 1875
***O*^{6}-Alkylguanine-DNA alkyltransferase**
effects on triazene-induced cytotoxicity and tumor cell immunogenicity, L1210 leukemia, 6231
O^6-(*p*-hydroxy[^{3}H]methylbenzyl)guanine labeling, 4085
ALL: *see* **Leukemia, acute lymphoblastic**
Allelic loss: *see also* **Loss of heterozygosity**
and breast cancer progression, 5180
chromosome 1, meningioma progression, 4696
chromosome 4, primary bladder carcinoma, 5396
chromosome 8p12-21, microdissected prostatic intraepithelial neoplasia, 2959
chromosome 10, meningioma progression, 4696
chromosome 10q, endometrial cancers, 1922
chromosome 11q13, microdissected and invasive breast cancer, 467
chromosome 14, meningioma progression, 4696
chromosome 16q, multiple breast cancers, 3395
Allelism
CYP2D6
and glioma risk, 4237
GSTT1 and GSTM1
and glioma risk, 4237
Allelotypes
childhood acute lymphoblastic leukemia, 5377
ductal carcinoma *in situ*
breast, 3399
lobular breast carcinoma, 3976
pancreatic adenocarcinoma, 4670
partial, bladder carcinoma *in situ*, 5213
Alu
sequence insertion, progesterone receptor gene, 2743
American Association for Cancer Research
Third Joint Meeting with JCA, meeting report, 5472
Ames test
with recombinant P4501A2, aromatic amines, 799
Amifostine
phase I trial, pediatric refractory cancer, 4069
Amino acids
cationic
reduction of renal uptake of antibody fragments, 3827
hepatic transport, tumor-bearing rats, 3525
3-Aminobenzamide
induction of GRP78 and VP-16 resistance, 868
δ-Aminolevulinic acid
-induced protoporphyrin
photosensitizer for photodynamic therapy, 1723
2-Amino-6-methoxypurine arabinoside
T-cell agent, 3352
2-Amino-3-methylimidazo-[4,5-*f*]quinoline
DNA adducts
colon, bladder, and kidney, *Ah/NAT* congenic mice, 3043
rat colonic wall, 2769
2-Amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine
chicken concentrations, 4516
two-generation exposure
mammary carcinoma risk, Sprague-Dawley rats, 4333
6-Aminonicotinamide
induction of GRP78 and VP-16 resistance, 868
[^{177}Lu]α-[2-(4-Aminophenyl)ethyl]-1,4,7,10-tetraaza-cyclodecane-1,4,7,10-tetraacetic acid
-CC49 Fab radioimmunoconjugate
renal excretion, lysine and, 5288
AML: *see* **Leukemia, acute myeloid**
Amplification
-associated cdk4 overexpression, malignant glial tumors, 4833
c-*erb*B2, endometrial cancers, 5693
c-*myc*
minisatellite instability and, methylcholanthrene-induced mouse sarcoma, 5670
DNA sequence, ovarian carcinoma, 3380
ERBB-2, breast cancer, 5400
HER-2/*neu*, endometrial cancers, 5693
ANBL6 cells
growth characteristics
activated N-*ras* effects, 3640
Androgen
effects on GAPDH, prostate carcinoma cells, 4234
-promoted carcinoma
tamoxifen chemoprevention, rat seminal vesicle and prostate, 5621
receptor
gene CAG and GGC microsatellites, and prostate cancer, 1937
gene mutations, latent prostatic carcinoma, Japanese men, 1621
protein expression, prostatic carcinoma metastases, 3068
-regulated epithelial cell adhesion molecule
tumor suppressive role, prostate cancer, 190
regulation of EGFR expression and binding affinity, PC3 cell lines, 3197
resistance
bcl-2-mediated, LNCaP cells, 735
bcl-2-mediated, prostate cancer, 4438
Anemia
Fanconi
Chinese hamster cell mutants resembling, 3412
-inducing substance
plasma, advanced malignant neoplasms, 3623
Aneuploidy
chromosomal
multiple myeloma, detection by FISH, 3854
Angio-associated migratory cell protein
new vascular protein, 2140
Angiogenesis
circulating inhibitors, 4230
colorectal tumors
microvessel quantitation with clinicopathological correlations, 5049
directed implantation
genetically modified endothelial cells, mice, 2240
MRI, 1956
EGF- and laminin-dependent
antagonism by murine EGF fragment (33-42), endothelial cells, 3772
endothelial cell
castanospermine effects, 2920
generation, ascites tumors, 376
linomide inhibition, rat prostatic cancers, 1499
pathways, superficial and invasive bladder cancer, 510
tenascin expression and, astrocytomas, 907
thymidine phosphorylase activity and, 1687
Anoxia
inducible endonuclease
and genomic instability, 1122
Anthracycline
-stimulated topoisomerase II DNA cleavage, 312
Antibodies: *see also* **Monoclonal antibodies**
anti-B-cell
anti-idiotype antibody, 5978s
anti-breast tumor, humanized, 5852s
anti-CEA
glycosylated fragments, site-specific modifications, 5721s
humanized fragment, Kemptide fusion protein, ^{P} labeling, 5968s
^{99m}Tc-labeled, complete vs fragmented, 5786s
^{99m}Tc-labeled, targeting liver metastases of colorectal carcinoma, 5777s
tumor-specific uptake, monoclonal antibody-cobra venom factor conjugate effects, 5749s
anti-idiotype
anti-B-cell antibody, 5978s
antilymphoma
glycosylated, site-specific modifications, 5721s
antimouse, human
suppression by deoxyspergualin, phase I study, 3060
anti-retinoic acid
binding to premalignant oral lesions, 5507
binding to cell surface antigens
functional affinity determination, 57332
bispecific
-mediated costimulation, 4409
-mediated immunotherapy, solid tumors, 4383
multistep tumor targeting, nude mice, 115
chimeric domain-deleted, biological properties, 5957s
fragment Kemptide fusion protein
P labeling, 5968s

fragments
renal uptake, reduction by cationic amino acids, 3827
human consensus
design, minimal positional templates, 5973s
^{11}iodine-labeled
radioimmunotherapy, vs external beam radiotherapy, 5811s
LL2
anti-idiotype antibody, 5978s
radiolabeled
combined with external radiotherapy, head and neck cancer, 1020
tumor localization, experimental approaches, 5729s
response to hepatitis C virus core protein and hepatocellular carcinoma, 111
RS7
reactivity, human breast cancer, 5857s
tumor necrosis factor
hepatic amino acid transport block, tumor-bearing rats, 3525
variable-region fragment: *see* **Fv**

Anticancer drugs
sensitivity
metallothionein null cells, 2021

Antiepileptics
and hepatobiliary cancer and malignant lymphoma, 294

Antigenic cancer cells
stimulation by host cells, 5094

Antigens
binding receptor peptide ligands
B-lymphoma cell activation, 5642
breast cancer
anti-idiotype mimicking, monkeys, 1525
DF3/MUC1, interaction with Grb2 and Sos/Ras, 4000
carcinoembryonic
anti-CEA chimeric T84.66, phase I therapy trial, 5929s
footprint analysis, colon carcinoma cells, 3873
galectin-3 ligand, colon carcinoma cells, 2191
humanized mAb, targeting, preclinical and clinical studies, 5935s
-induced adhesion molecule expression changes, 3250
^{99m}Tc-labeled antibodies, complete vs fragmented, 5786s
^{99m}Tc-labeled antibodies, targeting liver metastases of colorectal carcinoma, 5777s
cell surface
antibody binding, functional affinity determination, 57332
human leukocyte
-unrestricted cytotoxic T cell clones, leukemia-specific, 3835
human leukocyte, A2
-matched melanoma, TCRBV14 overexpression, 3374
human leukocyte, class I
molecules, quantitative recognition, 314
90K
tumor suppression, 3223
leukemia peptides, recognized by CTLs, 4781
melanoma
recognition by lymphocytes, 4972
-specific T-cell receptor, reconstitution, 748
polyvalent
antibody binding, functional affinity determination, 57332
proliferating cell nuclear
cyclin D1 subunit association, SV40 large T antigen immortalization and, 4651
prostate-specific
gene expression, ovarian carcinoma, 1603
mRNA, non-prostate cells, 2640
prognostic indicator, breast cancer, 2104
recombinant human, expression, transfected murine cells, 2455
-related genes, primates, 2455
RNA, alternatively splicing, 1441
sialylated
tumor-associated, expression, colonic mucosa, 1869
sialylated-Lewis
and MUC-1, pancreatic cancer cells, 3659
site-specific Thomsen-Friedenreich
definition by BW835, MUC1 tandem repeats, 4036
soluble
formulation, tumor vaccine, 3486
-specific cytotoxic T lymphocytes
quantitative recognition of HLA class I molecules, 3149
SV40 large T
immortalization, and cyclin D1, 4651
SV40 T
transgenic mice, astrocytic transformation, 4302

Antihormonal therapy
human breast cancer xenografts, 4146

Antineoplastic agents
cytotoxicity
topoisomerase IIα and β expression and, acute lymphoblastic leukemia, 78

Antisense
cyclin G1
inhibition of osteosarcoma cell proliferation, 5493
inhibition of L-*myc*, small cell lung cancer, 1559
K-*ras* construct
liposome-mediated gene transfer, pancreatic cancer, 3810
oligodeoxynucleotides
alterations of *c-myc* expression, and apoptosis, HL-60 cells, 1379
oligonucleotides
growth inhibition, 4092
RNA
IGF receptor, loss of metastatic phenotype, murine carcinoma cells, 1006
inhibition of FGF-2, hepatoma cells, 5075

Antitumor drugs
in vitro pharmacodynamic studies, design and analysis, 5315
platinum- and quinazoline-based molecules
initiatives, Fourteenth Bruce F. Cain Memorial Award lecture, 2761
quinolone compounds
A-8441, biological characterization, 830
sensitization
E2F1 deletion mutant, 2883

APC: *see* Adenomatous polyposis coli

APE/ref-1
cellular and subcellular expression, 6097

Apomucin
MUC-1
sialyl-Lewis^a and sialyl-Lewis^x, pancreatic cancer cells, 3659

Apoptin
p53-independent apoptosis induction, human osteosarcoma cells, 486

Apoptosis
bcl-2 protection, prostate cancer, 4438
caffeic acid phenethyl ester-induced, transformed rat fibroblast cells, 3576
ceramide-induced
Bcl-2 mRNA suppression and, 991
chemotherapy-induced
increase by Bcl-x_s, MCF-7 cells, 2507
modulation by Bcl-x_L, 2576
cisplatin-induced
mediation by ICE, malignant glioma cells, 6166
c-myc expression and, HL-60 cells, 1379
CTL-induced, BCR-ABL-expressing cells, 463
differentiation-induced alterations, neuroblastoma, 4711
drug-induced
inhibition by *BCL-2*, HeLa cells, 4922
PC-3 cells, 2122
enhancement
and non-small cell lung carcinoma, 5595
rapamycin, 1982
estrogen effects, MCF-7 cells, 2487
hyperthermia-induced, rats, 5459
and IGF-IR levels, 3739
induction
apoptin, human osteosarcoma cells, 486
5-azacytidine, 3093
HPR, neuroblastoma cells, 847
β-lapachone, prostate cancer cells, 3712
oxygen tensions and, 995
perillyl alcohol, liver tumors, 979
phenylacetate, MCF7ras cells and nude mice, 5156
sphingosine, HL-60 cells, 691
substrate release, colon adenoma cells, 5101
sulindac metabolites, 3110
TGF-β, colon adenoma cells, 5101
wild-type *p53* adenovirus, head and neck squamous cell carcinoma, 3117
inhibition
CD45, mouse malignant T-lymphoma cells, 2186
colorectal tumorigenesis, 1811
glucocorticoid modulator, CEM C-7 cells, 548
VEGF, hematopoietic cells, 5687
β-lapachone-mediated, HL-60 and prostate cancer cells, 3706
linomide-induced, prostatic cancer cells, 3517
mammary epithelial cells, stromelysin-1 transgenic mice, 1401
p53 gene mutations and, Wilms' tumors, 215
p53-induced
abrogation by HBV X gene, 6012
altered, human lymphoblast lines, 12
prevention
bcl-2 or *bcl-x_l*, myeloma cells, 2262
IGF-I receptor, 303, 2463
radiation-induced
and *Bcl-2* mRNA suppression, 991
effects of cell age and dose fractionation, 5207
Ewing's sarcoma cells, 4240
inhibition by VEGF, hematopoietic cells, 5687
radioresistant neuroblastoma cells, 4915
regulation by TGF-β
M1 cells ectopically expressing B-*myb*, 501
ovarian epithelial cells, 944

-related mRNA expression
breast carcinoma xenografts, radioimmunotherapy and, 5837s
resistance
androgen-induced, LNCaP prostate cancer cells, 735
human acute leukemic cell line, 348
senescent fibroblasts, 2284
serum-deprived PC12 cells, 1242
spontaneous
suppression by dichloroacetic acid, murine hepatocytes, 3702
TNF-induced, 444
and *Bcl-2* mRNA suppression, 991
and tumorigenesis, 3739
Apoptotic index
evaluation of antihormonal therapy of human breast cancer xenografts, 4146
Apurinic/apyrimidinic endonuclease
DNA repair enzyme
cellular and subcellular expression, 6097
AR230 cells
establishment
p230 BCR/ABL fusion protein, 3192
L-Arginine-nitric oxide pathway
activation by relaxin, breast cancer cells, 5265
Aroclor 1254
liver tumor promotion, mouse, 4875
Aromatase
inhibitor effects on mammary tumor growth, nude mouse model, 3073
Aromatic amines
acetyltransferases
and carcinogen-DNA adducts, bladder, 5230
Ames test with recombinant P4501A2, 799
Arsenic
internal cancers and, seven-year follow-up study, Taiwan, 1296
organic dimethylarsinic acid compound
enhancement of carcinogenesis, F344/DuCrj rats, 1271
Asbestos
c-*jun* activation, 2723
crocidolite
fibers, Kent cigarette smoke, 2232
and mitosis, living vertebrate lung epithelial cells, 792
induction of c-*fos* and c-*jun*, mesothelial cells, 2085
and pulmonary GSTM3 expression, lung cancer, 3305
-related human malignant mesothelioma
GSTM1 and *NAT2* defects and, 2981
-transformed mesothelial cells
TGFα autocrine growth stimulation, rat, 530
Ascites tumors
angiogenesis/stroma generation, 376
fibrinogen/fibrin deposition, 369
vascular permeability factor and, 360
Aspirin
thermotolerance enhancement, erythroleukemic cells, 4452
Astaxanthin
naturally occurring
chemoprevention, rat, 4059
Astemizole
carcinogenicity studies, mice and rats, 5589
Astrocytes
growth
loss of wild-type *p53* and, 2746
transformation, transgenic mice, 4302
Astrocytoma
malignant transformation
β2-chimaerin, 3456
MTS1 gene deletions, 20
peripheral-type benzodiazepine receptor expression, 2691
progression
Fas/APO-1 expression, 5528
susceptibility
detoxifying enzyme genotypes and, 4237
tenascin expression
and angiogenesis, 907
Ataxia-telangiectasia
ATM genomic organization, 6053
and cellular responses to DNA damage, 5991
defective induction of stress-activated protein kinase, 3242
ATM
genomic organization, 6053
ATP: ***see*** **Adenosine triphosphate**
Aza-aromatic carcinogens
polycyclic
human P450 metabolism, 1052
5-Azacytidine
induction of apoptosis, 3093
Azoxymethane
-induced colonic aberrant crypt foci
chemoprevention, naturally occurring products, F344 rats, 1277
-induced colonic carcinogenesis
chemoprevention, *S*-methyl methane thiosulfonate, male F344 rats, 4053
chemoprevention, ursodeoxycholate, rat model, 5257
inhibition, RO24-5531, 3050

B

2B1
phase I trial, 4586
B7–1
antitumor immunity induction
synergistic with IL-12, 4980
expression, non-antigen presenting cell-derived tumor, 2253
-induced natural killer cell-mediated cytotoxicity, 2730
B61
new growth factor, metastasis, 2528
B956
tumor xenograft growth inhibition, 5310
B cells: ***see*** **B lymphocytes**
B lymphocytes
anti-idiotype antibody, 5978s
antitumor response, 4747
chronic lymphocytic leukemia
D13S25 deletions, 3475
D13S25 deletions, cartography and mapping, 1355
D13S218 deletions, 2044
RB-1 deletions, 3475
epitopes
reactivity, hepatitis C virus core protein and hepatocellular carcinoma, 111
lymphoma
activation, microphysiometer measurement, 5642
anti-CD40 immunotoxin, 3099
dissemination retardation by IL-4, SCID mice, 3692
spontaneous, nitric oxide production and, SJL mice, 4391
malignancy
radioimmunotherapy, prognostic factors, 5893s
non-Hodgkin's lymphoma
staging, ^{67}Ga citrate vs ^{99m}Tc-labeled LL2-Fab′ fragment, 5771s
staging, ^{99m}Tc-labeled LL2 MAb fragment, 5764s
quiescent
Epstein-Barr virus infection, cell cycle activation, 4784
tumors
IgH/c-*myc* recombinations, 5012
large human, eradication with CD20 mAbs and IL-2, 2627
BA46
mAb Mc3
humanized, breast cancer therapy, 1717
BALB/c RLδ1 leukemia
antigen peptides, recognized by CTLs, 4781
BALB/MK cells
inhibition by TGFβ1, 3928
Barrett's esophagus
progression
genetic abnormalities, 1971
Base excision repair
T:G vs U:G, 3742
Basement membranes
proteins
colon cancer metastasis promotion, 2476
sea urchin embryo
invasion by metastatic tumor cells, 5085
Batimastat
organ invasion inhibition, colon carcinoma metastasis models, 3629
BAX
loss of expression
and breast cancer survival, 4471
BB-94
organ invasion inhibition, colon carcinoma metastasis models, 3629
B6C3F$_1$ mice
exposed to lead acetate
renal tubular tumors and atypical hyperplasia, 5265
bcl-2
deficiency
pleiotropic abnormalities, mice, 354
expression
colorectal neoplasia, 237
differentiation-induced, neuroblastoma, 4711
estrogen regulation, breast cancer cells, 3902
gliomas with wild-type p53, 999
-mediated apoptosis
androgen-induced resistance, LNCaP prostate cancer cells, 735
HeLa cells, 4922
myeloma cells, 2262
postradiation, TNF-α, and ceramide, 991
overexpression
inhibition of etoposide-induced genetic alterations, 4029
prostate cancer, 4438
regulation by *WT1*, 5386
suppression
failure, senescent fibroblasts, 2284
inhibition by phenylacetate, MCF7ras cells and nude mice, 5156
suppression of *p21$^{WAF1/CIP1}$* expression, breast epithelial cells, 4520
bcl-2/J$_H$
translocations, blood and organ samples, 2876
bcl-x$_L$
apoptosis prevention, myeloma cells, 2262
drug resistance mediation, neuroblastoma cells, 2576
bcl-x$_s$
chemotherapy-induced apoptosis increase,

MCF-7 cells, 2507
BCR-ABL
-dependent hematopoiesis
c-RAF-1 serine/threonine kinase, 2275
-expressing cells
CTL-induced apoptosis, 463
B6D2F1 mice
liver tumor promotion by TCDD or Aroclor 1254, 4875
Benign breast disease
genetic aspects, 4416
Benign nevi
p53 mutations, 4278
Benzo(*a*)pyrene
(+)-BPDE metabolite
-induced splicing mutations, *hprt* locus, Chinese Hamster V-79 cells, 1550
initiation of micronuclei, UDP-glucuronosyltransferase-deficient rat skin fibroblasts, 1045
Benzodiazepine
receptors
peripheral-type, expression, human astrocytomas, 2691
Benzo(*e*)pyrene
initiation of micronuclei, UDP-glucuronosyltransferase-deficient rat skin fibroblasts, 1045
***O*^{6}-Benzylguanine**
plasma and CSF pharmacokinetics, nonhuman primate, 4606
5-(Benzyloxybenzyl)barbituric acid acyclonucleoside
enhancement of FdUrd antitumor efficacy, 1092
4-[^{125}I]-*N*-(*N*-Benzylpiperidin-4-yl)-4-iodobenzamide
synthesis and pharmacological characterization, 3022
Biliary glycoprotein
expression, colonic mucosa, 2963
Biliary tract cancers
p16 and *p15* mutations, 2756
Biomonitoring
human assay, buccal mucosa, 1267
Biopsy
smoking-related DNA adducts, 1267
Biotransformation
ormaplatin
WR-2721 effects, F344 rat fibrosarcoma, 2837
***N,N′*-Bis(2-chloroethyl)-*N*-nitrosourea:** *see* **Carmustine**
Bisdioxopiperazine
derivatives
DNA topoisomerase II target, *S. cerevisiae*, 2299
1,15-Bis(ethylamino)-4,8,12-triazapentadecane
growth inhibition, human and mouse tumor cells, 2615
Bisimidazoacridones
mechanism of action, 2338
Bis-naphthalimides
LU 79553, preclinical evaluation, 1176
Bisnitroimidazoles
-bioreductive drug NSC 63982, 574
Bisphosphonate risedronate
effects on metastatic breast cancer in bone, nude mice, 3551
Blacks: *see* **African-Americans**
Bladder
carcinogen-DNA adducts
NAT1 and NAT2 and, 5230
IQ-DNA adducts, *Ah/NAT* congenic mice, 3043
NAT1 genotype and phenotype, 5226
Bladder carcinoma
chromosome 4 allelic losses, 5396
chromosome 14q suppressor loci, 3246
hCGβ expression and secretion, 1479
hydroxyurea and iododeoxyuridine radiosensitization, 2800
invasive
angiogenic pathways, 510
hCGβ gene expression, 3735
p16/CDKN2 methylation, 4525
superficial
angiogenic pathways, 510
hCGβ gene expression, 3735
suppression
gelsolin, 3228
transitional cell
autocrine cell growth, granulocyte-colony stimulating factor, 3438
Bladder carcinoma *in situ*
partial allelotype, 5213
Bladder tumors
recurrent
C-erbB-2 gene amplification, 2422
Bleomycin
-induced chromatid breaks
case-control study, lung cancer, 557
Blood
bcl-2/J$_H$ translocations, 2876
Blood, peripheral
CD34+ hematopoietic cells
generation of immunostimulatory dendritic cells, 1099
malignant melanoma cells
PCR-based semiquantitative assessment, 4065
progenitor cells
transfusions, radioimmunotherapy support, breast cancer, 5916s
T lymphocytes
VEGF synthesis, 4140
Blood lymphocytes
sister chromatid exchanges
suppression by ginsenoside Rh$_2$, **1221**
Blood mononuclear cells
DNA adducts
and tobacco carcinogen-induced lung damage, 4910
B-*myb*
TGF-β1-treated M1 cells ectopically expressing
apoptosis, 501
BNCT: *see* **Boron neutron capture therapy**
Bombesin
receptors
bronchial epithelial cells, 1853
human breast cancer, 280
Bone
breast cancer metastases
bisphosphonate risedronate effects, nude mice, 3551
osteoclastic resorption
suppression by suramin, nude mice, 1989
Bone marrow
autologous transplantation, high-dose chemotherapy and
breast cancer patients, cyclophosphamide pharmacokinetics, 810
CD34+ hematopoietic cells
generation of immunostimulatory dendritic cells, 1099
diffuse uptake
radioimmunotherapy, red marrow dosimetry by sacral scintigraphy, 5827s
Boron neutron capture therapy
effects on mouse brain dopaminergic neurons, 874
L-^{10}B-*p*-Boronophenylalanine-fructose
effects on mouse brain dopaminergic neurons, 874
Bowel: *see* **Intestine**
4-[^{125}I]BP: *see* **4-[^{125}I]-*N*-(*N*-Benzylpiperidin-4-yl)-4-iodobenzamide**
(+)-BPDE
-induced splicing mutations
hprt locus, Chinese Hamster V-79 cells, 1550
Brain
-derived neurotrophic factor
expression, neuroblastoma, 1792
dopaminergic neurons
effects of BNCT on, mouse, 874
edema
local IL-2 and IFN-γ, 1902
malignant tissue
ERCC1, *XPAC*, and *ERCC2* mRNA expression, 1261, 3933
melanoma metastases
MSH-R expression, murine, 141
-type human Rab GDI isoform
cloning and expression, neuroblastoma, 5445
Brain tumors
in situ cyclopentenylcytosine infusion therapy, 1306
neovascularization
VEGF and, 1189
nitric oxide synthase expression, 727
BRCA1
hormone-dependent regulation, breast cancer cells, 4561
loss of heterozygosity, prostate cancer, 1002
mutations
germline, Japanese breast cancer families, 3521
ovarian cancers, 2998
BRCA2
carriers
wild-type deletions, chromosome 1312-q13, 4830
BrdUrd: *see* **5-Bromo-2′-deoxyuridine**
Breast
epithelial cells
p16 inactivation, 2892
p21$^{WAF1/CIP1}$ expression, suppression by *bcl-2*, 4520
malignant epithelium
and IGF-II expression, breast stroma, 2448
stroma
IGF-II expression, 2448
tissue
PDGF-B and PDGFR expression, 2703
Breast adenocarcinoma
cell adhesion to human vascular endothelial cells
thrombospondin modulation, 166
Breast carcinoma
α6 integrin expression levels, 901
advanced
high-dose ^{90}Y, phase I trial, 5921s
anti-BA46 mAb Mc3
humanized, 1717
anti-EGFRvIII mAbs, 3140
antigen
anti-idiotype mimicking, monkeys, 1525
DF3/MUC1, interaction with Grb2 and Sos/Ras, 4000
antihormonal therapy, human xenografts,

4146
Bcl-2 expression
estrogen regulation, 3902
bombesin/GRP receptors, 280
BRCA1
germline mutations, Japanese families, 3521
hormone-dependent regulation, 4561
loss of heterozygosity, prostate cancer, 1002
mutations, ovarian cancers, 2998
BRCA2
carriers, wild-type deletions, chromosome 1312-q13, 4830
CD44 isoforms, 5424
chromosome 1p loss of heterozygosity, detection and cloning, 1752
chromosome 11q23.3 loss of heterozygosity, 3003
combination chemotherapy response rates
BAX expression loss and, 4471
CYP1A1 restriction fragment length polymorphism and, African-American women, 3757
differential screening, 2896
differentiation
emodin, 3890
20-epi-vitamin D_3 analogue effects, 2822
E-cadherin expression
silence by DNA hypermethylation, 5195
elafin expression, 2537
ENV gene-like sequences, 5173
epithelial cell tumors
Epstein-Barr virus, 39
ERBB-2 amplification and expression, 5400
estrogen receptor-negative
estrogen receptor gene expression, 2279
exon 5 deletion variant estrogen receptor, 288
genomic instability
p53 abnormalities and, 646
glycoproteins containing mannose 6-phosphate, 3424
hRARα
regulation by estradiol, 4999
HTLV-I pX transgenic rats, 2524
inhibition
emodin, 3890
myc promotor-binding protein, nude mice, 3747
invasive
allelic loss, 467
lobular
ductal carcinoma *in situ* allelotype, 3976
microsatellite instability, frequency, 3976
replication error phenotype, 3976
male
chromosome 8 loss of heterozygosity, 4995
MCF-7 cells
adhesion to human vascular endothelial cells, 166
apoptosis, estrogen effects, 2487
chemosensitivity, p53 and, 1649
chemotherapy-induced apoptosis, increase by Bcl-x_s, 2507
estrogen receptor variant coexpression, 2158
estrogen-independent, expressing 80-kDa estrogen receptor, 2583
glutathione levels, NMR detection, 2012
growth inhibition by retinoids, 4446
MCF7ras cells
phenylacetate effects, 5156
MDA-MB-231 cells
MT-MMP and MMP-2 activation, regulation by concanavalin A, 3273
metastasis
bisphosphonate risedronate, nude mice, 3551
high-dose chemotherapy and autologous bone marrow transplantation, cyclophosphamide pharmacokinetics, 810
idoxifene, phase I study, 1070
plasma TGF-β2 levels, 4512
TAG-72 expression, enhancement by IFN-α, 5925s
TAP 1 and MHC class I loss, 5191
MHC class I loss, 5191
mitoxantrone-resistant cells
topotecan cross-resistance, 4004
MRP-1/CD9 expression, 4127
m-THPP and m-THPC tumor distribution and photodynamic therapy, 2620
MTX-resistant
RFC1 and, 3790
multiple
histological observations and chromosome 16q allelic loss, 3395
nitric oxide production
activation by relaxin, 5265
p16/CDKN2
chromosome 9p allelic loss and, 2892
PDGF-B and PDGFR expression, 2703
postmenopausal risk
CYP1A1 and *GSTM1* polymorphisms and, 3483
pregnancy immunization, 2257
progesterone receptor A and B expression, 5063
prognosis
PAI-2 and, 1423
progression
allelic loss and, 5180
prolactin synthesis and secretion, 2591
proliferation
cell culture, 2516
spermine, 934
20-epi-vitamin D_3 analogue effects, 2822
PSA indicator, 2104
radiation-induced
latent *p53* mutation expression and, 3310
radioimmunotherapy
^{131}I-labeled chimeric L6 antibody, peripheral blood progenitor cell transfusions support, 5916s
RS7, reactivity, 5857s
tumor-specific epitopes, 5847s
retinoic acid and γ-IFN effects, 2135
survival
BAX expression loss and, 4471
p53 alterations and, racial disparity, 1465
PAI-2 and, 1423
tamoxifen-resistant
estrogen receptor, progesterone receptor, and pS2 expression, 3331
TAP 1 and MHC class I loss, 5191
T47D cells
morphine and somatostatin receptor SSTR2 cross-reaction, 5632
two-generation exposure to PhIP, Sprague-Dawley rats, 4333
vitamin D_3 regulation of TGF-β1, 1540
xenografts
antihormonal therapy, 4146
apoptosis mRNA, radioimmunotherapy and, 5837s
^{31}P MRS, 1664
radioimmunotherapy, iodogen- and MATE-labeled ICR12, 5842s
yttrium-90 chimeric L6 therapy, nude mice, 5837s
Breast carcinoma *in situ*
ductal
allelotyping, 3399
microdissected
allelic loss, 467
Breast milk
PhIP exposure
mammary carcinoma risk, Sprague-Dawley rats, 4333
Breast neoplasms
benign
genetic aspects, 4416
chromosome 11 loss of heterozygosity, 2660
DNA imbalances
comparative genomic hybridization detection, 5415
estrogen receptor variant coexpression, 2158
glutathione peroxidase expression, 957
humanized antibodies, 5852s
p185$^{new/erbB-2}$ activation, 1946
progression
metabolite markers, NMR spectroscopy study, 5140
xenografts
RS7 radioimmunotherapy, 5857s
5-Bromo-2′-deoxyuridine
incorporation into colorectal liver metastases and liver, 3687
Bronchial carcinoma
premalignant epithelium
gene losses, 5133
Bronchial epithelial cells
bombesin receptors, 1853
novel human lines
tumorigenic phenotype loss, 6215
Bronchial neoplasia
p53 and EGFR expression, 1365
Bryostatin 1
induction of CDK2 dephosphorylation, 3716
Buccal mucosa
human biomonitoring assay, 1267
Burkitt's lymphoma
IgH/c-*myc* recombinations, 5012
WAF/CIP1, 1431
Buthionine sulfoximine
phase I trial
population pharmacodynamic model, 4507
88BV59H21–2
Tc-99m-labeled
radioimmunoscintigraphy, colorectal carcinoma, 5774s
BW835
definition of site-specific Thomsen-Friedenreich antigen, MUC1 tandem repeats, 4036
BZA-5B
nuclear lamin and p21^{ras} farnesylation block, 3295

C

776C85
effects on tegafur antitumor activity, 6227
CAAX peptidomimetics
Ras FTI 276
tumor growth blockade, nude mice, 4243
Cachexia
cytokine network, colon 26 adenocarcinoma-bearing mice, 921
-induced tumors
lipid-mobilizing factor and, mice and humans, 1458
Cacodylic acid
enhancement of carcinogenesis, F344/DuCrj

rats, 1271
Cadherin-6
sequence and expression, 2206
E-Cadherin
expression
regulation by γ-linolenic acid, 5043
silence by DNA hypermethylation, breast and prostate carcinoma, 5195
Caffeic acid esters
chemoprevention, colon carcinogenesis, 2310
-induced apoptosis, transformed rat fibroblast cells, 3576
Caffeine
-induced radiosensitization
p53 and, 1643
cagA
H. pylori
and gastric adenocarcinoma risk, 2111
Cain Memorial Award
Thirteenth, lecture, 753
Fourteenth, lecture, 2761
Calorie restriction
reduction of mammary and submandibular gland EGF expression, 1289
Calreticulin
expression
ionizing radiation effects, squamous cell carcinoma, 3016
Camptothecins
analogues
resistance, mitoxantrone-resistant breast carcinoma cells, 4004
seven-substituted water-soluble, antitumor effects, 603
metastases growth inhibition, newly developed xenograft models, 5637
preclinical and clinical research, Thirteenth Bruce F. Cain Memorial Award lecture, 753
resistance
CEM/C2 cells, topoisomerase I mutation, 1339
sensitivity
determinants, National Cancer Institute Anticancer Screen, 2116
L-Canavanine
growth inhibition, pancreatic cancer, 4486
Cancer research
targets
Fifth Heidelberger Conference meeting report, 705
Cancer screening
differential, breast carcinoma, 2896
Cancerization
field effect, 149
head and neck skin, 3604
Canthaxanthin
naturally occurring
chemoprevention, rat, 4059
Capillary hemangioblastoma
VEGF and VEGF receptor up-regulation, 1358
Carbohydrates
cell surface
alterations by α1,3 galactosyltransferase gene transfection, 4168
complex
Keystone Symposium, 450
Carbon-11
-labeled diacylglycerol
glioma signal transduction probe, 4225
Carboxypeptidase
-activated methotrexate-α-phenylalanine prodrug, 478
Carcinoembryonic antigen
antibodies
chimeric T84.66, phase I therapy trial, 5929s
humanized, targeting, preclinical and clinical studies, 5935s
^{131}I-labeled, medullary thyroid carcinoma, 5946s
^{99m}Tc-labeled, complete vs fragmented, 5786s
^{99m}Tc-labeled, targeting liver metastases of colorectal carcinoma, 5777s
tumor-specific uptake, monoclonal antibody-cobra venom factor conjugate effects, 5749s
antibody fragments
glycosylated, site-specific modifications, 5721s
humanized, Kemptide fusion protein, ^{P} labeling, 5968s
footprint analysis, colon carcinoma cells, 3873
galectin-3 ligand, human colon carcinoma cells, 2191
gene, recombinant vaccinia expressing
combined with rV-B7, enhanced antitumor effects, 3598
-induced adhesion molecule expression changes, 3250
TJA-I reactive sugar chains
expression, colon adenocarcinoma, 1675
Carcinogenesis: *see also* **Tumorigenesis**
cervical
volume-sensitive chloride channels and, 6077
chemical
UDP-glucuronosyltransferase genoprotective effects, 1045
colonic
chemoprevention, *S*-methyl methane thiosulfonate, male F344 rats, 4053
chemoprevention, phenylethyl-3-methylcaffeate, 2310
chemoprevention, sulindac, 1464
chemoprotection, ursodeoxycholate, azoxymethane rat model, 5257
enhancement by dietary 6-phenylhexyl isothiocyanate, 4311
protein kinase C isoforms, 5257
enhancement by dimethylarsinic acid, F344/DuCrj rats, 1271
liver
perillyl alcohol and, 979
lung
retinoid refractoriness, 5603
multiorgan
chemoprevention by DHEA and indomethacin, rat model, 4870
multistage
acceleration, TG.AC transgenic mouse skin, 3171
nickel exposure, lung, 5251
oral
chemoprevention, naturally occurring xanthophylls, astaxanthin, and canthaxanthin, 4059
skin
promotional phase, cholesterol sulfate effects, mouse, 4865
stomach
inhibition by EGCG, rat, 2081
potassium chloride promotion effects, 5238
Carcinogenicity
astemizole, mice and rat studies, 5589
Carcinogens
DNA adducts
bladder NAT1, NAT2, and, 5230
fecal diacylglycerol modulation, 2293
PhIP
chicken concentrations, 4516
exposure, mammary carcinoma risk, Sprague-Dawley rats, 4333
polycyclic aza-aromatic
human P450 metabolism, 1052
tobacco
-induced lung damage, blood DNA adducts and, 4910
-treated livers
oval cell lines OC/CDE 6 and OC/CDE 22, phenotype and differentiation patterns, 1028
Carcinoid tumors
somatostatin receptor scintigraphy, 5801s
Carcinoma
androgen-promoted
tamoxifen chemoprevention, rat seminal vesicle and prostate, 5621
angiogenesis
microvessel quantitation with clinicopathological correlations, 5049
antibodies
chimeric domain-deleted, biological properties, 5957s
-associated hypercalcemia
suppression by suramin, nude mice, 1989
cell adhesion
anti-NFκB reagent blockade, 4162
familial syndromes
G_2 checkpoint control, 1763
IL4R-bearing
antitumor effects of circularly permuted IL4-toxin, 3357
lymphocytes infiltrating
VEGF synthesis, 4140
origins
somatic mutations and, 5489
rhodamine-123 selectivity
multidrug resistance and, 1633
thrombopoietin receptor expression, 3509
ulcerative colitis-associated
adenomatous polyposis coli mutations, 2035
Carcinoma, biliary tract
p16 and *p15* mutations, 2756
Carcinoma, bladder
chromosome 4 allelic losses, 5396
chromosome 14q suppressor loci, 3246
hCGβ expression and secretion, 1479
hydroxyurea and iododeoxyuridine radiosensitization, 2800
p16/CDKN2 methylation, 4525
Carcinoma, breast
α6 integrin expression levels, 901
advanced
high-dose ^{90}Y, phase I trial, 5921s
anti-BA46 mAb Mc3
humanized, 1717
anti-EGFRvIII mAbs, 3140
antigen
anti-idiotype mimicking, monkeys, 1525
DF3/MUC1, interaction with Grb2 and Sos/Ras, 4000
antihormonal therapy, human xenografts, 4146
Bcl-2 expression
estrogen regulation, 3902
bombesin/GRP receptors, 280
CD44 isoforms, 5424
chromosome 1p loss of heterozygosity, de-

tection and cloning, 1752
chromosome 11q23.3 loss of heterozygosity, 3003
combination chemotherapy response rates
BAX expression loss and, 4471
CYP1A1 restriction fragment length polymorphism and, African-American women, 3757
differential screening, 2896
differentiation
emodin, 3890
20-epi-vitamin D_3 analogue effects, 2822
E-cadherin expression
silence by DNA hypermethylation, 5195
elafin expression, 2537
ENV gene-like sequences, 5173
epithelial cell tumors
Epstein-Barr virus, 39
ERBB-2 amplification and expression, 5400
estrogen receptor-negative
estrogen receptor gene expression, 2279
exon 5 deletion variant estrogen receptor, 288
genomic instability
p53 abnormalities and, 646
germline *BRCA1* mutations, Japanese families, 3521
glycoproteins containing mannose 6-phosphate, 3424
hRARα
regulation by estradiol, 4999
HTLV-I pX transgenic rats, 2524
inhibition
emodin, 3890
myc promotor-binding protein, nude mice, 3747
MCF-7 cells
adhesion to human vascular endothelial cells, 166
apoptosis, estrogen effects, 2487
chemosensitivity, p53 and, 1649
chemotherapy-induced apoptosis, increase by Bcl-x_s, 2507
estrogen receptor variant coexpression, 2158
estrogen-independent, expressing 80-kDa estrogen receptor, 2583
glutathione levels, NMR detection, 2012
growth inhibition by retinoids, 4446
MCF7ras cells
phenylacetate effects, 5156
MDA-MB-231 cells
MT-MMP and MMP-2 activation, regulation by concanavalin A, 3273
metastasis
high-dose chemotherapy and autologous bone marrow transplantation, cyclophosphamide pharmacokinetics, 810
idoxifene, phase I study, 1070
plasma TGF-β2 levels, 4512
TAG-72 expression, enhancement by IFN-α, 5925s
TAP 1 and MHC class I loss, 5191
metastasis in bone
bisphosphonate risedronate effects, nude mice, 3551
MHC class I loss, 5191
MRP-1/CD9 expression, 4127
m-THPP and m-THPC tumor distribution and photodynamic therapy, 2620
MTX-resistant
RFC1 and, 3790
multiple
histological observations and chromosome 16q allelic loss, 3395
p16/CDKN2
chromosome 9p allelic loss and, 2892
PDGF-B and PDGFR expression, 2703
pregnancy immunization, 2257
progesterone receptor A and B expression, 5063
prognosis
PAI-2 and, 1423
progression
allelic loss and, 5180
prolactin synthesis and secretion, 2591
proliferation
cell culture, 2516
20-epi-vitamin D_3 analogue effects, 2822
PSA indicator, 2104
radiation-induced
latent *p53* mutation expression and, 3310
radioimmunotherapy
^{131}I-labeled chimeric L6 antibody, peripheral blood progenitor cell transfusions support, 5916s
RS7, reactivity, 5857s
tumor-specific epitopes, 5847s
retinoic acid and γ-IFN effects, 2135
survival
BAX expression loss and, 4471
p53 alterations and, racial disparity, 1465
PAI-2 and, 1423
tamoxifen-resistant
estrogen receptor, progesterone receptor, and pS2 expression, 3331
TAP 1 and MHC class I loss, 5191
T47D cells
morphine and somatostatin receptor SSTR2 cross-reaction, 5632
two-generation exposure to PhIP, Sprague-Dawley rats, 4333
vitamin D_3 regulation of TGF-β1, 1540
xenografts
antihormonal therapy, 4146
apoptosis mRNA, radioimmunotherapy and, 5837s
^{31}P MRS, 1664
radioimmunotherapy, iodogen- and MATE-labeled ICR12, 5842s
yttrium-90 chimeric L6 therapy, nude mice, 5837s
Carcinoma, bronchial
premalignant epithelium
gene losses, 5133
Carcinoma, cervical
c-*myb* expression, 4432
combined activity of RAR- and RXR-selective retinoids against, 232
metastasis
lactate levels and, 4757
prognosis
MMP:TMP ratio and, 267
proliferation and gene expression
IFN-α-2b and retinoic acid effects, 3158
Carcinoma, clear cell renal
t(3;8) loss of heterozygosity, 5348
Carcinoma, colonic
APC tumor suppression, 1531
bisimidazoacridones, mechanism of action, 2338
camptothecin sensitivity determinants, National Cancer Institute Anticancer Screen, 2116
carcinoembryonic antigen footprint analysis, 3873
α-catenin loss, 4722
$CD4^+$ T-cell immunity to mutated ras protein, 2984
chromosome 7q31.1 loss of heterozygosity, 1347
fractionated radioimmunotherapy, $_{125}$I-labeled mAb CC49
human xenografts, 5881s
h*MLH1* mutation screening, Swedish hereditary nonpolyposis families, 6092
human xenografts
fractionated radioimmunotherapy, $_{125}$I-labeled mAb CC49, 5881s
metastasis
hepatic, prevention by TNP-470, 836
hepatic, promotion by laminin α1 chain IKVAV-containing peptide, 2476
inhibition by BB-94, 3629
promotion by laminin α1 chain IKVAV-containing peptide, 2476
p16/CDKN2 methylation, 4525
phenotypes
transition from noninvasive to invasive, 4722
prostaglandin G/H synthase protein expression, 2557
protein metabolism, 1160
replication errors
comparative genomic hybridization, 6002
sialyl-Le^x-**positive mucins, 921**
substrate balances, humans, 1373
TGF-β-RII mutation, 5545
vascular endothelial growth factor expression, 3964
Carcinoma, colorectal
colon DNA adduct levels and, 5611
cyclooxygenase-1 and -2 expression, 3785
DNA damage tolerance, 2304
enzyme/prodrug gene therapy, 4808
FdUMP binding sites and folate pool, 3897
liver metastases
targeting, 5777s
malignancy
telomerase effects, 2533
radioimmunoscintigraphy
Tc-99m-labeled totally human mAb 88BV59H21–2, 5774s
risk
glutathione *S*-transferase and, 2789
NAT1 polymorphism and, 3537
secretory phospholipase A_2 alterations, 5184
sialyl-Le^x-**positive mucins, 921**
survival
p53 point mutations and, 5217
SW480 cells
PAb421 restoration of mutant p53 function, 3490
Carcinoma, endometrial
HER-2/*neu* (c-*erb*B2) amplification and overexpression, 5693
sporadic
DNA mismatch repair gene mutations, 5556
TGF-β-RII mutation, 5545
Carcinoma, epithelial
explants
migrating cell clusters, 4557
Carcinoma, gallbladder
mutations, Chile, 2511
Carcinoma, gastric
H. pylori infection establishment age and, 562
membrane-type matrix metalloproteinase expression, 3263
microsatellite instability and erbB-2 expression, 1428
telomerase activity, 3258
TGF-β-RII mutation, 5545
Carcinoma, gastrointestinal
clonal intratumor heterogeneity, 2866

metastatic
D612 combined with rhM-CSF, phase II trial, 4339
Carcinoma, head and neck
nonmelanoma skin
p53 mutations, 3604
radioimmunotherapy
radiolabeled antibody combined with external radiotherapy, 1020
squamous cell
chromosomal aberrations, nonrandom patterns, 5030
cytogenetics, 3204
differentiation, retinoid-induced suppression, athymic nude mice, 3183
TGFβ type II receptor missense mutations, 3982
Carcinoma, hepatocellular
adenovirus-mediated gene therapy, 5283
antibody response, 111
CD24 cloning and expression, 4717
gene therapy
HSV-TK gene and AFP promoter, 3105
ornithine decarboxylase gene point mutation, 3500
telomerase activity, 2734
variant estrogen receptor mRNA species, 498
vegetable consumption, serum retinol level, and, 1301
Carcinoma, internal
and arsenic, seven-year follow-up study, Taiwan, 1296
Carcinoma, invasive
bladder
angiogenic pathways, 510
hCGβ gene expression, 3735
breast
allelic loss, 467
colon
phenotype transition, 4722
laminin-5 marker, 4132
Carcinoma, islet cell
chromosome 9 and 16 tumor suppressor loci, transgenic mouse model, 6071
Carcinoma, large bowel
risk
smoking and, women, 4906
Carcinoma, laryngeal
squamous cell
cell kinetics, prognostic significance, 6103
Carcinoma, lobular breast
ductal carcinoma *in situ* allelotype, 3976
microsatellite instability, frequency, 3976
replication error phenotype, 3976
Carcinoma, lung
anti-EGFRvIII mAbs, 3140
bleomycin-induced chromatid breaks, case-control study, 557
cyclin-dependent kinase inhibitor mutations, 1448
hereditary microsatellite instability, 3996
metastatic MV522 xenografts
illudin analogue efficacy against, 4936
pulmonary GSTM3 expression, 3305
spicamycin derivative *in vitro* cytotoxicity, 1075
stromelysin-3 expression and regulation, 4120
tumor growth blockade
Ras CAAX peptidomimetic FTI 276, nude mice, 4243
Carcinoma, male breast
chromosome 8 loss of heterozygosity, 4995
Carcinoma, medullary thyroid
radioimmunotherapy
^{131}I-labeled anti-CEA mAbs, 5946s
Carcinoma, mesenchymal
explants
migrating cell clusters, 4557
Carcinoma, nasopharyngeal
p16 alterations, 2039
Carcinoma, non-small cell lung
chemotherapy
response, p53 expression and, 5038
chest CT and SPECT fusion, 5759s
chromosome 17q loss of heterozygosity, 4268
chromosomes 5q and 18q loss of heterozygosity, 220
DNA damage and clinical response, PCR assay, 2334
enhanced apoptosis and, 5595
microsatellite instability, 28
MRP-1/CD9 expression
and prognosis, 6040
p16 alterations, 514
deletions, 2968
p15 alterations, 514
deletion, 2968
$p16^{INK4A}$ inactivation, 6200
pituitary adenylate cyclase activating peptide receptors, 4886
Rb inactivation and $p16^{INK4}$ expression, 505
stage I oncogenes, 51
stromelysin-3 overexpression, 4120
surfactant protein gene expression, RT-PCR detection, 4283
type 2 cytokine pattern, 3847
Carcinoma, oral
chromosomes 11q and 18q21 loss of heterozygosity, 5465
human papillomavirus type 16, 5465
retinoid chemoprevention
p53 and, 16
squamous cell
differentiation, retinoid-induced suppression, athymic nude mice xenografts, 3183
Carcinoma, ovarian
adenosine triphosphate chemosensitivity testing, 5276
amplification, 3380
bilateral
X chromosome inactivation and microsatellite instability, 4793
BRCA1 mutations, 2998
epithelial
LHRH and LHRH receptor mRNA expression, 817
invasion
mediation by CSF-1, 1578
metastasis
uPA, uPA-R, and PAI-1/2 content, 3958
nm23-H1 suppression, 2645
PSA gene expression, 1603
uPA, uPA-R, and PAI-1/2 content, 3958
Carcinoma, pancreatic
$CD4^+$ T-cell immunity to mutated ras protein, 2984
c-*MET*-encoded HGF receptor expression, 1129
gene therapy
liposome-mediated, 3810
growth inhibition
L-canavanine, 4486
IGF-I overexpression, 2007
mAb-PAM4 targeting, 1105
MUC-1
sialyl-Lewis^a and sialyl-Lewis^x and, 3659
orthotopic
PAM4 targeting, initial studies, 5743s
pond frogs, 3781
Carcinoma, papillary serous
multifocal, peritoneum, 490
Carcinoma, papillary thyroid
Chernobyl tumors
RET rearrangements, 5617
Carcinoma, prostatic
androgen receptor gene CAG and GGC microsatellites and, 1937
androgen-promoted
tamoxifen chemoprevention, rat, 5621
apoptosis
β-lapachone, 3706, 3712
linomide-induced, 3517
bcl-2 overexpression, 4438
C-CAM1 adenovirus therapy, preclinical study, 2831
C-CAM expression, 1215
C-CAM tumor suppression, 190
chromosomal anomalies
FISH detection, 5408
chromosome 7q31.1 loss of heterozygosity, 4114
chromosome 10q23-25 loss, 4800
chromosome 17q loss of heterozygosity, 1002
coagulopathy
tumor necrosis factor and, 4881
E-cadherin expression
silence by DNA hypermethylation, 5195
gene therapy
adeno-associated virus-based plasmids complexed to cationic liposomes, 2366
p53 or *p21* adenovirus, 5151
genetic changes
comparative genomic hybridization, 342
high-intensity focused ultrasound effects, 3346
IL-6 resistance risk factor, 4633
latent
androgen receptor gene mutations, Japanese men, 1621
linomide effects, rats, 1499
LNCaP cells
androgen *bcl-2*-mediated apoptosis resistance, 735
TNF-induced death, prevention by sulfated glycoprotein-2, 2431
malignant phenotypes
suppression by chromosome 17q fragments, 3389
metastasis
androgen receptor protein expression, 3068
sialyl Lewis^x up-regulation, 1817
microsatellite instability
and clinicopathological variables, 2418
PC3 cells
β-2 microglobulin mitogenicity, 781
drug-induced apoptosis, 2122
EGFR expression and binding affinity, androgen up-regulation, 3197
suppression by chromosome 5, 4813
risk
SRD5A2 polymorphisms and, 3973
TGF-β1 effects, 2596
tumor suppressor gene chromosome 8p loci, 5390
Carcinoma, refractory
pediatric
amifostine and melphalan, phase I trial, 4069
Carcinoma, renal cell
CDDP sensitization by anti-IL-6/IL-6R

mAbs, 590
chromosome 9 deletions, 224
clonal T cell expansions, 685
constitutive activation of MAPK, 4182
genomic alterations and instabilities, 6189
growth suppression by *VHL*, 4804
nonpapillary
chromosome 3p deletions, 5383
Pax-2 expression, 4092
sarcomatoid
p53 mutations and p53 protein overexpression, 658
t(3;8) loss of heterozygosity, 5348
Carcinoma, small cell lung
CCK-B/gastrin receptor mRNA, 276
H69 cells
VP-16-selected, *MRP* and *mdr1* sequential coexpression, 459
Rb inactivation and $p16^{INK4}$ expression, 505
Carcinoma, spindle
tumor progression, spontaneous rat mammary tumor, 399
Carcinoma, squamous cell
calreticulin expression
radiation and, 3016
chromosome 7q31.1 loss of heterozygosity, 1347
esophageal
microsatellite alterations, chromosome 3p, 893
thrombomodulin expression, 4196
head and neck
adenovirus-mediated gene therapy, nude mouse model, 1080
apoptosis induction by wild-type *p53* adenovirus, 3117
cyclin D1 overexpression, and recurrence, 975
deletions and amplifications, CGH detection, 1010
D-type cyclin expression, 949
microscopic residual, wild-type *p53* adenovirus, 1
radiolabeled mAb pharmacokinetics, biodistribution, and dosimetry, 1060
HLA A2601-restricted CTLs, 4248
lung
hyaluronan receptor expression, 3908
UV-induced, p53 transgenic mice, 2070
Carcinoma, superficial bladder
angiogenic pathways, 510
hCGβ gene expression, 3735
Carcinoma, testis
tumor suppressor gene loss of heterozygosity, 2871
Carcinoma, thyroid
medullary
ret silencing, 2048
Carcinoma, tongue
SAS cells
superoxide dismutase, 6210
Carcinoma, upper digestive tract
p16/CDKN2 mutation frequency, 3421
Carcinoma *in situ*
bladder
partial allelotype, 5213
breast
microdissected, allelic loss, 467
ductal, breast
allelotype, 3399
allelotype, lobular carcinoma, 3976
Cardiac hemangioendothelial neoplasms
fish *R. marmoratus*, 2438
Carmustine
simvastatin-enhanced antitumor effects, 597
Cartography: *see* Mapping
Castanospermine
effects on endothelial cells, 2920
Catalase
growth-promoting factor, 1586
***α*-Catenin**
loss, human colon cancer cells, 4722
Caucasians
pancreatic cancer
alcohol and, United States, 4899
C57BL/6 mice
liver tumor promotion by TCDD or Aroclor 1254, 4875
CC-1065
analogue immunoconjugates
antitumor effects, 4079
CC49
Fab radioimmunoconjugates
renal excretion, lysine and, 5288
^{125}I-labeled mAb
fractionated radioimmunotherapy, human colon carcinoma xenografts, 5881s
radiolabeled mAb, tumor uptake
enhancement by IFN-α, metastatic breast cancer, 5925s
sFv
radioimmunodetection, 2858
C-CAM: *see* Cell adhesion molecules
CcnD3
and glucocorticoid resistance, 4188
CCRF-CEM cells
iron metabolism
hydroxyurea effects, 4361
CCRF-CEM lymphoblastic leukemia
-derived cells
5,10-dideazatetrahydrofolic acid resistance, 566
CD3
clonal granular lymphocytes
superantigen activation, 6140
CD4
T-cell immunity
mutated ras protein, pancreatic and colon cancer, 2984
CD5
bispecific antibody-mediated costimulation, 4409
CD8
cytotoxic T cells
leukemia-specific clones, 3835
T cells
induction by minimal determinant, 1741
CD19
anti-CD19 scFvs, development and characterization, 2346
unconjugated mAb
antitumor effects, nude mouse xenograft model, 840
CD20
mAbs
eradication of Daudi tumors, 2627
unconjugated, antitumor effects, nude mouse xenograft model, 840
CD22
anti-CD22 Fab′ fragment
^{99m}Tc-labeled, B-cell non-Hodgkin's lymphoma staging, 5771s
LL2 anti-CD22 mAb
treatment of non-Hodgkin's lymphoma, 5899s
CD24
cloning and expression, hepatocellular carcinoma, 4717
CD28
bispecific antibody-mediated costimulation, 4409
CD30
ligand signal transduction, Hodgkin's lymphoma, 4157
unconjugated mAbs
antitumor effects, anaplastic large-cell lymphoma xenografts, 5335
CD33
monoclonal antibody M195
radiolabeled, myeloid leukemias, 5908s
CD34
hematopoietic cells
generation of immunostimulatory dendritic cells, 1099
CD40
immunotoxin, B-cell lymphoma, 3099
CD44
gene transcripts
abnormal intron 9 retention, gastrointestinal tumors, 4273
isoforms
breast cancer, 5424
pancreatic adenocarcinoma, 1831
mRNA splicing, thyroid lesions, 4594
splice variants
expression, pancreatic adenocarcinoma, 5499
CD45
cell adhesion and apoptosis suppression, mouse malignant T-lymphoma cells, 2186
CD54
monoclonal antibody
antitumor effects, SCID mice with human myeloma cells, 610
cdc2
activation
HL60 apoptosis, 228
chromosomal mapping, 1199
-related kinase PISSLRE
cell growth activation, 3992
CDDP: *see cis*-Diamminedichloroplatinum(II)
CDK: *see* Cyclin-dependent kinase
CDKN2
alterations, ovarian neoplasia, 2150
deletions
detection by interphase FISH, tumor cell lines and glioma, 984
leukemias and lymphomas, 1436
mutations, neuroblastoma, 2053
CDKN2/MTS1
solid tumors
immunohistochemical detection, 6006
CDKN2/p16/MTS1
inactivation
and aberrant DNA methylation, 4525
cDNA: *see* Complementary DNA
***Ced-3/Ice* cysteine protease**
human *Mch2* gene
cloning, 2737
Cell adhesion
anti-NFκB reagent blockade, 4162
CD45, mouse malignant T-lymphoma cells, 2186
colon cancer
to E-, P-, and L-selectin, 4425
homotypic
mediation by galectin-3, 3267
leukocytes
TNFα-induced, 4824
Cell adhesion molecules
epithelial, C-CAM
expression, prostate cancer, 1215
tumor suppressive role, prostate cancer, 190

epithelial, C-CAM1
adenovirus, prostate cancer therapy, preclinical study, 2831
Cell clusters
migration
mesenchymal and epithelial cancer explants, 4557
Cell cycle
activation
Epstein-Barr virus infection, quiescent B lymphocytes, 4784
arrest
p16^{INK4}, 3250
checkpoints
energetic, HL-60 cell accumulation, 5164
peroxide- and radiation-induced, constraints, 5069
G_1 arrest
p21 and, cancer cells, 5187
p53 and, irradiated human tumor cells, 1842
radiation-induced, human thyroid cells, 2075
UVB induction, human melanocytes, 4047
G_2 arrest
inhibition by merbarone vs VM-26, 1509
G_1 checkpoint
-competent and -deficient cells, radiosensitivity, 1639
regulation, cyclin D, head and neck cancer, 949
regulation, cyclin D1, 4818
regulation, p16$^{INK4/CDKN2}$, 4818
regulation, p53-dependent, lymphoma cells, 2387
G_2 checkpoint
abrogation, and radiosensitivity, 1639
control, human fibroblasts, familial cancer syndromes, 1763
delay loss, SV40 transformation, 7
mismatch repair and, 3721
p21^{CIP1} independence, 2500
regulation
DAN gene product function, rat fibroblasts, 895
TGFβ and, 1452
regulatory factors
expression, differentiating osteoblasts, 5019
Cell death: *see also* **Apoptosis**
polyamine analogue induction, 3233
TNF-induced
prevention by sulfated glycoprotein-2, LNCaP cells, 2431
Cell differentiation
induction
emodin, breast cancer, 3890
retinoic acid, neuroblastoma, 847
lymphocytes
p16^{INK4} and p15^{INK4B} expression, 4010
monocyte/macrophage
p53-independent *WAF1/CIP1* induction and, leukemia cells, 668
neuroblastoma
brain-derived neurotrophic factor and p145^{TrkB} expression and, 1792
-induced Bcl-2 and drug resistance, 4711
$1,25(OH)_2D_3$-induced
PP1 translocation, HL-60 cells, 774
osteoblasts
cell cycle regulatory factors expression, 5019
ret silencing, Raf-1-induced medullary thyroid carcinoma, 2048
retinoid-induced suppression, head and neck squamous cell carcinoma, athymic nude mice, 3183
20-epi-vitamin D_3 analogue effects, breast carcinoma, 2822
Cell growth: *see also* **Tumor growth**
ANBL6
characteristics, activated N-*ras* effects, 3640
arrest
p53-independent *WAF1/CIP1* induction and, leukemia cells, 668
thioredoxin secretion rates and, hepatoma cells, 675
astrocytes
loss of wild-type *p53* and, 2746
autocrine
G-CSF, transitional cell carcinoma of bladder, 3438
castanospermine effects, endothelial cell, 2920
effects of tyrosine 950 mutation of IGF-I receptor on, 663
induction
bFGF overexpression, HEC-1-B cells, 4729
dihydrotestosterone, 3197
PISSLRE, 3992
inhibition
1,15-bis(ethylamino)-4,8,12-triazapentadecane, human and mouse tumor cells, 2615
bryostatin 1, and CDK2 dephosphorylation, leukemia, 3716
connexin genes, HeLa cells, 629
Egr-1, 5054
farnesyl transferase inhibitors, human tumor cells, 5302
linomide, rat prostatic cancers, 1499
nm23-H1, ovarian carcinoma, 2645
p16/CDKN2, glioma, 1351
phenylacetate, MCF7ras cells and nude mice, 5156
schwannomin, NIH3T3 cells, 2270
sulindac metabolites, 3110
VHL, renal cell carcinoma, 4804
PML nuclear body effect, 1590
serum-dependent
syndecan-1 expression levels and, 293T cells, 4676
Cell proliferation
carcinogenic estrogen effects and, hamster kidney, 4347
IFN-α-2b and retinoic acid effects, ME 180 cells, 3158
inhibition
antisense cyclin G1, osteosarcoma cells, 5493
fluoromevalonate, Ras-transformed cells, 1732
glucocorticoids, lymphoid cells, 4188
risk factor, doubtful validity, 3759
spermine, breast cancer cells, 934
TGF-β1 effects, prostate cancer, 2596
tracheal epithelial cells
and c-*jun* activation by asbestos and H_2O_2, 2723
Cell surface antigens
antibody binding
functional affinity determination, 57332
Cell transformation
astrocytes
loss of wild-type *p53* and, 2746
fibroblasts
caffeic acid phenethyl ester-induced apoptosis, 3576
3T3 cells
ras mutations and microsatellite instability, 3513
tracheal epithelial cells
and c-*jun* activation by asbestos and H_2O_2, 2723
tyrosine 950 mutation of IGF-I receptor effects, 663
urothelial cells
in vitro, enhancement by IL-6, rat, 4581
Cellular retinoic acid-binding protein
retinoic acid and γ-IFN effects, breast cancer, 2135
Cellular trafficking
and immunotoxin cytotoxicity, 3763
CEM/C2 cells
topoisomerase I mutation, 1339
CEM/C7 cells
glucocorticoid receptor
modulator inhibition, 548
Central nervous system tumors
nitric oxide synthase expression, 727
xenografts
temozolomide effects, 2853
Ceramide
-induced apoptosis
mediation by *Bcl-2* mRNA suppression, 991
c-*erb*B-2
amplification and overexpression, endometrial cancers, 5693
BsMAb 2B1, phase I trial, 4586
gene amplification, recurrent bladder tumors, 2422
homodimers and heterodimers, 5983s
c-*erb*B-2 p185
mAb ICR12
iodogen- and MATE-labeled, breast cancer xenograft radioimmunotherapy, 5842s
Cerebrospinal fluid
O^6-benzylguanine pharmacokinetics, nonhuman primate, 4606
Cervical carcinogenesis
volume-sensitive chloride channels and, 6077
Cervical carcinoma
c-*myb* expression, 4432
combined activity of RAR- and RXR-selective retinoids against, 232
metastasis
lactate levels and, 4757
prognosis
MMP:TMP ratio and, 267
proliferation and gene expression
IFN-α-2b and retinoic acid effects, 3158
c-*fos*
expression
asbestos induction, mesothelial cells, 2085
and cigarette smoke, quiescent Swiss 3T3 cells, 1927
-induced osteosarcoma, transgenic mice, 6244
C3H 10T½ mouse fibroblasts
TGF-β-induced cyclin E-cdk2 kinase activation and p27^{Kip1} down-regulation, 1413
chCE7
copper-67-labeled
processing by neuroblastoma cells, 46
Chelates
anti-renal cell carcinoma × anti-DTPA bispecific mAbs, 5864s
substitution
effects on 2IT-BAT-Lym-1 immunoreactivity and biodistribution, 878

Chemicals
carcinogenesis
UDP-glucuronosyltransferase genoprotective effects, 1045
-induced skin tumors
ras mutations and microsatellite instability, 3513
-induced thymic lymphoma
reduced fidelity of DNA synthesis, mice, 3777
Chemoprevention
chlorophyllin, 57
curcumin
colon cancer, 259
dehydroepiandrosterone and indomethacin, rat multiorgan carcinogenesis model, 4870
intermittent oltipraz dosing, 4319
naturally occurring products, colonic aberrant crypt foci, F344 rats, 1277
naturally occurring xanthophylls, astaxanthin, and canthaxanthin, 4059
phenylethyl-3-methylcaffeate, colon carcinogenesis, 2310
p53-knockout mice, 3949
retinoid
p53 and, oral carcinogenesis, 16
sulindac, colon carcinogenesis, 1464
sunlight, 4014
tamoxifen
androgen-promoted carcinoma, rat seminal vesicle and prostate, 5621
Chemopreventive agents
evaluation, rat tracheal epithelial cell culture transformation assay, 537
Chemoprotection
ursodeoxycholate, azoxymethane rat colonic carcinogenesis model, 5257
Chemosensitivity
adenosine triphosphate
testing, ovarian carcinoma, 5276
p53 and, MCF-7 cells, 1649
Chemotherapy
combined with P-450-based gene therapy, 581
Fifth Heidelberger Conference meeting report, 705
high-dose, and autologous bone marrow transplantation
breast cancer patients, cyclophosphamide pharmacokinetics, 810
-induced apoptosis
increase by Bcl-x_s, MCF-7 cells, 2507
modulation by Bcl-x_L, 2576
intrinsic resistance
DNA repair and, lung cancer, 4760
lung cancer
response, p53 expression and, 5038
time-dependent pharmacodynamic models, 4507
Chernobyl tumors
RET rearrangements, 5617
Chest computed tomography
fusion with SPECT, non-small cell lung cancer, 5759s
Chicken
anemia virus-derived VP3 protein: *see* **Apoptin**
PhIP concentrations, 4516
Childhood acute leukemia
leukemia-specific cytotoxic T cell clones, 3835
Childhood acute lymphoblastic leukemia
allelotype analysis, 5377
Childhood refractory cancer
amifostine and melphalan, phase I trial, 4069
Children
cyclophosphamide metabolism, 803
N-*myc* gene amplification, localized neuroblastoma
Pediatric Oncology Group Study, 721
Chile
gallbladder carcinoma, mutations, 2511
β2-Chimaerin
astrocytoma malignant transformation, 3456
Chimeric L6
yttrium-90
human breast cancer radioimmunotherapy, nude mice, 5837s
Chimeric T84.66
^{90}Yttrium-radiolabeled
phase I therapy trial, 5929s
Chinese hamster cells
CHL cells
CYP3A7 and CYP3A4 stable expression, 787
mutants resembling Fanconi anemia, 3412
ovary cells
2′,2′-difluorodeoxyguanosine metabolism and actions, 1517
V79 cells
(+)-BPDE-induced splicing mutations, *hprt* locus, 1550
microtubule disruption by natural estrogens, 1863
Chinese women
lung cancer
p53 mutations, Hong Kong, 5343
Chloride channels
volume-sensitive
and cervical carcinogenesis, 6077
Chlorin e_6
photodynamic effects
enhancement by insulin-mediated intracellular targeting, 1014
(*O*-Chloroacetyl-carbamoyl) fumagillol
disposition and metabolism, hepatocytes and tissue microsomes, 3036
2-Chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-adenine
metabolism and actions, lymphoblastoid cells, 2847
Chloroethyl-cyclohexyl-nitrosourea
mutation fingerprint, mammalian cells, 4658
Chlorophyllin
dietary
inhibition of AFB_1 hepatocarcinogenesis, rainbow trout, 57
Cholecystokinin-B/gastrin receptor
mRNA
small cell lung cancer, 276
Cholesterol sulfate
antipromoting effects, mouse skin carcinogenesis, 4865
Chromatid breaks
bleomycin-induced
case-control study, lung cancer, 557
Chromosomal mapping
cdc2 protein kinases and $p27^{Kip1}$, 1199
DPC/BRCA2, 4571
D13S25, B cell chronic lymphocytic leukemia, 1355
$p27^{Kip1}$, 1211
ssic1, mouse chromosome 4, 3179
Chromosome 1
allelic losses, meningioma progression, 4696
Chromosome 1p
deletion
neuroblastoma, short-tandem repeat polymorphisms analysis, 5681
and prognosis, neuroblastoma, 5366
loss of heterozygosity
breast cancer, detection and cloning, 1752
neuroblastoma, 4664
Chromosome 3p
microsatellite alterations, esophageal squamous cell carcinoma, 893
terminal deletions, nonpapillary renal cell carcinoma, 5383
Chromosome 4
allelic losses, primary bladder carcinoma, 5396
mouse
ssic1 map, 3179
Chromosome 5
suppression of PC3 cells, 4813
Chromosome 5q
loss of heterozygosity, non-small cell lung cancer, 220
Chromosome 6q
deletion mapping, borderline epithelial ovarian tumors, 2169
Chromosome 7q31.1
loss of heterozygosity
prostate cancer, 4114
squamous cell and colon carcinoma, 1347
Chromosome 8
loss of heterozygosity, male breast carcinoma, 4995
Chromosome 8p12-21
allelic loss, microdissected prostatic intraepithelial neoplasia, 2959
Chromosome 8p
tumor suppressor gene loci, human prostate cancer, 5390
Chromosome 8q11
scid factor, *HYRC1* locus, 1774
Chromosome 9
alterations, ovarian neoplasia, 2150
deletions, renal cell cancer, 224
mouse
tumor suppressor loci, transgenic islet cell carcinoma model, 6071
Chromosome 9p
loss of heterozygosity, breast cancer, 2892
Chromosome 10
allelic losses, meningioma progression, 4696
Chromosome 10q
allelic loss, endometrial cancers, 1922
Chromosome 10q23-25
loss, prostate cancer, 4800
Chromosome 11
duplications, murine plasmacytomas, 1181
loss of heterozygosity, primary human breast tumors, 2660
Chromosome 11p15
loss of heterozygosity, malignant glioma, 2166
seven-Mb YAC contig, 2904
Chromosome 11q13
allelic loss, microdissected and invasive breast cancer, 467
Chromosome 11q23
loss of heterozygosity, cutaneous malignant melanoma, 2494
Chromosome 11q
loss of heterozygosity, lung adenocarcinoma, 3988
Chromosome 11q23
translocation breakpoints, 4287
Chromosome 11q23.3
loss of heterozygosity, breast cancer, 3003
Chromosome 12p13
$p27^{Kip1}$ assignment, leukemias, 1206
Chromosome 12q13-14
amplification and loss of heterozygosity,

malignant glioma, 727
Chromosome 12q14-15
rearrangements, pulmonary chondroid hamartoma, 2497
Chromosome 13
tumor suppressor genes, 1613
Chromosome 13q12
DPC/BRCA2 region mapping, 4571
Chromosome 13q12-q13
wild-type deletions, BRCA2 carriers, 4830
Chromosome 13q14
D13S218 deletions, B-cell chronic lymphocytic leukemia, 2044
Chromosome 14
allelic losses, meningioma progression, 4696
homogeneously staining regions
correlation with AFP expression, McA-RH 7777 rat hepatoma clones, 3615
Chromosome 14q
suppressor loci, bladder cancer, 3246
Chromosome 16
LRP localization, 4214
mouse
tumor suppressor loci, transgenic islet cell carcinoma model, 6071
Chromosome 16q
allelic loss, multiple breast cancers, 3395
Chromosome 17
amplified sequences
ring 22 chromosomes, dermatofibrosarcoma protuberans, 2400
Chromosome 17q
fragments
suppression of malignant phenotypes, prostate cancer, 3389
loss of heterozygosity, prostate cancer, 1002
Chromosome 18q
loss of heterozygosity, non-small cell lung cancer, 220
Chromosome 22
amplified sequences
ring 22 chromosomes, dermatofibrosarcoma protuberans, 2400
Chromosomes
abnormalities
head and neck squamous cell carcinoma, 3204, 5030
pancreas adenocarcinoma, 2394
p53-deficient mice, 3883
prostatic carcinoma and prostatic intraepithelial neoplasia, FISH detection, 5408
aneuploidy
multiple myeloma, detection by FISH, 3854
breakage
interphase lymphocytes 1cen-1q12 region, 640
and *MRP* or *LRP* gene amplification, 4214
defective repair, radiosensitive leukemia fibroblasts, 1232
microdissection
amplification, ovarian carcinoma, 3380
Philadelphia
expressing p230 BCR/ABL fusion protein, AR230 establishment, 3192
ring 22, dermatofibrosarcoma protuberans
amplified 17 and 22 sequences, 2400
separation
inhibition by merbarone vs VM-26, 1509
translocations
IgH/c-*myc* recombinations, Burkitt's lymphoma vs mouse plasmacytoma, 5012
t(6;14)(p21↖4), endometrial polyps, 31
t(10;11), breakpoint heterogeneity, AML-M4/M5, 4220
t(12;16)(q13↔1), liposarcomas, 24
Cigarette smoking
and large bowel cancer risk, women, 4906
Cigarettes
filter fibers, 253
smoke
crocidolite asbestos fibers, Kent cigarettes, 2232
exposure, c-*fos* expression and, quiescent Swiss 3T3 cells, 1927
Cisplatin
glutathione adducts
transport, cisplatin-resistant cancer cells, 4297
-induced apoptosis
mediation by ICE, malignant glioma cells, 6166
-induced immunostimulation
nitric oxide production, macrophages, 5524
resistance
ATP chemosensitivity testing, ovarian carcinoma, 5276
cisplatin-glutathione adduct transport, 4297
cytokeratin 18 expression, ovarian adenocarcinoma, 5203
γ-glutamylcysteine synthetase expression, ovarian cancer cells, 4367
mixed tumor cell spheroids, 386
p53 expression and, lung cancer, 5038
prostatic tumor cells, 474
sensitivity
cellular thioredoxin levels and, 4293
cytokeratin 18 expression, ovarian adenocarcinoma, 5203
γ-glutamylcysteine synthetase expression, ovarian cancer, 4367
increase by rapamycin, 1982
p53 and, MCF-7 cells, 1649
Citrate
^{67}Ga
B-cell non-Hodgkin's lymphoma staging, 5771s
c-*jun*
induction by asbestos, mesothelial cells, 2085
induction by asbestos and H_2O_2, 2723
c-*kit*
receptor loss, and thyroid epithelium transformation, 1787
Clear cell renal carcinoma
t(3;8) loss of heterozygosity, 5348
Cl-F-ara-A: *see* **2-Chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-adenine**
CLL: *see* **Leukemia, chronic lymphocytic**
Clonality
growth
stimulation by nerve growth factor, lung cancer cell lines, 2212
intratumor heterogeneity, gastrointestinal cancers, 2866
melanoma progression
tissue microdissection and comparative genomic hybridization visualization, 3954
methylation- and transcription-based assays, meningioma, 3865
T cell
expansions, renal cell carcinoma, 685
TGF-β
TGF-β receptor interactions, 2056
Wilms' tumors
p53 gene mutations and, 215
Clones
CD3$^+$ granular lymphocytes
superantigen activation, 6140
human carbonyl reductase cDNA expression, K562 cells, 4646
McA-RH 7777 rat hepatoma
AFP expression, correlation with chromosome 14 homogeneously staining regions, 3615
Cloning
brain-type human Rab GDI isoform, neuroblastoma, 5445
CD24, hepatocellular carcinoma, 4717
chromosome 1p loss of heterozygosity region, breast cancer, 1752
human *Mch2*, 2737
MART-1-specific T-cell receptor, 748
MAT1, 6058
microdissection-based
malignant melanoma translocation breakpoint, 4640
mVHLh1 gene, 743
rat 3α-hydroxysteroid/dihydrodiol dehydrogenase gene, 4105
TCTA, 1917
Clusterin
prevention of TNF-induced cell death, LNCaP cells, 2431
c-*MET*
-encoded HGF receptor
expression, pancreatic cancer, 1129
c-*myb*
expression, cervical carcinoma, 4432
HPV-16 transactivation, 4432
c-*myc*
amplification
minisatellite instability and, methylcholanthrene-induced mouse sarcoma, 5670
expression
and apoptosis, HL-60 cells, 1379
and glucocorticoid resistance, 4188
recombinations, Burkitt's lymphoma, 5012
regulation by *WT1*, 5386
Coagulopathy
tumor necrosis factor and, prostate cancer, 4881
Cobra venom factor
monoclonal antibody conjugate, 5749s
Cold Spring Harbor Laboratory
targets for specific therapies in leukemia meeting report, 4488
Colitis
ulcerative
adenomatous polyposis coli mutations, 2035
Collagenase
M_r 92,000 type IV
expression induction by fibroblasts, squamous cell carcinoma cell line, 963
Collagenase stimulatory factor
tumor cell-derived, isolation, 434
Colon
aberrant crypt foci
chemoprevention by naturally occurring products, F344 rats, 1277
cellular hMSH2 expression, 5146
DNA adducts
and colorectal cancer, 5611
IQ, *Ah/NAT* congenic mice, 3043
IQ, rat, 2769
mucosa
biliary glycoprotein expression, 2963
tumor-associated sialylated antigen expression, 1869

NAT1 genotype and phenotype, 5226
sialyl-Le^x-positive mucins, 921
Colonic adenocarcinoma
cachexia
cytokine network, mice, 921
laminin-5 and uPA receptor coexpression, 4132
platelet-aggregating sialoglycoprotein gp44, 767
TJA-I reactive sugar chains expression, 1675
Colonic adenoma
apoptosis
induction by TGF-β and substrate release, 5101
Colonic carcinoma
bisimidazoacridones, mechanism of action, 2338
camptothecin sensitivity determinants, National Cancer Institute Anticancer Screen, 2116
carcinoembryonic antigen footprint analysis, 3873
α-catenin loss, 4722
$CD4^+$ T-cell immunity to mutated ras protein, 2984
cell adhesion to E-, P-, and L-selectin, 4425
chemoprevention
curcumin, 259
S-methyl methane thiosulfonate, male F344 rats, 4053
phenylethyl-3-methylcaffeate, 2310
sulindac, 1464
ursodeoxycholate, azoxymethane rat model, 5257
chromosome 7q31.1 loss of heterozygosity, 1347
enhancement by dietary 6-phenylhexyl isothiocyanate, 4311
galectin-3 ligands, 2191
invasive phenotypes
transition, 4722
metastasis
hepatic, prevention by TNP-470, 836
hepatic, promotion by laminin α1 chain IKVAV-containing peptide, 2476
inhibition, BB-94, 3629
mutations
h*MLH1*, screening, Swedish hereditary nonpolyposis families, 6092
TGF-β-RII, 5545
p16/CDKN2 methylation, 4525
prostaglandin G/H synthase protein expression, 2557
protein kinase C isoforms, 5257
protein metabolism, 1160
radioimmunotherapy
combined with radiotherapy, nude mice, 83
vs external beam radiotherapy, 5811s
fractionated, $_{125}$I-labeled mAb CC49, human xenografts, 5881s
repetitive sequence, instability, and risk, 174
replication errors
comparative genomic hybridization, 6002
sialyl-Le^x-positive mucins, 921
substrate balances, humans, 1373
tumor suppression
APC, 1531
vascular endothelial growth factor expression, 3964
Colonic neoplasms
adenomatous polyposis coli mutations, 2035
azoxymethane-induced
inhibition by RO24-5531, 3050
T:G mismatches
base excision repair, 3742
Colorectal adenocarcinoma
full-length APC protein cells
microsatellite instability, 4797
Colorectal adenoma
acetylation polymorphism and, 2017
GSTM1 null genotype, smoking, and, 1224
Colorectal carcinoma
colon DNA adduct levels and, 5611
cyclooxygenase-1 and -2 expression, 3785
DNA damage tolerance, 2304
enzyme/prodrug gene therapy, 4808
FdUMP binding sites and folate pool, 3897
FUra and IFN-α treatment, 3543
liver metastases
targeting, 5777s
malignancy
telomerase effects, 2533
microsatellite instability, 5548
mutations
p53, PAb421 restoration,SW480 cells, 3490
p53 point, and survival, 5217
TGF-β-RII, 5548
radioimmunoscintigraphy
Tc-99m-labeled totally human mAb 88BV59H21–2, 5774s
risk
glutathione *S*-transferase and, 2789
NAT1 polymorphism and, 3537
secretory phospholipase A_2 alterations, 5184
sialyl-Le^x-positive mucins, 921
Colorectal neoplasms
angiogenesis
microvessel quantitation with clinicopathological correlations, 5049
apoptosis inhibition, 1811
bcl-2 and p53 oncoprotein expression, 237
glutathione *S*-transferase π, 2696
plasmin-catalyzed proteolysis, 4688
thymidylate synthase expression and 5-FU response, 1407
Comparative genomic hybridization
colon carcinoma with replication error, 6002
detection of novel deletions and amplifications, head and neck squamous cell carcinoma, 1010
DNA imbalances, archived breast tumors, 5415
genetic changes, prostatic neoplasms, 342
osteosarcoma studies, 1334
visuality of melanoma clonal progression, 3954
Complementary DNA
cadherin-6
sequence analysis, 2206
cloned human carbonyl reductase
expression, K562 cells, 4646
γ-glutamylcystein synthetase subunits, transfection
and intracellular glutathione and melphalan resistance, 4771
highly conserved oncofetal rat liver, 1152
IL-6, transduction
IL-6 resistance, melanoma cells, 2200
oncofetal
highly conserved rat liver, 1152
PCR-amplified metalloproteinase
and cervical carcinoma prognosis, 267
Complementation analysis
methylation tolerance, 2569
Computed tomography
single photon emission
fusion with chest CT, non-small cell lung cancer, 5759s
threshold estimation, 5823s
Concanavalin A
regulation of MT-MMP and MMP-2 activation, MDA-MB-231 cells, 3273
Conference on Radioimmunodetection and Radioimmunotherapy of Cancer
Fifth, introduction, 5708s
Congenic mice
Ah/NAT
IQ-DNA adducts, 3043
Connexin genes
negative growth control of HeLa cells, 629
Contact formation
$\alpha 4\beta 1$ integrin-mediated
NG2 and, 2177
Copper-67
-labeled chCE7
processing, neuroblastoma cells, 46
CPENSpm
cell death induction, 3233
CRABP: *see* **Cellular retinoic acid-binding protein**
c-*raf*-1
BCR/ABL-dependent and normal hematopoiesis, 2275
and taxol induction of $p21^{WAF1}$ and p53, 4623
Creatine kinase
and antihormonal therapy of human breast cancer xenografts, 4146
Crocidolite asbestos
fibers, Kent cigarette smoke, 2232
and mitosis, living vertebrate lung epithelial cells, 792
Crypts
aberrant foci
colonic, chemoprevention by naturally occurring products, F344 rats, 1277
hyperplastic to adenomatous, 4743
cystic
N-ethyl-*N*-nitrosourea treatment and, *Min* mice, 4479
CSF-1: *see* **Macrophage colony-stimulating factor**
CTLs: *see* **Cytotoxic T lymphocytes**
Curcumin
dietary
colon cancer chemoprevention, 259
Cutaneous melanoma
malignant
chromosome 11q23 loss of heterozygosity, 2494
PA and PAI expression, transgenic melanoma-susceptible mice, 4681
progression
UVB irradiation and, 3669
Cyclic AMP
-regulated TIMP synthesis
HT1080 suppression, 2927
stimulation by fumonisin, 1655
Cyclin B
postproliferative up-regulation, osteoblasts, 5019
Cyclin B1/Cdc2 kinase
activation
HL60 apoptosis, 228
Cyclin D
expression, head and neck cancer, 949
Cyclin D1
expression
SV40 large T antigen immortalization and, 4651
oncogenic aberrations
cooperation with p16, 4818
overexpression, head and neck squamous

cell carcinoma
and recurrence, 975
and $p16^{INK4}$ expression, lung cancers, 505
subunit association with PCNA and Waf1
SV40 large T antigen immortalization and, 4651
synthesis
induction by p53, 4257
Cyclin D3
and glucocorticoid resistance, 4188
Cyclin E
activation
TGF-β-induced, C3H 10T½ mouse fibroblasts, 1413
postproliferative up-regulation, osteoblasts, 5019
Cyclin G1
antisense
inhibition of osteosarcoma cell proliferation, 5493
Cyclin-dependent kinase
-activating kinase
assembly factor MAT1, cloning, 6058
inhibitors, 1448
gene *p27/Kip1*, malignancy, molecular analysis, 2266
mutant p21, Burkitt's lymphoma, 1431
p16 and p15, lymphocyte activation and neuronal differentiation, 4010
Cyclin-dependent kinase 2
activation
TGF-β-induced, C3H 10T½ mouse fibroblasts, 1413
dephosphorylation
induction by bryostatin 1, 3716
Cyclin-dependent kinase 3
chromosomal mapping, 1199
Cyclin-dependent kinase 4
amplification-associated overexpression, malignant glial tumors, 4833
Cyclin-dependent kinase 6
chromosomal mapping, 1199
Cyclin-dependent kinase 7
-associated human MAT1
cloning, 6058
Cyclobutane pyrimidine dimers
induction by sunlight, mononuclear cells, 2245
Cyclocreatine
uptake, C6 spheroids, NMR microscopy, 153
***N*-Cyclohexyl-1,3-diaminopropane**
spermine depletion
antiproliferative effects, breast cancer cells, 934
Cyclooxygenase-1
expression, colorectal cancer, 3785
Cyclooxygenase-2
expression, colorectal cancer, 3785
Cyclopentenylcytosine
in situ infusion
brain tumor therapy, 1306
Cyclophosphamide
metabolism, children, 803
pharmacokinetics, metastatic breast cancer patients receiving high-dose chemotherapy and autologous bone marrow transplantation, 810
-resistant tumor cells
DNA damage, glutathione and, 1691
CYP1A1
polymorphisms
and breast cancer, African-American women, 3757
lung adenocarcinoma, African-Americans, 472
lung cancer risk and African-Americans, 6035
and postmenopausal breast cancer risk, 3483
transcription
and *GSTM1* genotype, 5520
4-*S*-Cysteaminylcatechol
antimelanoma effects, 2603
4-*S*-Cysteaminylphenol
activated form
antimelanoma effects, 2603
Cysteine protease
apoptotic Mch3, 6045
Ced-3/Ice family
human *Mch2* gene, cloning, 2737
Cystic crypts
N-ethyl-*N*-nitrosourea treatment and, *Min* mice, 4479
Cysts
epidermoid
N-ethyl-*N*-nitrosourea treatment and, *Min* mice, 4479
Cytochrome P450
1A1
gene transcription, and *GSTM1* genotype, 5520
polymorphisms, and postmenopausal breast cancer risk, 3483
1A2
inhibition by oltipraz, hepatocytes, 5574
recombinant, Ames test with, 799
3A4
inhibition by oltipraz, hepatocytes, 5574
stable expression, CHL cells, 787
3A7
stable expression, CHL cells, 787
allelism
and glioma risk, 4237
-based gene therapy, 581
metabolism of polycyclic aza-aromatic carcinogens, 1052
NNK activation, human lung microsomes, 5566
Cytogenetics
head and neck squamous cell carcinoma, 3204
low-grade glioma regional heterogeneity, 1569
subgroups, endometrial polyps, 1656
Cytokeratin
anti-idiotypic mAbs
improved tumor targeting, 5868s
Cytokeratin 18
expression
cisplatin-sensitive and -resistant ovarian adenocarcinoma cells, 5203
Cytokines
cachexia network, colon 21 adenocarcinoma-bearing mice, 921
gene transfer
direct, RG-2 glioma growth attenuation and brain edema, 1902
-producing mammary carcinoma, HTLV-I pX transgenic rats, 2524
type 2
non-small cell lung cancer cells, 3847
and VP-16
simultaneous treatment, 324
Cytosine deaminase/5-fluorocytosine enzyme/prodrug combination
vs thymidine kinase/ganciclovir enzyme/prodrug system, colorectal carcinoma cells, 4808
Cytotoxic agents
resistance
genetic radiotherapy, 5561
Cytotoxic T lymphocytes
antigen-specific
quantitative recognition of HLA class I molecules, 3149
antimelanoma
generation with dendritic cells, 5330
CD8+
induction by minimal determinant, 1741
HLA A2601-restricted, squamous cell carcinoma, 4248
human MHC nonrestricted line
glioblastoma treatment, 96
-induced apoptosis, BCR-ABL-expressing cells, 463
induction
soluble antigen formulation, 3486
leukemia antigen peptides recognized by, 4781
leukemia-specific clones, 3835
Cytotoxicity
antineoplastic agent
topoisomerase IIα and β expression and, acute lymphoblastic leukemia, 78
anti-osteosarcoma immunotoxin, 1321
CDDP and etoposide-mediated
IL-6 resistance risk factor, prostate carcinoma cell lines, 4633
daunorubicin
protection, carbonyl reductase cDNA expression, K562 cells, 4646
heregulin fused to PE38KDEL, 71
immunotoxin
trafficking and, 3763
in vitro
spicamycin derivative, lung cancer, 1075
natural killer cell-mediated
B7–1-induced, 2730
NB-506, 1310
triazene-induced
OGAT effects, L1210 leukemia, 6231

D

D612
combined with rhM-CSF
metastatic gastrointestinal cancer, phase II trial, 4339
DAN
cell cycle-regulatory function, rat fibroblasts, 895
Daudi tumors
eradication with CD20 mAbs and IL-2, 2627
Daunorubicin
cytotoxicity
protection, carbonyl reductase cDNA expression, K562 cells, 4646
-stimulated topoisomerase II DNA cleavage, 312
Daunorubicin reductase
expression, K562 cells, 4646
DBA/2 mice
liver tumor promotion by TCDD or Aroclor 1254, 4875
DC1
immunoconjugates
antitumor effects, 4079
3′-Deamino-3′-(2-methoxy-4-morpholinyl)-doxorubicin
phase I study, 2090
Defects
ERCC2
xeroderma pigmentosum group D, 5656
GSTM1 and *NAT2*
and human malignant mesothelioma, 2981
interferon, malignant melanoma, 4099

and microsatellite instability, human cancer cells, 6063
mismatch repair, uterine and ovarian sarcomas, 5664
Dehydroepiandrosterone
alone or combined with indomethacin chemoprevention, rat multiorgan carcinogenesis model, 4870
Deleted in colon cancer protein
distribution, human tissues, 5628
Deletion mapping
chromosome 6q, borderline epithelial ovarian tumors, 2169
D13S25, B cell chronic lymphocytic leukemia, 1355
esophageal squamous cell carcinoma, 1828
Deletions
CDKN2
interphase FISH detection, tumor cell lines and glioma, 984
CGH detection, head and neck squamous cell carcinoma, 1010
chromosome 1p
neuroblastoma, short-tandem repeat polymorphisms analysis, 5681
and prognosis, neuroblastoma, 5366
D13S25, B-cell chronic lymphocytic leukemia, 3475
D13S218, B-cell chronic lymphocytic leukemia, 2044
ductal carcinoma *in situ*, breast, 3399
E2F1
S phase lengthening and sensitization to antitumor drugs, 2883
p15, non-small cell lung carcinoma, 2968
$p15^{INK4B}$
monosomy 5 and, kidney epithelial cell lines, 1607
undifferentiated mouse skin tumors, 5168
p16, non-small cell lung carcinoma, 2968
$p16^{INK4}$
monosomy 5 and, kidney epithelial cell lines, 1607
$p16^{INK4a}$
undifferentiated mouse skin tumors, 5168
p53
Ras CAAX peptidomimetic FTI 276 tumor growth blockade, lung carcinoma, 4243
RB-1, B-cell chronic lymphocytic leukemia, 3475
terminal
chromosome 3p, nonpapillary renal cell carcinoma, 5383
wild-type
chromosome 13q12-q13, BRCA2 carriers, 4830
Demethylation
estrogen receptor gene, estrogen receptor-negative breast cancer cells, 2279
Dendritic cells
generation of antimelanoma CTLs, 5330
immunostimulatory
generation from CD34+ hematopoietic cells, 1099
2-Deoxy-D-glucose
effects on TNF-induced apoptosis, 444
Deoxyspergualin
human antimouse antibody suppression, phase I study, 3060
Dephosphorylation
cyclin-dependent kinase 2
induction by bryostatin 1, 3716
retinoblastoma protein
failure, drug-resistant cells, 5222
Dermatofibrosarcoma protuberans
ring 22 chromosomes
amplified 17 and 22 sequences, 2400
Detoxifying enzymes
genotypes
and glioma risk, 4237
Dewar valence isomers
induction by sunlight, mononuclear cells, 2245
Dextranation
polypeptides, 5710s
DF3/MUC1
interaction with Grb2 and Sos/Ras, 4000
DHEA: *see* **Dehydroepiandrosterone**
Diacylglycerol
carbon-11-labeled
glioma signal transduction probe, 4225
fecal
modulation by diet and carcinogen, 2293
***cis*-Diamminedichloroplatinum**
cytotoxicity
IL-6 resistance risk factor, prostate carcinoma cell lines, 4633
***cis*-Diamminedichloroplatinum(II)**
electrochemotherapy, antitumor effectiveness, mice, 3450
resistance genes
identification with retroviral insertional mutagenesis, 1139
sensitization
anti-IL-6/IL-6R mAbs, renal cell carcinoma, 590
Diazepam binding inhibitor
peripheral-type
expression, human astrocytomas, 2691
(3,5-Di-*tert*-butyl-4-hydroxybenzylidene)-malononitrile: *see* **AG17**
Dichloroacetic acid
suppression of spontaneous apoptosis, murine hepatocytes, 3702
5,10-Dideazatetrahydrofolic acid
resistance, CCRF-CEM-derived cells, 566
Diet
chlorophyllin
inhibition of AFB_1 hepatocarcinogenesis, rainbow trout, 57
curcumin
chemoprevention of colon cancer, 259
fecal diacylglycerol modulation, 2293
S-methyl methane thiosulfonate
chemoprevention, male F344 rats, 4053
6-phenylhexyl isothiocyanate
colon carcinogenesis enhancement, 4311
^{111}In-Diethylenetriaminepentaacetic acid
anti-renal cell carcinoma × anti-DTPA bispecific mAbs, 5864s
-monoclonal antibodies
metabolism, 5714s
^{111}In-Diethylenetriaminepentaacetic acid-D-[Phe^1]-octreotide
scintigraphy, 5794s
scintigraphy, pancreatic adenocarcinoma, 5805s
Diethylnitrosamine
-induced hepatoma
respiratory chain impairment, 3028
-treated hepatocytes
Ras-transduced, tumors, 5242
Differentiation
20-epi-vitamin D_3 analogue effects, breast cancer cell lines, 2822
2′,2′-Difluorodeoxyguanosine
metabolism and actions, CHO cells, 1517
Digestive tract cancers
p16/CDKN2 mutation frequency, 3421
3,3′-Dihexyloxacarbocyanine iodide
photosensitization, 2063
Dihydrodiol dehydrogenase
gene analysis, 4105
Dihydrotestosterone
induction of EGFR expression and cell growth, 3197
1α,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol
inhibition of azoxymethane-induced colonic tumorigenesis, 3050
1α,25-Dihydroxyvitamin D_3
analogue RO24-5531
inhibition of azoxymethane-induced colonic tumorigenesis, 3050
-induced differentiation
PP1 translocation, HL-60 cells, 774
regulation of TGF-β1, breast carcinoma cells, 1540
Dimethylarsinic acid
enhancement of carcinogenesis, F344/DuCrj rats, 1271
7,12-Dimethylbenzanthracene
-treated stromelysin-1 transgenic mice
mammary tumors, 1401
1,6-Dinitropyrene
DNA adducts and T-lymphocyte mutation induction, F344 rats, 2316
Dinucleotides
CpG
base transitions, *p53*, esophageal adenocarcinoma, 3406
β-L-Dioxolane-cytidine
anticancer effects, 3008
Diploid cells
mutant p53 and SDI1/WAF1, senescence, 2404
Disulfide
-stabilized anti-$p185^{HER2}$ Fv-β-lactamase fusion protein
humanized, 63
-stabilized anti-Tac Fv
biodistribution, nude mice, 5323
tumor imaging, 318
DNA
copy number changes, squamous cell head and neck tumors, 3055
-dependent protein kinase activity
tumor cell radiosensitivity and, 5200
etoposide-induced recombination
inhibition by Bcl-2, 4029
fragmentation
and radiation-induced apoptosis, Ewing's sarcoma cells, 4240
hypermethylation
E-cadherin expression silence, breast and prostate carcinoma, 5195
imbalances, archived breast tumors
comparative genomic hybridization detection, 5415
instability and repetitive sequences
colon cancer, 174
methylation
p16 inactivation, 4525
mini- and microsatellite markers
clonal intratumor heterogeneity detection, gastrointestinal cancer, 2866
mismatch
binding defects, colorectal carcinoma cell lines, 2304
T:G, base excision repair, 3742
U:G, base excision repair, 3742
mismatch repair
base excision, 3742
and cancer origins, 5489

defects, uterine and ovarian sarcomas, 5664
deficiency, and microsatellite instability, human cancer cells, 6063
and G_2 checkpoint, 3721
gene mutations, sporadic endometrial carcinomas, 5556
peripheral blood leukocyte
6-thioguanine quantitation, 1670
photoproducts
induction by sunlight, mononuclear cells, 2245
sequence amplification, ovarian carcinoma, 3380
sequence gains and losses, osteosarcoma
comparative genomic hybridization studies, 1334
synthesis
reduced fidelity, thymic lymphoma, 3777
tandem probes
interphase cell chromosomal breakage, 640
T:G mismatches
colonic neoplasms, base excision repair, 3742
topoisomerase I-mediated cleavage
induction by NB-506, 1310
U:G mismatch base excision repair, 3742
xrs-6 strand break rejoining defect
correction by human *Ku80*, 1235
DNA, complementary
cadherin-6
sequence analysis, 2206
cloned human carbonyl reductase
expression, K562 cells, 4646
γ-glutamylcystein synthetase subunits, transfection
and intracellular glutathione and melphalan resistance, 4771
highly conserved oncofetal rat liver, 1152
IL-6, transduction
IL-6 resistance, melanoma cells, 2200
PCR-amplified metalloproteinase
and cervical carcinoma prognosis, 267
DNA adducts
carcinogen
bladder NAT1, NAT2, and, 5230
colon levels
and colorectal cancer, 5611
1,6-dinitropyrene, F344 rats, 2316
IQ
colon, bladder, kidney, *Ah/NAT* congenic mice, 3043
colonic wall, rat, 2769
lung and blood, 4910
O^6-methylguanine
formation and modulation by ethanol, 6017
PAH-
immunohistochemistry, lymphocytes, 1417
smoking-related
mucosa vs biopsies, 1267
time-integrated
and PAH-induced adenoma, A/J mouse lung, 1039
DNA damage
breaks
and genomic instability, 1122
and hypomethylation, folate/methyl-deficient rat livers, 1894
cellular responses
ataxia-telangiectasia and, 5991
and clinical response, non-small cell lung cancer, 2334
cyclophosphamide-resistant tumor cells
glutathione and, 1691
double-strand breaks
defective repair, radiosensitive leukemia fibroblasts, 1232
repair, scid factor and, 1774
HL60 apoptosis
cyclin B1/Cdc2 kinase activation, 228
-resistance phenotype
human malignant melanoma cells, enhanced photoproduct repair, 181
tamoxifen-induced, rats, 544
tolerance, colorectal carcinoma cell lines, 2304
DNA damaging agents
prostatic epithelial cells
p53 and p21, 3726
DNA repair
defective, radiosensitive leukemia fibroblasts, 1232
double-strand breaks
scid factor and, 1774
eukaryotic genes and gene products, workshop meeting report, 968
genes
lymphocytes, amplification by multiplex RT-PCR, 5025
HL60 cells, 336
and intrinsic chemotherapy resistance, lung cancer, 4760
mismatch
base excision, 3742
and cancer origins, 5489
defects, uterine and ovarian sarcomas, 5664
deficiency, and microsatellite instability, human cancer cells, 6063
and G_2 checkpoint, 3721
geme mutations, sporadic endometrial carcinomas, 5556
xrs-6 defect
correction by human *Ku80*, 1235
DNA repair enzymes
apurinic/apyrimidinic endonuclease
cellular and subcellular expression, 6097
DNA topoisomerase I
levels and localization, myeloid maturation, 1255
-mediated cleavage
induction by NB-506, 1310
mutation, CEM/C2 cells, 1339
-related parameters
colon carcinoma, National Cancer Institute Anticancer Screen, 2116
DNA topoisomerase I/DNA complexes
and topotecan, analysis, 2097
DNA topoisomerase II
bisdioxopiperazine target, *S. cerevisiae*, 2299
cleavage
anthracycline-stimulated, 312
cleavage sites
chromosome 11q23 translocation breakpoints, 4287
inhibitors
merbarone vs VM-26 cellular actions, 1509
DNA topoisomerase IIα
acute lymphoblastic leukemia, 78
alterations, mitoxantrone-resistant HL-60 cells, 1707
cytoplasmic localization, lung cancer, 2129
expression
and alkylating agent resistance, 6109
etoposide/teniposide-resistant human cancer cells, 3860
truncated mRNA and protein, HL-60 cells, 4962
DNA topoisomerase IIβ
acute lymphoblastic leukemia, 78
alterations, mitoxantrone-resistant HL-60 cells, 1707
Dopaminergic neurons
effects of BNCT on, mouse brain, 874
DOTA: ***see*** **1,4,7,10-Tetraazacyclododecane-*N,N′,N″,N‴*-tetraacetic acid**
Doxorubicin
glutathione peroxidase effects, 4465
immunoconjugate
therapeutic efficacy, preclinical spontaneous metastatic human melanoma model, 2352
prodrug, combined with mAb β-lactamase conjugates
activation, 2357
sensitivity
cellular thioredoxin levels and, 4293
DPC/BRCA2
physical map, 4571
Drug resistance: ***see also*** **Multidrug resistance; Resistance**
differentiation-induced, neuroblastoma, 4711
mediation by Bcl-x_L, neuroblastoma cells, 2576
retinoblastoma protein dephosphorylation failure, 5222
TGF-β_1-mediated, 1758
Drug sensitivity
assays
riboflavin-mediated photosensitization of *Vinca* alkaloids and, 4837
cellular thioredoxin levels and, 4293
Drugs: ***see also*** **Prodrugs**
anticancer
sensitivity
metallothionein null cells, 2021
antiepileptics
and hepatobiliary cancer and malignant lymphoma, 294
antitumor
in vitro pharmacodynamic studies, design and analysis, 5315
platinum- and quinazoline-based molecules
initiatives, Fourteenth Bruce F. Cain Memorial Award lecture, 2761
quinolone compounds
A-8441, biological characterization, 830
sensitization
E2F1 deletion mutant, 2883
in vitro pharmacodynamic studies, design and analysis, 5315
bisnitroimidazole-bioreductive, 574
-induced apoptosis
inhibition by *BCL-2*, HeLa cells, 4922
PC-3 cells, 2122
platinum- and quinazoline-based
initiatives, Fourteenth Bruce F. Cain Memorial Award lecture, 2761
D13S25
deletions
B-cell chronic lymphocytic leukemia, 3475
cartography and mapping, B cell chronic lymphocytic leukemia, 1355
D13S218
deletions, B-cell chronic lymphocytic leukemia, 2044
DT-diaphorase
mRNA
alternatively spliced, normal and tumor tissues, 2542

DTMP
salvage
modulation by thymidylate synthase inhibitors, 1505
DTPA: *see* **Diethylenetriaminepentaacetic acid**
Ductal adenocarcinoma
pancreatic
genetic alterations, hamster, 2560
Ductal carcinoma *in situ*
breast
allelotype, 3399
allelotype, lobular carcinoma, 3976
Duodenal ulcer
risk
H. pylori infection establishment age and, 562
Duplications
chromosome 11, murine plasmacytomas, 1181
N-MYC, neuroblastoma cells, 3471
DX-52–1
efficacy against human melanoma lines, 862
Dysplasia
nevi
p53 mutations, 4278
ulcerative colitis-associated
adenomatous polyposis coli mutations, 2035

E

E6
inhibition, 4599
E7
gene inhibition, 4599
immunogenicity
HPV-16-transgenic mice, 2635
E1a
-mediated tumor suppression, 5551
EB1
APC binding, 2972
Edema
brain
local IL-2 and IFN-γ, 1902
E2F1
deletion mutant
S phase lengthening and sensitization to antitumor drugs, 2883
EGCG: *see* **(−)-Epigallocatechin gallate**
EGF: *see* **Epidermal growth factor**
Egr-1
inhibition of tumor cell growth, 5054
Eker rat model
preneoplastic renal cells
Knudson's two-hits, detection by laser microdissection, 989
Elafin
expression, mammary epithelial cells vs carcinoma, 2537
Electrochemotherapy
CDDP
antitumor effectiveness, mice, 3450
Embryo basement membranes
sea urchin
invasion by metastatic tumor cells, 5085
EMMPRIN
isolation, 434
Emodin
suppression and differentiation of breast cancer cells, 3890
Endocrine tumors
p53- and *Rb*-deficient mice, 1146
peroperative detection
[^{111}In]octreotide scintigraphy, 5794s
Endometrial carcinoma
chromosome 10q allelic closs and replication errors, 1922
HER-2/*neu* (c-*erb*B2) amplification and overexpression, 5693
sporadic
DNA mismatch repair gene mutations, 5556
TGF-β-RII mutation, 5545
Endometrial polyps
cytogenetic subgroups, 1656
t(6;14)(p21↖4) translocation, 31
Endometrium
HEC-1-B cells
bFGF overexpression, 4729
malignant transformation
lactoferrin mRNA and protein overexpression and, 1168
tissue
fucosyltransferase and α-L-fucosidase activities and fucose levels, 3654
Endonuclease
anoxia inducible
and genomic instability, 1122
Endothelial cell growth factors
platelet-derived
angiogenesis, thymidine phosphorylase activity and 1687
Endothelial cells
castanospermine effects, 2920
EGF- and laminin-dependent motility and angiogenesis
antagonism by murine EGF fragment (33-42), 3772
genetically modified
angiogenesis-directed implantation, mice, 2240
vascular
cancer cell adhesion, anti-NFκB reagent blockade, 4162
MCF-7 cell adhesion, 166
ENV
-like sequences, breast cancer, 5173
Enzyme/prodrug gene therapy
colorectal carcinoma
cystosine deaminase/5-fluorocytosine vs thymidine kinase/ganciclovir enzyme/prodrug systems, 4808
Enzymes
apurinic/apyrimidinic endonuclease DNA repair
cellular and subcellular expression, 6097
detoxifying
genotypes, and glioma risk, 4237
Lewis
expression, Lewis-negative cancer patients, 1473
xenobiotic metabolizing
expression, tamoxifen effects, rat liver, 1780
Epidermal growth factor
-dependent motility and angiogenesis
antagonism by murine EGF fragment (33-42), endothelial cells, 3772
mammary and submandibular gland expression
reduction by calorie restriction, 1289
murine fragment (33-42)
laminin antagonism, 3772
receptor
binding affinity, androgen up-regulation, PC3 cell lines, 3197
expression, androgen up-regulation, PC3 cell lines, 3197
expression, bronchial neoplasia and squamous cell carcinoma, 1365
ligands, and epidermal neoplasia, 1883
and ornithine decarboxylase transformation, NIH3T3 cells, 5358
receptor variant III
expression, multiple human tumors, 5536
mAbs, breast and lung carcinomas and malignant gliomas, 3140
mAbs, tumor-specific, 4375
Epidermal neoplasms
EGFR ligands and, 1883
integrin expression, 5434
Epidermal tumorigenesis
ornithine decarboxylase and, 1680
Epidermoid cysts
N-ethyl-*N*-nitrosourea treatment and, *Min* mice, 4479
(−)-Epigallocatechin gallate
inhibition of MNNG-induced carcinogenesis, rat glandular stomach, 2081
Epithelial carcinoma
explants
migrating cell clusters, 4557
ovarian
LHRH and LHRH receptor mRNA expression, 817
Epithelial cell adhesion molecule
adenovirus
prostate cancer therapy, preclinical study, 2831
expression, prostate cancer, 1215
tumor suppressive role, prostate cancer, 190
Epithelial cell tumors
Epstein-Barr virus, breast cancer study, 39
Epithelial cells
breast
p16 inactivation, 2892
$p21^{WAF1/CIP1}$ expression, suppression by *bcl-2*, 4520
bronchial
bombesin receptors, 1853
novel human lines, tumorigenic phenotype loss, 6215
intestinal
H-*ras*-transformed, TGF-β receptors, 6181
kidney
monosomy 5 and $p15_{INK4B}$/$p16_{INK4}$ deletions, 1607
living vertebrate lung
mitosis, crocidolite asbestos and, 792
mammary
apoptosis, stromelysin-1 transgenic mice, 1401
elafin expression, 2537
ovarian
apoptosis regulation by TGF-β, 944
prostatic
p53 and p21, 3726
rat tracheal culture transformation assay
chemopreventive agents, 537
reduced folate carrier functional activity, 3790
rhodamine-123 selectivity
multidrug resistance and, 1633
thyroid
mutant p21*ras* expression, induction of IGF-1 secretion, 915
tracheal
proliferation and transformation, and c-*jun* activation by asbestos and H_2O_2, 2723
Epithelial lesions
premalignant
progression to bronchial carcinoma, gene losses, 5133
Epithelial ovarian tumors
borderline
chromosome 6q deletion mapping, 2169

Epithelium
gastric
mucin gene expression, 2681
malignant breast
and IGF-II expression, breast stroma, 2448
thyroid
transformation, c-*kit* receptor loss and, 1787
Epothilones
microtubule-stabilizing agents, mechanism of action, 2325
Epstein-Barr virus
epithelial cell tumors, breast cancer study, 39
infection, quiescent B lymphocytes
cell cycle activation, 4784
-specific T-cell responses, Hodgkin's disease, 3675
erb*B-2*
amplification, breast cancer, 5400
expression
breast cancer, 5400
microsatellite instability and, gastric carcinoma, 1428
Erbstatin
methyl 2,5-dihydroxycinnamate analogue
cross-linking tumor cell proteins, 4950
ERCC1
mRNA expression, malignant brain tissue, 1261, 3933
ERCC2
defects, xeroderma pigmentosum group D, 5656
mRNA expression, malignant brain tissue, 1261, 3933
Erythrocytes
-derived growth-promoting factor
catalase, 1586
Erythroleukemia
K562 cells
differentiation, PML-RARα and, 440
thermotolerance
enhancement by aspirin, 4452
ESb metastases
inhibition
IFN-α/β and adoptively transferred immune cells, 6133
Escherichia coli
purine nucleoside phosphorylase
tumor sensitization, 3339
Esophageal adenocarcinoma
p53 mutations, 3406
Esophageal squamous cell carcinoma
deletion mapping, 1828
microsatellite alterations, chromosome 3p, 893
thrombomodulin expression, 4196
Esophagus, Barrett's
progression
genetic abnormalities, 1971
Estradiol
regulation of *hRARα* gene, breast carcinoma cells, 4999
Estrogen
carcinogenic effects, hamster kidney, 4347
dependence
effects on energy metabolism, ^{31}P MRS, breast cancer xenografts, 1664
effects on apoptosis, MCF-7 cells, 2487
effects on TGF-β1 expression and action, lactotropes, 4892
-independent MCF-7 cells, expressing 80-kDa estrogen receptor, 2583
natural
microtubule disruption, Chinese Hamster V79 cells, 1863
receptor
expression, estrogen receptor-negative breast cancer cells, 2279
expression, tamoxifen-resistant breast cancer, 3331
80-kDa, estrogen-independent MCF-7 cells expressing, 2583
regulation of *Bcl-2* expression, breast cancer cells, 3902
response elements
estradiol regulation of *hRARα*, breast carcinoma cells, 4999
variant receptor
coexpression, neoplastic breast tissues and MCF-7 cells, 2158
exon 5 deletion, breast cancer, 288
hepatocellular carcinoma species, 498
withdrawal
effects on energy metabolism, ^{31}P MRS, breast cancer xenografts, 1664
growth inhibition, human breast cancer xenografts, 4146
Ethanol
O^6-methylguanine-DNA adduct formation and modulation, 6017
5-Ethoxy-2′-deoxyuridine
treatment of colorectal cancer, 3543
***N*^{1}-Ethyl-*N*^{11}-((cyclopropyl)methyl)-4,8-diazaundecane**
cell death induction, 3233
Ethylmethanesulfonate
-induced *in vivo* mutagenesis
O^6-alkylguanine and, T-lymphocytes, 1875
***N*-Ethyl-*N*-nitrosourea**
-induced *in vivo* mutagenesis
O^6-alkylguanine and, T-lymphocytes, 1875
treatment of *Min* mice, 4479
5-Ethynyluracil
effects on tegafur antitumor activity, 6227
ET-18-OCH$_3$
inhibition of NF-κB activation by TBA, 4844
Etoposide
cytokines and
simultaneous treatment, 324
cytotoxicity
IL-6 resistance risk factor, prostate carcinoma cell lines, 4633
-induced apoptosis
IGF-I receptor prevention, 303
-induced genetic alterations
inhibition by Bcl-2, 4029
resistance
DNA topoisomerase IIα gene expression, cancer cells, 3860
mechanism, murine leukemia cells, 4352
by poly(ADP-ribose) polymerase inhibitors, 868
-selected H69 cells
MRP and *mdr1* sequential coexpression, 459
sensitivity
cellular thioredoxin levels and, 4293
Eukaryotes
DNA repair genes and gene products, workshop meeting report, 968
Ewing's sarcoma
apoptosis
radiation-induced, 4240
EWS/FL11 fusion gene
expression, biphenotypic sarcomas, 1385
EWS/FL11
expression, biphenotypic sarcomas, 1385
Exchange proteins
Sos/Ras
interaction with DF3/MUC1, 4000
Explants
mesenchymal and epithelial cancer
migrating cell clusters, 4557
Exposure
asbestos
and pulmonary GSTM3 expression, lung cancer, 3305
cigarette smoke
c-*fos* expression and, quiescent Swiss 3T3 cells, 1927
lead acetate
renal tubular tumors and atypical hyperplasias, B6C3F$_1$ mice, 5265
nickel
carcinogenic effects, lung, 5251
N-nitrosodimethylamine
ethanol O^6-methylguanine-DNA adduct formation and modulation and, 6017
PhIP
two-generation, mammary carcinoma risk, Sprague-Dawley rats, 4333
External beam radiotherapy
tumor dose response reconciliation
vs radioimmunotherapy, 5811s
Extracellular matrix
modulation of TGF-β1 effects on prostate cancer, 2596

F

F344 rats: *see* **Fischer 344 rats**
Fab′ fragments
anti-CEA antibody, ^{99m}Tc-labeled
targeting liver metastases of colorectal carcinoma, 5777s
Familial cancer syndromes
G_2 checkpoint control, 1763
Fanconi anemia
Chinese hamster cell mutants resembling, 3412
Farnesyl transferase
inhibitors
B956, inhibition of tumor xenograft growth, 5310
BZA-5B, nuclear lamin and p21^{ras} farnesylation block, 3295
human tumor cells, 5302
NF1 malignant phenotype block, 3569
Farnesylation
nuclear lamins and p21^{ras}
BZA-5B block, 3295
Fas/APO-1
expression, astrocytoma progression, 5528
gene transfer, malignant glioma, 2936
Fat
dietary
fecal diacylglycerol modulation, 2293
FCE 23762
phase I study, 2090
FcγRIII
BsMAb 2B1, phase I trial, 4586
FdUMP: *see* **5-Fluoro-2′-deoxyuridine-5′-monophosphate**
FdUrd: *see* **5-Fluoro-2′-deoxyuridine**
Feces
diacylglycerol
modulation by diet and carcinogen, 2293
Female genital tract
X chromosome inactivation, 5080
α-Fetoprotein
expression, McA-RH 7777 rat hepatoma

clones, 3615
gene therapy, hepatocellular carcinoma, 3105
Fetus
-specific CYP3A7
expression, CHL cells, 787
tissues
ethanol, O^6-methylguanine-DNA adduct formation and modulation, 6017
Fiber
cigarette filters, 253
crocidolite asbestos, Kent cigarette smoke, 2232
dietary
fecal diacylglycerol modulation, 2293
Fibrinogen/fibrin
deposition, ascites tumors, 369
Fibroblast growth factor
basic
overexpression, HEC-1-B cells, 4729
protective effects against radiation pneumonitis, mice, 298
Fibroblast growth factor 2
expression
inhibition by antisense RNA, hepatoma cells, 5075
Fibroblasts
C3H 10T½ mouse
TGF-β-induced cyclin E-cdk2 kinase activation and $p27^{Kip1}$ down-regulation, 1413
DAN gene product cell cycle-regulatory function, rat, 895
E2F1 deletion mutant expression
S phase lengthening and sensitization to antitumor drugs, 2883
G_2 checkpoint control, familial cancer syndromes, 1763
immortalization by SV40 large T antigen, 4651
induction of MMP-9 expression, squamous cell carcinoma cell line, 963
psoralen mutagenesis, mouse, 1283
pulmonary
stromelysin-3 regulation by retinoic acid, 4120
radiosensitive leukemia
defective repair of DNA double-strand breaks and chromosome damage, 1232
senescent
apoptosis resistance, 2284
transformed
caffeic acid phenethyl ester-induced apoptosis, 3576
invasive phenotype, aODN effects, 90
UDP-glucuronosyltransferase-deficient skin micronuclei initiation by benzo(*a*)pyrene and benzo(*e*)pyrene, 1045
Fibrosarcoma
HT1080 cells
suppression, cAMP-regulated TIMP synthesis, 2927
in vivo gene targeting, grp78/BiP promoter, 1660
mixed tumor cell spheroids
cisplatin resistance, 386
ormaplatin biotransformation
WR-2721 effects, F344 rat, 2837
Field cancerization
effect, 149
head and neck skin, 3604
Filters
cigarette
fibers released, 253
Fischer 344 rats
colonic aberrant crypt foci
chemoprevention by naturally occurring products, 1277
DNA adducts and T-lymphocyte mutation induction by 1,6-dinitropyrene, 2316
fibrosarcoma
ormaplatin biotransformation, WR-2721 effects, 2837
male
S-methyl methane thiosulfonate chemoprevention, 4053
NNK tissue distribution
phenethyl isothiocyanate effects, 5580
Fischer 344/DuCrj rats
carcinogenesis enhancement by dimethylarsinic acid, 1271
Fish
cardiac hemangioendothelial neoplasms, 2438
FISH: *see* **Fluorescence *in situ* hybridization**
Florence, Italy
K-*ras* and *p53* mutations, gastric adenocarcinoma, 2665
Flow cytometry
human tumor xenografts measured
cell proliferation kinetics, 392
low-grade glioma regional heterogeneity, 1569
Fluid pressure
interstitial
solid tumors, 5451
Fluorescence *in situ* hybridization
chromosomal aneuploidy, multiple myeloma, 3854
chromosomal anomalies, prostatic intraepithelial neoplasia and prostatic carcinoma, 5408
interphase
detection of *CDKN2* deletions by, tumor cell lines and glioma, 984
multicolor
interphase cell chromosomal breakage, 640
RB-1 and *D13S25* deletions, B-cell chronic lymphocytic leukemia, 3475
t(10;11) breakpoint heterogeneity, AML-M4/M5, 4220
5-Fluoro-2′-deoxyuridine
antitumor efficacy
enhancement by 5-(benzyloxybenzyl)barbituric acid acyclonucleoside, 1092
5-Fluoro-2′-deoxyuridine-5′-monophosphate
binding sites, colorectal carcinoma tissues, 3897
Fluoromevalonate
suppression of Ras-transformed cells, 1732
5-Fluorouracil
antitumor effects
attenuation by (*R*)-5-fluoro-5,6-dihydrouracil, 1239
combined with interferon
treatment of colorectal cancer, 3543
effects on FdUMP binding sites and folate pool, colorectal carcinoma, 3897
response
thymidylate synthase expression and, colorectal and gastric tumors, 1407
tegafur prodrug
5-ethynyluracil effects, 6227
FMS
DNA repair, HL60 cells, 336
Focal adhesion kinase
overexpression, invasive tumors, 2752
Folate
-binding protein
epithelial cells expressing, reduced folate carrier functional activity, 3790
deficiency
DNA breaks and hypomethylation, rat livers, 1894
pool, colorectal carcinoma tissues, 3897
receptor gene
dominant negative mutant, 847
Folic acid
oral
enhancement of 1843U89 antitumor effects, 6117
Folylpoly-γ-glutamate synthetase
gene organization, 6030
Food-derived carcinogens
PhIP
chicken concentrations, 4516
exposure, mammary carcinoma risk, Sprague-Dawley rats, 4333
6-*N*-Formylamino-12,13-dihydro-1,11-dihydroxy-13-(β-D-glucopyranosyl)-5*H*-indolo[2,3-α]pyrrolo[3,4-*c*]carbazole-5,7(6*H*)-dione: *see* **NB-506**
French-American-British Classification
M4-M5 subtypes
ALL-1 gene rearrangements and, acute myeloid leukemia, 1625
Frogs
pond
pancreatic carcinoma, 3781
FTI 276
tumor growth blockade, nude mice, 4243
5-FU: *see* **5-Fluorouracil**
Fucose
endometrial tissue levels, 3654
α-L-Fucosidase
endometrial tissue, 3654
Fucosyltransferase
endometrial tissue, 3654
Fumonisin
repression of PKC and cAMP stimulation, 1655
FUra: *see* **5-Fluorouracil**
Fusion genes: *see also* **Genes**
AF10 and *MLL*
t(10;11) breakpoint heterogeneity, AML-M4/M5, 4220
EWS/FL11
expression, biphenotypic sarcomas, 1385
Fusion proteins: *see also* **Proteins**
humanized disulfide-stabilized anti-$p185^{HER2}$ Fv-β-lactamase, 63
Kemptide
antibody fragment, ^{P} labeling, 5968s
p230 BCR/ABL, 3192
PML-RARα
and K562 cell erythroid differentiation, 440
Fv fragment
anti-CD19 single-chain, development and characterization, 2346
anti-c-erbB-2 single-chain monomers and dimers, 5983s
antimelanoma single-chain, tumor-infiltrating lymphocytes, 3584
anti-Tac disulfide-stabilized
biodistribution, nude mice, 5323
tumor imaging, 318
CC49 single-chain
radioimmunodetection, 2858
Fv-β-lactamase
humanized disulfide-stabilized anti-$p185^{HER2}$ fusion protein, 63

G

G185
NIH3T3 cells transfected, effects of PGP

inhibitors on, 1086
G207
treatment of malignant meningiomas, 4752
D-Galactose-β-[1→3]-*N*-acetyl-D-galactosamine
expression, adenocarcinomas, 149
α-Galactosyl
epitopes
inhibition of melanoma metastases, 4168
α1,3 Galactosyltransferase
gene transfection
alteration of cell surface carbohydrates and inhibition of melanoma metastases, 4168
Galectin-3
ligands, human colon carcinoma cells, 2191
mediation of homotypic cell adhesion, 3267
Gal-GalNAc: *see* **D-Galactose-β-[1→3]-*N*-acetyl-D-galactosamine**
Gallbladder carcinoma
mutations, Chile, 2511
Gallium chelate
immunoscintigraphy with PET
multistep tumor targeting, nude mice, 115
Gallium-67 citrate
-labeled LL2-Fab′ fragment
B-cell non-Hodgkin's lymphoma staging, 5771s
Gallium nitrate
normocalcemic effects, hypercalcemic rat model, 307
Gangliosides
human tumor
in vivo immunosuppression, 211
Gastric adenocarcinoma
K-*ras* and *p53* mutations, Florence, Italy, 2665
microsatellite alterations, 1933
risk
H. pylori cagA and, 2111
Gastric adenoma
microsatellite alterations, 1933
Gastric carcinogenesis
potassium chloride promotion effects, 5238
Gastric carcinoma
H. pylori infection establishment age and, 562
membrane-type matrix metalloproteinase expression, 3263
microsatellite instability and erbB-2 expression, 1428
telomerase activity, 3258
TGF-β-RII mutation, 5545
Gastric epithelium
mucin gene expression, 2681
Gastric tumors
thymidylate synthase expression and 5-FU response, 1407
Gastric ulcer
H. pylori infection establishment age and, 562
Gastrin-releasing peptide
receptors
expression, bombesin growth response, bronchial epithelial cells, 1853
human breast cancer, 280
Gastroduodenal tumors
somatic APC gene mutations, 3165
Gastrointestinal cancer
clonal intratumor heterogeneity, 2866
metastatic
D612 combined with rhM-CSF, phase II trial, 4339
Gastrointestinal tumors
abnormal intron 9 retention, CD44 gene transcripts, 4273
G-CSF: *see* **Granulocyte-colony stimulating factor**
GDP dissociation inhibitor
human Rab
brain-type isoform, cloning and expression, neuroblastoma, 5445
Gel analysis
2-dimensional
detection of genomic aberrations, hepatoblastoma, 4549
Gelatinase A: *see* **Matrix metalloproteinase-2**
Gelatinase B
92-kDa
expression, advanced stage melanoma cells, 4174
Gelsolin
tumor suppression, bladder cancer, 3228
Gene amplification
C-erbB-2, recurrent bladder tumors, 2422
CGH detection, head and neck squamous cell carcinoma, 1010
chromosome 12q13-14, malignant glioma, 727
MRP or *LRP*
chromosome breakage and, 4214
N-*myc*, localized neuroblastoma, Pediatric Oncology Group Study, 721
TGF-β_1-mediated, 1758
Gene products
CDKN2/MTS1
solid tumors, immunohistochemical detection, 6006
DAN
cell cycle-regulatory function, rat fibroblasts, 895
DNA repair
eukaryotic, workshop meeting report, 968
MAGE-3
identification and intracellular location, 2236
protein tyrosine phosphatase
binding and activation by triphosphorylated nucleosides, 4855
$p21^{WAF1/CIP1}$
expression, topological control, 2910
retinoblastoma, acute myeloid leukemia, 4552
schwannomin
growth suppression, NIH3T3 cells, 2270
von Hippel-Lindau disease
-binding proteins, 4544
Gene promoters
α-fetoprotein
gene therapy, hepatocellular carcinoma, 3105
Gene radiotherapy
manganese superoxide dismutase reduction of tumor control dose, 2490
Gene therapy
adeno-associated virus-based plasmids complexed to cationic liposomes, prostate cancer, 2366
adenovirus-mediated
head and neck squamous cell carcinoma, nude mouse model, 1080
hepatocellular carcinoma, 5283
direct cytokine transfer
RG-2 glioma growth attenuation and brain edema, 1902
HSV-TK gene and AFP promoter
hepatocellular carcinoma, 3105
in vivo targeting
grp78/BiP promoter, fibrosarcoma, 1660
liposome-mediated, pancreatic cancer, 3810
MHC class I and IL-2, melanoma, 4941
p53 or *p21* adenovirus, prostate cancer, 5151
P-450-based, 581
Gene transfer
α1,3 galactosyltransferase
alteration of cell surface carbohydrates and inhibition of melanoma metastases, 4168
expression imaging, 6126
Fas/APO-1, malignant glioma, 2936
liposome-mediated
antisense K-*ras* construct, pancreatic cancer, 3810
retroviral vector-mediated, antisense cyclin G1
inhibition of osteosarcoma cell proliferation, 5493
two-gene
MDR1 and GSTπ, NIH 3T3 cells, 4073
Genes: *see also* **Proto-oncogenes**
activated N-*ras*
effects on ANBL6 cell growth characteristics, 3640
AF10
t(10;11) breakpoint heterogeneity, AML-M4/M5, 4220
androgen receptor
CAG and GGC microsatellites, and prostate cancer, 1937
APC
alternatively spliced transcripts, 3732
biallelic inactivation, hepatoblastoma, 5007
somatic mutations, gastroduodenal tumors, 3165
tumor suppression, colon cancer cell lines, 1531
BAX
loss of expression, and breast cancer survival, 4471
BRCA1
loss of heterozygosity, prostate cancer, 1002
mutations, ovarian cancers, 2998
CcnD3
and glucocorticoid resistance, 4188
CD24
cloning and expression, hepatocellular carcinoma, 4717
CDDP resistance
identification with retroviral insertional mutagenesis, 1139
CDKN2
alterations, ovarian neoplasia, 2150
deletions, detection by interphase FISH, tumor cell lines and glioma, 984
leukemias and lymphomas, 1436
CDKN2/p16/MTS1
inactivation, and aberrant DNA methylation, 4525
c-*fos*
expression, and cigarette smoke exposure, quiescent Swiss 3T3 cells, 1927
chromosome 8p loci, human prostate cancer, 5390
chromosome 13, 1613
c-Myc
and glucocorticoid resistance, 4188
connexin
negative growth control of HeLa cells, 629
CYP1A1
African-American polymorphism, lung adenocarcinoma, 472

polymorphisms, and postmenopausal breast cancer risk, 3483
restriction fragment length polymorphism, and breast cancer, African-American women, 3757
dihydrodiol dehydrogenase, analysis, 4105
DNA repair
eukaryotic, workshop meeting report, 968
lymphocytes, amplification by multiplex RT-PCR, 5025
mutations, sporadic endometrial carcinomas, 5556
DNA topoisomerase IIα
expression, etoposide/teniposide-resistant human cancer cells, 3860
E6 and *E7*
inhibition, 4599
encoding mammary-derived growth inhibitor
tumor suppressor effects, 2225
ENV
-like sequences, breast cancer, 5173
ERBB-2
amplification and expression, breast cancer, 5400
ERCC1
mRNA expression, malignant brain tissue, 1261, 3933
ERCC2
defects, xeroderma pigmentosum group D, 5656
mRNA expression, malignant brain tissue, 1261, 3933
estrogen receptor
expression, estrogen receptor-negative breast cancer cells, 2279
EWS/FL11
expression, biphenotypic sarcomas, 1385
folate receptor
dominant negative mutant, 847
folypoly-γ-glutamate synthetase, organization, 6030
glucocorticoid receptor
splice site mutation, resistance to glucocorticoid-induced apoptosis, 348
γ-glutamylcysteine synthetase
expression, cisplatin-sensitive and cisplatin-resistant ovarian cancer cells, 4367
GSTM1
polymorphisms, and postmenopausal breast cancer risk, 3483
H19
normal imprinting, neuroblastoma, 3386
paternally derived, trophoblasts, 1111
HBx
abrogation of p53-induced apoptosis, 6012
hCGβ
expression, superficial and invasive bladder carcinoma, 3735
HMG1-C
fusion transcript with mitochondrial aldehyde dehydrogenase gene, 6038
hRARα
regulation by estradiol, breast carcinoma cells, 4999
H-*ras*
and retinoic acid metabolism, NIH3T3 cells, 4850
3α-hydroxysteroid/dihydrodiol dehydrogenase
rat, analysis, 4105
IGF2
normal imprinting, neuroblastoma, 3386
KDR
expression, hematopoietic cells, 5687
K-*ras*
mutations, gastric adenocarcinoma, Florence, Italy, 2665
mutations, lung adenocarcinoma, 1444
mutations, minisatellite instability and, methylcholanthrene-induced mouse sarcoma, 5670
Ku80
correction of *xrs*-6 DNA repair defect, 1235
loss of heterozygosity, testis cancer, 2871
losses, premalignant bronchial epithelium, 5133
Mch2, human
cloning, 2737
mdr1
expression, VP-16-selected H69 cells, 459
ME 180 cell expression
IFN-α-2b and retinoic acid effects, 3158
MLH1
locus structure, 242
MLL
t(10;11) breakpoint heterogeneity, AML-M4/M5, 4220
MRP
expression, VP-16-selected H69 cells, 459
MRP-1/CD9
expression, and prognosis, non-small cell lung cancer, 6040
MTS1
homozygous deletions, astrocytomas, 20
MTS2
alterations, non-small cell lung cancers, 514
mucin
expression, gastric epithelium, 2681
multidrug resistance
sequential coexpression, VP-16-selected H69 cells, 459
multiple preneoplastic and neoplastic lung lesion changes
independent, 135
mVHLh1
cloning and characterization, 743
NAT1
polymorphism, and colorectal cancer risk, 3537
NF2
mutations, mesothelioma, 1227
nm23-H1
mRNA, hepatocellular carcinoma, 652
suppressive role, ovarian carcinoma, 2645
nm23-H2
mRNA, hepatocellular carcinoma, 652
nm23-M1 and *nm23-M2*
metastatic suppression, murine melanoma, 1971
ornithine decarboxylase
point mutation, hepatocellular carcinoma, 3500
p15
alterations, non-small cell lung cancers, 514
deletions, non-small cell lung carcinoma, 2968
$p15^{INK4B}$
deletions, monosomy 5 and, kidney epithelial cell lines, 1607
deletions and alterations, undifferentiated mouse skin tumors, 5168
loss, sporadic melanoma, 5531
$p15^{INK4B}$/MTS2
leukemias and lymphomas, 1436
mutations, biliary tract cancers, 2756
mutations, lung cancer, 1448
p16
alterations, nasopharyngeal carcinoma, 2039
alterations, non-small cell lung cancers, 514
deletions, non-small cell lung carcinoma, 2968
structure and regulation, 2988
p16/CDKN2
loss of expression, melanocytic lesions, 2713
methylation, and gene silencing, 4525
mutation frequency, upper digestive tract cancers, 3421
suppression of human glioma cell growth, 1351
$p16^{INK4}$, 3250
deletions, monosomy 5 and, kidney epithelial cell lines, 1607
$p16^{INK4}$/CDKN2
mutations, biliary tract cancers, 2756
$p16^{INK4}$/MTS1/CDKN2
mutations, lung cancer, 1448
$p16^{INK4A}$
deletions and alterations, undifferentiated mouse skin tumors, 5168
$p16^{INK4A}$/MTS1
leukemias and lymphomas, 1436
p18
mutations, lung cancer, 1448
$p21^{WAF1}$
tumor suppression, 4536
$p27^{Kip1}$
analysis, leukemias, 1206
chromosomal mapping and genetic analysis, 1211
malignancy, molecular analysis, 2266
p53
abnormalities, and genomic instability, breast carcinoma, 646
alterations, breast cancer survival and, racial disparity, 1465
breaks, and hypomethylation, folate/methyl-deficient rat livers, 1894
-deficient mice, endocrine tumors, 1146
expression, bronchial neoplasia and squamous cell carcinoma, 1365
mutational hotspot, U:G mismatch base excision repair, 3742
mutations, and apoptosis, Wilms' tumors, 215
mutations, benign and dysplastic nevi, 4278
mutations, esophageal adenocarcinoma, 3406
mutations, gastric adenocarcinoma, Florence, Italy, 2665
mutations, latent expression, and radiation-induced mammary cancer, 3310
mutations, lung cancer, Chinese women, Hong Kong, 5343
mutations, nonmelanoma head and neck skin cancer, 3604
mutations, sarcomatoid renal cell carcinoma, 658
P-glycoprotein sister, identification, 2029
progesterone receptor
Alu insertion, 2743
prostate cancer changes
comparative genomic hybridization, 342
PSA
expression, ovarian carcinoma, 1603
PSA-related, primates, 2455
pX
HTLV-I transgenic rats, mammary carcinoma, 2524

qin
transcriptional repressor, 5540
ras
mutations, VEGF/VPF expression upregulation, 4575
transformation, SCH 51344 inhibition, 5106
Rb
-deficient mice, endocrine tumors, 1146
loss of heterozygosity, aggressive pituitary tumors, 1613
ret
silencing, medullary thyroid carcinoma, 2048
RFC1
and MTX-resistant breast cancer cells, 3790
silencing
p16/CDKN2 methylation and, 4525
SRD5A2
polymorphisms, and prostate cancer risk, 3973
ssic1
mouse chromosome 4 mapping, 3179
stage I non-small cell lung cancer, 51
suppressor elements
Thirteenth Cornelius P. Rhoads Memorial Award lecture, 4023
surfactant protein
expression, non-small cell lung carcinomas, RT-PCR detection, 4283
TCTA
cloning and characterization, 1917
TEL
fusion, activation of *ABL*, 34
TGF-β-RII
mutations, colon and gastric cancer, 5545
mutations, colorectal cancer, 5548
tumor marker
expression, glutathione transferase P enhancer I, 2651
urokinase receptor
aODN inhibition, and transformed human fibroblast invasive phenotype, 90
vascular endothelial growth factor
expression, wild-type p53 and v-SRC effects, 6161
VHL
growth suppression, renal cell carcinoma, 4804
homologous mouse gene, cloning and characterization, 743
WAF1/CIP1
Burkitt's lymphoma, 1431
p53-independent induction, leukemia cells, 668
WT1
regulation of *bcl-2* and c-*myc*, 5386
XPA
overexpression, and UV radiation resistance, 6152
XPAC
mRNA expression, malignant brain tissue, 1261
Genital tract
female
X chromosome inactivation, 5080
Genomes
alterations, renal cell carcinoma, 6189
instability
anoxia inducible endonuclease and enhanced DNA breakage, 1122
p53 abnormalities and, breast carcinoma, 646
instability of microsatellite repeats
and erbB-2 expression, gastric carcinoma, 1428
glioma, 1547
non-small cell lung cancer, 28
prostate cancer, and clinicopathological variables, 2418
Genoprotection
UDP-glucuronosyltransferases, chemical carcinogenesis, 1045
Genotoxicity
UDP-glucuronosyltransferase and, 1045
Genotypes
detoxifying enzyme
and glioma risk, 4237
GSTM1
CYP1A1 transcription and, 5520
NAT1, bladder and colon tissue, 5226
Gestation
lead acetate exposure
renal tubular tumors and atypical hyperplasias, $B6C3F_1$ mice, 5265
Ginsenoside Rh_2
sister chromatid exchange suppression, human blood lymphocytes, 1221
Glial fibrillary acidic protein
astrocytic transformation, transgenic mice, 4302
Glial tumors
malignant
$p16^{INK4}$, pRB, and cdk4 overexpression, 4833
Glioblastoma
clonal growth
stimulation by nerve growth factor, 2212
treatment with human MHC nonrestricted cytotoxic T cell line, 96
Glioma
C6 multicellular spheroids
cyclocreatine uptake, NMR microscopy, 153
implanted, neovascularization induced growth, MRI, 1956
CDKN2 deletions
detection by interphase FISH, 984
cell growth
suppression by *p16/CDKN2*, 1351
high-grade
absent $P16^{INK4}$ expression, 1941
low-grade
regional heterogeneity, 1569
malignant
anti-EGFRvIII mAbs, 3140
chromosome 11p15 loss of heterozygosity, 2166
chromosome 12q13-14 amplification and loss of heterozygosity, 727
cisplatin-induced apoptosis, mediation by ICE, 6166
Fas/APO-1 gene transfer, 2936
intralesional radioimmunotherapy, 5952s
melphalan treatment
human xenografts, athymic rats, 3803
microsatellite instability, 1547
RG-2
growth attenuation by local IL-2 and IFN-γ, 1902
risk
detoxifying enzyme genotypes and, 4237
signal transduction
carbon-11-labeled diacylglycerol probe, 4225
wild-type p53
bcl-2 expression, 999
Glucocorticoids
-induced apoptosis
modulator inhibition, CEM C-7 cells, 548
resistance, human acute leukemic cell line, 348
inhibition of lymphoid cell proliferation, 4188
receptors
gene, splice site mutation, resistance to glucocorticoid-induced apoptosis, 348
modulator inhibition, CEM C-7 cells, 548
variant, mRNA expression, multiple myeloma, 2727
resistance, 4188
Glucokinase
high K_m activities, tumor cells, 3278
Glucose
phosphorylation
high K_m activities, tumor cells, 3278
Glucose-regulated stress protein
M_r 78,000
BiP promoter, *in vivo* fibrosarcoma gene targeting, 1660
induction and VP-16 resistance by poly(ADP-ribose) polymerase inhibitors, 868
α-Glucosidase I
inhibitor castanospermine
effects on endothelial cells, 2920
γ-Glutamylcysteine synthetase
expression, cisplatin-sensitive and cisplatin-resistant ovarian cancer cells, 4367
subunit cDNA transfection
and intracellular glutathione and melphalan resistance, 4771
Glutathione
cisplatin adducts
transport, cisplatin-resistant cancer cells, 4297
depletion
population pharmacodynamic model, 4507
and DNA damage, cyclophosphamide-resistant tumor cells, 1691
GST-mediated conjugation of thiotepa, 1701
intracellular
γ-glutamylcysteine synthetase subunit cDNA transfection and, 4771
levels
and asbestos, mesothelial cells, 2085
NMR detection, MCF-7 cells, 2012
Glutathione peroxidase
expression, breast tumor cell lines, 957
protective effects against hydroperoxides, radiation, doxorubicin, 4465
Glutathione *S*-transferase
allelism
and glioma risk, 4237
and colorectal cancer risk, 2789
induction
intermittent oltipraz dosing, 4319
M1
null genotype, and colorectal adenomas, 1224
null genotype, human *CYP1A1* transcription and, 5520
polymorphisms, and postmenopausal breast cancer risk, 3483
M3
pulmonary expression, lung cancer, 3305
mediation of glutathione conjugation of thiotepa, 1701
μ class
expression, and colorectal cancer risk, 2789
P
suppression by peroxisome proliferators, rat, 5370

P enhancer I
tumor marker gene expression, 2651
π class
colorectal tumors, 2696
two-gene transduction, NIH 3T3 cells, 4073
Glyceraldehyde-3-phosphate dehydrogenase
androgen effects, prostate carcinoma cells, 4234
Glycerol
metabolism, tumorous rats, ^{13}C NMR study, 761
Glycoconjugates
galectin-3 ligand, human colon carcinoma cells, 2191
Glycoproteins
biliary
expression, colonic mucosa, 2963
containing mannose 6-phosphate, breast carcinoma, 3424
mucin-type
and colon cancer cell adhesion to selectins, 4425
sialoglycoproteins
platelet-aggregating gp44, mouse colon adenocarcinoma 26, 767
TJA-I reactive sugar chains
expression, colon adenocarcinoma, 1675
Glycosylation
antibody fragments, site-specific modifications, 5721s
endothelial cell
castanospermine effects, 2920
G_{M2}-KLH conjugate vaccine
melanoma, 2783
Granular lymphocytes
clonal $CD3^+$
superantigen activation, 6140
lymphoproliferative disease of
T cell receptor, 6140
Granulocyte-colony stimulating factor
autocrine cell growth, transitional cell carcinoma of bladder, 3438
Granulocyte-macrophage colony-stimulating factor
inhibition by suramin, 5161
Granulocyte-macrophage progenitor cells
reduction by IFN-γ/TNF-α
enhancement of IL-2 immunotherapy, 885
Granulocytes
partial degradation of T-cell signal transduction molecules, 3840
Granulopoiesis
DNA topoisomerase I levels and localization, 1255
Grb2
interaction with DF3/MUC1, 4000
Growth arrest
p53-independent *WAF1/CIP1* induction and, leukemia cells, 668
thioredoxin secretion rates and, hepatoma cells, 675
Growth factors
B61 protein, metastasis, 2528
basic fibroblast
protective effects against radiation pneumonitis, mice, 298
epidermal
-dependent motility and angiogenesis, antagonism by murine EGF fragment (33-42), 3772
mammary and submandibular gland expression, reduction by calorie restriction, 1289
murine fragment (33-42), laminin antagonism, 3772
receptor, and ornithine decarboxylase transformation, NIH3T3 cells, 5358
receptor expression, bronchial neoplasia and squamous cell carcinoma, 1365
receptor expression and binding affinity, androgen up-regulation, PC3 cell lines, 3197
receptor ligands, and epidermal neoplasia, 1883
receptor variant III, tumor-specific mAbs, 4375
receptor variant III expression, multiple human tumors, 5536
fibroblast, 2
inhibition by antisense RNA, hepatoma cells, 5075
hepatocyte
c-*MET*-encoded receptor, expression, pancreatic cancer, 1129
insulin-like
receptor, and metastasis, murine carcinoma cells, 1006
insulin-like, 1
expression, sarcoma, 129
receptor expression, sarcoma, 129
secretion induction by mutant p21*ras* expression, thyroid epithelial cells, 915
insulin-like, 2
expression, sarcoma, 129
WT1 induction, Wilms' tumor cells, 4540
insulin-like, I
apoptosis prevention, 303
overexpression, human pancreatic cancer, 2007
receptor, 249
receptor, apoptosis prevention, 303
receptor, tyrosine 950 mutation, effects on cell growth and transformation, 663
receptors, apoptosis and, 3739
insulin-like, II
expression, mesothelial cells, 3634
modulation of TGF-β1 effects on prostate cancer, 2596
nerve
stimulation of clonal growth, lung cancer cell lines, 2212
platelet-derived
receptor β expression, breast tissue and carcinoma, 2703
platelet-derived, B-chain
expression, breast tissue and carcinoma, 2703
platelet-derived endothelial cell
angiogenesis, thymidine phosphorylase activity and, 1687
therapy
simultaneous with VP-16, 324
transforming, α
autocrine growth stimulation, rat mesothelial cells, 530
and epidermal neoplasia, 1883
-induced mammary gland tumorigenesis, transgenic mice, 3915
transforming, β
antitumor T-cell response, gut-associated lymphoid tissue, 6146
and cell cycle regulation, 1452
-induced cyclin E-cdk2 kinase activation, C3H 10T½ mouse fibroblasts, 1413
induction of apoptosis, colon adenoma cells, 5101
receptor interactions, clonal differences, 2056
receptor regulation, H-*ras*-transformed rat intestinal epithelial cells, 6181
receptor type II gene mutations, colon and gastric cancer, 5545
receptor type II gene mutations, colorectal cancer, 5548
receptor type II missense mutations, head and neck squamous carcinoma cells, 3982
transforming, β1
β-2 microglobulin antagonism, 781
expression and action, estrogen effects, lactotropes, 4892
induction, RA-treated neuroblastoma, 2380
inhibition of BALB/MK cells, 3928
-treated M1 cells ectopically expressing B-*myb*, apoptosis, 501
transforming, β2
plasma levels, metastatic breast cancer, 4512
vascular endothelial
apoptosis inhibition, hematopoietic cells, 5687
expression, colon cancer, 3964
expression, wild-type p53 and v-SRC effects, 6161
expression upregulation by mutant *ras*, 4575
monoclonal antibody, antitumor effects, 5296
and neovascularization, brain tumors, 1189
receptor expression, colon cancer, 3964
receptor expression, hematopoietic cells, 5687
receptor up-regulation, VHL disease-associated and sporadic hemangioblastomas, 1358
synthesis by T lymphocytes, 4140
up-regulation, VHL disease-associated and sporadic hemangioblastomas, 1358
Growth-promoting factor
erythrocyte-derived catalase, 1586
GRP: *see* **Gastrin-releasing peptide**
GRP78: *see* **Glucose-regulated stress protein, M_r 78,000**
grp78/BiP promoter
in vivo fibrosarcoma gene targeting, 1660
GST: *see* **Glutathione *S*-transferase**
GSTM1
defects
and human malignant mesothelioma, 2981
genotype
CYP1A1 transcription and, 5520
null genotype
and colorectal adenomas, 1224
polymorphisms
and postmenopausal breast cancer risk, 3483
and pulmonary GSTM3 expression, lung cancer, 3305
Gut-associated lymphoid tissue
antitumor T-cell response
TGF-β, 6146
Gynecological sarcomas
microsatellite instability, 5664

H

H19
normal imprinting, neuroblastoma, 3386
paternally derived
expression, trophoblasts, 1111
H69 cells
VP-16-selected
MRP and *mdr1* sequential coexpression, 459

Hair
hypopigmentation
bcl-2$^{-/-}$ mice, 354
Hamartoma
pulmonary chondroid
chromosome 12q14-15 rearrangements, 2497
HBx
abrogation of p53-induced apoptosis, 6012
HCC: *see* **Hepatocellular carcinoma**
hCG: *see* **Human chorionic gonadotropin**
HCT 116 cells
mitomycin C resistance
NAD(P)H:quinone oxidoreductase and, 330
Head and neck skin cancer
nonmelanoma
p53 mutations, 3604
Head and neck squamous cell carcinoma
adenovirus-mediated gene therapy, nude mouse model, 1080
apoptosis
induction by wild-type *p53* adenovirus, 3117
chromosomal aberrations, nonrandom patterns, 5030
cyclin D1 overexpression
and recurrence, 975
cytogenetics, 3204
deletions and amplifications, CGH detection, 1010
differentiation
retinoid-induced suppression, athymic nude mice, 3183
DNA copy number changes, 3055
D-type cyclin expression, 949
microsatellites motif loss of heterozygosity, 2656
microscopic residual
wild-type *p53* adenovirus, 1
radioimmunotherapy
radiolabeled antibody combined with external radiotherapy, 1020
radiolabeled mAb pharmacokinetics, biodistribution, and dosimetry, 1060
TGFβ type II receptor missense mutations, 3982
Heat shock response
modulation
aspirin, erythroleukemic cells, 4452
mitogen-activated protein kinase, NIH3T3 cells, 5512
HEC-1-B cells
bFGF overexpression, 4729
Heidelberger Conference on transformation and chemotherapy
Fifth, meeting report, 705
HeLa cells
drug-induced apoptosis
inhibition by *BCL-2*, 4922
negative growth control by connexin genes, 629
Helicobacter pylori
cagA strains
and gastric adenocarcinoma risk, 2111
infection
establishment age, and gastric cancer, 562
Hemangioblastoma
spontaneous
VEGF and VEGF receptor up-regulation, 1358
VHL disease-associated
VEGF and VEGF receptor up-regulation, 1358
Hemangioendothelial neoplasms
cardiac, fish *R. marmoratus*, 2438
Hematopoiesis
BCR/ABL-dependent and normal
c-RAF-1 serine/threonine kinase, 2275
normal and malignant
Sixth Annual Pezcoller Symposium, 3462
Hematopoietic cells
apoptosis
inhibition by VEGF, 5687
bone marrow
nitrosoureas resistance, 2608
CD34+
generation of immunostimulatory dendritic cells, 1099
KDR expression, 5687
Hematopoietic stem cells
autologous
radioimmunotherapy support, advanced breast cancer, phase I trial, 5921s
Hepadnaviral infection
synergy with dietary aflatoxin B_1, woodchucks, 3318
Hepatitis B virus
-related hepatocellular carcinoma
mutant p53 and, 6084
X gene
abrogation of p53-induced apoptosis, 6012
Hepatitis C virus
core protein
antibody response, 111
Hepatobiliary neoplasms
antiepileptics and, 294
Hepatoblastoma
biallelic *APC* inactivation, 5007
genomic aberrations
2-dimensional gel analysis detection, 4549
loss of imprinting, 1836
promotion by TCDD or Aroclor 1254, mice, 4875
Hepatocarcinogenesis
AFB_1
chlorophyllin inhibition, rainbow trout, 57
hepadnaviral infection and dietary aflatoxin B_1 synergy, woodchucks, 3318
Hepatocellular carcinoma
antibody response, 111
CD24 cloning and expression, 4717
gene therapy
adenovirus-mediated, 5283
HSV-TK gene and AFP promoter, 3105
HBV-related
mutant p53 and, 6084
NM23-H1 and *NM23-H2* mRNA, 652
ornithine decarboxylase gene point mutation, 3500
telomerase activity, 2734
variant estrogen receptor mRNA species, 498
vegetable consumption, serum retinol level, and, 1301
Hepatocellular tumors
promotion by TCDD or Aroclor 1254, mice, 4875
Hepatocyte growth factor
receptor
c-*MET*-encoded, expression, pancreatic cancer, 1129
Hepatocytes
apoptosis
spontaneous, suppression by dichloroacetic acid, murine, 3702
CYP1A2 and CYP3A4 inhibition by oltipraz, 5574
Ras-transduced diethylnitrosamine-treated tumors, 5242
TNP-470 disposition and metabolism, 3036
Hepatoma
diethylnitrosamine-induced
respiratory chain impairment, 3028
FGF-2 expression
inhibition by antisense RNA, 5075
growth arrest
thioredoxin secretion rates and, 675
highly conserved oncofetal cDNA, rat, 1152
McA-RH 7777 rat clones
AFP expression, correlation with chromosome 14 homogeneously staining regions, 3615
HepG2 cells
proliferation
inhibition by extracellular thiols, 675
Hepsulfam
molecular pharmacology, 1491
Heregulin toxin, 71
HER-2/*neu*
amplification
breast cancer, 5400
endometrial cancers, 5693
expression, breast cancer, 5400
overexpression
breast cancer cells, suppression and differentiation by emodin, 3890
endometrial cancers, 5693
Herpes simplex virus
thymidine kinase gene therapy, hepatocellular carcinoma, 3105
Herpes simplex virus 1
multimutated G207
treatment of malignant meningioma, 4752
Heterodimers
anti-c-erbB-2, 5983s
Heterozygosity, loss of
chromosome 1p
breast cancer, detection and cloning, 1752
neuroblastoma, 4664
chromosome 7q31.1
prostate cancer, 4114
squamous cell and colon carcinoma, 1347
chromosome 8
male breast carcinoma, 4995
chromosome 9p
breast cancer, 2892
chromosome 10q
endometrial cancers, 1922
chromosome 11
breast tumors, 2660
chromosome 11p15
malignant glioma, 2166
chromosome 11q
lung adenocarcinoma, 3988
oral carcinoma, 5465
chromosome 11q13
microdissected and invasive breast cancer, 467
chromosome 11q23.3
breast cancer, 3003
chromosome 11q23
cutaneous malignant melanoma, 2494
chromosome 12q13-14
malignant glioma, 727
chromosome 17q
non-small cell lung cancer, 4268
prostate cancer, 1002
chromosome 18q21
oral carcinoma, 5465
microsatellite motif, head and neck squamous carcinoma, 2656
RB, aggressive pituitary tumors, 1613
t(3;8), renal cell carcinoma, 5348
tumor suppressor genes, testis cancer, 2871
HGF: *see* **Hepatocyte growth factor**
hImmu-14-N
glycosylated fragments, site-specific modifi-

cations, 5721s
Histone H1 kinase
p34^{cdc2} activation and, 1994
HL-60 cells
accumulation, energetic checkpoints, 5164
apoptosis
cyclin B1/Cdc2 kinase activation, 228
β-lapachone-mediated, 3706
sphingosine induction, 691
c-myc expression and apoptosis, 1379
DNA repair, 336
mitoxantrone-resistant
topoisomerase IIα alterations, 1707
$1,25(OH)_2D_3$-induced differentiation
PP1 translocation, 774
truncated topoisomerase IIα mRNA and protein, 4962
HMG1-C
fusion transcript with mitochondrial aldehyde dehydrogenase gene, 6038
h*MLH1*
mutation screening, Swedish hereditary nonpolyposis colon cancer families, 6092
hMN-14
Kemptide fusion protein, ^{P} labeling, 5968s
HMSH2
microsatellite instability, uterine sarcoma cells, 5664
H_2O_2
c-*jun* activation, 2723
Hodgkin's disease
CD30 ligand signal transduction, 4157
EBV-specific responses T-cell responses, 3675
radioimmunotherapy, studies review, 5888s
HOENU: *see* ***N*-(2-Hydroxyethyl)-*N*-nitrosourea**
Homeobox proto-oncogenes
HOX-11 (*TCL-3*)
up-regulation, T-cells, 1117
Homodimers
anti-c-erbB-2, 5983s
Hong Kong
Chinese women
lung cancer, *p53* mutations, 5343
Hormones
-independent prostatic tumor cells
metallothionein localization and cisplatin resistance, 474
-refractory prostatic adenocarcinoma, metastatic
somatostatin receptor expression, 5805s
Host cells
antigenic cancer cell stimulation, 5094
HOX-11
up-regulation, T-cells, 1117
HPR: *see* ***N*-(4-Hydroxyphenyl)retinamide**
hprt
(+)-BPDE-induced splicing mutations, Chinese Hamster V-79 cells, 1550
HOENU-induced *in vivo* mutagenesis
O^6-alkylguanine and, T-lymphocytes, 1875
h*RARα*
regulation by estradiol, breast carcinoma cells, 4999
H-*ras*
and retinoic acid metabolism, NIH3T3 cells, 4850
-transformed intestinal epithelial cells
TGF-β receptors, 6181
HSV-*tk*
gene therapy, hepatocellular carcinoma, 3105
HT1080 cells
suppression, cAMP-regulated TIMP synthesis, 2927
HTLV: *see* **Human T cell leukemia virus**
Human biomonitoring assay
buccal mucosa, 1267
Human carbonyl reductase
expression, K562 cells, 4646
Human chorionic gonadotropin
β subunit
expression, superficial and invasive bladder carcinoma, 3735
expression and secretion, bladder carcinoma, 1479
Human immunodeficiency virus
induction
salicylic acid inhibition, 1696
Human leukocyte antigen
A2-matched melanoma
TCRBV14 overexpression, 3374
A2601-restricted CTLs, squamous cell carcinoma, 4248
class I molecules, quantitative recognition, 314
-unrestricted T cell clones
leukemia-specific, 3835
Human papillomavirus 16
E6
gene inhibition, 4599
mutagenesis, transfected cells, 4420
E7
gene inhibition, 4599
immunogenicity, transgenic mice, 2635
integration, oral carcinoma, 5465
transactivation
c-*myb*, 4432
Human T cell leukemia virus
type I
pX transgenic rats, mammary carcinoma, 2524
tax, IL-8 gene transactivation, 3592
Human vascular endothelial cells
TSP modulation of MCF-7 cell adhesion, 166
Humanization method
antibody design, 5973s
HUVECs: *see* **Human vascular endothelial cells**
Hyaluronan
receptors
expression, squamous cell lung carcinoma cells, 3908
and tumor metastasis, 428
Hydroperoxides
glutathione peroxidase effects, 4465
NNK activation, human lung microsomes, 5566
4-Hydroperoxycyclophosphamide
resistant MCF-7 cells
glutathione levels, NMR detection, 2012
***N*-Hydroxyarylamides**
activation
recombinant human NAT2 allozymes, 3531
***N*-Hydroxyarylamines**
activation
recombinant human NAT2 allozymes, 3531
sulfotransferase, 525
Hydroxyethyl starch deferoxamine conjugate
combined with IgG mAb ATRA
lymphoma inhibition, 3817
***N*-(2-Hydroxyethyl)-*N*-nitrosourea**
-induced *in vivo* mutagenesis
O^6-alkylguanine and, T-lymphocytes, 1875
***N*-Hydroxyheterocyclicamines**
metabolic activation, sulfotransferase, 525
O^6-(*p*-Hydroxy[^{3}H]methylbenzyl)guanine
alkyltransferase labeling, 4085
***N*-(4-Hydroxyphenyl)retinamide**
induction of apoptosis, neuroblastoma cells, 847
3α-Hydroxysteroid/dihydrodiol dehydrogenase
rat gene analysis, 4105
Hydroxyurea
effects on cellular iron metabolism, CCRF-CEM cells, 4361
interaction with iododeoxyuridine
radiosensitization, bladder cancer, 2800
resistance
ribonucleotide reductase overexpression and, KB cells, 1328
ribonucleotide reductase R1 and R2 mRNA stability and tumor promotion, 4503
Hypercalcemia
cancer-associated
suppression by suramin, nude mice, 1989
gallium nitrate effects, rat model, 307
Hypermethylation
E-cadherin expression silence, breast and prostate carcinoma, 5195
Hyperplasia
aberrant crypt foci
adenomatous aberrant crypt foci from, 4743
atypical renal tubular, $B6C3F_1$ mice exposed to lead acetate, 5265
Hypersensitivity
mitomycin C
Chinese hamster cell mutants, resembling Fanconi anemia, 3412
Hyperthermia
-induced apoptosis, rats, 5459
Hyperthermic killing
enhancement by protease inhibitors, L5178Y cells, 739
Hypomethylation
DNA breaks and, folate/methyl-deficient rat livers, 1894
Hypopigmentation
hair
bcl-2$^{-/-}$ mice, 354
Hypoxia
-specific marker
VEGF hypoxia inducibility mapping, 6222
VEGF inducibility
mapping, multicellular tumor spheroids, 6222
HYRC1
scid factor complementation, 1774

I

ICE: *see* **Interleukin 1β-converting enzyme**
ICR12
iodogen- and MATE-labeled
breast cancer xenograft radioimmunotherapy, 5842s
ICRF-159
DNA topoisomerase II target, *S. cerevisiae*, 2299
ICRF-193
DNA topoisomerase II target, *S. cerevisiae*, 2299
Idoxifene
phase I study, metastatic breast cancer, 1070
IFN: *see* **Interferon**
IGF: *see* **Insulin-like growth factor**
IGF2
normal imprinting, neuroblastoma, 3386

IGROV-1 cells
reduced folate carrier functional activity, 3790
IL-2: *see* **Interleukin-2**
Ileum
cellular hMSH2 expression, 5146
Illudin
acylfulvene analogues
efficacy, 4936
Imaging: *see also specific modalities*
planar
clinical radioimmunotherapy, 5823s
transfected gene expression, 6126
tumor
anti-Tac(dsFv), 318
Immortalization
SV40 large T antigen, and cyclin D1, 4651
Immune cells
ESb
IFN-α/β and, ESb metastases inhibition, 6133
Immune sera
definition of two sialyl Tn configurations, tumor cells, 3364
Immunity
antitumor
synergistic induction by B7–1 and IL-12, 4980
T-cell
mutated ras protein, pancreatic and colon cancer, 2984
Immunization
against breast cancer
pregnancy, 2257
Immunoconjugates
DC1
antitumor effects, 4079
doxorubicin
therapeutic efficacy, preclinical spontaneous metastatic human melanoma model, 2352
2IT-BAT-Lym-1
immunoreactivity and biodistribution, 878
Immunodeficiency
AIDS-related Kaposi's sarcoma
retinoid inhibition, 823
severe combined, mice
human myeloma cells, anti-CD54 antitumor effects, 610
lymphoma dissemination retardation by IL-4, 3692
tumor rejection, MHC class I expression and, 1911
Immunogenicity
E7
HPV-16-transgenic mice, 2635
G_{M2}-KLH conjugate vaccine, melanoma, 2783
tumor cell
OGAT effects, murine L1210 leukemia, 6231
Immunoglobulin G
anti-CEA antibody, ^{99m}Tc-labeled
targeting liver metastases of colorectal carcinoma, 5777s
mAb ATRA, combined with hydroxyethyl starch deferoxamine conjugate
lymphoma inhibition, 3817
Immunoglobulin H
recombinations, Burkitt's lymphoma, 5012
Immunoglobulin M
mAb conjugate AC6C3–2B12
^{111}In-labeled, intraperitoneal administration, preclinical analysis, 5736
Immunoglobulins
anticarcinoma
chimeric domain-deleted, biological properties, 5957s
heavy chain/c-*myc* recombinations
Burkitt's lymphoma vs mouse plasmacytoma, 5012
new superfamily vascular protein, 2140
radiolabeled therapy
Hodgkin's disease, studies review, 5888s
tumor cell-derived collagenase stimulatory factor (EMMPRIN), 434
Immunohistochemistry
PAH-DNA adducts, lymphocytes, 1417
Immunoscintigraphy
with PET, 115
SPECT
with chest CT, non-small cell lung cancer, 5759s
Immunosuppression
in vivo
human tumor gangliosides, 211
Immunotherapy: *see also* **Radioimmunotherapy**
adoptive
tumor microcirculation and, 4627
bispecific antibody-mediated, solid tumors, 4383
IL-2
enhancement by reduction of GM suppressor cells, 885
low and high affinity mAbs, nude mouse xenograft model, 4398
Immunotoxins
anti-CD40, B-cell lymphoma, 3099
anti-osteosarcoma
cytotoxicity, 1321
trafficking and cytotoxicity, 3763
Implants
C6 glioma multicellular spheroids
neovascularization induced growth, MRI, 1956
genetically modified endothelial cells
angiogenic sites, mice, 2240
Imprinting, loss of
hepatoblastoma, 1836
Indium-111
-DOTA-peptide
L6 prelabeling, 5726s
-DTPA-monoclonal antibodies
metabolism, 5714s
-DTPA-octreotide scintigraphy, 5794s
carcinoid tumors, 5801s
pancreatic adenocarcinoma, 5805s
-labeled AC6C3–2B12
intraperitoneal, preclinical analysis, 5736
Indolocarbazoles
compound NB-506
antitumor effects, mice, 1316
cytotoxicity and mechanism, 1310
-resistant SBC-3/NB cells, 2806
Indomethacin
alone or combined with dehydroepiandrosterone
chemoprevention, rat multiorgan carcinogenesis model, 4870
Infection
H. pylori
establishment age, and gastric cancer, 562
hepadnaviral
synergy with dietary aflatoxin B_1, woodchucks, 3318
Inflammation
PML nuclear body effect, 1590
Injury
ischemia reperfusion
tumors, oxygen radicals and nitric oxide, 6021
Insulin-like growth factor
expression, sarcoma, 129
IGF2 gene
normal imprinting, neuroblastoma, 3386
induction
mutant p21*ras* expression, thyroid epithelial cells, 915
WT1, Wilms' tumor cells, 4540
receptors
expression, sarcoma, 129
and metastasis, murine carcinoma cells, 1006
Insulin-like growth factor I
apoptosis prevention, 303
overexpression, human pancreatic cancer, 2007
receptors, 249
apoptosis and, 3739
apoptosis prevention, 303
apoptosis prevention *in vivo*, 2463
tyrosine 950 mutation, effects on cell growth and transformation, 663
Insulin-like growth factor II
expression
breast stroma, 2448
mesothelial cells, 3634
Integrins
$\alpha 4\beta 1$
mAb, inhibition of IL-1-enhanced metastasis, 414
-mediated contact formation, NG2 and, 2177
$\alpha 6$
expression levels, human breast carcinoma, 901
$\beta 1$
laminin mitogenic effects, melanoma and melanocytes, 4702
expression, human epidermal neoplasms, 5434
Interferon
defects, malignant melanoma, 4099
α-Interferon
combined with 5-fluorouracil
treatment of colorectal cancer, 3543
combined with RAR- and RXR-selective retinoids, 232
enhancement of TAG-72 expression, metastatic breast cancer, 5925s
suppression of saccharin-induced mutagenicity, human RSa cells, 4253
α-2b-Interferon
combined with retinoic acid
effects on proliferation and gene expression, cervical carcinoma, 3158
α/β-Interferon
and adoptively transferred immune cells
ESb metastases inhibition, 6133
γ-Interferon
combined with TNF-α
reduction of GM suppressor cells and enhancement of IL-2 immunotherapy, 885
effects on carcinoembryonic antigen footprint analysis, colon carcinoma, 3873
effects on RAR and CRABP, breast cancer, 2135
local production
RG-2 glioma growth attenuation and brain edema, 1902
radioimmunodetection, 2858
Interleukin 1
-enhanced metastasis
anti-VLA-4 inhibition, 414
Interleukin 1β-converting enzyme
mediation of cisplatin-induced apoptosis,

malignant glioma cells, 6166
Interleukin 2
combined vaccination with MHC class I, melanoma cells, 4941
eradication of Daudi tumors, 2627
immunotherapy
enhancement by reduction of GM suppressor cells, 885
-induced pulmonary vascular leak syndrome attenuation by oral methotrexate, 4929
local production
RG-2 glioma growth attenuation and brain edema, 1902
receptor
-bearing tumors, anti-Tac(dsFv) uptake, 318
Interleukin 4
circularly permuted toxin *in vivo*, 3357
lymphoma dissemination retardation, SCID mice, 3692
receptor
-bearing carcinoma, antitumor effects of circularly permuted IL4-toxin, 3357
recombinant human
antiproliferative effects, human tumor cell lines, 2173
Interleukin 6
anti-IL-6 mAb
CDDP sensitization, renal cell carcinoma, 590
cDNA transduction
IL-6 resistance, melanoma cells, 2200
-dependent myeloma ANBL6 cells
growth characteristics, activated N-*ras* effects, 3640
enhancement of transformation *in vitro*, rat urothelial cells, 4581
expression
regulation by photodynamic therapy, 2373
-mediated up-regulation of *bcl-x_l*
prevention of apoptosis, myeloma cells, 2262
receptors
anti-IL-6R mAb, CDDP sensitization, renal cell carcinoma, 590
resistance
IL-6 cDNA transduction, melanoma cells, 2200
risk factor, prostate carcinoma cell lines, 4633
Interleukin 8
expression
regulation by organ environment, melanoma cells, 2471
induction
ultraviolet B irradiation, 3669
production, adult T-cell leukemia cells, 3592
Interleukin 12
induction of antitumorimmunity
synergistic with B7–1, 4980
murine, recombinant vaccinia virus encoding antitumor effects, 4765
recombinant
antimetastatic effects, 4404
Interleukin 15
LAK induction, melanoma patient lymphocytes, 4988
Interstitial fluid pressure
solid tumors, 5451
Intestinal adenomas
N-ethyl-*N*-nitrosourea treatment and, *Min* mice, 4479
Intestinal epithelial cells
H-*ras*-transformed
TGF-β receptors, 6181
Intestinal polyps
formation
Apc mutations, 2719
Intestine
large: *see also* **Colon**
cancer risk, smoking and, women, 4906
cellular hMSH2 expression, 5146
small
cellular hMSH2 expression, 5146
distorted, *bcl-2*$^{-/-}$ mice, 354
Intracellular adhesion molecule-1
antitumor effects, SCID mice with human myeloma cells, 610
Intraepithelial neoplasia, prostatic
chromosomal anomalies
FISH detection, 5408
chromosome 8p12-21 allelic loss
microdissected, 2959
Intron 9
abnormal retention
CD44 gene transcripts, gastrointestinal tumors, 4273
Invasion
inhibition by urinary trypsin inhibition-derived peptides, 1847
molecular insights, 1856
neuroblastoma
brain-derived neurotrophic factor and p145^{TrkB} expression and, 1792
Invasive carcinoma
bladder
angiogenic pathways, 510
hCGβ gene expression, 3735
breast
allelic loss, 467
colon
phenotype transition, 4722
laminin-5 marker, 4132
Invasive neoplasms
cardiac hemangioendothelial
fish *R. marmoratus*, 2438
focal adhesion kinase overexpression, 2752
Invasive squamous cell carcinoma
head and neck
microsatellites motif loss of heterozygosity, 2656
Iodine
residualizing radiolabels
monoclonal antibodies, 3132
Iodine-11
-labeled antibodies
radioimmunotherapy, vs external beam radiotherapy, 5811s
Iodine-131
-labeled anti-CEA mAbs
radioimmunotherapy, medullary thyroid carcinoma, 5946s
-labeled mAbs
intralesional radioimmunotherapy, malignant glioma, 5952s
Iododeoxyuridine
interaction with hydroxyurea
radiosensitization, bladder cancer, 2800
labeling
human tumor xenografts measured, cell proliferation kinetics, 392
Iodogen
-labeled ICR12
breast cancer xenograft radioimmunotherapy, 5842s
Ionizing radiation: *see* **Radiation**
IQ: *see* **2-Amino-3-methylimidazo-[4,5-*f*]quinoline**
Iron
cellular metabolism
hydroxyurea effects, CCRF-CEM cells, 4361
deprivation
combined treatment of lymphoma, 3817
Irradiation: *see* **Radiation**
Ischemia reperfusion injury
tumors
oxygen radicals and nitric oxide, 6021
Islet cell carcinoma
transgenic mouse model
chromosome 9 and 16 tumor suppressor loci, 6071
2IT-BAT-Lym-1
immunoreactivity and biodistribution, 878

J

Japanese
breast cancer families
germline *BRCA1* mutations, 3521
latent prostatic carcinoma
androgen receptor gene mutations, 1621
Japanese Cancer Association
Third Joint Meeting with AACR, meeting report, 5472
JCA: *see* **Japanese Cancer Association**

K

90K
tumor suppression, 3223
K562 cells
carbonyl reductase cDNA expression, 4646
erythroid differentiation
PML-RARα and, 440
Kaposi's sarcoma
AIDS-related
retinoid inhibition, 823
Karyotypes
pancreas adenocarcinoma, 2394
KB cells
reduced folate carrier functional activity, 3790
ribonucleotide reductase overexpression and hydroxyurea resistance, 1328
KDR
expression
colon cancer, 3964
hematopoietic cells, 5687
Kemptide fusion protein
antibody fragment
^{P} labeling, 5968s
Kent cigarettes
smoke
crocidolite asbestos fibers, 2232
Keratinocytes
BALB/MK cells
inhibition by TGFβ1, 3928
Kidney: *see also under* **Renal**
antibody fragment uptake
reduction by cationic amino acids, 3827
carcinogenic estrogen effects, hamster, 4347
epithelial cell lines
monosomy 5 and *$p15_{INK4B}$/$p16_{INK4}$* deletions, 1607
IQ-DNA adducts, *Ah/NAT* congenic mice, 3043
polycystic
bcl-2$^{-/-}$ mice, 354
radioimmunoconjugate excretion
lysine and, 5288
Knudson's two hits
preneoplastic renal cells
detection by laser microdissection, Eker rat model, 989
K-*ras*
antisense construct

liposome-mediated gene transfer, pancreatic cancer, 3810
mutations
gastric adenocarcinoma, Florence, Italy, 2665
lung adenocarcinoma, 1444
minisatellite instability and, methylcholanthrene-induced mouse sarcoma, 5670
pancreatic adenocarcinoma and pancreatitis, 4264
Ras CAAX peptidomimetic FTI 276 tumor growth blockade, lung carcinoma, 4243
Ku80
correction of *xrs*-6 DNA repair defect, 1235
KW2152
efficacy against human melanoma lines, 862

L

L6
human antimouse antibody response
suppression by deoxyspergualin, phase I study, 3060
^{125}I-labeled radioimmunotherapy
targeting enhancement by combining preload and immunoadsorption, 5874s
^{131}I-labeled radioimmunotherapy
peripheral blood progenitor cell transfusions support, breast cancer, 5916s
β-Lactamase
fusion proteins
humanized disulfide-stabilized anti-p185^{HER2} Fv-, 63
mAb conjugates
combined with doxorubicin prodrug, activation, 2357
combined with prodrugs, melanoma xenograft treatment, 3558
Fv-β-Lactamase
humanized disulfide-stabilized anti-p185^{HER2} fusion protein, 63
Lactate
cervical cancer levels, and metastasis, 4757
Lactation
lead acetate exposure
renal tubular tumors and atypical hyperplasias, B6C3F$_1$ mice, 5265
Lactoferrin
mRNA and protein overexpression
and malignant transformation of endometrium, 1168
Lactotropes
TGF-β1 expression and action
estrogen effects, 4892
Laminin
antagonism by murine EGF fragment (33-42), 3772
mitogenic effects, melanoma and melanocytes, 4702
Laminin α1
chain IKVAV-containing peptide
promotion of liver colonization, colon cancer cells, 2476
Laminin 5
coexpression with uPA receptor, colon adenocarcinoma, 4132
marker, invading human cancer, 4132
β-Lapachone
apoptosis induction
HL-60 and prostate cancer cells, 3706
prostate cancer cells, 3712
Large cell lymphoma
anaplastic xenografts
antitumor effects of unconjugated CD30 mAbs, 5335
Large intestine: *see also* **Colon**
cancer risk
smoking and, women, 4906
cellular hMSH2 expression, 5146
Larynx
squamous cell carcinoma
cell kinetics, prognostic significance, 6103
theoretical phantom, radioimmunotherapy dosimetry, 1020
Laser microdissection
detection of Knudson's two hits in preneoplastic renal cells by, Eker rat model, 989
Lead acetate
exposure
renal tubular tumors and atypical hyperplasias, B6C3F$_1$ mice, 5265
Lesions: *see also* **Neoplasms; Tumors**
epithelial
premalignant, progression to bronchial carcinoma, gene losses, 5133
melanocytic
loss of *p16/CDKN2* expression, 2713
oral
premalignant, anti-retinoic acid antibody binding, 5507
thyroid
CD44 mRNA splicing, 4594
Letters to the Editor
re: Dabholkar, *55:* 1261–1266, 3933
re: Swaffar, *54;* 6045–6048, 4486
L-[1-^{13}C]Leucine
in vivo modified tracer technique
protein metabolism, colon carcinoma, 1160
Leukemia
adult T-cell
IL-8 production, 3592
antigen peptides, recognized by CTLs, 4781
CCRF-CEM cells
iron metabolism, hydroxyurea effects, 4361
CDKN2 (*p16^{INK4A}/MTS1*) and *p15^{INK4B}/MTS2*, 1436
CEM/C2 cells
topoisomerase I mutation, 1339
CEM/C7 cells
glucocorticoid receptor, modulator inhibition, 548
etoposide resistance
mechanism, murine cells, 4352
inhibition by bryostatin 1
and CDK2 dephosphorylation, 3716
K562 cells
carbonyl reductase cDNA expression, 4646
L1210
triazene-induced cytotoxicity and tumor cell immunogenicity, OGAT effects, 6231
MHC class II-negative cell lines
superantigen-induced lysis, 623
Moloney murine virus
integration impairment, 3211
p53-independent *WAF1/CIP1* induction, 668
p27^{Kip1} genetic analysis, 1206
radiosensitive
fibroblasts, defective repair of DNA double-strand breaks and chromosome damage, 1232
-specific cytotoxic T cell clones, 3835
therapy targets, meeting report, 4488
topoisomerase IIα alterations, mitoxantrone-resistant HL-60 cells, 1707
Leukemia, acute
leukemia-specific cytotoxic T clones, 3835
resistance to glucocorticoid-induced apoptosis, 348
Leukemia, acute lymphoblastic
childhood
allelotype analysis, 5377
gene rearrangements, acute myeloid leukemia, 1625
topoisomerase IIα and β, 78
Leukemia, acute myeloid
ALL-1 rearrangements, 1625
M4/M5
t(10;11) breakpoint heterogeneity, 4220
retinoblastoma gene product, 4552
Leukemia, chronic lymphocytic
B-cell
D13S25 deletion cartography and mapping, 1355
D13S218 deletions, 2044
RB-1 and *D13S25* deletions, 3475
Leukemia, lymphoblastic
CCRF-CEM, -derived cells
5,10-dideazatetrahydrofolic acid resistance, 566
Leukemia, myeloid
radiolabeled anti-CD33 monoclonal antibody M195, 5908s
Leukemia, promyelocytic
HL-60 cells
accumulation, energetic checkpoints, 5164
nuclear body effect on inflammation and cell growth, 1590
retinoblastoma gene product, 4552
Leukocytes
adhesion
TNFα-induced, 4824
damaged *in vitro*
PCR assay, DNA damage and clinical response, non-small cell lung cancer, 2334
peripheral blood
6-thioguanine quantitation, 1670
Lewis enzyme
expression, Lewis-negative cancer patients, 1473
LHRH: *see* **Luteinizing hormone-releasing hormone**
Li-Fraumeni syndrome
Met overexpression, 1963
p53 replication error, 3237
γ-Linolenic acid
regulation of E-cadherin expression, 5043
Linomide
effects on prostatic cancers, rats, 1499
-induced apoptosis, prostatic cancer cells, 3517
Lipid-mobilizing factor
and cachexia-induced tumors, mice and humans, 1458
Lipopeptide CGP 31362
hepatic metastases, nitric oxide-mediated regression, 3123
Liposarcoma
myxoid
t(12;16)(q13↔1) translocation, 24
round cell
t(12;16)(q13↔1) translocation, 24
Liposomes
cationic, complexed to adeno-associated virus-based plasmids
prostate cancer gene therapy, 2366
-mediated gene therapy, pancreatic cancer, 3810
Lipoxygenase
NNK activation, human lung microsomes,

5566
Listeria monocytogenes
oral recombinant vaccine
tumor regression, 4776
Liver: *see also* **Hepatocellular carcinoma**
amino acid transport, tumor-bearing rats, 3525
BrdUrd incorporation, 3687
carcinogen-treated
oval cell lines OC/CDE 6 and OC/CDE 22, phenotype and differentiation patterns, 1028
chronic disease
telomerase activity, 2734
folate/methyl-deficient
DNA breaks and hypomethylation, rat, 1894
metastases
colonic, promotion by laminin α1 chain IKVAV-containing peptide, 2476
colorectal, BrdUrd incorporation, 3687
colorectal, targeting, 5777s
nitric oxide-mediated regression, 3123
prevention by TNP-470, 836
telomerase activity, 2734
xenobiotic metabolizing enzyme expression
tamoxifen effects, rat, 1780
Liver tumors
apoptosis
induction by perillyl alcohol, 979
glycerol metabolism, ^{13}C NMR study, 761
tamoxifen-induced, rats, 544
LL2
anti-CD22 mAb
treatment of non-Hodgkin's lymphoma, 5899s
anti-idiotype antibody, 5978s
glycosylated, site-specific modifications, 5721s
^{99m}Tc-labeled Fab′ fragment
B-cell non-Hodgkin's lymphoma staging, 5771s
^{99m}Tc-labeled fragment
B-cell non-Hodgkin's lymphoma staging, 5764s
L-*myc*
antisense inhibition, small cell lung cancer, 1559
LNCaP cells
androgen *bcl-2*-mediated apoptosis resistance, 735
TNF-induced death
prevention by sulfated glycoprotein-2, 2431
Lobular breast carcinoma
ductal carcinoma *in situ* allelotype, 3976
microsatellite instability, frequency, 3976
replication error phenotype, 3976
Localization
metallothionein, prostatic tumor cells, 474
Lonidamine
mechanism of action, NMR studies, 2815
Loss of heterozygosity
chromosome 1p
breast cancer, detection and cloning, 1752
neuroblastoma, 4664
chromosome 7q31.1
prostate cancer, 4114
squamous cell and colon carcinoma, 1347
chromosome 8
male breast carcinoma, 4995
chromosome 9p
breast cancer, 2892
chromosome 10q
endometrial cancers, 1922
chromosome 11
breast tumors, 2660
chromosome 11p15
malignant glioma, 2166
chromosome 11q
lung adenocarcinoma, 3988
oral carcinoma, 5465
chromosome 11q13
microdissected and invasive breast cancer, 467
chromosome 11q23.3
breast cancer, 3003
chromosome 11q23
cutaneous malignant melanoma, 2494
chromosome 12q13-14
malignant glioma, 727
chromosome 17q
non-small cell lung cancer, 4268
prostate cancer, 1002
chromosome 18q21
oral carcinoma, 5465
microsatellite motif, head and neck squamous carcinoma, 2656
RB, aggressive pituitary tumors, 1613
t(3;8), renal cell carcinoma, 5348
tumor suppressor genes, testis cancer, 2871
Loss of imprinting
hepatoblastoma, 1836
Low density lipoprotein
receptor
-related protein, PDT-resistant tumor cells, 1817
LRP
localization and genetic characterization, 4214
LU79553
preclinical evaluation, 1176
LU103793
interaction with microtubules, 3085
Luminescence
microplate adenosine triphosphate assay
chemosensitivity testing, ovarian carcinoma, 5276
Lung
A/J mouse
time-integrated DNA adducts and PAH-induced adenoma, 1039
carcinogenic effects of nickel exposure, 5251
chondroid hamartoma
chromosome 12q14-15 rearrangements, 2497
fibroblasts
stromelysin-3 regulation by retinoic acid, 4120
living vertebrate
epithelial cells, mitosis, crocidolite asbestos and, 792
metastasis
B16 melanoma, microvessel origin and distribution, 4627
and mouse monocyte chemotactic protein 1, 4458
postsurgical established, MHC class I and IL-2 gene therapy, 4941
recombinant IL-12 effects, 4404
microsomes
NNK activation, 5566
preneoplastic lesions
multiple, independent genetic changes, 135
tobacco carcinogen-induced damage
blood DNA adducts and, 4910
vascular leak syndrome
IL-2-induced, attenuation by oral methotrexate, 4929
Lung adenocarcinoma
African-American *CYP1A1* polymorphism, 472
chromosome 11q loss of heterozygosity, 3988
K-*ras* mutations, 1444
metastasis
surfactant protein gene expression, RT-PCR detection, 4283
peripheral
β-adrenergic mitogenic signal transduction, 3504
Lung carcinogenesis
retinoid refractoriness, 5603
Lung carcinoma
anti-EGFRvIII mAbs, 3140
bleomycin-induced chromatid breaks, case-control study, 557
clonal growth
stimulation by nerve growth factor, 2212
cyclin-dependent kinase inhibitor mutations, 1448
drug-resistant
topoisomerase IIα cytoplasmic localization, 2129
hereditary microsatellite instability, 3996
intrinsic resistance to chemotherapy
DNA repair and, 4760
metastatic MV522 xenografts
illudin analogue efficacy against, 4936
non-small cell
chemotherapy response, p53 expression and, 5038
chest CT and SPECT fusion, 5759s
chromosome 17q loss of heterozygosity, 4268
DNA damage and clinical response, PCR assay, 2334
enhanced apoptosis and, 5595
loss of heterozygosity at 5q and 18q, 220
microsatellite instability, 28
MRP-1/CD9 expression, and prognosis, 6040
p15 alterations, 514
p15 alterations, deletion, 2968
p16 alterations, 514
p16 alterations, deletion, 2968
$p16^{INK4A}$ **inactivation, 6200**
pituitary adenylate cyclase activating peptide receptors, 4886
Rb inactivation and $p16^{INK4}$ expression, 505
stage I oncogenes, 51
stromelysin-3 overexpression, 4120
surfactant protein gene expression, RT-PCR detection, 4283
type 2 cytokine pattern, 3847
p53 mutations
lung cancer, Chinese women, Hong Kong, 5343
pulmonary GSTM3 expression, 3305
risk
and *CYP1A1* polymorphisms, African-Americans, 6035
small cell
antisense inhibition of L-*myc*, 1559
CCK-B/gastrin receptor mRNA, 276
H69 cells, VP-16-selected, *MRP* and *mdr1* sequential coexpression, 459
Rb inactivation and $p16^{INK4}$ expression, 505
spicamycin derivative *in vitro* cytotoxicity, 1075
squamous cell
hyaluronan receptor expression, 3908

stromelysin-3 expression and regulation, 4120
tumor growth blockade
Ras CAAX peptidomimetic FTI 276, nude mice, 4243
Lung neoplasms
multiple
independent genetic changes, 135
Luteinizing hormone-releasing hormone
mRNA expression, ovarian epithelial carcinoma, 817
receptor
mRNA expression, ovarian epithelial carcinoma, 817
L5178Y cells
hyperthermic killing enhancement by protease inhibitors, 739
Lymph nodes
metastasis
recombinant IL-12 effects, 4404
thrombomodulin expression and, 4196
micrometastases, RT-PCR, 3417
Lymphoblastic leukemia
acute
topoisomerase IIα and β, 78
CCRF-CEM, -derived cells
5,10-dideazatetrahydrofolic acid resistance, 566
Lymphoblastoid cells
Cl-F-ara-A metabolism and actions, 2847
Lymphoblasts
induced mutation and apoptosis
altered p53-affected, 12
Lymphocytes: *see also* **B lymphocytes; Cytotoxic T lymphocytes; T lymphocytes**
activation
$p16^{INK4}$ and $p15^{INK4B}$ expression, 4010
bleomycin-induced chromatid breaks, lung cancer, case-control study, 557
differentiation
$p16^{INK4}$ and $p15^{INK4B}$ expression, 4010
DNA repair genes and β-actin
simultaneous amplification by multiplex RT-PCR, 5025
granular
clonal $CD3^+$, superantigen activation, 6140
lymphoproliferative disease of, T cell receptor, 6140
interphase, 1cen-1q12 region
chromosomal breakage, 640
melanoma
LAK induction by IL-15, 4988
PAH-DNA adducts, immunohistochemistry, 1417
recognition of melanoma antigen, 4972
sister chromatid exchange
suppression by ginsenoside Rh_2, 1221
tumor-infiltrating
monoclonal antimelanoma scFv antibody, 3584
VEGF synthesis, 4140
Lymphoid cells
accelerated death, thymus and spleen
bcl-2$^{-/-}$ mice, 354
inhibition by glucocorticoids, 4188
Lymphoid tissue, gut-associated
antitumor T-cell response
TGF-β, 6146
Lymphokine-activated killer
induction by IL-15, melanoma patient lymphocytes, 4988
Lymphoma
antibodies
glycosylated, site-specific modifications, 5721s
B-cell
anti-CD40 immunotoxin, 3099
spontaneous, nitric oxide production and, SJL mice, 4391
Burkitt's
IgH/c-*myc* recombinations, 5012
WAF/CIP1, 1431
CDKN2 (*$p16^{INK4A}$/MTS1*) and *$p15^{INK4B}$/MTS2*, 1436
dissemination
retardation by IL-4, SCID mice, 3692
Hodgkin's
CD30 ligand signal transduction, 4157
inhibition
hydroxyethyl starch deferoxamine conjugate combined with IgG mAb ATRA, 3817
malignant
antiepileptics and, 294
non-Hodgkin's
B-cell, staging, ^{67}Ga citrate vs ^{99m}Tc-labeled LL2-Fab′ fragment, 5771s
B-cell, staging, ^{99m}Tc-labeled LL2 MAb fragment, 5764s
metabolic characterization, proton-decoupled phosphorus MRS, 3278
radioimmunotherapy, LL2 anti-CD22 mAb, 5899s
radioimmunotherapy, red marrow dosimetry by sacral scintigraphy, 5827s
p53-dependent G_1 checkpoint regulation, 2387
RAW117 cells
mouse monocyte chemotactic protein 1 chemoattractant, 4458
T-cell
malignant, CD45 cell adhesion and apoptosis suppression, 2186
metastatic, B7–1 expression, induction of natural killer cell-mediated cytotoxicity, 2730
thymic
reduced fidelity of DNA synthesis, mice, 3777
U937 cells
TNF-induced apoptosis, 444
unconjugated CD19 and CD20 mAb antitumor effects, nude mouse xenograft model, 840
unconjugated CD30 mAb antitumor effects, anaplastic large-cell xenografts, 5335
v-*abl*-induced, 6196
Lymphoproliferative disease
granular lymphocytes
T cell receptor, 6140
Lymphotoxin
-mediated tumor growth inhibition, 4747
Lysine
and renal excretion of radioimmunoconjugates, 5288
Lysis
superantigen-induced, leukemia cell lines, 623

M

M1 cells
TGF-β1-treated, ectopically expressing B-*myb*
apoptosis, 501
M195
radiolabeled
myeloid leukemia, 5908s
MA104 cells
reduced folate carrier functional activity, 3790
Macroglobulin
receptor α-2
-related protein, PDT-resistant tumor cells, 1817
Macrophage colony-stimulating factor
mediation of invasion of ovarian cancer cells, 1578
Macrophages
infiltration
linomide inhibition, rat prostatic cancers, 1499
monocyte differentiation
p53-independent *WAF1/CIP1* induction and, leukemia cells, 668
nitric oxide production
cisplatin-induced immunostimulation, 5524
MAGE-1
spermatogonia and spermatocytes, testis, 3478
MAGE-3
identification and intracellular location, 2236
MAGE-4
spermatogonia and spermatocytes, testis, 3478
Magnetic resonance microimaging
neovascularization-induced tumor growth, implanted C6 multicellular spheroids, 1956
Magnetic resonance spectroscopy
^{31}P
antihormonal therapy of human breast cancer xenografts, 4146
breast cancer xenografts, 1664
proton-decoupled, non-Hodgkin's lymphoma *in vivo*, 3278
Major histocompatibility complex
class I
-associated peptides, Meth A sarcoma-derived, 124
-associated peptides, methylcholanthrene-induced expression, 5648
combined vaccination with IL-2, melanoma cells, 4941
expression, and tumor rejection, SCID mice, 1911
loss, metastatic vs primary breast cancer, 5191
class II
-negative leukemia cell lines, superantigen-induced lysis, 623
Male breast carcinoma
chromosome 8 loss of heterozygosity, 4995
Malignancy
advanced
plasma anemia-inducing substance, 3623
antiepileptics and, 294
B-lymphocytic
radioimmunotherapy, prognostic factors, 5893s
ERCC1, *XPAC*, and *ERCC2* mRNA expression, brain tissue, 1261, 3933
fucosyltransferase and α-L-fucosidase activities and fucose levels, endometrial tissue, 3654
glial tumors
$p16^{INK4}$, pRB, and cdk4 overexpression, 4833
glioma
anti-EGFRvIII mAbs, 3140
chromosome 11p15 loss of heterozygosity, 2166
chromosome 12q13-14 amplification and loss of heterozygosity, 727
cisplatin-induced apoptosis, mediation by ICE, 6166

Fas/APO-1 gene transfer, 2936
intralesional radioimmunotherapy, 5952s
hematopoiesis
Sixth Annual Pezcoller Symposium, 3462
IGF-II expression, breast stroma, 2448
melanoma
cutaneous, chromosome 11q23 loss of heterozygosity, 2494
interferon defects, 4099
peripheral blood cells, PCR-based semiquantitative assessment, 4065
thrombin receptor, 1629
translocation breakpoint, microdissection based cloning, 4640
meningioma
chromosomes 14, 10, and 1 allelic losses, 4696
G207 treatment, 4752
mesothelioma
GSTM1 and *NAT2* defects and, 2981
phenotypes
NFI, farnesyltransferase inhibitor block, 3569
suppression, chromosomal 17q fragments, prostate cancer, 3389
p27/Kip1, molecular analysis, 2266
plasma cells
adhesion molecules, 3646
T-cell
2-amino-6-methoxypurine arabinoside agent, 3352
telomerase effects, colorectal cancer, 2533
teratoma protection against, 3664
T-lymphoma
CD45 cell adhesion and apoptosis suppression, 2186
transformation
astrocytoma, β2-chimaerin, 3456
endometrial, lactoferrin mRNA and protein overexpression and, 1168
trophoblasts
paternally derived *H19* expression, 1111
Wnt-5A expression, 3495

Mammalian cells
chloroethyl-cyclohexyl-nitrosourea mutation fingerprint, 4658

Mammary gland
EGF expression
reduction by calorie restriction, 1289
epithelial cells
apoptosis, stromelysin-1 transgenic mice, 1401
elafin expression, 2537
tumorigenesis
TGF-α-induced, transgenic mice, 3915

Mammary neoplasms: *see also* **Breast neoplasms**
growth
aromatase inhibitor effects, nude mouse model, 3073
progression, spontaneous rat, 399
psychosocial stressor-induced changes, natural killer cells, 617
stromelysin-1 transgenic mice, 1401

Mammary tumor virus
ENV gene-like sequences, breast cancer, 5173

Mammary-derived growth inhibitor
gene encoding
tumor suppressor effects, 2225

Manganese superoxide dismutase
reduction of tumor control radiation dose, 2490

Mannoheptulose
tumor growth inhibition, 3278

Mannose 6-phosphate
glycoproteins containing, breast carcinoma, 3424

MAPK: *see* **Mitogen-activated protein kinase**

Mapping
chromosomal
cdc2 protein kinases and $p27^{Kip1}$, 1199
DPC/BRCA2, 4571
D13S25, B cell chronic lymphocytic leukemia, 1355
$p27^{Kip1}$, 1211
ssic1, mouse chromosome 4, 3179
deletion
chromosome 6q, borderline epithelial ovarian tumors, 2169
D13S25, B cell chronic lymphocytic leukemia, 1355
esophageal squamous cell carcinoma, 1828
VEGF hypoxia inducibility, multicellular tumor spheroids, 6222

MART-1
-specific T-cell receptor, reconstitution, 748

MAT1
molecular cloning, 6058

MATE: *see* ***N*-Succinimidyl 4-methyl-3-(tri-*n*-butylstannyl)-benzoate**

Matrigel
invasion
inhibition by urinary trypsin inhibition-derived peptides, 1847

Matrix metalloproteinase
inhibitor batimastat
organ invasion inhibition, colon carcinoma metastasis models, 3629
membrane-type
expression, gastric carcinoma, 3263
expression, regulation by concanavalin A, MDA-MB-231 cells, 3273
PCR-amplified cDNA
and cervical carcinoma prognosis, 267
ratio to TIMPs
and cervical carcinoma prognosis, 267

Matrix metalloproteinase-2
activation
progelatinase B, 2548
regulation by concanavalin A, MDA-MB-231 cells, 3273

Matrix metalloproteinase-9
activation
fibroblasts, squamous cell carcinoma cell line, 963
gelatinase A, 2548

MBP-1: *see* **myc promoter-binding protein**

Mc3
humanized, breast cancer therapy, 1717

McA-RH 7777 rat hepatoma clones
AFP expression
correlation with chromosome 14 homogeneously staining regions, 3615

MCF-7 cells
adhesion to human vascular endothelial cells
TSP modulation, 166
apoptosis
chemotherapy-induced, increase by Bcl-x_s, 2507
estrogen effects, 2487
chemosensitivity
p53 and, 1649
estrogen receptor variant coexpression, 2158
estrogen-independent, expressing 80-kDa estrogen receptor, 2583
glutathione levels, NMR detection, 2012
growth inhibition by retinoids, 4446

MCF7ras cells
phenylacetate effects, 5156

Mch2
human
cloning, 2737

Mch3
apoptotic cysteine protease, 6045

M-CSF: *see* **Monocyte colony-stimulating factor**

MDA-MB-231 cells
MT-MMP and MMP-2 activation
regulation by concanavalin A, 3273

MDR: *see* **Multidrug resistance**

mdr1
expression, VP-16-selected H69 cells, 459
two-gene transduction, NIH 3T3 cells, 4073

ME 180 cells
proliferation and gene expression
IFN-α-2b and retinoic acid effects, 3158

Medullary thyroid carcinoma
radioimmunotherapy
^{131}I-labeled anti-CEA mAbs, 5946s
ret silencing, 2048

Meeting reports
AACR/JCA, third joint meeting
molecular biology, cancer, 5472
eukaryotic DNA repair genes
gene products, 968
Heidelberger conference, fifth
targets for cancer research, 705
Keystone symposium
complex carbohydrates, 450
leukemia
specific therapies, targets, 4488
Pezcoller symposium, sixth
hematopoiesis, normal and malignant, 3462
Sapporo cancer seminar, fourteenth
genetic polymorphism, cancer susceptibility, 710

Melanocytes
G_1 arrest
induction by UVB light, 4047
laminin mitogenic effects, 4702
responses to ultraviolet B irradiation, 4041

Melanocyte-stimulating hormone
receptor
expression, murine melanoma brain metastases, 141

Melanocyte-stimulating hormone 2
human
cellular expression, small and large intestine, 5146

Melanocytic lesions
loss of *p16/CDKN2* expression, 2713

Melanoma
advanced stage
92-kDa gelatinase B expression, 4174
antigen
MART-1, -specific T-cell receptor, reconstitution, 748
recognition by lymphocytes, 4972
-associated proteoglycan
and α4β1 integrin-mediated contact formation, 2177
B16
pulmonary metastases, microvessel origin and distribution, 4627
bystander killing
E. coli purine nucleoside phosphorylase test, 3339
carcinoembryonic antigen expression
-induced adhesion molecule expression changes, 3250
cutaneous

PA and PAI expression, transgenic melanoma-susceptible mice, 4681
progression, UVB irradiation and, 3669
4-*S*-cysteaminylcatechol effects, 2603
cytotoxic T lymphocytes
generation with dendritic cells, 5330
early stage
somatic cell hybridization, suppression of 92-kDa gelatinase B expression, 4174
G_{M2}-KLH conjugate vaccine, 2783
HLA class I recognition, quantitative, 3149
HLA-A2-matched
TCRBV14 overexpression, 3374
IL-6 resistance
IL-6 cDNA transduction, 2200
IL-8 expression
regulation by organ environment, 2471
inhibitory activity
identification, mRNA differential display, 6237
K-1735
brain metastases, MSH-R expression, 141
laminin mitogenic effects, 4702
lymphocytes
LAK induction by IL-15, 4988
mAb β-Lactamase conjugates combined with prodrugs treatment, xenografts, 3558
metastasis
inhibition, α-galactosyl epitopes, 4168
inhibition, *nm23-M1* and *nm23-M2*, murine, 1971
spontaneous, doxorubicin immunoconjugates efficacy against, preclinical human model, 2352
MHC class I and IL-2 gene therapy, 4941
monoclonal scFv antibody, tumor-infiltrating lymphocytes, 3584
mRNAs
identification, mRNA differential display, 6237
progression
B61 expression and receptor up-regulation, 2528
clonal, tissue microdissection and comparative genomic hybridization visualization, 3954
sialyl Lewis^a expression and, 1748
quinocarmycin efficacy against, human lines, 862
spontaneous
nonhybrid *Xiphophorus*, 159
sporadic
$p15_{INK4B}$ loss, 5531
survival and extravasation, 2520
-susceptible transgenic mice
cutaneous melanoma, PA and PAI expression, 4681
xenografts
mAb β-Lactamase conjugates combined with prodrugs treatment, 3558

Melanoma, malignant
cutaneous
chromosome 11q23 loss of heterozygosity, 2494
enhanced photoproduct repair, 181
interferon defects, 4099
peripheral blood cells
PCR-based semiquantitative assessment, 4065
thrombin receptor, 1629
translocation breakpoint
microdissection based cloning, 4640

Melphalan
intraarterial
intracranial human glioma xenograft treatment, athymic rats, 3803
phase I trial
pediatric refractory cancer, 4069
population pharmacodynamic model, 4507
resistance
γ-glutamylcysteine synthetase subunit cDNA transfection and, 4771

Meningeal cells
metabolic profiles, 420

Meningioma
atypical
chromosomes 14, 10, and 1 allelic losses, 4696
clonality assays
methylation- and transcription-based, 3865
malignant
chromosomes 14, 10, and 1 allelic losses, 4696
G207 treatment, 4752
metabolic profiles, 420
progression, genetic model, 4696
susceptibility
detoxifying enzyme genotypes and, 4237

Merbarone
cellular actions
comparison with VM-26, 1509

6-Mercaptopurine
-based maintenance therapy
6-thioguanine quantitation, peripheral blood leukocyte DNA, 1670

Mesenchymal cancer
explants
migrating cell clusters, 4557

Mesothelial cells
c-*fos* and c-*jun* expression
induction by asbestos, 2085
insulin-like growth factor II expression, 3634
TGFα autocrine growth stimulation, rat, 530

Mesothelioma
malignant
GSTM1 and *NAT2* defects and, 2981
NF2 mutations, 1227
spontaneous
insulin-like growth factor II expression, 3634

Messenger RNA
apoptosis-related expression
breast carcinoma xenografts, radioimmunotherapy and, 5837s
Bcl-2
suppression, mediation of apoptosis after radiation, TNF-α, and ceramide, 991
biliary glycoprotein
expression, colonic mucosa, 2963
CCK-B/gastrin receptor
small cell lung cancer, 276
CD44
splicing, thyroid lesions, 4594
differential display
identification of mRNAs, melanoma cell lines, 6237
ERCC1 and *ERCC2*
expression, malignant brain tissue, 1261, 3933
estrogen receptor variants
coexpression, breast neoplasia and MCF-7 cells, 2158
GAPDH
androgen effects, prostate carcinoma, 4234
lactoferrin
overexpression, and malignant transformation of endometrium, 1168
LHRH and LHRH receptor
expression, ovarian epithelial carcinoma, 817
MLH1
alternative splicing, normal cells, 1839
NM23-H1 and *NM23-H2*, hepatocellular carcinoma, 652
NQO_1
alternatively spliced, normal and tumor tissues, 2542
polynucleotide vaccine vector, characterization, 1397
PSA, non-prostate cells, 2640
ribonucleotide reductase R1 and R2
stability and tumor promotion, hydroxyurea-resistant cells, 4503
thymidine kinase
modulation by WR1065, 4788
topoisomerase IIα
truncated, HL-60 cells, 4962
variant estrogen receptor
exon 5 deletion, expression, breast cancer, 288
hepatocellular carcinoma species, 498
variant glucocorticoid receptor
expression, multiple myeloma, 2727
XPAC
expression, malignant brain tissue, 1261

Met
overexpression, p53-deficient and Li-Fraumeni tumors, 1963

Metabolism
post radiation changes
in vitro and *in vivo* ^{31}P NMR measurements, 1248
transformation-induced changes
tumor-host interaction role, 4151

Metabolite E
microsomal activation, 3012

Metallothionein
localization, prostatic tumor cells, 474
null cells
sensitivity to anticancer drugs, 2021

Metastasis
B61 growth factor, 2528
breast cancer
high-dose chemotherapy and autologous bone marrow transplantation, cyclophosphamide pharmacokinetics, 810
idoxifene, phase I study, 1070
plasma TGF-β2 levels, 4512
TAG-72 expression, enhancement by IFN-α, 5925s
TAP 1 and MHC class I loss, 5191
breast cancer in bone
bisphosphonate risedronate effects, nude mice, 3551
cardiac hemangioendothelial neoplasms
fish *R. marmoratus*, 2438
cervical cancer
lactate levels and, 4757
colonic cancer
organ invasion inhibition by BB-94, 3629
promotion by laminin α1 chain IKVAV-containing peptide, 2476
vascular endothelial growth factor expression and, 3964
colorectal liver
BrdUrd incorporation, 3687
ESb
inhibition, IFN-α/β and adoptively transferred immune cells, 6133
gastrointestinal cancer
D612 combined with rhM-CSF, phase II trial, 4339

growth inhibition
camptothecins, newly developed xenograft models, 5637
hepatic
colorectal carcinoma, targeting, 5777s
nitric oxide-mediated regression, 3123
prevention by TNP-470, 836
hormone-refractory prostatic adenocarcinoma
somatostatin receptor expression, 5805s
hyaluronan and, 428
IGF receptor and, murine cells, 1006
IL-1-enhanced
inhibition by anti-VLA-4, 414
inhibition
anti-VEGF mAb, 5296
linomide inhibition, rat prostatic cancers, 1499
lung
B16 melanoma, microvessel origin and distribution, 4627
illudin analogue efficacy against, carcinoma MV522 xenografts, 4936
and mouse monocyte chemotactic protein 1, 4458
postsurgical established, MHC class I and IL-2 gene therapy, 4941
lung adenocarcinoma
surfactant protein gene expression, RT-PCR detection, 4283
lymph node
thrombomodulin expression and, 4196
melanoma
inhibition by α-galactosyl epitopes, 4168
spontaneous, therapeutic efficacy of doxorubicin immunoconjugates, preclinical human model, 2352
suppression, *nm23-M1* and *nm23-M2*, murine, 1971
melanoma brain
MSH-R expression, murine, 141
ovarian cancer
uPA, uPA-R, and PAI-1/2 content, 3958
pancreatic adenocarcinoma
CD44 isoform expression, 1831
prostatic carcinoma
androgen receptor protein expression, 3068
sialyl Lewis^x up-regulation, 1817
recombinant IL-12 effects, 4404
sea urchin embryo basement membranes, 5085
T lymphoma
B7–1 expression, induction of natural killer cell-mediated cytotoxicity, 2730
Methotrexate
oral
attenuation of IL-2-induced pulmonary vascular leak syndrome, 4929
-resistant breast cancer cells
RFC1 and, 3790
Methotrexate-α-phenylalanine
carboxypeptidase-activated prodrug, 478
Methoxymorpholinyldoxorubicin
phase I study, 2090
8-Methoxypsoralen
photoadducts
mutagenesis, mouse fibroblasts, 1283
Methyl
deficiency
DNA breaks and hypomethylation, rat livers, 1894
8-Methylangelicin
photoadducts
mutagenesis, mouse fibroblasts, 1283
Methylation
-based clonality assays, meningioma, 3865
DNA
p16 inactivation, 4525
p16/CDKN2
and gene silencing, 4525
tolerance
complementation analysis, 2569
Methylcholanthrene
-induced expression of MHC class I-associated peptides, 5648
-induced sarcoma
c-*myc* amplification and K-*ras* mutation, minisatellite instability and, 5670
Methyl 2,5-dihydroxycinnamate
cross-linking tumor cell proteins, 4950
O^6-Methylguanine
DNA adducts
formation and modulation by ethanol, 6017
***O*^{6}-Methylguanine-DNA-methyltransferase**
peripheral blood mononuclear cell
inhibition, nonhuman primate, 4606
***S*-Methyl methane thiosulfonate**
dietary
chemoprevention, male F344 rats, 4053
***N*-[2-(2-Methyl-5-nitroimidazolyl)ethyl]-4-(2-nitroimidazolyl)butanamide**
bisnitroimidazole-bioreductive drug, 574
***N*-Methyl-*N'*-nitro-*N*-nitrosoguanidine**
-induced carcinogenesis
inhibition by EGCG, rat glandular stomach, 2081
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone
activation, human lung microsomes, 5566
tissue distribution
phenethyl isothiocyanate effects, F344 rats, 5580
MHC: ***see*** **Major histocompatibility complex**
Microcirculation
tumor
and adoptive immunotherapy, 4627
Microdissection
-based cloning
malignant melanoma translocation breakpoint, 4640
breast tumors
allelic loss, 467
chromosome
amplification, ovarian carcinoma, 3380
laser
detection of Knudson's two hits in preneoplastic renal cells by, Eker rat model, 989
prostatic intraepithelial neoplasia
chromosome 8p12-21 allelic loss, 2959
tissue
visuality of melanoma clonal progression, 3954
Microglobulin
β-2
mitogenic properties, 781
Micrometastasis
lymph nodes, RT-PCR, 3417
pulmonary adenocarcinoma
surfactant protein gene expression, RT-PCR detection, 4283
Micronuclei
initiation by benzo(*a*)pyrene and benzo(*e*)pyrene, UDP-glucuronosyltransferase-deficient rat skin fibroblasts, 1045
Microphysiometry
measurement of B-lymphoma cell activation, 5642
Microplate adenosine triphosphate luminescence assay
chemosensitivity testing, ovarian carcinoma, 5276
Microsatellites
alterations
chromosome 3p, esophageal squamous cell carcinoma, 893
gastric adenoma and gastric adenocarcinoma, 1933
neurofibroma of von Recklinghausen's disease, 5677
androgen receptor gene CAG and GGC, and prostate cancer, 1937
genomic instability of repeats
and erbB-2 expression, gastric carcinoma, 1428
glioma, 1547
non-small cell lung cancer, 28
prostate cancer, and clinicopathological variables, 2418
instability
bilateral ovarian carcinoma, 4793
chemically induced mouse skin tumors and transformed 3T3 cells, 3513
and c-*myc* amplification and K-*ras* mutation, methylcholanthrene-induced mouse sarcoma, 5670
colorectal adenocarcinoma cells with full-length APC protein, 4797
gynecological sarcomas, 5664
hereditary, lung cancer, 3996
lobular breast carcinoma, frequency, 3976
mismatch repair deficiency, genetic defects, and, human cancer cells, 6063
neuroblastoma, short-tandem repeat polymorphisms analysis, 5681
pancreatic adenocarcinoma and pancreatitis, 4264
and TGF-β-RII gene mutations, colorectal cancer, 5548
motifs
loss of heterozygosity, head and neck squamous carcinoma, 2656
Microscopy
NMR
cyclocreatine uptake in C6 spheroids, 153
Microsomes
NNK activation, human lung, 5566
tissue
TNP-470 disposition and metabolism, 3036
Microtubules
disruption
natural estrogens, Chinese Hamster V79 cells, 1863
interaction with LU103793, 3085
-stabilizing agents
epithilones, mechanism of action, 2325
structure
photosensitization, 2063
Microvessels
quantitation and clinicopathological correlations, colorectal tumors, 5049
Midkine
expression, neuroblastoma, 1792
Migration
mesenchymal and epithelial cancer explants, 4557
***Min* mice**
N-ethyl-*N*-nitrosourea treatment, 4479
Minimal determinant
induction of therapeutic antitumor T_{CD8+}, 1741
Minisatellite instability
and c-*myc* amplification and K-*ras* mutation, methylcholanthrene-induced mouse sarcoma, 5670

Mismatch repair
base excision, 3742
and cancer origins, 5489
defects, uterine and ovarian sarcomas, 5664
deficiency
and microsatellite instability, human cancer cells, 6063
and G_2 checkpoint, 3721
gene mutations, sporadic endometrial carcinomas, 5556
Missense mutations
and pVHL-binding proteins, 4544
Mitochondria
impairment
tyrphostin AG17, 2794
respiratory chain impairment
and oxidative stress, 3028
Mitogen-activated protein kinase
and CD30 ligand signal transduction, Hodgkin's lymphoma, 4157
constitutive activation, human renal cell carcinoma, 4182
negative regulator of heat shock response, NIH3T3 cells, 5512
Mitogenesis
β-adrenergic signal transduction, peripheral lung adenocarcinoma, 3504
laminin, melanoma and melanocytes, 4702
β-2 microglobulin, PC-3 cells, 781
Mitomycin C
-hypersensitive Chinese hamster cell mutants, resembling Fanconi anemia, 3412
resistance
NAD(P)H:quinone oxidoreductase and, 330
sensitivity
cellular thioredoxin levels and, 4293
Mitosis
inhibition
LU103793, 3085
living vertebrate lung epithelial cells
crocidolite asbestos and, 792
Mitoxantrone
resistance
topoisomerase IIα alterations, HL-60 cells, 1707
topotecan cross-resistance, breast carcinoma cells, 4004
MLH1
locus structure, human, 242
mRNA
alternative splicing, normal cells, 1839
MLL
fusion with *AF10*
t(10;11) breakpoint heterogeneity, AML-M4/M5, 4220
MMP: *see* **Matrix metalloproteinase**
MNNG: *see* ***N*-Methyl-*N'*-nitro-*N*-nitrosoguanidine**
Modified tracer technique
in vivo with L-[1-^{13}C]leucine
protein metabolism, colon carcinoma, 1160
Modulator
glucocorticoid receptor inhibition, CEM C-7 cells, 548
Molecular biology
implications for prevention and therapy
Third Joint Meeting of the AACR and JCA meeting report, 5472
Molecule B7
gene, recombinant vaccinia expressing
combined with rV-CEA, enhanced antitumor effects, 3598
Moloney murine leukemia virus
integration impairment, 3211
Mom1
human homologue candidate *PLA2s-II*, 5504
Monoclonal antibodies
17–1A
immunotherapy, nude mouse xenograft carcinoma model, 4398
323/A3
immunotherapy, nude mouse xenograft carcinoma model, 4398
anti-BA46 Mc3
humanized, breast cancer therapy, 1717
anti-CD19
unconjugated, antitumor effects, nude mouse xenograft model, 840
anti-CD20
eradication of Daudi tumors, 2627
unconjugated, antitumor effects, nude mouse xenograft model, 840
anti-CD22 (LL2)
^{99m}Tc-labeled fragment, B-cell non-Hodgkin's lymphoma staging, 5764s
treatment of non-Hodgkin's lymphoma, 5899s
anti-CD30
unconjugated, antitumor effects, anaplastic large-cell lymphoma xenografts, 5335
anti-CD33 (M195)
radiolabeled, myeloid leukemias, 5908s
anti-CD54 (ICAM-1)
antitumor effects, SCID mice with human myeloma cells, 610
anti-CEA
humanized, targeting, preclinical and clinical studies, 5935s
^{131}I-labeled, medullary thyroid carcinoma, 5946s
anti-EGFRvIII, 4375
breast and lung carcinomas and malignant gliomas, 3140
anti-idiotype
anticytokeratin, improved tumor targeting, 5868s
B-lymphoma cell activation, 5642
murine, mimicking breast cancer antigen, monkeys, 1525
-reactive T lymphocytes, 1824
anti-IL-6
CDDP sensitization, renal cell carcinoma, 590
anti-IL-6R
CDDP sensitization, renal cell carcinoma, 590
antimelanoma scFv, tumor-infiltrating lymphocytes, 3584
anti-VEGF
antitumor effects, 5296
anti-VLA-4
inhibition of IL-1-enhanced metastasis, 414
biodistribution
scale-up, physiologically based pharmacokinetic model, 4611
bispecific
anti-renal cell carcinoma × anti-DTPA, development and characterization, 5864s
2B1, phase I trial, 4586
88BV59H21–2
Tc-99m-labeled, radioimmunoscintigraphy, colorectal carcinoma, 5774s
BW835
definition of site-specific Thomsen-Friedenreich antigen, MUC1 tandem repeats, 4036
carboxypeptidase A conjugate
-activated methotrexate-α-phenylalanine prodrug, 478
cobra venom factor conjugate, 5749s
^{67}Cu-chCE7
processing by neuroblastoma cells, 46
D612
combined with rhM-CSF, metastatic gastrointestinal cancer, phase II trial, 4339
definition of two sialyl Tn configurations, tumor cells, 3364
^{111}In-diethylenetriaminepentaacetic acid-
metabolism, 5714s
fragments
renal uptake, reduction by cationic amino acids, 3827
ICR12
iodogen- and MATE-labeled, breast cancer xenograft radioimmunotherapy, 5842s
IgG ATRA, combined with hydroxyethyl starch deferoxamine conjugate
lymphoma inhibition, 3817
IgM conjugate AC6C3–2B12
^{111}In-labeled, intraperitoneal administration, preclinical analysis, 5736
^{125}I-labeled
L6-biotin, radioimmunotargeting enhancement by combining preload and immunoadsorption, 5874s
^{131}I-labeled
intralesional, malignant glioma, 5952s
L6
human antimouse antibody response, suppression by deoxyspergualin, phase I study, 3060
prelabeling with ^{90}Y- and ^{111}In-DOTA-peptide, 5726s
β-lactamase conjugates
combined with doxorubicin prodrug, activation, 2357
combined with prodrugs, melanoma xenograft treatment, 3558
low and high affinity
immunotherapy, nude mouse xenograft carcinoma model, 4398
PAb421
restoration of mutant p53 function, SW480 cells, 3490
PAM4
tumor targeting, biodistribution, and pharmacokinetic evaluation, pancreatic cancer, 5911s
tumor targeting, orthotopic pancreatic cancer, initial studies, 5743s
tumor targeting, pancreatic cancer, 1105
radioconjugated
renal excretion, lysine and, 5288
radiolabeled
pharmacokinetics, biodistribution, and dosimetry, head and neck squamous cell carcinoma, 1060
radiolabels
residualizing, 3132
^{186}Re-labeled
intraperitoneal, dosimetry, 5817s
tumor vessel-directed TV-1, 2673
Monocyte chemotactic protein 1
mouse, purification and identification, 4458
Monocyte colony-stimulating factor
recombinant human, combined with D612
metastatic gastrointestinal cancer, phase II trial, 4339
Monocytes
macrophage differentiation
p53-independent *WAF1/CIP1* induction and, leukemia cells, 668

1,25$(OH)_2D_3$-induced differentiation of HL-60 cells
PP1 translocation, 774
Mononuclear cells
blood
DNA adducts, and tobacco carcinogen-induced lung damage, 4910
DNA photoproducts
induction by sunlight, 2245
peripheral blood
melanoma, LAK induction by IL-15, 4988
O^6-methylguanine-DNA-methyltransferase inhibition, nonhuman primate, 4606
Monosomy 5
and $p15_{INK4B}/p16_{INK4}$ deletions, kidney epithelial cell lines, 1607
Morphine
cross-reaction with somatostatin receptor, T47D cells, 5632
Motility related protein 1
expression
breast cancer, 4127
and prognosis, non-small cell lung cancer, 6040
Mouse chromosome 4
ssic1 map, 3179
Mouse colon adenocarcinoma 26
platelet-aggregating sialoglycoprotein gp44, 767
Mouse genes
homologous to human VHL gene, cloning and characterization, 743
Mouse human antibody
suppression by deoxyspergualin, phase I study, 3060
mRNA: *see* **Messenger RNA**
MRP: *see* **Multidrug resistance protein**
MRP
expression, VP-16-selected H69 cells, 459
gene amplification
chromosome breakage and, 4214
overexpression
ATP-dependent VP-16 efflux, murine leukemia cells, 4352
MRP-1: *see* **Motility related protein 1**
MRP-1/CD9
expression
and prognosis, non-small cell lung cancer, 6040
MSH: *see* **Melanocyte-stimulating hormone**
m-THPC: *see meso*-**Tetra(hydroxyphenyl)chlorin**
m-THPP: *see meso*-**Tetra(hydroxyphenyl)porphine**
MT-MMP: *see* **Matrix metalloproteinase, membrane-type**
MTS1
alterations, non-small cell lung cancers, 514
homozygous deletions, astrocytomas, 20
structure and regulation, 2988
MTS2
alterations, non-small cell lung cancers, 514
leukemias and lymphomas, 1436
MUC1
human T-cell response, 2257
sialyl-Lewis^a and sialyl-Lewis^x, pancreatic cancer cells, 3659
tandem repeats
BW835 definition of site-specific Thomsen-Friedenreich antigen, 4036
Mucin
gene expression, gastric epithelium, 2681
sialyl-Le^x**-positive**
colon, colon carcinoma, colorectal cancer, 921
-type glycoproteins
and colon cancer cell adhesion to selectins, 4425
Mucosa
buccal
human biomonitoring assay, 1267
colonic
biliary glycoprotein expression, 2963
tumor-associated sialylated antigen expression, 1869
-preferential IQ-DNA adducts, rat colonic wall, 2769
Multicellular tumor spheroids
VEGF hypoxia inducibility mapping, 6222
Multidrug resistance
PGP inhibitor effects, 1086
and rhodamine-123 selectivity, tumor vs normal epithelial cells, 1633
two-gene transduction with *MDR1* and GSTπ, NIH 3T3 cells, 4073
Multidrug resistance protein
expression, NIH/3T3 cells, 5342
gene coexpression, VP-16-selected H69 cells, 459
gene overexpression
ATP-dependent VP-16 efflux, murine leukemia cells, 4352
M_r 190,000
characterization, 102
Multidrug transporters
mutations
NIH3T3 cells transfected, effects of PGP inhibitors on, 1086
wild-type
NIH3T3 cells transfected, effects of PGP inhibitors on, 1086
Multimutation
G207
treatment of malignant meningioma, 4752
Multiple myeloma
chromosomal aneuploidy, detection by FISH, 3854
variant glucocorticoid receptor mRNA expression, 2727
Multiple tumor suppressor gene 1
alterations, non-small cell lung cancers, 514
homozygous deletions, astrocytomas, 20
structure and regulation, 2988
Multiple tumor suppressor gene 2
alterations, non-small cell lung cancers, 514
leukemias and lymphomas, 1436
Mutagenesis
HOENU-induced *in vivo*
O^6-alkylguanine and, T-lymphocytes, 1875
HPV E6-transfected cells, 4420
retroviral insertional
identification of CDDP resistance genes, 1139
Mutagenicity
saccharin-induced
suppression by IFN-α, human RSa cells, 4253
Mutations: *see also* **Deletions**
androgen receptor gene, latent prostatic carcinoma, Japanese men, 1621
APC
intestinal polyp formation, 2719
ulcerative colitis, 2035
(+)-BPDE-induced splicing
hprt locus, Chinese Hamster V-79 cells, 1550
BRCA1, ovarian cancers, 2998
CDKN2, neuroblastoma, 2053
Chinese hamster cell, resembling Fanconi anemia, 3412
chloroethyl-cyclohexyl-nitrosourea fingerprint, mammalian cells, 4658
DNA mismatch repair genes, sporadic endometrial carcinomas, 5556
dominant negative folate receptor, 847
effects on $p16^{INK4a}$, 2503
etoposide-induced
inhibition by Bcl-2, 4029
gallbladder carcinoma, Chile, 2511
germline
BRCA1, Japanese breast cancer families, 3521
hMLH1
screening, Swedish hereditary nonpolyposis colon cancer families, 6092
hMSH2
microsatellite instability, uterine sarcoma cells, 5664
K-*ras*
gastric adenocarcinoma, Florence, Italy, 2665
lung adenocarcinoma, 1444
minisatellite instability and, methylcholanthrene-induced mouse sarcoma, 5670
pancreatic adenocarcinoma and pancreatitis, 4264
Ras CAAX peptidomimetic FTI 276 tumor growth blockade, lung carcinoma, 4243
missense
and pVHL-binding proteins, 4544
TGFβ type II receptor, head and neck squamous carcinoma cells, 3982
multidrug transporters
NIH3T3 cells transfected, effects of PGP inhibitors on, 1086
multimutations
G207, treatment of malignant meningioma, 4752
NF2
mesothelioma, 1227
$p15^{INK4B}$/MTS2
biliary tract cancers, 2756
lung cancer, 1448
p16/CDKN2
frequency, upper digestive tract cancers, 3421
$p16^{INK4}$/CDKN2
biliary tract cancers, 2756
$p16^{INK4}$/MTS1/CDKN2
lung cancer, 1448
p18
lung cancer, 1448
p21
Burkitt's lymphoma, 1431
$p21^{ras}$
expression, induction of IGF-1 secretion, thyroid epithelial cells, 915
p53
and apoptosis in Wilms' tumors, 215
benign and dysplastic nevi, 4278
esophageal adenocarcinoma, 3406
functional restoration by PAb421, SW480 cells, 3490
gastric adenocarcinoma, Florence, Italy, 2665
HBV-related hepatocellular carcinoma, 6084
hotspot, U:G mismatch base excision repair, 3742
human lymphoblast lines, 12
latent expression, and radiation-induced mammary cancer, 3310
lung cancer, Chinese women, Hong Kong, 5343

nonmelanoma head and neck skin cancer, 3604
sarcomatoid renal cell carcinoma, 658
and SDI1, senescence, 2404
point
ornithine decarboxylase gene, hepatocellular carcinoma, 3500
p53, and colorectal cancer survival, 5217
ras
$CD4^+$ T-cell immunity, pancreatic and colon cancer, 2984
chemically induced mouse skin tumors and transformed 3T3 cells, 3513
VEGF/VPF expression upregulation, 4575
somatic
APC, gastroduodenal tumors, 3165
and cancer origins, 5489
splice site
glucocorticoid receptor gene, resistance to glucocorticoid-induced apoptosis, 348
T lymphocyte
induction by 1,6-dinitropyrene, F344 rats, 2316
TGF-β-RII
colon and gastric cancer, 5545
colorectal cancer, 5548
topoisomerase I N7223
and camptothecin resistance, CEM/C2 cells, 1339
topoisomerase IIα
cytoplasmic localization, lung cancer, 2129
tyrosine 950
IGF-I receptor, effects on cell growth and transformation, 663
Mutators
phenotypes, colorectal carcinoma cell lines, 2304
MV522 xenografts
illudin analogue efficacy against, 4936
m*VHLh1*
cloning and characterization, 743
Mx-diethylenetriaminepentaacetic acid-BrE-3
high-dose ^{90}Y
advanced breast cancer, phase I trial, 5921s
MYC
DNA repair, HL60 cells, 336
Myc promoter-binding protein
tumor growth inhibition, nude mice carcinoma cells, 3747
Myeloid cells
maturation
DNA topoisomerase I levels and localization, 1255
Myeloid leukemia
radiolabeled anti-CD33 monoclonal antibody M195, 5908s
Myeloid zinc finger
oncogenic aberrant gene expression, 3610
Myeloma
adhesion molecules, 3646
ANBL6 cells
growth characteristics, activated N-*ras* effects, 3640
apoptosis
prevention by *bcl-2* or *bcl-x_l*, 2262
human, SCID mice
anti-CD54 antitumor effects, 610
multiple
chromosomal aneuploidy, detection by FISH, 3854
variant glucocorticoid receptor mRNA expression, 2727
Myositis
nitric oxide production and, SJL mice, 4391
MZF-1
oncogenic aberrant expression, 3610

N

N7223
and camptothecin resistance, CEM/C2 cells, 1339
NAD(P)H:quinone oxidoreductase
and mitomycin C resistance, 330
mRNA
alternatively spliced, normal and tumor tissues, 2542
NAD-poly(ADP-ribose)
metabolism
and p53 regulation, 3697
Nasopharyngeal carcinoma
p16 alterations, 2039
NAT: ***see N*-Acetyltransferase**
NAT1
genotype and phenotype, bladder and colon tissue, 5226
polymorphism
and colorectal cancer risk, 3537
NAT2
defects
and human malignant mesothelioma, 2981
recombinant human allozymes
activation of *N*-hydroxyarylamines and *N*-hydroxyarylamides, 3531
National Cancer Institute Anticancer Screen
camptothecin sensitivity determinants, 2116
Natural estrogens
microtubule disruption, Chinese Hamster V79 cells, 1863
Natural killer cells
-mediated cytotoxicity
B7–1-induced, 2730
psychosocial stressor-induced changes, mouse mammary tumor growth, 617
Naturally occurring products
chemoprevention, colonic aberrant crypt foci, F344 rats, 1277
NB-506
antitumor effects, mice, 1316
cytotoxicity and mechanism, 1310
-resistant SBC-3/NB cells, 2806
Neoplasia
prostatic intraepithelial
chromosomal anomalies, FISH detection, 5408
microdissected, chromosome 8p12-21 allelic loss, 2959
reversion
adenoviral-mediated delivery of anti-ras ribozyme, 2024
Neoplasms: ***see also*** **Lesions; Tumors**
advanced malignant
plasma anemia-inducing substance, 3623
breast
estrogen receptor variant coexpression, 2158
bronchial
p53 and EGFR expression, 1365
colon
adenomatous polyposis coli mutations, 2035
colorectal
bcl-2 and p53 oncoprotein expression, 237
hereditary nonpolyposis, kindred analysis, 242
plasmin-catalyzed proteolysis, 4688
epidermal
EGFR ligands and, 1883
integrin expression, 5434
gastric epithelium
mucin gene expression, 2681
hemangioendothelial
cardiac, fish *R. marmoratus*, 2438
hepatobiliary
antiepileptics and, 294
mammary
tumor progression, spontaneous rat, 399
ovarian
chromosome 9 alterations, 2150
$p21^{WAF1/CIP1}$ tissue expression
topological control, 2910
thyroid
CD44 mRNA splicing, 4594
Neovascularization
-induced tumor growth
implanted C6 multicellular spheroids, MRI, 1956
VEGF and, brain tumors, 1189
Nerve growth factor
stimulation of clonal growth, lung cancer cell lines, 2212
Neuroblastoma
advanced
pleiotrophin and midkine expression, 1792
apoptosis
induction by HPR, 847
Bcl-x_L expression, 2576
brain-derived neurotrophic factor and $p145^{TrkB}$ expression, 1792
brain-type human Rab GDI isoform expression, 5445
CDKN2 mutations, 2053
chromosome 1p deletions and microsatellite instability, short-tandem repeat polymorphisms analysis, 5681
chromosome 1p loss of heterozygosity, 4664
^{67}Cu-chCE7 processing, 46
differentiation
-induced Bcl-2 and drug resistance, 4711
induction by retinoic acid, 847
localized
N-*myc* gene amplification, Pediatric Oncology Group Study, 721
N-MYC duplication, 3471
normal *H19* and *IGF2* imprinting, 3386
prognosis
chromosome 1p deletion and, 5366
radioresistant variant
apoptosis, 4915
RA-treated
TGF-β1 induction, 2380
Neurofibroma
von Recklinghausen's disease
microsatellite alterations, 5677
Neurofibromatosis
type I malignant phenotype
farnesyltransferase inhibitor block, 3569
type 2 gene
mutations, mesothelioma, 1227
product schwannomin, growth suppression, NIH3T3 cells, 2270
Neurons
dopaminergic
effects of BNCT on, mouse brain, 874
Neurotrophic factor
brain-derived
expression, neuroblastoma, 1792
Nevi
benign and dysplastic
p53 mutations, 4278
NF: ***see*** **Neurofibromatosis**
Nickel oxide
exposure

carcinogenic effects, lung, 5251
Nickel subsulfide
exposure
carcinogenic effects, lung, 5251
Nickel sulfate hexahydrate
exposure
carcinogenic effects, lung, 5251
NIH3T3 cells
heat shock response
negative regulation by mitogen-activated protein kinase, 5512
ornithine decarboxylase transformation
EGF-R activity and, 5358
retinoic acid metabolism
H-*ras* and, 4850
schwannomin growth suppression, 2270
transfectants
G185 or V185 multidrug transporter, PGP inhibitor effects, 1086
multidrug resistance protein, 5342
two-gene transduction with *MDR1* and GSTπ, 4073
Nitric oxide
ischemia reperfusion injury, tumors, 6021
-mediated regression of hepatic metastases, 3123
production
activation by relaxin, breast cancer cells, 5265
cisplatin-induced immunostimulation, macrophages, 5524
production, SJL mice, 4391
Nitric oxide synthase
expression, CNS tumors, 727
and regression of hepatic metastases, 3123
***N*-Nitrosodimethylamine**
exposure
ethanol O^6-methylguanine-DNA adduct formation and modulation and, 6017
-initiated hepatocellular tumors
promotion by TCDD or Aroclor 1254, mice, 4875
Nitrosoureas
resistance, bone marrow, 2608
nm*23-H1*
mRNA, hepatocellular carcinoma, 652
suppressive role, ovarian carcinoma, 2645
nm*23-H2*
mRNA, hepatocellular carcinoma, 652
nm*23-M1*
metastatic suppression, murine melanoma, 1971
nm*23-M2*
metastatic suppression, murine melanoma, 1971
NMR: *see* **Nuclear magnetic resonance**
N-*myc*
amplification, localized neuroblastoma, Pediatric Oncology Group Study, 721
duplication, neuroblastoma cells, 3471
NNK: *see* **4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone**
Nocodazole
effects on p53 levels, 6021
Non-antigen presenting cell
-derived tumors
B7–1 expression, 2253
Non-Hodgkin's lymphoma
B-cell
staging, ^{67}Ga citrate vs ^{99m}Tc-labeled LL2-Fab′ fragment, 5771s
staging, ^{99m}Tc-labeled LL2 MAb fragment, 5764s
metabolic characterization, proton-decoupled phosphorus MRS, 3278
radioimmunotherapy
LL2 anti-CD22 mAb, 5899s
red marrow dosimetry by sacral scintigraphy, 5827s
Non-small cell lung carcinoma
chemotherapy
response, p53 expression and, 5038
chest CT and SPECT fusion, 5759s
DNA damage and clinical response, PCR assay, 2334
enhanced apoptosis and, 5595
loss of heterozygosity
chromosome 5q, 220
chromosome 17q, 4268
chromosome 18q, 220
microsatellite instability, 28
MRP-1/CD9 expression
and prognosis, 6040
p15 alterations, 514
codeletion, 2968
p16 alterations, 514
codeletion, 2968
$p16^{INK4A}$ inactivation, 6200
pituitary adenylate cyclase activating peptide receptors, 4886
Rb inactivation and $p16^{INK4}$ expression, 505
stage I oncogenes, 51
stromelysin-3 overexpression, 4120
surfactant protein gene expression, RT-PCR detection, 4283
type 2 cytokine pattern, 3847
Nonsteroidal anti-inflammatory agents
sulindac
chemoprevention, colon carcinogenesis, 1464
NQO_1: *see* **NAD(P)H:quinone oxidoreductase**
N-*ras*
activated
effects on ANBL6 cell growth characteristics, 3640
NSC 63982
bisnitroimidazole-bioreductive drug, 574
NSC 3296801
molecular pharmacology, 1491
NSC D-669356
interaction with microtubules, 3085
Nuclear antigen
proliferating cell
cyclin D1 subunit association, SV40 large T antigen immortalization and, 4651
Nuclear bodies
PML
effect on inflammation and cell growth, 1590
Nuclear factor κB
activation
TPA, inhibition by ET-18-OCH_3, 4844
anti-NFκB reagents
inhibition of cancer cell adhesion, 4162
Nuclear lamins
farnesylation
BZA-5B block, 3295
Nuclear magnetic resonance
glutathione detection, MCF-7 cells, 2012
glycerol metabolism study, tumorous rats, 761
lonidamine mechanism studies, 2815
metabolic changes post radiation
in vitro and *in vivo* measurements, 1248
microscopy
cyclocreatine uptake in C6 spheroids, 153
phosphorus
non-Hodgkin's lymphoma *in vivo*, 3278
proton spectroscopy
cell type-specific fingerprinting of meningioma and meningeal cells, 420
spectroscopy
study of breast cancer progression metabolite markers, 5140
Nuclear tyrosine kinase
Rak
and retinoblastoma protein, 3969
Nucleosides
novel analogue **β-L-dioxolane-cytidine**
anticancer effects, 3008
transporters
expression, modulation by thymidylate synthase inhibitors, 1505
triphosphorylated
PTP-γ binding and activation, 4855
Nude mouse models
head and neck squamous cell carcinoma
adenovirus-mediated gene therapy, 1080
mammary tumors
aromatase inhibitor effects, 3073
phenylacetate effects, 5156
tumor growth blockade
Ras CAAX peptidomimetic FTI 276, 4243
xenograft
immunotherapy, low and high affinity mAbs, 4398
unconjugated mAb CD19 and CD20 antitumor effects, 840

O

OC/CDE 6 cells
phenotype and differentiation patterns, 1028
OC/CDE 22 cells
phenotype and differentiation patterns, 1028
[^{111}In]Octreotide
biodistribution and scintigraphy, 5794s
carcinoid tumors, 5801s
ODC: *see* **Ornithine decarboxylase**
OGAT: *see* ***O*^{6}-Alkylguanine-DNA alkyltransferase**
$1,25(OH)_2D_3$: *see* **1α,25-Dihydroxyvitamin D_3**
Oligodeoxynucleotides
anti-messenger
effects on invasive phenotype of transformed human fibroblasts, 90
antisense
alterations of *c-myc* expression, and apoptosis, HL-60 cells, 1379
Oligonucleotides
antisense
growth inhibition, 4092
Oligosaccharides
sialyl Lewis^x
up-regulation, metastatic prostate cancer, 1817
Oltipraz
CYP1A2 and CYP3A4 inhibition, hepatocytes, 5574
intermittent dosing
chemoprevention, 4319
Oncofetal complementary DNA
highly conserved rat liver, 1152
Oncogenes: *see also* **Genes; Proto-oncogenes**
activated N-*ras*
effects on ANBL6 cell growth characteristics, 3640
H-*ras*
and retinoic acid metabolism, NIH3T3 cells, 4850
K-*ras*
mutations, lung adenocarcinoma, 1444
qin

transcriptional repressor, 5540
ras
mutations, VEGF/VPF expression upregulation, 4575
stage I non-small cell lung cancer, 51
Oncoproteins: *see also* **Proteins**
bcl-2
expression, colorectal neoplasia, 237
erbB-2
expression, microsatellite instability and, gastric carcinoma, 1428
p53
expression, colorectal neoplasia, 237
Oral carcinoma
chemoprevention
naturally occurring xanthophylls, astaxanthin, and canthaxanthin, 4059
retinoid, p53 and, 16
human papillomavirus type 16, 5465
11q and 18q21 loss of heterozygosity, 5465
squamous cell xenografts
differentiation, retinoid-induced suppression, athymic nude mice, 3183
Oral lesions
premalignant
anti-retinoic acid antibody binding, 5507
Ormaplatin
disposition and biotransformations
WR-2721 effects, F344 rat fibrosarcoma, 2837
Ornithine decarboxylase
and epidermal tumorigenesis, 1680
gene
point mutation, hepatocellular carcinoma, 3500
overexpression
and spontaneous skin tumors, transgenic mice, 4205
transformation
EGF-R activity and, NIH3T3 cells, 5358
Osteoblasts
differentiating
cell cycle regulatory factors expression, 5019
Osteoclasts
bone resorption
suppression by suramin, nude mice, 1989
Osteosarcoma
cell proliferation
inhibition by antisense cyclin G1, 5493
c-*fos*-induced, transgenic mice, 6244
comparative genomic hybridization studies, 1334
immunotoxin
cytotoxicity, 1321
p53-independent apoptosis
induction by apoptin, 486
Oval cells
OC/CDE 6 and OC/CDE 22
phenotype and differentiation patterns, 1028
Ovarian adenocarcinoma
cisplatin-sensitive and -resistant
cytokeratin 18 expression, 5203
Ovarian carcinoma
adenosine triphosphate chemosensitivity testing, 5276
amplification, 3380
-associated *Taq*I restriction fragment length polymorphism, progesterone receptor gene, 2743
bilateral
X chromosome inactivation and microsatellite instability, 4793
BRCA1 mutations, 2998
epithelial
LHRH and LHRH receptor mRNA expression, 817
invasion
mediation by CSF-1, 1578
metastasis
uPA, uPA-R, and PAI-1/2 content, 3958
nm23-H1 suppression, 2645
PSA gene expression, 1603
uPA, uPA-R, and PAI-1/2 content, 3958
Ovarian epithelial cells
apoptosis
regulation by TGF-β, 944
Ovarian neoplasms
borderline epithelial
chromosome 6q deletion mapping, 2169
chromosome 9 alterations, 2150
genetic analysis, 6172
Ovarian sarcomas
mismatch repair defects, 5664
Oxazaphosphorines
combined with P-450-based gene therapy, 581
Oxidative stress
respiratory chain impairment and, 3028
Oxygen radicals
antitumor effects, 1617
ischemia reperfusion injury, tumors, 6021
mediation of apoptotic signaling, 995
Oxygen tension
tumor
after x-ray irradiation, 2249

P

p15
alterations, non-small cell lung cancers, 514
deletions, non-small cell lung carcinoma, 2968
p15^{INK4B}
alterations, undifferentiated mouse skin tumors, 5168
deletions
monosomy 5 and, kidney epithelial cell lines, 1607
undifferentiated mouse skin tumors, 5168
expression, lymphocyte activation and neuronal differentiation, 4010
loss, sporadic melanoma, 5531
p15^{INK4B}/MTS2
leukemias and lymphomas, 1436
mutations
biliary tract cancers, 2756
lung cancer, 1448
p16
alterations
nasopharyngeal carcinoma, 2039
non-small cell lung cancers, 514
deletions, non-small cell lung carcinoma, 2968
gene structure and regulation, 2988
inactivation
breast epithelial cells, 2892
DNA methylation, 4525
increased levels
and pRb alterations, human urothelial cells, 493
p16/CDKN2
breast cancer
chromosome 9p allelic loss and, 2892
loss of expression, melanocytic lesions, 2713
methylation
and gene silencing, 4525
mutations
frequency, upper digestive tract cancers, 3421
suppression of human glioma cell growth, 1351
p16^{INK4}
deletions, monosomy 5 and, kidney epithelial cell lines, 1607
expression
absent, high-grade gliomas, 1941
lymphocyte activation and neuronal differentiation, 4010
Rb inactivation and, lung cancer, 505
malignant glial tumors, 4833
tumor suppressor gene effects, 3250
p16^{INK4}/CDKN2
mutations, biliary tract cancers, 2756
oncogenic aberrations
cooperation with cyclin D1, 4818
p16^{INK4}/MTS1/CDKN2
mutations, lung cancer, 1448
p16^{INK4A}
archival human solid tumors
immunohistochemical detection, 6006
deletions and alterations, undifferentiated mouse skin tumors, 5168
inactivation, non-small cell lung cancer cells, 6200
mutational effects, 2503
novel transcript, 2995
p16^{INK4A}/MTS1
leukemias and lymphomas, 1436
p18
mutations, lung cancer, 1448
p21
adenovirus
gene therapy, prostate cancer, 5151
and G_1 arrest, cancer cells, 5187
mutant, Burkitt's lymphoma, 1431
prostatic epithelial cells, 3726
p21^{Cip1}
-independent G_2 checkpoint, 2500
p21^{ras}
expression
induction of IGF-1 secretion, thyroid epithelial cells, 915
farnesylation
BZA-5B block, 3295
p21^{WAF1}
induction by taxol, 4623
tumor suppression, 4536
p21$^{WAF1/CIP1}$
expression
suppression by *bcl-2*, breast epithelial cells, 4520
topological control, 2910
p53 induction of cyclin D1 synthesis and, 4257
stability
G_1 arrest and, lymphoma cells, 2387
p21$^{WAF1/SDI1/CIP1}$
long-term expression
UVB inhibition of retinoblastoma protein phosphorylation and, human melanocytes, 4047
p27^{Kip1}
chromosomal mapping, 1199
chromosomal mapping and genetic analysis, 1211
down-regulation
TGF-β-induced, C3H 10T½ mouse fibroblasts, 1413
genetic analysis, leukemias, 1206
malignancy, molecular analysis, 2266
p34^{cdc2}
activation, 1994
p53
adenovirus

gene therapy, prostate cancer, 5151
alterations
breast cancer survival and, racial disparity, 1465
and genomic instability, breast carcinoma, 646
and caffeine-induced radiosensitization, 1643
and chemosensitivity, MCF-7 cells, 1649
deficiency
chromosomal abnormalities, mice, 3883
endocrine tumors, mice, 1146
Met overexpression, 1963
deletions
Ras CAAX peptidomimetic FTI 276 tumor growth blockade, lung carcinoma, 4243
-dependent G_1 checkpoint
regulation, lymphoma cells, 2387
expression
and chemotherapy response, locally advanced non-small cell lung cancer, 5038
expression, bronchial neoplasia and squamous cell carcinoma, 1365
function
G_1 arrest and, irradiated human tumor cells, 1842
gene breaks
and hypomethylation, folate/methyl-deficient rat livers, 1894
inactivation by HPV E6
mutagenesis, 4420
-independent apoptosis
induction by apoptin, human osteosarcoma cells, 486
-independent *WAF1/CIP1* induction, leukemia cells, 668
-induced apoptosis
abrogation by HBV X gene, 6012
induction of cyclin D1 synthesis, 4257
-knockout mice
chemoprevention, 3949
levels
microtubule-active drug effects, 6021
mutational hotspot
U:G mismatch base excision repair, 3742
mutations
and apoptosis in Wilms' tumors, 215
benign and dysplastic nevi, 4278
esophageal adenocarcinoma, 3406
functional restoration by PAb421, SW480 cells, 3490
gastric adenocarcinoma, Florence, Italy, 2665
HBV-related hepatocellular carcinoma, 6084
induced mutation and apoptosis affects, human lymphoblast lines, 12
latent expression, and radiation-induced mammary cancer, 3310
lung cancer, Chinese women, Hong Kong, 5343
nonmelanoma head and neck skin cancer, 3604
sarcomatoid renal cell carcinoma, 658
and SDI1, senescence, 2404
overexpression, sarcomatoid renal cell carcinoma, 658
point mutations, and colorectal cancer survival, 5217
prostatic epithelial cells, 3726
protein expression, colorectal neoplasia, 237
regulation
NAD-poly(ADP-ribose) metabolism and, 3697
taxol, 4623
replication error, Li-Fraumeni syndrome, 3237
retinoid chemoprevention of oral carcinogenesis, 16
serine phosphorylation
transactivation facilitation, 2410
transgenic mice
UV-induced squamous cell carcinoma, 2070
wild-type
adenovirus, induction of apoptosis, head and neck squamous cell carcinoma, 3117
adenovirus, microscopic residual disease, 1
adenovirus-mediated expression, prostatic tumor cells, 4210
effects on VEGF gene expression, 6161
gliomas with, bcl-2 expression, 999
loss, and astrocyte growth, 2746
p53-WAF1/Cip1
mediation of radiation-induced G_1 arrest, human thyroid cells, 2075
$p125^{FAK}$
overexpression, invasive tumors, 2752
$p145^{TrkB}$
expression, neuroblastoma, 1792
$p185^{HER2}$
humanized disulfide-stabilized Fv-β-lactamase fusion protein against, 63
overexpression
ADEPT, 63
breast cancer, 5400
$p185^{neu/erbB-2}$
activation, breast tumors, 1946
p230 BCR/ABL
fusion protein, 3192
PAb421
restoration of mutant p53 function, SW480 cells, 3490
Paclitaxel
tumor radioresponse enhancement, 3564
PAH: *see* **Polycyclic aromatic hydrocarbons**
PAI: *see* **Plasminogen activator inhibitor**
PAM4
tumor targeting
and biodistribution and pharmacokinetic evaluation, pancreatic cancer, 5911s
orthotopic pancreatic cancer, initial studies, 5743s
pancreatic cancer, 1105
Pancreatic adenocarcinoma
allelotypes, 4670
CD44 isoform expression, 1831
CD44 splice variants expression, 5499
chromosome abnormalities, 2394
[^{111}In]DTPA-D-[Phe^1]-octreotide scintigraphy, 5805s
ductal
genetic alterations, hamster, 2560
microsatellite instability and K-*ras* mutations, 4264
photodynamic therapy
in vitro, 3078
Pancreatic carcinoma
alcohol and, blacks and whites, United States, 4899
$CD4^+$ T-cell immunity to mutated ras protein, 2984
c-*MET*-encoded HGF receptor expression, 1129
gene therapy
liposome-mediated, 3810
growth inhibition
L-canavanine, 4486
IGF-I overexpression, 2007
mAb-PAM4 tumor targeting, 1105
and biodistribution, and pharmacokinetic evaluation, 5911s
MUC-1
sialyl-Lewis^a and sialyl-Lewis^x and, 3659
orthotopic
PAM4 targeting, initial studies, 5743s
pond frogs, 3781
Pancreatitis
microsatellite instability and K-*ras* mutations, 4264
Papillary serous carcinoma
peritoneum
multifocal, 490
Papillary thyroid carcinoma
Chernobyl tumors
RET rearrangements, 5617
Papilloma
skin
telomerase activity, mouse, 4566
Pax-2
expression, renal cell carcinoma, 4092
PC3 cells
β-2 microglobulin mitogenicity, 781
drug-induced apoptosis, 2122
EGFR expression and binding affinity, androgen up-regulation, 3197
suppression by chromosome 5, 4813
PC12 cells
serum-deprived
apoptosis, 1242
PCR: *see* **Polymerase chain reaction**
PD128763
induction of GRP78 and VP-16 resistance, 868
PDGF: *see* **Platelet-derived growth factor**
PDT: *see* **Photodynamic therapy**
Pediatric Oncology Group Study
N-*myc* gene amplification, localized neuroblastoma, 721
Pediatrics
acute leukemia
leukemia-specific cytotoxic T cell clones, 3835
acute lymphoblastic leukemia
allelotype analysis, 5377
cyclophosphamide metabolism, 803
refractory cancer
amifostine and melphalan, phase I trial, 4069
PE38KDEL
heregulin fused, 71
Pentoxifylline
chemosensitivity
p53 and, MCF-7 cells, 1649
Peptides
gastrin-releasing
receptor expression, bombesin growth response, bronchial epithelial cells, 1853
laminin α1 chain IKVAV-containing
promotion of liver colonization, colon cancer cells, 2476
leukemia antigen, recognized by CTLs, 4781
Meth A sarcoma-derived class I MHC-associated, 124
MHC class I-associated
methylcholanthrene-induced expression, 5648
MUC-1
human T-cell response, 2257
synthetic
LU103793, interaction with microtubules, 3085

urinary trypsin inhibition-derived
inhibition of tumor cell invasion, 1847
VTSA, MUC1 tandem repeats motif
BW835 definition of site-specific Thomsen-Friedenreich antigen, 4036
Peptidomimetics
farnesyl transferase inhibitors, human tumor cells, 5302
Ras CAAX FTI 276
tumor growth blockade, nude mice, 4243
Perillyl alcohol
apoptosis induction, liver tumors, 979
Peripheral blood
CD34+ hematopoietic cells
generation of immunostimulatory dendritic cells, 1099
leukocyte DNA
6-thioguanine quantitation, 1670
lymphocytes
recognition of melanoma antigen, 4972
malignant melanoma cells
PCR-based semiquantitative assessment, 4065
mononuclear cells
melanoma, LAK induction by IL-15, 4988
O^6-methylguanine-DNA-methyltransferase inhibition, nonhuman primate, 4606
progenitor cells
transfusions, radioimmunotherapy support, breast cancer, 5916s
T lymphocytes
VEGF synthesis, 4140
Peripheral lung adenocarcinoma
β-adrenergic mitogenic signal transduction, 3504
Peritoneal cavity
ascites tumors
angiogenesis/stroma generation, 376
fibrinogen/fibrin deposition, 369
vascular permeability factor and, 360
Peritoneum
multifocal papillary serous carcinoma, 490
Peroxide
-induced inhibitory checkpoints, 5069
Peroxisome
proliferators
suppression of GST-P expression, rat, 5370
Perspectives in Cancer Research
cancer invasion, molecular insights
prevention and intervention strategies, 1856
cell proliferation
risk factor for cancer, 3759
insulin-like growth factor I receptor
tumor growth, 249
mismatch repair, somatic mutations
origins of cancer, 5489
sunlight and cancer, 4014
transforming growth factor β
cell cycle regulation, 1452
PET: *see* **Positron emission tomography**
Pezcoller Symposium
Sixth Annual, meeting report, 3462
P-glycoprotein
inhibitors
effects on MDR cells, 1086
sister gene, identification, 2029
PGP: *see* **P-glycoprotein**
Pharmacodynamics
buthionine sulfoxime model, 4507
in vitro studies, design and analysis, 5315
Phenethyl isothiocyanate
effects on NNK tissue distribution, F344 rats, 5580
Phenobarbital
promotion of tamoxifen-induced DNA damage and liver tumors, rats, 544
Phenotypes
colon cancer
transition from noninvasive to invasive, 4722
malignant
NFI, farnesyltransferase inhibitor block, 3569
suppression, chromosomal 17q fragments, prostate cancer, 3389
mutator, colorectal carcinoma cell lines, 2304
NAT1, bladder and colon tissue, 5226
replication error, lobular breast carcinoma, 3976
tumorigenic
loss, novel human bronchial epithelial cell lines, 6215
Phenylacetate
effects, MCF7ras cells and nude mice, 5156
Phenylethyl-3-methylcaffeate
chemoprevention, colon carcinogenesis, 2310
6-Phenylhexyl isothiocyanate
dietary
colon carcinogenesis enhancement, 4311
Philadelphia chromosome
expressing p230 BCR/ABL fusion protein
AR230 establishment, 3192
PhIP: *see* **2-Amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine**
Phosphocholine
breast cancer progression marker, NMR spectroscopy study, 5140
Phospholipase A_2
secretory
alterations, colorectal cancer, 5184
secretory type II
human homologue of *Mom1* candidate, 5504
Phospholipase C β_1
down-regulation
tiazofurin, 2978
Phosphorylation
glucose
high K_m activities, tumor cells, 3278
$p34^{cdc2}$ activation and, 1994
retinoblastoma protein
inhibition by UVB light, human melanocytes, 4047
serine
p53, transactivation facilitation, 2410
tyrosine
and *HOX-11* up-regulation, T-cells, 1117
Photoadducts
8-methoxypsoralen and 8-methoxylangelicin mutagenesis, mouse fibroblasts, 1283
Photodynamic therapy
δ-ALA-induced protoporphyrin photosensitizer, 1723
chlorin e^6
enhancement by insulin-mediated intracellular targeting, 1014
IL-6 regulation, 2373
m-THPP and m-THPC, mammary carcinoma, 2620
pancreatic adenocarcinoma *in vitro*, 3078
-resistant mouse tumor cells
α-2 MR/LRP expression, 1817
Photoproducts
DNA
induction by sunlight, mononuclear cells, 2245
repair
enhanced human melanoma, 181
ultraviolet
removal, trichothiodystrophy cells, 4325
Photosensitization
3,3′-dihexyloxacarbocyanine iodide, 2063
riboflavin-mediated
Vinca alkaloids, and drug sensitivity assays, 4837
PISSLRE
cell growth activation, 3992
chromosomal mapping, 1199
PITALRE
chromosomal mapping, 1199
Pituitary, anterior
estrogen-induced tumorigenesis
effects on TGF-β1 expression and action, lactotropes, 4892
Pituitary adenylate cyclase activating peptide
receptors, non-small cell lung cancer cells, 4886
Pituitary tumors
aggressive
RB loss of heterozygosity, 1613
Placenta
ethanol exposure
O^6-methylguanine-DNA adduct formation and modulation, 6017
PhIP exposure
mammary carcinoma risk, Sprague-Dawley rats, 4333
Planar imaging
clinical radioimmunotherapy, 5823s
Plasma
anemia-inducing substance, advanced malignant neoplasms, 3623
O^6-benzylguanine pharmacokinetics, nonhuman primate, 4606
malignant cells
adhesion molecules, 3646
TGF-β2 levels, metastatic breast cancer, 4512
Plasmacytoma
chromosome 11 duplications, murine, 1181
IgH/c-*myc* recombinations, 5012
Plasmids
adeno-associated virus-based, complexed to cationic liposomes
prostate cancer gene therapy, 2366
Plasmin
-catalyzed proteolysis, colorectal neoplasia, 4688
Plasminogen activator
expression
cutaneous melanoma, transgenic melanoma-susceptible mice, 4681
Plasminogen activator inhibitor
expression
cutaneous melanoma, transgenic melanoma-susceptible mice, 4681
type 1
ovarian cancer tumor vs metastasis content, 3958
type 2
and breast cancer prognosis, 1423
ovarian cancer tumor vs metastasis content, 3958
Platelet-derived growth factor
angiogenesis
thymidine phosphorylase activity and, 1687
B-chain
expression, breast tissue and carcinoma, 2703

receptor β
expression, breast tissue and carcinoma, 2703
Platelets
-aggregating sialoglycoprotein gp44, mouse colon adenocarcinoma 26, 767
Platinum
-based antitumor molecules
initiatives, Fourteenth Bruce F. Cain Memorial Award lecture, 2761
***cis*-Platinum**
-induced HIV
salicylic acid inhibition, 1696
Pleiotrophin
expression, neuroblastoma, 1792
Pleiotropic abnormalities
bcl-2$^{-/-}$ mice, 354
PML: *see* Leukemia, promyelocytic
Pneumonitis
radiation
bFGF protection against, mice, 298
pO_2: *see* Oxygen tension
Point mutations
p53, and colorectal cancer survival, 5217
Pokeweed antiviral protein
anti-osteosarcoma immunotoxin
cytotoxicity, 1321
Polyadenylation polymorphisms
NAT1
and colorectal cancer risk, 3537
Poly(ADP-ribose) polymerase
inhibitors
induction of GRP78 and VP-16 resistance, 868
proteolysis
and radiation-induced apoptosis, Ewing's sarcoma cells, 4240
Polyamine analogues
antitumor effects, 2615
cell death induction, 3233
Polycyclic aromatic hydrocarbons
-DNA adducts
immunohistochemistry, lymphocytes, 1417
-induced adenoma
time-integrated DNA adduct levels and, A/J mouse lung, 1039
Polycyclic aza-aromatic carcinogens
human P450 metabolism, 1052
Polymerase chain reaction
-amplified MMP cDNA
and cervical carcinoma prognosis, 267
DNA damage and clinical response, non-small cell lung cancer, 2334
quantitative assay
bcl-2/J$_H$ translocations, blood and organ samples, 2876
reverse transcriptase
micrometastases, lymph nodes, 3417
multiplex, lymphocytes, 5025
semiquantitative assay
malignant melanoma cells, peripheral blood, 4065
Polymorphisms
acetylation
and colorectal adenomas, 2017
CYP1A1
and breast cancer, African-American women, 3757
and breast cancer risk, postmenopausal, 3483
lung adenocarcinoma, African-Americans, 472
lung cancer risk and, African-Americans, 6035
Fourteenth Sapporo Cancer Seminar meeting report, 710
GSTM1
and postmenopausal breast cancer risk, 3483
and pulmonary GSTM3 expression, lung cancer, 3305
and human malignant mesothelioma, 2981
NAT1
bladder and colon tissue, 5226
and colorectal cancer risk, 3537
restriction fragment length
CYP1A1, and breast cancer, African-American women, 3757
*Taq*I, ovarian carcinoma-associated, progesterone receptor gene, 2743
short-tandem repeat analysis
chromosome 1p deletions and microsatellite instability, neuroblastoma, 5681
SRD5A2
and prostate cancer risk, 3973
Polynucleotide vaccine vector
mRNA, characterization, 1397
Polypeptides
dextranation and labeling with technetium-99m, 5710s
Polyps
endometrial
cytogenetic subgroups, 1656
t(6;14)(p21↖4) translocation, 31
intestinal
formation, *Apc* mutations, 2719
Pond frogs
pancreatic carcinoma, 3781
Positron emission tomography
immunoscintigraphy, 115
Potassium chloride
promotion effects, stomach carcinogenesis, 5238
PP1: *see* Protein phosphatase 1
pRb: *see* Retinoblastoma protein
Pregnancy
immunization against breast cancer, 2257
Preneoplasia
gastric epithelium
mucin gene expression, 2681
lung lesions
multiple, independent genetic changes, 135
renal cells
Knudson's two-hits, laser microdissection detection, Eker rat model, 989
Pristane
protein kinase C activation and translocation, 518
Proapoptotic genes
BAX
loss of expression, and breast cancer survival, 4471
Prodrugs
combined with mAb β-lactamase conjugates
activation, 2357
melanoma xenograft treatment, 3558
methotrexate-α-phenylalanine
carboxypeptidase-activated, 478
Progelatinase B: *See* Matrix metalloproteinase-9
Progenitor cells
peripheral blood
transfusions, radioimmunotherapy support, breast cancer, 5916s
Progesterone
receptor
expression, human breast cancer, 5063
expression, tamoxifen-resistant breast cancer, 3331
gene *Alu* insertion, 2743
Prolactin
synthesis and secretion, breast cancer cells, 2591
Proliferating cell nuclear antigen
cyclin D1 subunit association
SV40 large T antigen immortalization and, 4651
Proliferation
colon cancer
vascular endothelial growth factor expression and, 3964
20-epi-vitamin D_3 analogue effects, breast cancer cell lines, 2822
Promyelocytic leukemia
-retinoic acid α receptor
and erythroid differentiation of K562 cells, 440
Prostaglandin G/H synthase
protein expression, colon cancer, 2557
Prostate-specific antigen
expression
ovarian carcinoma, 1603
transfected murine cells, 2455
mRNA, non-prostate cells, 2640
prognostic indicator, breast cancer, 2104
-related genes, primates, 2455
RNA
alternatively splicing, 1441
Prostatic adenocarcinoma
metastatic hormone-refractory
somatostatin receptor expression, 5805s
Prostatic carcinoma
androgen receptor gene CAG and GGC microsatellites and, 1937
androgen-promoted
tamoxifen chemoprevention, rat, 5621
apoptosis
β-lapachone, 3706, 3712
linomide-induced, 3517
bcl-2 overexpression, 4438
C-CAM expression, 1215
C-CAM tumor suppression, 190
chromosomal anomalies, FISH detection, 5408
chromosome 7q31.1 loss of heterozygosity, 4114
chromosome 10q23-25 loss, 4800
chromosome 17q loss of heterozygosity, 1002
coagulopathy
tumor necrosis factor and, 4881
E-cadherin expression
silence by DNA hypermethylation, 5195
GAPDH activity and mRNA content
androgen effects, 4234
gene therapy
adeno-associated virus-based plasmids complexed to cationic liposomes, 2366
C-CAM1 adenovirus, preclinical study, 2831
p53 or *p21* adenovirus, 5151
genetic changes
comparative genomic hybridization, 342
genetic complementation, 3389
high-intensity focused ultrasound effects, 3346
latent
androgen receptor gene mutations, Japanese men, 1621
linomide effects, rats, 1499
LNCaP cells
androgen *bcl-2*-mediated apoptosis resistance, 735
TNF-induced death, prevention by sulfated glycoprotein-2, 2431

malignant phenotypes
suppression by chromosome 17q fragments, 3389
metastasis
androgen receptor protein expression, 3068
sialyl Lewis^x up-regulation, 1817
microsatellite instability
and clinicopathological variables, 2418
PC3 cells
β-2 microglobulin mitogenicity, 781
drug-induced apoptosis, 2122
EGFR expression and binding affinity, androgen up-regulation, 3197
suppression by chromosome 5, 4813
risk factors
IL-6 resistance, 4633
SRD5A2 polymorphisms, 3973
TGF-β1 effects, 2596
tumor suppressor gene chromosome 8p loci, 5390
Prostatic epithelial cells
p53 and p21, 3726
Prostatic intraepithelial neoplasia
chromosomal anomalies, FISH detection, 5408
microdissected
chromosome 8p12-21 allelic loss, 2959
Prostatic neoplasms
adenovirus-mediated wild-type *p53* expression, 4210
hormone-independent cells
metallothionein localization and cisplatin resistance, 474
Proteases
inhibitors
hyperthermic killing enhancement, L5178Y cells, 739
partial degradation of T-cell signal transduction molecules, 3840
Protein kinase C
activation and translocation, pristane, 518
activators
induction of cyclin-dependent kinase 2 dephosphorylation, 3716
isoforms
colonic carcinogenesis, 5257
η second messenger cholesterol sulfate antipromoting effects, mouse skin carcinogenesis, 4865
repression by fumonisin, 1655
Protein kinases
cdc2
activation, HL60 apoptosis, 228
chromosomal mapping, 1199
-related kinase PISSLRE, cell growth activation, 3992
DNA-dependent activity
tumor cell radiosensitivity and, 5200
mitogen-activated
and CD30 ligand signal transduction, Hodgkin's lymphoma, 4157
constitutive activation, human renal cell carcinoma, 4182
Protein phosphatase 1
translocation
1,25$(OH)_2D_3$-induced differentiation, HL-60 cells, 774
Protein tyrosine phosphatase
gene product
binding and activation by triphosphorylated nucleosides, 4855
Proteins
androgen receptor
expression, prostatic carcinoma metastases, 3068
angio-associated migratory cell, 2140
B61
new growth factor, metastasis, 2528
bcl-2
expression, colorectal neoplasia, 237
inhibition of etoposide-induced genetic alterations, 4029
overexpression, prostate cancer, 4438
cellular retinoic acid-binding
retinoic acid and γ-IFN effects, breast cancer, 2135
c-RAF-1
BCR/ABL-dependent and normal hematopoiesis, 2275
deleted in colon cancer
distribution, human tissues, 5628
EB1
APC binding, 2972
erbB-2
expression, microsatellite instability and, gastric carcinoma, 1428
folate-binding
epithelial cells expressing, reduced folate carrier functional activity, 3790
glial fibrillary acidic
astrocytic transformation, transgenic mice, 4302
glycoproteins
biliary, expression, colonic mucosa, 2963
containing mannose 6-phosphate, breast carcinoma, 3424
mucin-type, and colon cancer cell adhesion to selectins, 4425
TJA-I reactive sugar chains, expression, colon adenocarcinoma, 1675
humanized disulfide-stabilized anti-p185^{HER2} Fv-β-lactamase, 63
Kemptide
antibody fragment, ^{P} labeling, 5968s
lactoferrin
overexpression, and malignant transformation of endometrium, 1168
MAGE-1
spermatogonia and spermatocytes, testis, 3478
MAGE-3
identification and intracellular location, 2236
MAGE-4
spermatogonia and spermatocytes, testis, 3478
mannose 6-phosphorylated, breast carcinoma, 3424
metabolism, colon carcinoma, 1160
mouse monocyte chemotactic, 1
purification and identification, 4458
myc promotor-binding
tumor growth inhibition, nude mice carcinoma cells, 3747
nuclear lamins
farnesylation, BZA-5B block, 3295
p16^{INK4a}
mutational effects, 2503
p21$^{Cip/Waf1}$
stability, G_1 arrest and, lymphoma cells, 2387
p21^{ras}
farnesylation, BZA-5B block, 3295
p21$^{Waf-1/SDI-1/Cip-1}$
long-term expression, human melanocytes, 4047
p53
cyclin D1 synthesis induction, 4257
-dependent G_1 checkpoint, regulation, lymphoma cells, 2387
expression, colorectal neoplasia, 237
-independent *WAF1/CIP1* induction, leukemia cells, 668
mutations, HBV-related hepatocellular carcinoma, 6084
overexpression, sarcomatoid renal cell carcinoma, 658
p125^{FAK}
overexpression, invasive tumors, 2752
p230 BCR/ABL, 3192
PML-RARα
and K562 cell erythroid differentiation, 440
pokeweed antiviral
anti-osteosarcoma immunotoxin, cytotoxicity, 1321
prostaglandin G/H synthase
expression, colon cancer, 2557
pVHL-binding, 4544
ras
mutated, CD4$^+$ T-cell immunity, pancreatic and colon cancer, 2984
retinoblastoma
alterations, increased p16 levels and, human urothelial cells, 493
dephosphorylation failure, drug-resistant cells, 5222
inactivation, and p16^{INK4} expression, lung cancer, 505
malignant glial tumors, 4833
phosphorylation, inhibition by UVB light, human melanocytes, 4047
Rak and, 3969
retinoblastoma susceptibility
inactivation, and p16^{INK4} expression, lung cancer, 505
sialoglycoproteins
platelet-aggregating gp44, mouse colon adenocarcinoma 26, 767
Sos/Ras
interaction with DF3/MUC1, 4000
topoisomerase IIα
truncated, HL-60 cells, 4962
transporter in antigen processing 1 transport
loss, metastatic vs primary breast cancer, 5191
tumor cell
cross-linking by methyl 2,5-dihydroxycinnamate, 4950
Proteoglycan
melanoma-associated
and $\alpha4\beta1$ integrin-mediated contact formation, 2177
Proteolysis
plasmin-catalyzed, colorectal neoplasia, 4688
poly(ADP-ribose) polymerase
and radiation-induced apoptosis, Ewing's sarcoma cells, 4240
Proton nuclear magnetic resonance spectroscopy
cell type-specific fingerprinting of meningioma and meningeal cells, 420
Proto-oncogenes
ABL
activation, fusion to *TEL*, 34
bcl-2
expression, breast cancer cells, estrogen regulation, 3902
inhibition of drug-induced apoptosis, HeLa cells, 4922
WT1 regulation, 5386
c-*fos*
asbestos induction, mesothelial cells, 2085
c-*jun*
asbestos and H_2O_2 induction, 2723

asbestos induction, mesothelial cells, 2085
c-*myc*
WT1 regulation, 5386
FMS
DNA repair, HL60 cells, 336
HER-2/neu
-overexpressing breast cancer cells, suppression and differentiation by emodin, 3890
HOX-11 (*TCL-3*) homeobox
up-regulation, T-cells, 1117
MYC
DNA repair, HL60 cells, 336
rck/p54
identification and expression, human and mouse tissues, 3444
RET
rearrangements, Chernobyl papillary thyroid carcinomas, 5617
Protoporphyrin
δ-ALA-induced
photosensitizer for photodynamic therapy, 1723
pS2
expression, tamoxifen-resistant breast cancer, 3331
PSA: *see* **Prostate-specific antigen**
Psoralens
mutagenesis, mouse fibroblasts, 1283
Psychosocial stressors
-induced changes, mouse mammary tumor growth
natural killer cells, 617
PTPγ
binding and activation by triphosphorylated nucleosides, 4855
Pulmonary vascular leak syndrome
IL-2-induced
attenuation by oral methotrexate, 4929
Purine nucleoside phosphorylase
E. coli
tumor sensitization, 3339
pVHL
-binding proteins, 4544
p*X*
HTLV-I transgenic rats
mammary carcinoma, 2524
Pyrimidine(6-4)pyrimidone photoproducts
induction by sunlight, mononuclear cells, 2245
Pyruvate
breast cancer progression marker, NMR spectroscopy study, 5140

Q

qin
transcriptional repressor, 5540
QS-21
G_{M2}-KLH conjugate vaccine administered with, melanoma, 2783
Quinazoline
-based antitumor molecules
initiatives, Fourteenth Bruce F. Cain Memorial Award lecture, 2761
Quinocarmycins
efficacy against human melanoma lines, 862
Quinolone
novel antitumor A-8441, biological characterization, 830
Quinone reductase
and mitomycin C resistance, 330

R

RA: *see* **all-*trans*-Retinoic acid**
Rab GDP dissociation inhibitor
human
brain-type isoform, cloning and expression, neuroblastoma, 5445
Race
p53 alterations and breast cancer survival and, 1465
Radiation
and calreticulin expression, squamous cell carcinoma, 3016
exposed ataxia-telangiectasia cells
defective induction of stress-activated protein kinase, 3242
G_2 checkpoint response
human thyroid cells, 2075
$p21^{CIP1}$-independent, 2500
and p53 status, human tumor cells, 1842
γ
p53-dependent G_1 checkpoint regulation, lymphoma cells, 2387
glutathione peroxidase effects, 4465
-induced apoptosis
cell age and dose fractionation and, 5207
Ewing's sarcoma cells, 4240
inhibition, VEGF, hematopoietic cells, 5687
mediation, *Bcl-2* mRNA suppression, 991
-induced chromosomal abnormalities, *p53*-deficient mice, 3883
-induced inhibitory checkpoints, 5069
-induced mammary cancer
latent *p53* mutation expression and, 3310
metabolic changes
in vitro and *in vivo* ^{31}P NMR measurements, 1248
resistant neuroblastoma cells
apoptosis, 4915
tumor cell survival
stem cell factor effects, 3431
tumor control dose
reduction by manganese superoxide dismutase, 2490
ultraviolet
human melanocyte responses, 4041
induction of squamous cell carcinoma, p53 transgenic mice, 2070
and melanoma progression, 3669
x-ray
tumor oxygen tension, 2249
Radiation pneumonitis
bFGF protection against, mice, 298
Radioimmunoconjugates
renal excretion, lysine and, 5288
Radioimmunodetection
CC49 sFv and IFN-γ, 2858
Fifth Conference, introduction, 5708s
prelabeling L6 with ^{90}Y- and ^{111}In-DOTA-peptide, 5726s
role, 5756s
Radioimmunoscintigraphy
Tc-99m-labeled totally human mAb 88BV59H21–2, colorectal carcinoma, 5774s
Radioimmunotargeting
anticytokeratin monoclonal anti-idiotypic antibodies, 5868s
^{125}I-labeled L6-biotin monoclonal antibodies combining preload and immunoadsorption, 5874s
Radioimmunotherapy
B-lymphocytic malignancies
prognostic factors, 5893s
breast tumor epitopes, 5847s
combined with radiotherapy
human colon carcinoma grafted in nude mice, 83
dosimetry
head and neck squamous cell carcinoma, 1060
intraperitoneal ^{186}Re-labeled, 5817s
red marrow, sacral scintigraphy, 5827s
theoretical larynx phantom, 1020
experimental
overview of studies, 5832s
Fifth Conference, introduction, 5708s
head and neck cancer
radiolabeled antibody combined with external radiotherapy, 1020
Hodgkin's disease, studies review, 5888s
^{131}I-labeled chimeric L6 antibody
peripheral blood progenitor cell transfusions support, breast cancer, 5916s
^{125}I-labeled mAb CC49
fractionated, human colon carcinoma xenografts, 5881s
intralesional, malignant glioma, 5952s
intraperitoneal ^{186}Re-labeled
dosimetry, 5817s
iodogen- and MATE-labeled ICR12 breast cancer xenografts, 5842s
^{131}I-labeled anti-CEA mAbs, medullary thyroid carcinoma, 5946s
mAbs
pharmacokinetics, biodistribution, and dosimetry, head and neck squamous cell carcinoma, 1060
planar imaging, 5823s
RS7, reactivity
breast cancer, 5857s
tumor dose response reconciliation
vs external beam radiotherapy, 5811s
tumor localization, experimental approaches, 5729s
^{90}Yttrium-radiolabeled chimeric L6
human breast cancer, nude mice, 5837s
^{90}Yttrium-radiolabeled chimeric T84.66, phase I therapy trial, 5929s
Radioisotopes
tumor accretion
residualizing radiolabels on mAbs and, 3132
Radiolabels
residualizing
monoclonal antibodies, 3132
Radioprotectors
WR1065
modulation of thymidine kinase mRNA expression, 4788
Radiosensitivity
leukemia fibroblasts
defective repair of DNA double-strand breaks and chromosome damage, 1232
tumor cell
and DNA-protein kinase activity, 5200
Radiosensitization
caffeine-induced
p53 and, 1643
G_2 checkpoint abrogation and, 1639
hydroxyurea and iododeoxyuridine, bladder cancer, 2800
Radiotherapy
combined with radioimmunotherapy
human colon carcinoma grafted in nude mice, 83
external beam
combined with radiolabeled antibody, head and neck cancer, 1020
tumor dose response reconciliation, vs radioimmunotherapy, 5811s
genetic, 5561
tumor response
paclitaxel enhancement, 3564

Raf-1
-induced medullary thyroid carcinoma
ret silencing, 2048
Rak
and retinoblastoma protein, 3969
Rana nigromaculata
pancreatic carcinoma, 3781
Rapamycin
enhancement of apoptosis, 1982
RAR: *see* **Retinoic acid receptor**
ras
CAAX peptidomimetic FTI 276
tumor growth blockade, nude mice, 4243
mutations
$CD4^+$ T-cell immunity, pancreatic and colon cancer, 2984
chemically induced mouse skin tumors and transformed 3T3 cells, 3513
VEGF/VPF expression upregulation, 4575
ribozyme
adenoviral-mediated delivery, neoplastic reversion, 2024
-transduced diethylnitrosamine-treated hepatocytes
tumors, 5242
transformation
SCH 51344 inhibition, 5106
-transformed cells
suppression by fluoromevalonate, 1732
Rat tracheal epithelial cell culture transformation assay
chemopreventive agents, 537
RAW117 cells
mouse monocyte chemotactic protein 1 chemoattractant, 4458
RB
-deficient mice
endocrine tumors, 1146
loss of heterozygosity, aggressive pituitary tumors, 1613
Rb: *see* **Retinoblastoma protein**
RB-1
deletions, B-cell chronic lymphocytic leukemia, 3475
Rck/p54
candidate proto-oncogene product
identification and expression, human and mouse tissues, 3444
Receptors
β-adrenergic
mitogenic signal transduction, peripheral lung adenocarcinoma, 3504
androgen
gene CAG and GGC microsatellites, and prostate cancer, 1937
gene mutations, latent prostatic carcinoma, Japanese men, 1621
protein expression, prostatic carcinoma metastases, 3068
antigen binding
peptide ligands, B-lymphoma cell activation, 5642
B61
up-regulation, melanoma progression, 2528
benzodiazepine
peripheral-type, expression, human astrocytomas, 2691
bombesin
bronchial epithelial cells, 1853
human breast cancer, 280
CCK-B
mRNA, small cell lung cancer, 276
c-*kit*
loss, and thyroid epithelium transformation, 1787
epidermal growth factor
expression, bronchial neoplasia and squamous cell carcinoma, 1365
expression and binding affinity, androgen up-regulation, PC3 cell lines, 3197
and ornithine decarboxylase transformation, NIH3T3 cells, 5358
epidermal growth factor, variant III
expression, multiple human tumors, 5536
mAbs, breast and lung carcinomas and malignant gliomas, 3140
tumor-specific mAbs, 4375
estrogen
exon 5 deletion variant, breast cancer, 288
expression, estrogen receptor-negative breast cancer cells, 2279
expression, tamoxifen-resistant breast cancer, 3331
80-kDa, estrogen-independent MCF-7 cells expressing, 2583
variant coexpression, neoplastic breast tissues and MCF-7 cells, 2158
variant mRNA species, hepatocellular carcinoma, 498
folate
dominant negative mutant, 847
gastrin
mRNA, small cell lung cancer, 276
gastrin-releasing peptide
expression, bombesin growth response, bronchial epithelial cells, 1853
human breast cancer, 280
glucocorticoid
gene splice site mutation, resistance to glucocorticoid-induced apoptosis, 348
modulator inhibition, CEM C-7 cells, 548
variant, mRNA expression, multiple myeloma, 2727
hyaluronan
expression, squamous cell lung carcinoma cells, 3908
insulin-like growth factor
and metastasis, murine carcinoma cells, 1006
insulin-like growth factor-1
expression, sarcoma, 129
insulin-like growth factor I, 249
apoptosis and, 3739
apoptosis prevention, 303
apoptosis prevention *in vivo*, 2463
tyrosine 950 mutation, effects on cell growth and transformation, 663
interleukin 2
-bearing tumors, anti-Tac(dsFv) uptake, 318
interleukin 4
-bearing carcinoma, antitumor effects of circularly permuted IL4-toxin, 3357
interleukin 6
anti-IL-6R mAb, CDDP sensitization, renal cell carcinoma, 590
ligands
epidermal growth factor, and epidermal neoplasia, 1883
low density lipoprotein
-related protein, PDT-resistant tumor cells, 1817
luteinizing hormone-releasing hormone
mRNA expression, ovarian epithelial carcinoma, 817
macroglobulin, α-2
-related protein, PDT-resistant tumor cells, 1817
melanocyte-stimulating hormone
expression, murine melanoma brain metastases, 141
MET/hepatocyte growth factor
expression, pancreatic cancer, 1129
pituitary adenylate cyclase activating peptide, non-small cell lung cancer cells, 4886
platelet-derived growth factor, β
expression, breast tissue and carcinoma, 2703
progesterone
expression, tamoxifen-resistant breast cancer, 3331
gene, *Alu* insertion, 2743
progesterone, A and B
expression, human breast cancer, 5063
retinoic acid
expression, mouse skin tumor progression, 2774
inhibition of AIDS-Kaposi's sarcoma, 823
retinoic acid and γ-IFN effects, breast cancer, 2135
-selective retinoids, and retinoid X receptor-selective retinoids, 232
retinoic acid, α
promyelocytic leukemia-, and erythroid differentiation of K562 cells, 440
retinoid binding affinity, and retinoid inhibition of MCF-7 cell growth, 4446
retinoid X
expression, mouse skin tumor progression, 2774
-selective retinoids, and retinoic acid-selective retinoids, 232
sigma
4-[^{125}I]BP ligand, 3022
subtypes, tumor cell lines, 408
somatostatin
expression, metastatic hormone-refractory prostatic adenocarcinoma, 5805s
scintigraphy, carcinoid tumors, 5801s
somatostatin, SSTR2
morphine cross-reaction, T47D cells, 5632
T cell
β-chain variable region TCRBV14, overexpression, HLA-A2-matched primary melanomas, 3374
lymphoproliferative disease of granular lymphocytes, 6140
MART-1-specific, reconstitution, 748
-transduced T cells, antitumor effects, 3369
thrombin
malignant melanoma cells, 1629
solid tumor cells, 698
thrombopoietin
expression, human cancer cell lines and primary tissues, 3509
transferrin
IgG mAb, combined with hydroxyethyl starch deferoxamine conjugate, lymphoma inhibition, 3817
transforming growth factor β
interactions, clonal differences, 2056
regulation, H-*ras*-transformed rat intestinal epithelial cells, 6181
transforming growth factor β type II
missense mutations, head and neck squamous carcinoma cells, 3982
mutations, colon and gastric cancer, 5545
mutations, colorectal cancer, 5548
urokinase-type plasminogen activator
coexpression with laminin-5, colon adenocarcinoma, 4132
ovarian cancer tumor vs metastasis content, 3958
vascular endothelial growth factor

expression, colon cancer, 3964
expression, hematopoietic cells, 5687
up-regulation, VHL disease-associated and sporadic hemangioblastomas, 1358
Red marrow dosimetry
sacral scintigraphy, 5827s
Reduced folate carrier
functional activity, KB, MA104, and IGROV-1 cells, 3790
gene
and MTX-resistant breast cancer cells, 3790
Refractoriness
retinoid, lung carcinogenesis, 5603
Refractory cancer
pediatric
amifostine and melphalan, phase I trial, 4069
Rejection
tumor
MHC class I expression and, SCID mice, 1911
Rejection antigen peptides
BALB/c RL♂1 leukemia, recognized by CTLs, 4781
Relaxin
activation of NO production, breast cancer cells, 5265
Renal carcinoma, clear cell
t(3;8) loss of heterozygosity, 5348
Renal cell carcinoma
anti-renal cell carcinoma × anti-DTPA bispecific mAbs, 5864s
CDDP sensitization by anti-IL-6/IL-6R mAbs, 590
chromosome 9 deletions, 224
clonal T cell expansions, 685
constitutive activation of MAPK, 4182
genomic alterations and instabilities, 6189
growth suppression by *VHL*, 4804
nonpapillary
chromosome 3p deletions, 5383
Pax-2 expression, 4092
radioimmunotherapy
two-phase targeting, bispecific mAbs, 5864s
sarcomatoid
p53 mutations and p53 protein overexpression, 658
t(3;8) loss of heterozygosity, 5348
Renal cells
preneoplastic
Knudson's two-hits, detection by laser microdissection, Eker rat model, 989
Renal tubules
tumors and atypical hyperplasias, $B6C3F_1$ mice exposed to lead acetate, 5265
Repair genes
XPA
overexpression, and UV radiation resistance, 6152
Replication errors
colon carcinoma
comparative genomic hybridization, 6002
endometrial cancers, 1922
p53
Li-Fraumeni syndrome, 3237
phenotype
lobular breast carcinoma, 3976
Resistance: *see also* **Drug resistance; Multidrug resistance**
alkylating agents
DNA topoisomerase II α expression and, 6109
androgen
mediation by bcl-2, prostate cancer, 4438
androgen *bcl-2*-mediated apoptosis, LNCaP prostate cancer cells, 735
apoptosis, senescent fibroblasts, 2284
camptothecin
CEM/C2 cells, topoisomerase I mutation, 1339
camptothecin analogues, mitoxantrone-resistance breast carcinoma cells, 4004
CDDP
genes, identification with retroviral insertional mutagenesis, 1139
cisplatin
ATP chemosensitivity testing, ovarian carcinoma, 5276
cisplatin-glutathione adduct transport, 4297
cytokeratin 18 expression, ovarian adenocarcinoma, 5203
γ-glutamylcysteine synthetase expression, ovarian cancer cells, 4367
prostatic tumor cells, 474
cyclophosphamide
DNA damage, glutathione and, 1691
cytotoxic agents
genetic radiotherapy, 5561
5,10-dideazatetrahydrofolic acid, CCRF-CEM-derived cells, 566
etoposide
DNA topoisomerase IIα gene expression, cancer cells, 3860
mechanism, murine leukemia cells, 4352
poly(ADP-ribose) polymerase inhibitors, 868
glucocorticoid, 4188
4-hydroperoxycyclophosphamide
glutathione levels, NMR detection, MCF-7 cells, 2012
hydroxyurea
ribonucleotide reductase overexpression and, KB cells, 1328
ribonucleotide reductase R1 and R2 mRNA stability and tumor promotion, 4503
interleukin 6
IL-6 cDNA transduction, melanoma cells, 2200
risk factor, prostate carcinoma cell lines, 4633
intrinsic chemotherapy
DNA repair and, lung cancer, 4760
melphalan
γ-glutamylcysteine synthetase subunit cDNA transfection and, 4771
methotrexate
breast cancer cells, *RFC1* and, 3790
mitoxantrone
topotecan cross-resistance, breast carcinoma cells, 4004
NB-506, SBC-3/NB cells, 2806
nitrosoureas, bone marrow, 2608
radiation
neuroblastoma cells, apoptosis, 4915
tamoxifen, breast cancer
estrogen receptor, progesterone receptor, and pS2 expression, 3331
teniposide
DNA topoisomerase IIα gene expression, cancer cells, 3860
topotecan, mitoxantrone-resistance breast carcinoma cells, 4004
ultraviolet radiation
XPA overexpression adn, 6152
Respiratory chain
mitochondrial
impairment, and oxidative stress, 3028
Restriction fragment length polymorphisms
CYP1A1
and breast cancer, African-American women, 3757
*Taq*I
ovarian carcinoma-associated, progesterone receptor gene, 2743
ret
rearrangements, Chernobyl papillary thyroid carcinomas, 5617
silencing, medullary thyroid carcinoma, 2048
Reticulum cell sarcoma
M5076
hepatic metastases, nitric oxide-mediated regression, 3123
Retinoblastoma
gene product, acute myeloid leukemia, 4552
Retinoblastoma protein
alterations
increased p16 levels and, human urothelial cells, 493
dephosphorylation failure, drug-resistant cells, 5222
inactivation
and $p16^{INK4}$ expression, lung cancer, 505
malignant glial tumors, 4833
phosphorylation
inhibition by UVB light, human melanocytes, 4047
Rak and, 3969
Retinoic acid
antibody
binding to premalignant oral lesions, 5507
combined with IFN-α-2b
effects on proliferation and gene expression, cervical carcinoma, 3158
effects on RAR and CRABP, breast cancer, 2135
induction of neuroblastoma cell differentiation, 847
metabolism
H-*ras* and, NIH3T3 cells, 4850
stromelysin-3 regulation, pulmonary fibroblasts, 4120
all-*trans*-Retinoic acid
-treated neuroblastoma
TGF-β1 induction, 2380
9-*cis*-Retinoic acid
pharmacokinetics, rhesus monkey, 482
Retinoic acid receptor
expression, mouse skin tumor progression, 2774
inhibition of AIDS-Kaposi's sarcoma, 823
retinoic acid and γ-IFN effects, breast cancer, 2135
-selective retinoids
and retinoid X receptor-selective retinoids, combined activity, 232
Retinoic acid receptor α
human
gene regulation by estradiol, breast carcinoma cells, 4999
promyelocytic leukemia-
and erythroid differentiation of K562 cells, 440
retinoid binding affinity
and retinoid inhibition of MCF-7 cell growth, 4446
Retinoid X
receptors
expression, mouse skin tumor progression, 2774
-selective retinoids, combined activity

with retinoic acid-selective retinoids, 232
Retinoids
chemoprevention
p53 and, oral carcinogenesis, 16
-induced suppression
head and neck squamous cell carcinoma differentiation, athymic nude mice, 3183
MCF-7 cell growth inhibition, 4446
RARα binding affinity
and retinoid inhibition of MCF-7 cell growth, 4446
refractoriness, lung carcinogenesis, 5603
retinoic acid receptor- and retinoid X receptor-selective
combined activity, 232
Retinol
serum level
and hepatocellular carcinoma, 1301
Retrovirus
ABL-MYC
-induced chromosome 11 duplications, murine plasmacytomas, 1181
insertional mutagenesis
identification of CDDP resistance genes, 1139
-mediated gene transfer, antisense cyclin G1
inhibition of osteosarcoma cell proliferation, 5493
Review article
ataxia telangiectasia
cellular responses, DNA damage, 5991
RFC1
and MTX-resistant breast cancer cells, 3790
(*R*)-5-Fluoro-5,6-dihydrouracil
attenuation of 5-FU therapy, 1239
RG-2 cells
growth attenuation by local IL-2 and IFN-γ, 1902
Rhoads Memorial Award
Thirteenth, lecture, 4023
Rhodamine-123
selectivity
multidrug resistance and, tumor vs normal epithelial cells, 1633
Riboflavin
-mediated photosensitization
Vinca alkaloids, and drug sensitivity assays, 4837
Ribonucleotide reductase
overexpression, KB cells
and hydroxyurea resistance, 1328
Ribonucleotide reductase R1
mRNA
stability and tumor promotion, hydroxyurea-resistant cells, 4503
Ribonucleotide reductase R2
mRNA
stability and tumor promotion, hydroxyurea-resistant cells, 4503
Ribozyme
anti-ras
adenoviral-mediated delivery, neoplastic reversion, 2024
Ring 22 chromosomes
dermatofibrosarcoma protuberans
amplified 17 and 22 sequences, 2400
Rivulus marmoratus
cardiac hemangioendothelial neoplasms, 2438
RNA: *see also* **Messenger RNA**
antisense
inhibition of FGF-2, hepatoma cells, 5075
antisense to IGF receptor
loss of metastatic phenotype, murine carcinoma cells, 1006
prostate-specific membrane antigen
alternatively splicing, 1441
RO24-5531: *see* **1α,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol**
RS7
reactivity, human breast cancer, 5857s
RSa cells
saccharin-induced mutagenicity
suppression by IFN-α, 4253
RT-PCR: *see* **Polymerase chain reaction, reverse transcriptase**

S

S phase
lengthening
E2F1 deletion mutant, 2883
-specific toxins
sensitization, E2F1 deletion mutant, 2883
Saccharin
-induced mutagenicity
suppression by IFN-α, human RSa cells, 4253
Saccharomyces cerevisiae
bisdioxopiperazines
DNA topoisomerase II target, 2299
Sacral scintigraphy
red marrow dosimetry, 5827s
Salicylic acid
inhibition of HIV induction, 1696
Sapporo Cancer Seminar
Fourteenth, meeting report, 710
Sarcoma
AIDS-Kaposi's
retinoid inhibition, 823
biphenotypic
EWS/FL11 fusion gene expression, 1385
Ewing's
EWS/FL11 fusion gene expression, biphenotypic sarcomas, 1385
radiation-induced apoptosis, 4240
gynecological
microsatellite instability, 5664
M5076 reticulum cell
hepatic metastases, nitric oxide-mediated regression, 3123
Met overexpression and, 1963
Meth A
-derived class I MHC-associated peptides, 124
methylcholanthrene-induced
c-*myc* amplification and K-*ras* mutation, minisatellite instability and, 5670
expression of MHC class I-associated peptides, mouse, 5648
osteogenic
inhibition by antisense cyclin G1, 5493
ovarian
mismatch repair defects, 5664
primary human
insulin-like growth factor expression, 129
renal cell carcinoma transformation
p53 mutations and p53 protein overexpression, 658
uterine
mismatch repair defects, 5664
SAS cells
superoxide dismutase, 6210
SBC-3/NB cells
NB-506-resistant, 2806
SCH 51344
inhibition of *ras* transformation, 5106
Schwannomin
growth suppression, NIH3T3 cells, 2270
SCID: *see* **Severe combined immunodeficiency**
scid factor
V(D)J recombination coding joint formation and dsb repair, 1774
Scintigraphy
[^{111}In]DTPA-D-[Phe^1]-octreotide, 5794s
pancreatic adenocarcinoma, 5805s
sacral
red marrow dosimetry, 5827s
somatostatin receptor, carcinoid tumors, 5801s
Tc-99m-labeled totally human mAb 88BV59H21–2, colorectal carcinoma, 5774s
Screening
differential, breast carcinoma, 2896
h*MLH1* mutation, Swedish hereditary nonpolyposis colon cancer families, 6092
SDI1/WAF1
mutant p53 and, senescence, 2404
Sea urchin
embryo basement membranes
invasion by metastatic tumor cells, 5085
Selectins
colon cancer cell adhesion, 4425
Selenium
-dependent glutathione peroxidase
expression, breast tumor cell lines, 957
Seminal vesicles
androgen-promoted carcinoma
tamoxifen chemoprevention, rat, 5621
Senescence
apoptosis resistance, fibroblasts, 2284
mutant p53 and SDI1/WAF1, 2404
Sensitivity
camptothecin
determinants, National Cancer Institute Anticancer Screen, 2116
cisplatin
cytokeratin 18 expression, ovarian adenocarcinoma, 5203
γ-glutamylcysteine synthetase expression, ovarian cancer cells, 4367
increase by rapamycin, 1982
drug
assays, riboflavin-mediated photosensitization of *Vinca* alkaloids and, 4837
cellular thioredoxin levels and, 4293
E2F1 deletion mutant, 2883
metallothionein null cells, 2021
Sensitization
CDDP
anti-IL-6/IL-6R mAbs, renal cell carcinoma, 590
tumor
E. coli purine nucleoside phosphorylase, 3339
Serine phosphorylation
p53
transactivation facilitation, 2410
Serous carcinoma
multifocal papillary, peritoneum, 490
Serum
-dependent growth
syndecan-1 expression levels and, 293T cells, 4676
-deprived PC12 cells
apoptosis, 1242
immune
definition of two sialyl Tn configurations, tumor cells, 3364
retinol level
and hepatocellular carcinoma, 1301
Severe combined immunodeficiency
mice

human myeloma cells, anti-CD54 antitumor effects, 610
lymphoma dissemination retardation by IL-4, 3692
tumor rejection, MHC class I expression and, 1911
Sialoglycoproteins
platelet-aggregating gp44, mouse colon adenocarcinoma 26, 767
Sialylated antigens
tumor-associated
expression, colonic mucosa, 1869
Sialyl-Lewis^a
expression, and tumor progression, melanoma, 1748
and MUC-1 apomucin, pancreatic cancer cells, 3659
Sialyl-Lewis^x
and MUC-1 apomucin, pancreatic cancer cells, 3659
-positive mucins, colon, colon carcinoma, colorectal cancer, 921
up-regulation, metastatic prostate cancer, 1817
Sialyl-Tn tumor antigen
two configuration definitions, tumor cells, 3364
Sigma receptors
4-[^{125}I]BP ligand
synthesis and pharmacological characterization, 3022
expression, human and rodent tumor cell lines, 408
Signal transduction
β-adrenergic mitogenic, peripheral lung adenocarcinoma, 3504
apoptotic
oxygen radicals mediation, 995
CD30 ligand, Hodgkin's lymphoma, 4157
glioma
carbon-11-labeled diacylglycerol probe, 4225
T-cell molecules
partial degradation, granulocytes, 3840
Silencing
ret, medullary thyroid carcinoma, 2048
Simian virus 40
large T antigen
immortalization, and cyclin D1, 4651
transgenic mice, astrocytic transformation, 4302
transformation
loss of G_2 delay, 7
Simvastatin
-enhanced carmustine antitumor effects, 597
Single photon emission computed tomography
fusion with chest CT, non-small cell lung cancer, 5759s
threshold estimation, 5823s
Sister chromatid exchanges
suppression by ginsenoside Rh_2, human blood lymphocytes, 1221
SJL mice
nitric oxide production, 4391
Skin
E7 immunogenicity, HPV-16-transgenic mice and, 2635
fibroblasts
UDP-glucuronosyltransferase-deficient micronuclei initiation by benzo(*a*)pyrene and benzo(*e*)pyrene, 1045
head and neck
field cancerization, 3604
Skin carcinogenesis
multistage
acceleration, TG.AC transgenic mouse, 3171
promotional phase
cholesterol sulfate effects, mouse, 4865
Skin carcinoma
nonmelanoma
p53 mutations, head and neck, 3604
Skin papilloma
telomerase activity, mouse, 4566
Skin tumors
chemically induced
ras mutations and microsatellite instability, 3513
progression
premalignant, telomerase activity, mouse, 4566
retinoic acid receptor and retinoid X receptor expression, mouse, 2774
spontaneous
ODC overexpression and, transgenic mice, 4205
undifferentiated
p15^{INK4b} and *p16*^{INK4a} deletions and alterations, mouse, 5168
Small cell lung carcinoma
antisense inhibition of L-*myc*, 1559
CCK-B/gastrin receptor mRNA, 276
H69 cells
VP-16-selected, *MRP* and *mdr1* sequential coexpression, 459
Rb inactivation and p16^{INK4} expression, 505
Small intestine
cellular hMSH2 expression, 5146
distorted
bcl-2$^{-/-}$ mice, 354
Smoke, cigarette
exposure
c-*fos* expression and, quiescent Swiss 3T3 cells, 1927
Kent cigarettes
crocidolite asbestos fibers, 2232
Smoking, cigarette
and colorectal adenomas, 1224
and large bowel cancer risk, women, 4906
and pulmonary GSTM3 expression, lung cancer, 3305
-related DNA adducts
mucosa vs biopsies, 1267
Sodium phenylacetate
effects, MCF7ras cells and nude mice, 5156
Solid tumors
bispecific antibody-mediated immunotherapy, 4383
interstitial fluid pressure modulation, 5451
p16^{INK4A}
immunohistochemical detection, 6006
thrombin receptors, 698
Somatic cells
hybridization with early stage melanoma cells
suppression of 92-kDa gelatinase B expression, 4174
Somatic mutations
and cancer origins, 5489
Somatostatin
receptor
expression, metastatic hormone-refractory prostatic adenocarcinoma, 5805s
scintigraphy, carcinoid tumors, 5801s
SSTR2 morphine cross-reaction, T47D cells, 5632
Sos/Ras
interaction with DF3/MUC1, 4000
Sp1 motifs
estradiol regulation of *hRARα*, breast carcinoma cells, 4999
Special lectures
Fourteenth Cain Award, K. R. Harrap
platinum- and quinazoline-based antitumor molecules, 2761
Thirteenth Cain Award, M. E. Wall, M. C. Wani
camptothecin and taxol, 753
Thirteenth Rhoads Award, I. B. Roninson
genetic suppressor elements, 4023
Spectroscopy
NMR
study of breast cancer progression metabolite markers, 5140
proton NMR
cell type-specific fingerprinting of meningioma and meningeal cells, 420
Spermatocytes
MAGE-1 and MAGE-4 proteins, testis, 3478
Spermatogonia
MAGE-1 and MAGE-4 proteins, 3478
Spermine
proliferative effects, breast cancer cells, 934
Spheroids
C6 glioma multicellular
cyclocreatine uptake, NMR microscopy, 153
neovascularization induced growth, MRI, 1956
mixed tumor cell
cisplatin resistance, 386
multicellular tumor
VEGF hypoxia inducibility mapping, 6222
Sphingosine
apoptosis induction, HL-60 cells, 691
Spicamycin
derivative
in vitro cytotoxicity, lung cancer, 1075
Spindle carcinoma
tumor progression, spontaneous rat mammary tumor, 399
Spleen
accelerated lymphoid cell death in *bcl-2*$^{-/-}$ mice, 354
T-cells
protein extraction from tumor-bearing mice, T-cell signaling molecule reduction, 3840
Spontaneous apoptosis
suppression by dichloroacetic acid, murine hepatocytes, 3702
Spontaneous B-cell lymphoma
nitric oxide production and, SJL mice, 4391
Spontaneous chromosomal abnormalities
p53-deficient mice, 3883
Spontaneous hemangioblastoma
VEGF and VEGF receptor up-regulation, 1358
Spontaneous melanoma
nonhybrid *Xiphophorus*, 159
Spontaneous mesothelioma
insulin-like growth factor II expression, 3634
Spontaneous metastasis
melanoma
therapeutic efficacy of doxorubicin immunoconjugates, preclinical human model, 2352
recombinant IL-12 effects, 4404
Spontaneous tumorigenesis
chemoprevention, p53-knockout mice, 3949
Spontaneous tumors
mammary
tumor progression, rat, 399

skin
ODC overexpression and, transgenic mice, 4205
Squamous cell carcinoma
bronchial
p53 and EGFR expression, 1365
calreticulin expression
radiation and, 3016
chromosome 7q31.1 loss of heterozygosity, 1347
esophageal
deletion mapping, 1828
microsatellite alterations, chromosome 3p, 893
thrombomodulin expression, 4196
head and neck
adenovirus-mediated gene therapy, nude mouse model, 1080
apoptosis induction by wild-type *p53* adenovirus, 3117
chromosomal aberrations, nonrandom patterns, 5030
cyclin D1 overexpression, and recurrence, 975
cytogenetics, 3204
deletions and amplifications, CGH detection, 1010
differentiation, retinoid-induced suppression, athymic nude mice, 3183
DNA copy number changes, 3055
D-type cyclin expression, 949
microsatellites motif loss of heterozygosity, 2656
microscopic residual, wild-type *p53* adenovirus, 1
radiolabeled mAbs, pharmacokinetics, biodistribution, and dosimetry, 1060
TGFβ type II receptor missense mutations, 3982
HLA A2601-restricted CTLs, 4248
laryngeal
cell kinetics, prognostic significance, 6103
lung
hyaluronan receptor expression, 3908
MMP-9 expression
induction by fibroblasts, 963
oral
differentiation, retinoid-induced suppression, athymic nude mice xenografts, 3183
UV-induced, p53 transgenic mice, 2070
SRD5A2
polymorphisms
and prostate cancer risk, 3973
ssic*1*
mouse chromosome 4 mapping, 3179
Stem cell factor
effects on growth and radiation survival, tumor cells, 3431
Stem cells
autologous hematopoietic
radioimmunotherapy support, advanced breast cancer, phase I trial, 5921s
peripheral blood
radioimmunotherapy support, breast cancer, 5916s
Stomach: *see also under* **Gastric**
EGCG inhibition of MNNG-induced carcinogenesis, rat, 2081
Stress
-activated protein kinase
defective induction, ataxia-telangiectasia cells, 3242
oxidative
respiratory chain impairment and, 3028
Stressors
psychosocial
-induced changes, mouse mammary tumor growth, 617
Stroma
breast
IGF-II expression, 2448
generation, ascites tumors, 376
pulmonary elements
stromelysin-3 overexpression, non-small cell lung cancer, 4120
Stromelysin-1
mammary tumors, transgenic mice, 1401
Stromelysin-3
expression and regulation, lung cancer, 4120
Submandibular gland
EGF expression
reduction by calorie restriction, 1289
Substrates
balances, colonic carcinoma, humans, 1373
release
apoptosis induction, colon adenoma cells, 5101
***N*-Succinimidyl 4-methyl-3-(tri-*n*-butylstannyl)benzoate**
-labeled ICR12
breast cancer xenograft radioimmunotherapy, 5842s
Sugar chains
TJA-I reactive
expression, colon adenocarcinoma, 1675
Sulfated glycoprotein-2
overexpression
prevention of TNF-induced cell death, LNCaP cells, 2431
Sulfone
induction of apoptosis, 3110
Sulfotransferase
metabolic activation of *N*-hydroxy arylamines and *N*-hydroxy heterocyclic amines, 525
Sulindac
chemoprevention, colon carcinogenesis, 1464
metabolites
induction of apoptosis, 3110
Sunlight
cancer prevention, 4014
DNA photoproducts, mononuclear cells, 2245
Superantigens
-induced lysis, leukemia cell lines, 623
Superficial carcinoma, bladder
angiogenic pathways, 510
hCGβ gene expression, 3735
Superoxide dismutase
SAS tongue carcinoma cells, 6210
Suppressor cells
granulocyte-macrophage
reduction by IFN-γ/TNF-α, enhancement of IL-2 immunotherapy, 885
Suppressor elements
Thirteenth Cornelius P. Rhoads Memorial Award lecture, 4023
Suramin
analogues
antiproliferative and angiostatic effects, 4957
GM-CSF inhibition, 5161
suppression of hypercalcemia and osteoclastic bone resorption, nude mice, 1989
Surfactant protein
gene expression, non-small cell lung carcinomas
RT-PCR detection, 4283
Susceptibility
Fourteenth Sapporo Cancer Seminar meeting report, 710
SW480 cells
PAb421 restoration of mutant p53 function, 3490
Swedish hereditary nonpolyposis colon cancer families
h*MLH1* mutation screening, 6092
Swiss 3T3 cells
cigarette smoke exposure
c-*fos* expression and, 1927
Syndecan-1
expression levels
and serum-dependent growth, 293T cells, 4676
Synthetic peptides
LU103793
interaction with microtubules, 3085

T

T cells: *see* **Cytotoxic T lymphocytes; T lymphocytes**
3T3 cells
transformed
ras mutations and microsatellite instability, 3513
293T cells
serum-dependent growth
syndecan-1 expression levels and, 4676
T lymphocytes: *see also* **Cytotoxic T lymphocytes**
adult leukemia cells
IL-8 production, 3592
anti-idiotype-reactive, 1824
antitumor response
gut-associated lymphoid tissue, TGF-β, 6146
clonal
expansions, renal cell carcinoma, 685
EBV-specific responses, Hodgkin's disease, 3675
HOENU-induced *in vivo* mutagenesis
O^6-alkylguanine and, T-lymphocytes, 1875
HOX-11 (*TCL-3*) up-regulation, 1117
immunity
mutated ras protein, pancreatic and colon cancer, 2984
malignancy
2-amino-6-methoxypurine arabinoside agent, 3352
MUC-1 peptide response, 2257
mutations
induction by 1,6-dinitropyrene, F344 rats, 2316
receptor
β-chain variable region TCRBV14 overexpression, HLA-A2-matched primary melanomas, 3374
lymphoproliferative disease of granular lymphocytes, 6140
MART-1-specific, reconstitution, 748
receptor-transduced
antitumor effects, 3369
resting
bispecific antibody-mediated costimulation, 4409
signal transduction molecules
partial degradation by proteases, 3840
VEGF synthesis, 4140
T lymphoma
malignant
CD45 cell adhesion and apoptosis suppression, 2186

metastatic
B7–1 expression, induction of natural killer cell-mediated cytotoxicity, 2730
TA1
highly conserved oncofetal rat liver cDNA, 1152
Tac
disulfide-stabilized Fv
biodistribution, nude mice, 5323
tumor imaging, 318
TAG-72
expression
enhancement by IFN-α, metastatic breast cancer, 5925s
Taiwan
arsenic and internal cancer, seven-year follow-up study, 1296
TALL-104
treatment of glioblastoma, 96
Tamoxifen
chemopreventive effects
androgen-promoted carcinoma, rat seminal vesicle and prostate, 5621
derivative metabolite E
microsomal activation, 3012
DNA damage and liver tumors, rats, 544
effects on xenobiotic metabolizing enzyme expression, rat liver, 1780
metastatic breast cancer treatment
plasma TGF-β2 levels, 4512
-resistant breast cancer
estrogen receptor, progesterone receptor, and pS2 expression, 3331
tumor growth inhibition, human breast cancer xenografts, 4146
TAP 1: *see* Transporter in antigen processing 1
***Taq*I restriction fragment length polymorphism**
ovarian carcinoma-associated, progesterone receptor gene, 2743
Taxol
effects on p53 levels, 6021
induction of $p21^{WAF1}$ and p53, 4623
modulation of rhodamine-123 influx, epithelial cells, 1633
preclinical and clinical research, Thirteenth Bruce F. Cain Memorial Award lecture, 753
TCL-3
up-regulation, T-cells, 1117
TCTA
cloning and characterization, 1917
T47D cells
morphine and somatostatin receptor SSTR2 cross-reaction, 5632
Technetium-99m
-labeled anti-CEA antibodies
complete vs fragmented, 5786s
targeting liver metastases of colorectal carcinoma, 5777s
-labeled 88BV59H21–2
radioimmunoscintigraphy, colorectal carcinoma, 5774s
-labeled LL2 MAb fragment
B-cell non-Hodgkin's lymphoma staging, 5764s
-labeled LL2-Fab′ fragment
B-cell non-Hodgkin's lymphoma staging, 5771s
polypeptide labeling, 5710s
Tegafur
antitumor activity and pharmacokinetics
5-ethynyluracil effects, 6227
effects on FdUMP binding sites and folate pool, colorectal carcinoma, 3897
TEL
ABL activation, 34
Telangiectasia: *see* Ataxia-telangiectasia
Telomerase
colorectal cancer malignancy effects, 2533
gastric cancer activity, 3258
liver tissue activity, 2734
premalignant skin progression activity, mouse, 4566
Temozolomide
effects on CNS tumor xenografts, 2853
Tenascin
expression, astrocytomas and angiogenesis, 907
Teniposide
resistance
DNA topoisomerase IIα gene expression, cancer cells, 3860
Teratoma
protection against malignant tumors, 3664
Testis
spermatocytes
MAGE-1 and MAGE-4 proteins, 3478
Testis cancer
tumor suppressor gene loss of heterozygosity, 2871
1,4,7,10-Tetraazacyclododecane-*N,N′,N″,N‴*-tetraacetic acid chelates
^{90}Yttrium- and ^{111}Indium-prelabeling L6, 5726s
2,3,7,8-Tetrachlorodibenzo-*p*-dioxin
liver tumor promotion, mouse, 4875
12-*O*-Tetradecanoylphorbol-13-acetate
NF-κB activation
inhibition by ET-18-OCH_3, 4844
***meso*-Tetra(hydroxyphenyl)chlorin**
uptake, localization, and photodynamic effects, mammary carcinoma, 2620
***meso*-Tetra(hydroxyphenyl)porphine**
uptake, localization, and photodynamic effects, mammary carcinoma, 2620
2,6,10,14-Tetramethylpentadecane: *see* Pristane
TG.AC transgenic mice
multistage skin carcinogenesis, acceleration, 3171
TGF: *see* Transforming growth factor
Thermotolerance
enhancement by aspirin, erythroleukemic cells, 4452
6-Thioguanine
quantitation, peripheral blood leukocyte DNA, 1670
Thiols
extracellular
inhibition of HepG2 cell proliferation, 675
Thioredoxin
cellular levels
and drug sensitivity, 4293
secretion rates
and growth arrest, hepatoma cells, 675
Thiotepa
GST-mediated glutathione conjugation, 1701
Thomsen-Friedenreich antigen
site-specific
definition by BW835, MUC1 tandem repeats, 4036
Threonine
linked site-specific Thomsen-Friedenreich disaccharide
definition bu BW835, MUC1 tandem repeats, 4036
Thrombin
receptor
malignant melanoma cells, 1629
solid tumor cells, 698
Thrombomodulin
expression, esophageal squamous cell carcinoma, 4196
Thrombopoietin
receptor
expression, human cancer cell lines and primary tissues, 3509
Thrombospondin
modulation of MCF-7-endothelium interactions, 166
Thymic lymphoma
reduced fidelity of DNA synthesis, mice, 3777
Thymidine kinase
modulation by thymidylate synthase inhibitors, 1505
mRNA expression
modulation by WR1065, 4788
Thymidine kinase/ganciclovir enzyme/prodrug system
vs cytosine deaminase/5-fluorocytosine enzyme/prodrug combination, colorectal carcinoma cells, 4808
Thymidine phosphorylase
activity, and angiogenesis, 1687
Thymidylate synthase
expression
and 5-FU response, colorectal and gastric tumors, 1407
FdUMP binding sites, colorectal carcinoma tissues, 3897
inhibitors
modulation of dTMP salvage, 1505
1843U89 antitumor effects, enhancement by oral folic acid, 6117
Thymus
accelerated lymphoid cell death
bcl-2$^{-/-}$ mice, 354
Thyroid
cells
radiation-induced G_1 arrest, human, 2075
epithelium
mutant p21*ras* expression, induction of IGF-1 secretion, 915
transformation, c-*kit* receptor loss and, 1787
Thyroid carcinoma
medullary
^{131}I-labeled anti-CEA mAb radioimmunotherapy, 5946s
ret silencing, 2048
papillary
Chernobyl tumors, *RET* rearrangements, 5617
Thyroid lesions
CD44 mRNA splicing, 4594
Tiazofurin
phospholipase C β_1 down-regulation, 2978
Tissue factor
-initiated thrombin generation
activation of thrombin receptor, malignant melanoma cells, 1629
Tissue inhibitors of metalloproteinase
cAMP-regulated synthesis
HT1080 suppression, 2927
MMP ratio
and prognosis in cervical carcinoma, 267
Tissue microsomes
TNP-470 disposition and metabolism, 3036
TJA-I: *see Trichosanthes japonica* agglutinin I
TNF: *see* Tumor necrosis factor
TNP-470
disposition and metabolism, hepatocytes and

tissue microsomes, 3036
prevention of hepatic metastasis, 836
Tobacco carcinogen
-induced lung damage
blood DNA adducts and, 4910
Tolerance
DNA damage, colorectal carcinoma cell lines, 2304
methylation
complementation analysis, 2569
thermo
enhancement by aspirin, erythroleukemic cells, 4452
Tongue carcinoma
SAS cells
superoxide dismutase, 6210
Topotecan
resistance, mitoxantrone-resistance breast carcinoma cells, 4004
topoisomerase I/DNA complexes and, analysis, 2097
Toxicity: *see also* **Cytotoxicity**
nitrosoureas
bone marrow resistance, 2608
UDP-glucuronosyltransferase and, 1045
Toxins
aflatoxin
-induced tumorigenesis, chemoprevention, intermittent oltipraz dosing, 4319
aflatoxin B_1
chlorophyllin inhibition, rainbow trout, 57
dietary, synergy with hepadnaviral infection, woodchucks, 3318
metabolism, oltipraz effects, hepatocytes, 5574
anti-CD40, B-cell lymphoma, 3099
anti-osteosarcoma
cytotoxicity, 1321
circularly permuted IL4, *in vivo*, 3357
heregulin, 71
-mediated tumor growth inhibition, 4747
trafficking and cytotoxicity, 3763
TPA: *see* **12-*O*-Tetradecanoylphorbol-13-acetate**
Tracer technique
in vivo modified, L-[1-^{13}C]leucine
protein metabolism, colon carcinoma, 1160
Trachea
epithelial cells
proliferation and transformation, and c-*jun* activation by asbestos and H_2O_2, 2723
rat culture transformation assay, chemopreventive agents, 537
Transactivation
facilitation by p53 serine phosphorylation, 2410
Transcription
activation function
restoration to mutant p53, PAb421, SW480 cells, 3490
-based clonality assays, meningioma, 3865
CYP1A1
and *GSTM1* genotype, 5520
repressor *qin*, 5540
Transcription factors
anti-NFκB reagents
inhibition of cancer cell adhesion, 4162
E2F1
deletion mutant, S phase lengthening and sensitization to antitumor drugs, 2883
Transfectants
NIH/3T3 multidrug resistance protein, 5342
Transferrin
receptor
IgG mAb, combined with hydroxyethyl starch deferoxamine conjugate, lymphoma inhibition, 3817
immunotoxins, trafficking and, 3763
Transformation
astrocytic, transgenic mice, 4302
breast cancer
suppression by emodin, 3890
fibroblasts
caffeic acid phenethyl ester-induced apoptosis, 3576
Fifth Heidelberger Conference meeting report, 705
-induced metabolic changes
tumor-host interaction role, 4151
malignant
astrocytoma, β2-chimaerin, 3456
endometrium, lactoferrin mRNA and protein overexpression and, 1168
oncogenic
syndecan-1 expression levels and, 293T cells, 4676
ormaplatin
WR-2721 effects, F344 rat fibrosarcoma, 2837
ornithine decarboxylase
EGF-R activity and, NIH3T3 cells, 5358
ras
SCH 51344 inhibition, 5106
sarcomatoid, renal cell carcinoma
p53 mutations and p53 protein overexpression, 658
3T3 cells
ras mutations and microsatellite instability, 3513
thyroid epithelium
c-*kit* receptor loss and, 1787
tracheal epithelial cells
and c-*jun* activation by asbestos and H_2O_2, 2723
tyrosine 950 mutation of IGF-I receptor effects, 663
in vitro
enhancement by IL-6, rat urothelial cells, 4581
Transforming growth factor α
autocrine growth stimulation, rat mesothelial cells, 530
and epidermal neoplasia, 1883
-induced mammary gland tumorigenesis, transgenic mice, 3915
Transforming growth factor β
antitumor T-cell response, gut-associated lymphoid tissue, 6146
apoptosis regulation
colon adenoma cells, 5101
ovarian epithelial cells, 944
and cell cycle regulation, 1452
-induced cyclin E-cdk2 kinase activation, C3H 10T½ mouse fibroblasts, 1413
receptors
interactions, clonal differences, 2056
regulation, H-*ras*-transformed rat intestinal epithelial cells, 6181
type II receptor
gene mutations, colon and gastric cancer, 5545
gene mutations, colorectal cancer, 5548
missense mutations, head and neck squamous carcinoma cells, 3982
Transforming growth factor β1
β-2 microglobulin antagonism, 781
BALB/MK cell inhibition, 3928
estrogen effects, lactotropes, 4892
induction, RA-treated neuroblastoma, 2380
-mediated drug resistance and gene amplification, 1758
prostate cancer effects, 2596
regulation, vitamin D_3, breast carcinoma cells, 1540
-treated M1 cells ectopically expressing B-*myb*
apoptosis, 501
Transforming growth factor β2
plasma levels, metastatic breast cancer, 4512
Transfusions
peripheral blood progenitor cells
radioimmunotherapy support, breast cancer, 5916s
Transgenic mice
astrocytic transformation, 4302
c-*fos*-induced osteosarcoma, 6244
HPV-16-
E7 immunogenicity, 2635
islet cell carcinoma model
chromosome 9 and 16 tumor suppressor loci, 6071
mammary gland tumorigenesis
TGF-α-induced, 3915
melanoma-susceptible
cutaneous melanoma, PA and PAI expression, 4681
p53
UV-induced squamous cell carcinoma, 2070
stromelysin-1
mammary tumors, 1401
TG.AC
skin, multistage carcinogenesis acceleration, 3171
Transgenic rats
HTLV-I pX
mammary carcinoma, 2524
Transitional cell carcinoma, bladder
autocrine cell growth
granulocyte-colony stimulating factor, 3438
Translocations
bcl-2/J$_H$, blood and organ samples, 2876
chromosome band 11q23 breakpoints, 4287
IgH/c-*myc* recombinations
Burkitt's lymphoma vs mouse plasmacytoma, 5012
malignant melanoma breakpoint
microdissection based cloning, 4640
protein kinase C
pristane, 518
protein phosphatase 1
1,25$(OH)_2D_3$-induced differentiation, HL-60 cells, 774
t(6;14)(p21↖4)
endometrial polyps, 31
t(10;11)
breakpoint heterogeneity, AML-M4/M5, 4220
t(12;16)(q13↔1)
liposarcomas, 24
Transplantation
autologous bone marrow, high-dose chemotherapy and
breast cancer patients, cyclophosphamide pharmacokinetics, 810
Transporter in antigen processing 1 transport protein
loss
metastatic vs primary breast cancer, 5191
Triazene
-induced cytotoxicity
OGAT effects, L1210 leukemia, 6231
***Trichosanthes japonica* agglutinin I**
reactive sugar chains

expression, colon adenocarcinoma, 1675
Trichothiodystrophy
ultraviolet photoproducts removal, 4325
Triphosphorylated nucleosides
PTPγ binding and activation, 4855
Trisomy 11
murine plasmacytomas, 1181
Trophoblasts
paternally derived *H19* expression, 1111
TSP: *see* **Thrombospondin**
Tumor angiogenesis
directed into implanted spheroids
MRI, 1956
Tumor antigen
sialyl Tn
two configuration definitions, tumor cells, 3364
Tumor cells
CDKN2 deletions
detection by interphase FISH, 984
-derived collagenase stimulatory factor
isolation, 434
growth
stem cell factor effects, 3431
growth inhibition
1,15-bis(ethylamino)-4,8,12-triazapentadecane, human and mouse, 2615
high K_m glucose-phosphorylating activities, 3278
immunogenicity
OGAT effects, murine L1210 leukemia, 6231
irradiated
G_1 arrest and p53 status, 1842
PDT-resistant
α-2 MR/LRP expression, 1817
proliferation
inhibition, $p16^{INK4}$, 3250
proteins
cross-linking by methyl 2,5-dihydroxycinnamate, 4950
radiation survival
stem cell factor effects, 3431
radiosensitivity
and DNA-protein kinase activity, 5200
rhIL-4 antiproliferative effects, 2173
sigma receptor subtypes, human and rodent, 408
surface hyaluronan
and metastasis, 428
two sialyl Tn configuration definitions, 3364
Tumor ganglioside
in vivo immunosuppression, 211
Tumor growth: *see also* **Cell growth**
aromatase inhibitor effects, nude mouse model, 3073
inhibition
antisense oligonucleotides, 4092
anti-VEGF mAb, 5296
B956, 5310
L-canavanine, pancreatic cancer, 4486
Egr-1, 5054
farnesyl transferase inhibitors, human tumor cells, 5302
gelsolin, bladder cancer, 3228
90K, 3223
mannoheptulose, 3278
myc promotor-binding protein, nude mice breast carcinoma cells, 3747
Ras CAAX peptidomimetic FTI 276, nude mice, 4243
tyrphostin AG17, 2794
neovascularization induced
implanted C6 multicellular spheroids, MRI, 1956
ribonucleotide reductase R1 and R2 mRNA, hydroxyurea-resistant cells, 4503
stem cell factor effects, 3431
suppression
adenovirus *E1a*-mediated, 5551
Tumor markers
gene expression
glutathione transferase P enhancer I, 2651
Tumor necrosis factor
antibody
hepatic amino acid transport block, tumor-bearing rats, 3525
apoptosis, 444
and coagulopathy, prostate cancer, 4881
Tumor necrosis factor α
combined with IFN-γ
reduction of GM suppressor cells and enhancement of IL-2 immunotherapy, 885
-induced apoptosis
mediation by *Bcl-2* mRNA suppression, 991
-induced cell death
prevention by sulfated glycoprotein-2, LNCaP cells, 2431
-induced leukocyte adhesion, 4824
Tumor progression
allelic loss and, breast cancer, 5180
astrocytoma
Fas/APO-1 expression, 5528
Barrett's esophagus
genetic abnormalities, 1971
breast cancer
metabolite markers, NMR spectroscopy study, 5140
host organ-determined, 681
melanoma
B61 expression and receptor up-regulation, 2528
sialyl Lewis^a expression and, 1748
premalignant
skin, telomerase activity, mouse, 4566
premalignant epithelial lesions
gene losses, 5133
skin tumors
retinoic acid receptor and retinoid X receptor expression, mouse, 2774
spontaneous rat mammary tumor, 399
Tumor regression
oral recombinant *L. monocytogenes* vaccine, 4776
soluble antigen formulation, 3486
Tumor spheroids
multicellular
VEGF hypoxia inducibility mapping, 6222
Tumor suppression
APC, colon cancer cell lines, 1531
gene encoding mammary-derived growth inhibitor, 2225
genetic suppressor elements, Thirteenth Cornelius P. Rhoads Memorial Award lecture, 4023
mouse chromosomes 9 and 16 loci, transgenic islet cell carcinoma model, 6071
$p21^{WAF1}$, 4536
Tumor suppressor genes: *see also* **Genes**
APC
tumor suppression, colon cancer cell lines, 1531
chromosome 8p loci, human prostate cancer, 5390
chromosome 13, 1613
loss of heterozygosity, testis cancer, 2871
p16/CDKN2
loss of expression, melanocytic lesions, 2713
methylation, and gene silencing, 4525
$p16^{INK4}$, 3250
p53
abnormalities, and genomic instability, breast carcinoma, 646
mutations and apoptosis, Wilms' tumors, 215
RB
loss of heterozygosity, aggressive pituitary tumors, 1613
VHL
homologous mouse gene, cloning and characterization, 743
WT1
regulation of *bcl-2* and c-*myc*, 5386
Tumor suppressor proteins: *see also* **Proteins**
$p16^{INK4a}$
mutational effects, 2503
Tumor suppressors
C-CAM, prostate cancer, 190
Tumor vaccine
soluble antigen formulation, 3486
Tumorigenesis
aflatoxin-induced
chemoprevention, intermittent oltipraz dosing, 4319
anterior pituitary
estrogen-induced, effects on TGF-β1 expression and action, lactotropes, 4892
apoptosis and, 3739
colonic
azoxymethane-induced, inhibition by RO24-5531, 3050
colorectal
apoptosis inhibition, 1811
epidermal
ornithine decarboxylase and, 1680
mammary gland
TGF-α-induced, transgenic mice, 3915
ornithine decarboxylase
EGF-R activity and, NIH3T3 cells, 5358
spontaneous
chemoprevention, p53-knockout mice, 3949
Tumorigenic phenotypes
loss
novel human bronchial epithelial cell lines, 6215
Tumor-infiltrating lymphocytes
monoclonal antimelanoma scFv antibody, 3584
VEGF synthesis, 4140
Tumors: *see also* **Neoplasms; Wilms' tumors**
alternatively spliced NQO_1 mRNA, 2542
apoptosis
hyperthermia-induced, rats, 5459
ascites
angiogenesis/stroma generation, 376
fibrinogen/fibrin deposition, 369
vascular permeability factor and, 360
-associated sialylated antigens
expression, colonic mucosa, 1869
B-cell
IgH/c-*myc* recombinations, 5012
large human, eradication with CD20 mAbs and IL-2, 2627
bladder
recurrent, *C-erbB-2* gene amplification, 2422
brain
in situ cyclopentenylcytosine infusion therapy, 1306
neovascularization
VEGF and, 1189

breast
aromatase inhibitor effects, nude mouse model, 3073
chromosome 11 loss of heterozygosity, 2660
DNA imbalances, comparative genomic hybridization detection, 5415
glutathione peroxidase expression, 957
humanized antibodies, 5852s
metabolite markers, NMR spectroscopy study, 5140
p185$^{neu/erbB-2}$ activation, 1946
psychosocial stressor-induced changes, natural killer cells, 617
RS7 radioimmunotherapy, xenografts, 5857s
stromelysin-1 transgenic mice, 1401
cachexia-induced
lipid-mobilizing factor and, mice and humans, 1458
carcinoid
somatostatin receptor scintigraphy, 5801s
central nervous system
nitric oxide synthase expression, 727
temozolomide effects, xenografts, 2853
Chernobyl
RET rearrangements, 5617
colon
T:G mismatches, base excision repair, 3742
colorectal
angiogenesis, microvessel quantitation with clinicopathological correlations, 5049
glutathione *S*-transferase π, 2696
thymidylate synthase expression and 5-FU response, 1407
Daudi
eradication with CD20 mAbs and IL-2, 2627
EGFRvIII expression, 5536
endocrine
p53- and *Rb*-deficient mice, 1146
epithelial cell
Epstein-Barr virus, breast cancer study, 39
epithelial ovarian
borderline, chromosome 6q deletion mapping, 2169
gastric
thymidylate synthase expression and 5-FU response, 1407
gastroduodenal
somatic APC gene mutations, 3165
gastrointestinal
abnormal intron 9 retention, CD44 gene transcripts, 4273
glycerol metabolism, ^{13}C NMR study, 761
hepatic amino acid transport, rats, 3525
hepatocellular
promotion by TCDD or Aroclor 1254, mice, 4875
-host interaction
transformation-induced metabolic changes, 4151
IL-2 receptor-bearing
uptake of anti-Tac(dsFv), 318
imaging
anti-Tac(dsFv), 318
invasive
focal adhesion kinase overexpression, 2752
ischemia reperfusion injury
oxygen radicals and nitric oxide, 6021
liver
apoptosis, perillyl alcohol, 979
tamoxifen-induced, rats, 544
malignant
teratoma protection against, 3664
microcirculation
and adoptive immunotherapy, 4627
multicell spheroids
cisplatin resistance, 386
non-antigen presenting cell-derived
B7–1 expression, 2253
ovarian
genetic analysis, 6172
overexpressing p185^{HER2}
ADEPT, 63
oxygen tension
after x-ray irradiation, 2249
pituitary
aggressive, *RB* loss of heterozygosity, 1613
prostatic
adenovirus-mediated wild-type *p53* expression, 4210
radioisotope accretion
residualizing radiolabels on mAbs and, 3132
radioresponse
paclitaxel enhancement, 3564
Ras-transduced diethylnitrosamine-treated hepatocytes, 5242
rejection
MHC class I expression and, SCID Mice, 1911
renal tubular, B6C3F$_1$ mice exposed to lead acetate, 5265
resistance to cytotoxic agents
genetic radiotherapy, 5561
sensitization
E. coli purine nucleoside phosphorylase, 3339
skin
chemically induced, *ras* mutations and microsatellite instability, 3513
retinoic acid receptor and retinoid X receptor expression, mouse, 2774
spontaneous, ODC overexpression and, transgenic mice, 4205
undifferentiated, *p15/p16*^{INK4b} deletions and alterations, mouse, 5168
solid
bispecific antibody-mediated immunotherapy, 4383
interstitial fluid pressure modulation, 5451
p16^{INK4A}, immunohistochemical detection, 6006
thrombin receptors, 698
squamous cell head and neck
DNA copy number changes, 3055
vascular permeability, xenografts, 3752
vessel-directed mAb TV-1, 2673
TV-1
tumor vessel-directed mAb, 2673
Tyramine-cellobiose radioiodination method
enhancement of anti-EGFRvIII cellular retention and uptake, tumor xenografts, 4375
Tyrosine
phosphorylation
and *HOX-11* up-regulation, T-cells, 1117
Tyrosine 950
mutations
IGF-1 receptor, effects on cell growth and transformation, 663
Tyrosine kinase
activation
and CD30 ligand signal transduction, Hodgkin's lymphoma, 4157
nuclear Rak
and retinoblastoma protein, 3969
Tyrphostin AG17
tumor growth inhibition, 2794

U

506U
T-cell agent, 3352
1843U89
antitumor effects
oral folic acid enhancement, 6117
U937 cells
apoptosis induced by tumor necrosis factor, 444
UDP-glucuronosyltransferases
genoprotective effects, chemical carcinogenesis, 1045
Ulcerative colitis
adenomatous polyposis coli mutations, 2035
Ulcers
duodenal
risk, *H. pylori* infection establishment age and, 562
gastric
H. pylori infection establishment age and, 562
Ultrasound
high-intensity focused
effects on prostate cancer, 3346
Ultraviolet
-induced HIV
salicylic acid inhibition, 1696
induction of squamous cell carcinoma, p53 transgenic mice, 2070
-irradiated HL60 cells
DNA repair, 336
photoproducts
removal, trichothiodystrophy cells, 4325
resistance
XPA overexpression adn, 6152
Ultraviolet B
human melanocyte responses, 4041
induction of G$_1$ arrest, human melanocytes, 4047
and melanoma progression, 3669
United States
blacks and whites
pancreatic cancer, alcohol and, 4899
uPA: *see* **Urokinase-type plasminogen activator**
Upper digestive tract cancers
p16/CDKN2 mutation frequency, 3421
Uracil
effects on FdUMP binding sites and folate pool, colorectal carcinoma, 3897
Uridine phosphorylase
inhibitor
enhancement of FdUrd antitumor efficacy, 1092
Urinary trypsin
inhibitors
derived peptides, inhibition of tumor cell invasion, 1847
Urokinase
colorectal neoplasia, 4688
CSF-1 mediation of invasion of ovarian cancer cells, 1578
receptor gene
aODN inhibition, effects on invasive phenotype of transformed human fibroblasts, 90
Urokinase-type plasminogen activator
ovarian cancer tumor vs metastasis content, 3958
receptor

coexpression with laminin-5, colon adenocarcinoma, 4132
ovarian cancer tumor vs metastasis content, 3958
Urothelial cells
pRb alterations
increased p16 levels and, 493
transformation *in vitro*
enhancement by IL-6, 4581
Ursodeoxycholate
chemoprotection, azoxymethane rat colonic carcinogenesis model, 5257
Uterine sarcoma
hMSH2 mutant cells
microsatellite instability, 5664
mismatch repair defects, 5664

V

V185
NIH3T3 cells transfected, effects of PGP inhibitors on, 1086
V79 cells
(+)-BPDE-induced splicing mutations, *hprt* locus, 1550
microtubule disruption by natural estrogens, 1863
v-*abl*
-induced lymphomagenesis, 6196
Vaccines
G_{M2}-KLH conjugate, melanoma, 2783
MHC class I and IL-2, melanoma cells, 4941
oral recombinant *L. monocytogenes*
tumor regression, 4776
tumor
soluble antigen formulation, 3486
vectors
polynucleotide mRNA, characterization, 1397
Vaccinia murine B7
recombinant
combined with rV-CEA, enhanced antitumor effects, 3598
Vaccinia virus
recombinant
encoding mIL-12, antitumor effects, 4765
minimal determinant, induction of therapeutic antitumor T_{CD8+}, 1741
Vascular endothelial cells
cell adhesion
cancer cells, anti-NFκB reagent blockade, 4162
MCF-7 cells, TSP modulation, 166
Vascular endothelial growth factor
apoptosis inhibition, hematopoietic cells, 5687
expression
colon cancer, 3964
upregulation by mutant *ras*, 4575
wild-type p53 and v-SRC effects, 6161
hypoxia inducibility
mapping, multicellular tumor spheroids, 6222
monoclonal antibody
antitumor effects, 5296
and neovascularization, brain tumors, 1189
receptor
expression, colon cancer, 3964
expression, hematopoietic cells, 5687
up-regulation, VHL disease-associated and sporadic hemangioblastomas, 1358
synthesis, T lymphocytes, 4140
up-regulation, VHL disease-associated and sporadic hemangioblastomas, 1358
Vascular permeability
tumor xenografts, 3752
Vascular permeability factor
and ascites tumor growth, 360
expression
upregulation by mutant *ras*, 4575
monoclonal antibody
antitumor effects, 5296
Vascularity
colon cancer
vascular endothelial growth factor expression and, 3964
Vascularization
induced by bFGF overexpression, HEC-1-B cells, 4729
V(D)J recombination coding
joint formation, scid factor and, 1774
Vegetables
consumption
and hepatocellular carcinoma, 1301
VEGF: *see* **Vascular endothelial growth factor**
Vertebrates
lung epithelial cells
mitosis, crocidolite asbestos and, 792
Very late antigen 4
mAb
inhibition of IL-1-enhanced metastasis, 414
v-Ha-*ras*
acceleration of multistage carcinogenesis, TG.AC transgenic mouse skin, 3171
VHL
growth suppression, renal cell carcinoma, 4804
homologous mouse gene, cloning and characterization, 743
Vinblastine
effects on p53 levels, 6021
modulation of rhodamine-123 influx, epithelial cells, 1633
***Vinca* alkaloids**
riboflavin-mediated photosensitization
effects on drug sensitivity assays, 4837
Viruses
adeno-associated
-based plasmids, complexed to cationic liposomes, prostate cancer gene therapy, 2366
mammary tumor
ENV gene-like sequences, breast cancer, 5173
recombinant vaccinia, encoding mIL-12
antitumor effects, 4765
Vitamin D_3
regulation of TGF-β1, breast carcinoma cells, 1540
20-epi-Vitamin D_3 analogues
effects on proliferation and differentiation, breast cancer cell lines, 2822
VLA-4: *see* **Very late antigen 4**
VM-26
cellular actions
comparison with merbarone, 1509
von Hippel-Lindau disease
-associated hemangioblastoma
VEGF and VEGF receptor up-regulation, 1358
gene
cloning and characterization, 743
growth suppression of RCC cells, 4804
gene product-binding proteins, 4544
von Recklinghausen's disease
neurofibroma
microsatellite alterations, 5677
VP-3: *see* **Apoptin**
VP-16: *see* **Etoposide**
v-*ras*^{Ha}
-induced epidermal neoplasia
EGFR ligands and, 1883
v-Src
effects on VEGF gene expression, 6161
VTSA
-peptide motif, MUC1 tandem repeats
BW835 definition of site-specific Thomsen-Friedenreich antigen, 4036

W

Waf1
cyclin D1 subunit association
SV40 large T antigen immortalization and, 4651
WAF1/CIP1
Burkitt's lymphoma, 1431
p53-independent induction, leukemia cells, 668
Water
-soluble camptothecin analogues, antitumor effects, 603
Whites: *see* **Caucasians**
Wild-type deletions
chromosome 13q12-q13, BRCA2 carriers, 4830
Wild-type multidrug transporters
NIH3T3 cells transfected
PGP inhibitor effects, 1086
Wild-type *p53*
adenovirus
apoptosis induction, head and neck squamous cell carcinoma, 3117
-mediated expression, prostatic tumor cells, 4210
gliomas
bcl-2 expression, 999
loss
and astrocyte growth, 2746
and VEGF gene expression, 6161
Wilms' tumors
clonal expansion and apoptosis
p53 gene mutations and, 215
suppressor gene *WT1*
induction of IGF2, 4540
regulation of *bcl-2* and c-*myc*, 5386
Withdrawal
estrogen
and energy metabolism, ^{31}P MRS, breast cancer xenografts, 1664
growth inhibition, human breast cancer xenografts, 4146
WN
anti-B-cell antibody, 5978s
Wnt-5A
expression, malignancy, 3495
Women
African-American
breast cancer, *CYP1A1* restriction fragment length polymorphism and, 3757
Chinese
lung cancer, *p53* mutations, Hong Kong, 5343
large bowel cancer risk
smoking and, 4906
WR-1065
modulation of thymidine kinase mRNA expression, 4788
WR-2721
effects on ormaplatin transformation, F344 rat fibrosarcoma, 2837
phase I trial, pediatric refractory cancer, 4069

WT1
induction of IGF2, Wilms' tumor cells, 4540
regulation of *bcl-2* and c-*myc*, 5386

X

X chromosome
inactivation
bilateral ovarian carcinoma, 4793
female genital tract, 5080
Xanthophylls
naturally occurring
chemoprevention, rat, 4059
Xenobiotic metabolizing enzymes
expression
tamoxifen effects, rat liver, 1780
Xenografts
anaplastic large-cell lymphoma
antitumor effects of unconjugated CD30 mAbs, 5335
breast carcinoma
antihormonal therapy, 4146
^{31}P MRS, 1664
radioimmunotherapy, and apoptosis mRNA, 5837s
radioimmunotherapy, iodogen- and MATE-labeled ICR12, 5842s
radioimmunotherapy, RS7, 5857s
radioimmunotherapy, yttrium-90 chimeric L6, nude mice, 5837s
CNS tumors
temozolomide effects, 2853
colon carcinoma
fractionated radioimmunotherapy, $_{125}$I-labeled mAb CC49, 5881s
glioma
intraarterial melphalan treatment, athymic rats, 3803
growth inhibition
B956, 5310
immunotherapy
low and high affinity mAbs, nude mouse carcinoma model, 4398
metastases growth inhibition
camptothecins, newly developed models, 5637
MV522
illudin analogue efficacy against, 4936
oral squamous cell carcinoma
differentiation, retinoid-induced suppression, athymic nude mice, 3183
pancreatic carcinoma
enrichment, 4670
mAb-PAM4 targeting, 1105
proliferation
calculation, 392
heterogeneity, 392
tumor
anti-EGFRvIII cellular retention and uptake, 4375
vascular permeability, 3752
unconjugated mAb CD19 and CD20 antitumor effects, nude mouse model, 840
Xeroderma pigmentosum
group D
ERCC2 defects, 5656
ultraviolet photoproducts removal, 4325
Xiphophorus
nonhybrid, spontaneous melanoma, 159
XPA
overexpression
and UV radiation resistance, 6152
XPAC
mRNA expression, malignant brain tissue, 1261
X-rays
tumor oxygen tension, 2249

Y

YAC: *see* **Yeast artificial chromosome**
Yeast: *see* ***Saccharomyces cerevisiae***
Yeast artificial chromosome
contig
seven-Mb, region 11p15, 2904
Yttrium-90
chimeric L6 radioimmunotherapy
human breast cancer, nude mice, 5837s
prelabeling, 5726s
chimeric T84.66 radioimmunotherapy
phase I therapy trial, 5929s
high-dose
advanced breast cancer, phase I trial, 5921s

Z

ZR-75-1 cells
MTX-resistant
RFC1 and, 3790